UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
18595,Euroclear,Twitter API,Twitter,@EuroclearGroup @sudipchatterjee Euroclear thieves  they have robbed millions of private citizens. This is a dishonorable company!!!,nan,@EuroclearGroup @sudipchatterjee Euroclear thieves  they have robbed millions of private citizens. This is a dishonorable company!!!,negative,0.0,0.01,0.99,negative,0.0,0.01,0.99,True,English,"['Euroclear thieves', 'private citizens', 'dishonorable company', 'EuroclearGroup', 'millions', 'Euroclear thieves', 'private citizens', 'dishonorable company', 'EuroclearGroup', 'millions']",2023-02-16,2023-02-18,Unknown
18596,Euroclear,Twitter API,Twitter,@EuroclearGroup Euroclear thieves  they have robbed millions of private citizens. This is a dishonorable company!!!,nan,@EuroclearGroup Euroclear thieves  they have robbed millions of private citizens. This is a dishonorable company!!!,negative,0.0,0.01,0.99,negative,0.0,0.01,0.99,True,English,"['private citizens', 'dishonorable company', 'millions', 'private citizens', 'dishonorable company', 'millions']",2023-02-16,2023-02-18,Unknown
18602,Deutsche Boerse,Twitter API,Twitter,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/FI84Sgrtx4,nan,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/FI84Sgrtx4,neutral,0.04,0.95,0.01,neutral,0.04,0.95,0.01,True,English,"['new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone', 'FI84Sgrtx4', 'new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone', 'FI84Sgrtx4']",2023-02-16,2023-02-18,Unknown
18603,Deutsche Boerse,Twitter API,Twitter,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets businessâ€¦ https://t.co/bM8Jr5p1Gh,nan,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets businessâ€¦ https://t.co/bM8Jr5p1Gh,neutral,0.06,0.93,0.01,neutral,0.06,0.93,0.01,True,English,"['digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone', 'digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone']",2023-02-16,2023-02-18,Unknown
18604,Deutsche Boerse,Twitter API,Twitter,Deutsche BÃ¶rse Group and Google Cloud Team Up to Advance Financial Services with Digital Assets Business Platform (â€¦ https://t.co/Mh8J26otKX,nan,Deutsche BÃ¶rse Group and Google Cloud Team Up to Advance Financial Services with Digital Assets Business Platform (â€¦ https://t.co/Mh8J26otKX,neutral,0.13,0.85,0.02,neutral,0.13,0.85,0.02,True,English,"['Deutsche BÃ¶rse Group', 'Digital Assets Business Platform', 'Google Cloud', 'Financial Services', 'Deutsche BÃ¶rse Group', 'Digital Assets Business Platform', 'Google Cloud', 'Financial Services']",2023-02-15,2023-02-18,Unknown
18605,Deutsche Boerse,Twitter API,Twitter,Retweet selected by the https://t.co/kmOCQTFIJb team |  Deutsche Boerse  Swisscom Settle Securities with Corda andâ€¦ https://t.co/nFDpN3XFJa,nan,Retweet selected by the https://t.co/kmOCQTFIJb team |  Deutsche Boerse  Swisscom Settle Securities with Corda andâ€¦ https://t.co/nFDpN3XFJa,neutral,0.13,0.86,0.01,neutral,0.13,0.86,0.01,True,English,"['kmOCQTFIJb team', 'Deutsche Boerse', 'Retweet', 'Swisscom', 'Securities', 'Corda', 'kmOCQTFIJb team', 'Deutsche Boerse', 'Retweet', 'Swisscom', 'Securities', 'Corda']",2023-02-15,2023-02-18,Unknown
18606,Deutsche Boerse,Twitter API,Twitter,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/1ncAbUwAd2,nan,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/1ncAbUwAd2,neutral,0.04,0.95,0.01,neutral,0.04,0.95,0.01,True,English,"['new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone', 'new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone']",2023-02-15,2023-02-18,Unknown
18607,Deutsche Boerse,Twitter API,Twitter,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/EoclLhsMmB,nan,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/EoclLhsMmB,neutral,0.13,0.86,0.01,neutral,0.13,0.86,0.01,True,English,"['new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone', 'new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone']",2023-02-14,2023-02-18,Unknown
18608,Deutsche Boerse,Twitter API,Twitter,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/EcU90JeE3s,nan,ðŸ“£ Deutsche BÃ¶rse has selected Google Cloud to provide the backbone for a new digital asset business platform that wâ€¦ https://t.co/EcU90JeE3s,neutral,0.08,0.9,0.01,neutral,0.08,0.9,0.01,True,English,"['new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone', 'new digital asset business platform', 'Deutsche BÃ¶rse', 'Google Cloud', 'backbone']",2023-02-14,2023-02-18,Unknown
18689,Euroclear,NewsApi.org,https://finance.yahoo.com/news/notice-convening-annual-general-meeting-151900392.html,Notice convening the Annual General Meeting 2023 of Essity Aktiebolag (publ),"Notice is given to the shareholders of Essity Aktiebolag (publ) Reg. No. 556325-5511 (""Essity"") of the Annual General Meeting to be held on Wednesday  29...","STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- Notice is given to the shareholders of Essity Aktiebolag (publ) Reg. No. 556325-5511 (""Essity"") of the Annual General Meeting to be held on Wednesday  29 March 2023 at 3 p.m. at Stockholm Waterfront Congress Centre  Nils Ericsons Plan 4  Stockholm (registration from 2 p.m.)The shareholders also have the opportunity to exercise their voting rights by voting in advance (so-called postal voting) ahead of the Annual General Meeting. Shareholders may thereby choose to exercise their voting rights at the Annual General Meeting 2023 by attending in person  through a proxy or by advance voting as instructed below.A. Right to participate at the MeetingShareholders who wish to participate in the Annual General Meeting mustbe listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB as of Tuesday  21 March 2023; andgive notice of its intention to participate in the Meeting in accordance with the instructions set out in section ""B. Notice of participation at the meeting venue in person or by proxy""no later than Thursday  23 March 2023  or by submitting its advance vote in accordance with the instructions under section ""C. Advance voting"" no later than Thursday  23 March 2023.For shareholders who have their shares registered through a bank or other nominee  the following applies in order to be entitled to participate in the Meeting. In addition to giving notice of participation  such shareholder must re-register its shares in its own name so that the shareholder is listed in the presentation of the share register as of the record date Tuesday  21 March 2023. Such re-registration may be temporary (so-called voting rights registration)  and request for such voting rights registration shall be made to the nominee in accordance with the nominee's routines  at such a time in advance as decided by the nominee. Voting rights registration that has been made by the nominee no later than Thursday  23 March 2023  will be considered in the presentation of the share register.Story continuesB. Notice of participation at the meeting venue in person or by proxyA person who wishes to participate at the meeting venue in person or by proxy must give notice to the company as instructed below:by telephone +46 8 402 90 80  weekdays between 8 a.m. and 5 p.m. on the company website www.essity.com by mail to Essity Aktiebolag (publ)  ""Annual General Meeting""  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden  orby email to GeneralMeetingService@euroclear.comName  personal identity number/corporate registration number  address and telephone number  and number of accompanying persons (no more than two)  if any  should be stated when notification is given. Shareholders represented by proxy shall issue a dated written proxy for their representative signed by the shareholder. A proxy is valid one (1) year from its issue date or such longer period as set out in the proxy  however not more than five (5) years. Proxy forms are available upon request and on the company's website  www.essity.com. Anyone representing a legal entity must present a copy of the registration certificate or equivalent authorization document  not older than one (1) year  listing the authorized signatories. To facilitate registration at the Meeting  the proxy as well as the registration certificate and other authorization document should be sent to the company at the address stated above well in advance of the Meeting and no later than Thursday  23 March 2023.C. Advance votingShareholders may exercise their voting rights at the Annual General Meeting by voting in advance  so-called postal voting. A person who wishes to attend the meeting venue in person or by proxy must however give notice in accordance with the instructions under section ""B. Notice of participation at the meeting venue in person or by proxy"" above. This means that a notice of participation only through advance voting is not sufficient for shareholders who wish to attend the meeting venue.A special form must be used for the advance vote. The form is available on Essity's website  www.essity.com. Submission of the form in accordance with the instructions set out below is considered as notice of participation in the Annual General Meeting. The completed form must be received by Euroclear Sweden AB no later than Thursday  23 March 2023. The completed form may be sent to Essity Aktiebolag (publ)  ""Annual General Meeting""  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden. A completed form may also be submitted electronically. Electronic submission can be made either through verification with BankID in accordance with instructions at https://anmalan.vpc.se/euroclearproxy  or by sending the completed form by email to GeneralMeetingService@euroclear.com. Electronic submission must be made no later than Thursday  23 March 2023.Shareholders may not provide specific instructions or conditions to the advance vote. If so  the entire advance vote is invalid. Further instructions and conditions can be found in the advance voting form.Shareholders submitting their advance vote by proxy must issue a dated written proxy for their representative signed by the shareholder  which must be enclosed with the advance voting form. A proxy is valid one (1) year from its issue date or such longer period as set out in the proxy  however not more than five (5) years. Proxy forms are available upon request and on the company's website  www.essity.com. If the shareholder is a legal entity  a registration certificate or equivalent authorization document  not older than one (1) year  listing the authorized signatories shall be appended to the advance voting form.Proposed agenda1. Election of Chairman of the Meeting.2. Preparation and approval of the voting list.3. Election of two persons to check the minutes.4. Determination of whether the Meeting has been duly convened.5. Approval of the agenda.6. Presentation of the annual report and the auditor's report and the consolidated financial statements and the auditor's report on the consolidated financial statements and the auditor's statement regarding whether the guidelines for remuneration for the senior management have been complied with.7. Resolutions ona. adoption of the income statement and balance sheet  and of the consolidated income statement and the consolidated balance sheet;b. appropriations of the company's earnings under the adopted balance sheet and record date for dividend; andc. discharge from personal liability of the Board of Directors and the President for 2022.8. Resolution on the number of directors and deputy directors.9. Resolution on the number of auditors and deputy auditors.10. Resolution on remuneration for the Board of Directors and the auditor.11. Election of directors and deputy directors.Re-election ofa. Ewa BjÃ¶rlingb. PÃ¤r Bomanc. Annemarie Gardshold. Magnus Grothe. TorbjÃ¶rn LÃ¶Ã¶ff. Bert Nordbergg. Barbara Milian ThoralfssonNew election ofh. Maria Carelli. Jan Gurander12. Election of Chairman of the Board of Directors.13. Election of auditors and deputy auditors.14. Resolution on approval of the Board's report on remuneration for the senior management.15. Resolution on cash-based incentive program.16. Resolution on authorisation for the Board of Directors to resolve ona. acquisition of own shares; andb. transfer of own shares on account of company acquisitions.Proposal for resolution under Item 1The Nomination Committee proposes attorney-at-law Carl SvernlÃ¶v as Chairman of the Meeting.Proposal for resolution under Item 2The voting list proposed to be approved is the voting list prepared by Euroclear Sweden AB on behalf of Essity  based on the Annual General Meeting's share register  shareholders having given notice of participation and being present at the meeting venue and received advance votes.Proposal for resolution under Item 7.bThe Board of Directors proposes a dividend for the financial year 2022 of SEK 7.25 per share. As record date for the dividend  the Board of Directors proposes Friday  31 March 2023. If the Meeting resolves in accordance with this proposal  the dividend is expected to be distributed by Euroclear Sweden AB on Wednesday  5 April 2023.Proposal for resolution under Item 8â€“13The Nomination Committee proposes the following:The number of directors shall be nine with no deputy director.The number of auditors shall be one with no deputy auditor.The remuneration to each director elected by the Annual General Meeting and who is not employed by the company shall amount to SEK 875 000 and the Chairman of the Board of Directors is to receive SEK 2 625 000. Members of the Remuneration Committee are each to receive an additional remuneration of SEK 130 000  while the Chairman of the Remuneration Committee is to receive an additional remuneration of SEK 155 000. Members of the Audit Committee are each to receive an additional remuneration of SEK 300 000  while the Chairman of the Audit Committee is to receive an additional remuneration of SEK 425 000. Members of the Portfolio Development Committee are each to receive an additional remuneration of SEK 300 000  while the Chairman of the Portfolio Development Committee is to receive an additional remuneration of SEK 425 000. Remuneration to the auditor is to be paid according to approved invoice.Re-election of the directors Ewa BjÃ¶rling  PÃ¤r Boman  Annemarie Gardshol  Magnus Groth  TorbjÃ¶rn LÃ¶Ã¶f  Bert Nordberg and Barbara Milian Thoralfsson and new election of Maria Carell and Jan Gurander. BjÃ¸rn Gulden  Louise Svanberg and Lars Rebien SÃ¸rensen have declined re-election.Maria Carell  born 1973  has since 2017 been the President and CEO of RG  an esthetics and skincare specialized company based in Dallas  USA. She is a Swedish citizen and has lived in the USA since 2012. Maria Carell has a solid pharmaceutical and med-tech background including previous leading positions in i.a. Exeltis  Meda  Q-MED  Actavis  Novartis and Jensen-Cilag. She has served as a board member in several companies during the last 20 years but today only has a board assignment in RG Holdco. Maria Carell has a M.Sc. in Business Administration and Economics with focus on international business.Jan Gurander  born 1961  was during 2016-2022 deputy CEO in the Volvo Group and was also CFO for the Volvo Group during 2014-2018. He is a Swedish citizen. Jan Gurander has experience from leading positions in listed large international industrial companies and from the financial sector  such as MAN  Volvo Cars  Swedbank Robur  Scania and Investor. Today he has a board assignment in one listed company (Skanska)  where he is also serving as a member in all of the board committees. Jan Gurander has a M.Sc. in Business and Economics from Stockholm School of Economics.Re-election of PÃ¤r Boman as Chairman of the Board of Directors.Re-election of the registered accounting firm Ernst & Young AB  in accordance with the Audit Committee's recommendation  for the period until the end of the Annual General Meeting 2024. If elected  Ernst & Young AB has announced its appointment of Erik SandstrÃ¶m as auditor in charge.Proposal for resolution under Item 15The Board of Directors proposes that the Annual General Meeting 2023 resolves to approve a cash-based incentive program which is directed to senior management as well as certain other executives and key employees in Essity (the ""Program"") as follows. In order to encourage a common interest for the participants and the shareholders of long-term good return and the company's ability to recruit and retain key employees  the Board of Directors considers that the company shall have cash-based incentive programs. Such programs should be approved annually and have performance conditions related to (i) the relative value development of Essity's class B share  and (ii) reduction of greenhouse gas emissions. The Board of Directors also considers that there should be a requirement for the participants' own investment in Essity shares and that such shares should be held for a period of at least three years. It is noted that the Program is exclusively cash-based and does not result in any dilution or other impact on the rights of the shares.Essity has for a number of years resolved on similar cash-based programs  which are described in the company's Annual and Sustainability Report and in the remuneration report approved by the Annual General Meeting 2022. The Board of Directors' assessment is that these programs have worked very well.Against this background  the Board of Directors proposes that the Annual General Meeting 2023 resolves on a cash-based incentive program  as further described below.Principal terms and conditions of the ProgramThe proposed Program for 2023â€“2025 shall be based on the following principal terms and conditions.a. The Program is proposed to be open to senior management as well as certain other executives and key employees in the Essity group  a total of approximately 380 persons (the ""Participants"").b. The Participants shall have the opportunity  depending on satisfaction of certain performance conditions in accordance with paragraph (c) below  to obtain a cash remuneration (the ""Cash Remuneration"") after the end of a measurement period which covers the years 2023â€“2025 (the ""Measurement Period""). The Cash Remuneration for each Participant may not exceed a certain percentage of the Participant's fixed annual salary (gross) for 2025  as follows: (i) for the President  a maximum of 50 per cent  (ii) for other members of the senior management  a maximum of 80 per cent and (iii) for other Participants  a maximum of 50 per cent. The maximum variable remuneration level shall be determined per individual  taking into account the total remuneration in relation to the specific role  the local market  the terms of employment or the individual performance.c. Payment of the Cash Remuneration shall depend on the degree on satisfaction of the following performance conditions for the Program under the Measurement Period:i. A financial target consisting of the total shareholder return (""TSR"") on the company's class B share under the Measurement Period in relation to a benchmark group of other companies (the ""TSR Condition"").[1] The benchmark group shall to 60 per cent consist of companies which are comparable with the operations in the company's business area Consumer Goods and to 20 per cent each consist of companies that are comparable with the operations in the business area Health & Medical and Professional Hygiene  respectively.[2]A condition for payment is that the TSR of Essity's class B share is not lower than the weighted TSR outcome for the benchmark group under the Measurement Period (the ""TSR Minimum Level""). If the TSR Minimum Level is not reached  no payment of Cash Remuneration related to the TSR Condition will be made. For maximum payment (100 per cent)  it is required that the TSR of Essity's class B share exceeds the weighted TSR outcome for the Benchmark Group with at least 5 percentage points during the Measurement Period (the ""TSR Maximum Level""). Should the TSR of Essity's class B share be between the TSR Minimum Level and the TSR Maximum Level during the Measurement Period  a linear payment will be made.ii. A sustainability target related to the company's reduction of greenhouse gas emissions during the Measurement Period (the ""Sustainability Condition"").[3]A condition for payment of Cash Remuneration related to Sustainability Condition is that the company reduces greenhouse gas emissions during the Measurement Period by at least 7.5 per cent compared to the base year 2016 (the ""Sustainability Target""). If the Sustainability Target is reached  full payment of Cash Remuneration relating to the Sustainability Condition will be made. If the Sustainability Target is not reached  no payment relating to this target will be made.iii. The TSR Condition will be weighted 80 per cent and the Sustainability Condition 20 per cent  when payment of the Cash Remuneration is decided.d. Cash Remuneration will normally be paid only after the expiration of the Measurement Period and shall in general not qualify for the basis for pension computation.e. Participants shall normally be invited to the Program during the first year of the Program. A prerequisite for a Participant to be able to receive full Cash Remuneration  is that the Participant has been permanently employed withing the Essity group throughout the Measurement Period. If a Participant has commenced its employment within the Essity group during the Measurement Period  the payment of Cash Remuneration shall be made pro rata.f. Each Participant shall undertake  for as long as the Participant is employed within the Essity group  to acquire Essity shares for (i) the total paid net amount of the Cash Remuneration regarding senior management  and (ii) at least half the total paid net amount regarding other Participants  no later than 30 June 2026 (or as soon as possible thereafter if the Participant has been prevented from acquiring Essity shares at such time due to applicable insider rules)  and to retain such shares for a period of at least three years after the acquisition  with certain exemptions approved by the Board of Directors. If a Participant does not acquire or retain Essity shares in accordance with the above  the Participant's right to payment under future incentive programs to which the Participant has been invited to participate  shall lapse.g. If extraordinary changes in the Essity group or in the market occur which  in the opinion of the Board of Directors  would result in a situation where the conditions for Cash Remuneration under the Program become unreasonable  the Board of Directors shall be entitled to make adjustments to the Program  including  among other things  be entitled to resolve on a reduced right to Cash Remuneration  or that no Cash Remuneration shall be paid at all.h. The Board of Directors shall be authorized to establish the detailed terms and conditions for the Program. The Board of Directors may  in that regard  make necessary adjustments of these general terms and conditions due to changed circumstances or to satisfy certain regulations or market conditions outside Sweden.i. Participation in the Program presupposes that such participation is legally possible in the various jurisdictions concerned.Measurement Period and vesting periodThe Measurement Period for the performance conditions under the proposed Program will cover the financial years 2023â€“2025. The intention of the Board of Directors is that also future programs shall have a measurement period of three years. In order to receive full Cash Remuneration  employment within the Essity group throughout the vesting period is required. Further  the vesting period  which is three years  shall be combined with a requirement that the Participant must undertake to acquire and hold Essity shares for at least a three-year period after the acquisition  in accordance with above. Required long-term nature of the Program is achieved by the above stated requirements which totals six years.Costs for the Program  dilution  etc.The cost for the Program  including social security charges  including approximately 380 employees  amounts to a maximum of SEK 260 million assuming 100 per cent satisfaction of all of the performance conditions for all Participants in the Program. The cost of the Program amounts to a maximum of 1.7 per cent of Essity's total cost for salaries and remuneration  including social security charges.The Program is cash-based and does not entail any dilution for the company's shareholders. No hedging arrangements are intended to be made with regard to the Program's financial exposure.Preparations of the proposalThe proposed Program has been prepared by Essity's Remuneration Committee. The Remuneration Committee has presented documentation to the Board of Directors  whereafter the Board of Directors has resolved that the Program shall be referred to the Annual General Meeting 2023 for approval.Majority requirementsThe Annual General Meeting's resolution on approval of the Program requires a simple majority of the votes cast.Previous incentive programs in EssityThe company's other incentive programs are described more in detail in Essity's report on remuneration for 2022  which is included in the company's Annual and Sustainability Report 2022 and available on the company's website  www.essity.com.Proposal for resolution under Item 16The Board of Directors makes the assessment that it would be advantageous for the company to be able to adapt the capital structure and to be able to acquire own shares to be used as payment or financing on account of company acquisitions and thereby contribute to increased shareholder value. Hence  the Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to resolve on acquisition and transfer of own class B shares mainly as follows.a. Acquisition of own sharesAcquisition of class B shares shall be made on Nasdaq Stockholm at a price within the at each time prevailing price interval for the share on the marketplace  meaning the interval between the highest purchase price and the lowest selling price. Payment for the shares shall be made in cash. The authorisation may be utilised on one or several occasions until the Annual General Meeting 2024. A maximum of so many class B shares may be acquired that Essity's holding at each time amount to a maximum of 10 per cent of the total number of outstanding shares in Essity.The Board of Directors has issued a statement pursuant to Chapter 19  Section 22 of the Swedish Companies Act.b. Transfer of own shares on account of company acquisitionsTransfer of class B shares may be made on Nasdaq Stockholm  as well as outside of Nasdaq Stockholm  with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind or set-off rights. The shares may be used as payment upon acquisition of companies or businesses or as to finance acquisition of companies or businesses. Transfer may be made of the maximum number of shares held by Essity at the time of the Board of Directors' resolution. The authorisation may be utilized on one or several occasions until the Annual General Meeting 2024. Transfer upon acquisition of companies or businesses may be made at a minimum price per share corresponding to an amount in close connection with the price of the company's class B shares on Nasdaq Stockholm at the time of the decision of transfer. Transfers made on Nasdaq Stockholm to finance acquisition of companies or businesses may be made at a price within the each time prevailing price interval of the share.The purpose of the authorisation to acquire shares in the company is to be able to adapt the company's capital structure and to be able to use repurchased shares in connection with the potential company acquisitions and thereby contribute to increased shareholder value. The purpose of the authorisation to transfer own shares is to give the Board of Directors increased flexibility when financing company acquisitions. The reason for deviation from the shareholders' preferential rights is to create alternative forms of payment upon acquisition of companies or businesses.Majority requirementsThe Meeting's resolution under Item 16 requires that shareholders representing at least two-thirds of the votes cast as well as of the shares represented at the Meeting approve the resolution.The Nomination CommitteeThe Nomination Committee for the Annual General Meeting 2023 is composed of Helena Stjernholm  AB IndustrivÃ¤rden  the Chairman of the Nomination Committee  Anders Oscarsson  AMF and AMF Fonder  Ola Peter Krohn Gjessing  Norges Bank Investment Management  Marianne Nilsson  Swedbank Robur Fonder and PÃ¤r Boman  Chairman of the Board of Essity.Shares and votesThe total number of shares in the company amounts to 702 342 489 shares  of which 61 158 914 are class A shares and 641 183 575 are class B shares  representing a total of 1 252 772 715 votes. The class A share carries ten votes  and the class B share carries one vote. No shares are held by Essity. The information pertains to the circumstances as per the time of issuing this notice.Additional informationThe financial statements  the auditor's report  the Board of Directors' complete proposals including the Board of Directors' statements pursuant to Chapter 18  Section 4 and Chapter 19  Section 22 of the Swedish Companies Act  the Board of Directors' report on remuneration pursuant to Chapter 8  Section 53 a of the Swedish Companies Act  and the auditor's statement pursuant to Chapter 8  Section 54 of the Swedish Companies Act regarding the remuneration guidelines for the senior management  will be available at the company and on the company's website  www.essity.com  no later than Wednesday  8 March 2023. Information about the proposed board members and the proposed auditor  the Nomination Committee's statement  proxy forms  and forms for advance voting are available on the company's website  www.essity.com. The documents will be distributed free of charge to shareholders who so request and state their address and will be available at the General Meeting.The Board of Directors and the president shall  if any shareholder so requests and the Board of Directors believes that it can be done without material harm to the company  provide information regarding circumstances that may affect the assessment of an item on the agenda  and regarding circumstances that can affect the assessment of the company's or its subsidiaries' financial situation or the company's relation to other companies within the group.Processing of personal dataFor information on how your personal data is processed  please see https://www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdfStockholm in February 2023Essity Aktiebolag (publ)The Board of Directors[1] The calculation of TSR is done as follows. The volume weighted average price of the share during the fourth quarter 2022 is compared with the volume weighted average price of the share during the fourth quarter 2025  including dividend and other return.[2] When implementing the Program  the benchmark group comprises of the following companies. For Consumer Goods: Procter & Gamble  Kimberly-Clark  Unicharm and Ontex. For Health & Medical: Smith & Nephew  Convatec and Hartman. For Professional Hygiene: Kimberly-Clark  Ecolab and Diversey. Each company has the same significance within the respective business area. The benchmark group can be adjusted according to the Board of Directors' decision if the Board of Directors deems it appropriate.[3] The calculation of greenhouse gas emissions shall be based on the target adopted by the company according to Science Based Targets (SBTi) in Scope 1 and 2. The assessment shall be made on the basis of the actual greenhouse gas emissions within the specified classes during the Measurement Period  taking into account acquisitions or divestments made. For more information about SBTi and the company's target  see Essity's Annual and Sustainability report 2022  and www.essity.com/sustainability/why-we-do-it/science-based-targets/.For further information  please contact:Per Lorentz  Vice President Corporate Communications  +46 733 13 30 55  per.lorentz@essity.comJohan Karlsson  Vice President Investor Relations  +46 705 11 15 81  johan.ir.karlsson@essity.comThe following files are available for download:https://mb.cision.com/Main/15798/3717980/1858340.pdf Notice convening the Annual General Meeting 2023 of Essity Aktiebolag (publ)CisionView original content:https://www.prnewswire.com/news-releases/notice-convening-the-annual-general-meeting-2023-of-essity-aktiebolag-publ-301749900.htmlSOURCE Essity",neutral,0.0,0.99,0.0,mixed,0.5,0.16,0.34,True,English,"['Annual General Meeting', 'Essity Aktiebolag', 'Notice', 'Stockholm Waterfront Congress Centre', 'Nils Ericsons Plan', 'P.O. Box', 'equivalent authorization document', 'other authorization document', 'Euroclear Sweden AB', 'personal identity number', 'Annual General Meeting', 'corporate registration number', 'C. Advance voting', 'entire advance vote', 'voting rights registration', 'postal voting', 'registration certificate', 'meeting venue', 'Reg. No.', 'share register', 'record date', 'accompanying persons', 'issue date', 'longer period', 'five (5) years', 'legal entity', 'one (1) year', 'authorized signatories', 'telephone number', 'other nominee', 'Electronic submission', 'Essity Aktiebolag', 'special form', 'completed form', 'specific instructions', 'Further instructions', 'written proxy', 'Proxy forms', 'B. Notice', 'company website', 'Feb.', 'shareholders', 'Wednesday', 'March', 'opportunity', 'A.', 'presentation', 'Tuesday', 'intention', 'section', 'participation', 'Thursday', 'accordance', 'shares', 'bank', 'order', 'addition', 'name', 'Such', 're-registration', 'request', 'routines', 'time', 'Story', '8 a', 'mail', 'publ', 'GeneralMeetingService', 'address', 'notification', 'dated', 'representative', 'Anyone', 'copy', 'verification', 'anmalan', 'vpc', 'euroclearproxy', 'conditions', '3', '2']",2023-02-17,2023-02-18,finance.yahoo.com
18690,Euroclear,NewsApi.org,https://finance.yahoo.com/news/board-directors-proposals-aktia-bank-061000006.html,Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023,Aktia Bank Plc Stock Exchange Release 17 February 2023 at 8.10 a.m. Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023 The Board...,"Aktia Bank PlcAktia Bank PlcStock Exchange Release17 February 2023 at 8.10 a.m.Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023The Board of Directors of Aktia Bank Plc (hereinafter ""Aktia"" or ""company"") has decided that the Annual General Meeting will be held on 5 April 2023 at 4.00 pm at Stock Exchange Building  Fabianinkatu 14 in Helsinki.The company will publish the invitation to the Annual General Meeting separately later. The invitation will contain more detailed information on registration and attendance at the General Meeting.In addition to the proposals set forth by the Board of Directors below  the proposals of the Shareholders' Nomination Board for the Annual General Meeting 2023 concerning the number of members and election of the Board of Directors and the remuneration of the Board of Directors have been published in a separate Stock Exchange Release on 31 January 2023.Adoption of the financial statements and the consolidated financial statementsThe Board of Directors proposes that the Annual General Meeting will decide on confirming the financial statements. The companyâ€™s auditor has recommended confirming the financial statements.Resolution on the use of the profit shown in the balance sheet and the payment of dividendThe Board of Directors proposes that a dividend of EUR 0.43 per share shall be paid for the financial year 2022.Shareholders registered in the register of shareholders of the company maintained by Euroclear Finland Ltd on the record date for the dividend payment 11 April 2023 are entitled to the dividend. The Board of Directors proposes that the dividend shall be paid out on 18 April 2023 in accordance with the rules of Euroclear Finland Ltd.Aktia Bank Plc's Remuneration Report for 2022The Board of Directors proposes to the Annual General Meeting that the Remuneration Report for the companyâ€™s governing bodies be confirmed. The Remuneration Report is expected to be published on or about 15 March 2023.Story continuesResolution on the auditor's remunerationThe Board of Directors proposes  based on the recommendation of the Board of Directors' Audit Committee  that remuneration shall be paid to the auditor against the auditorâ€™s reasonable invoice.Election of the auditorThe Board of Directors proposes  based on the recommendation of the Board of Directorsâ€™ Audit Committee  that KPMG Oy Ab  a firm of authorised public accountants  shall be elected as auditor  with Marcus TÃ¶tterman  M.Sc. (Econ.)  APA  as auditor-in-charge for a term of office beginning when the Annual General Meeting 2023 is closed and continuing up until the Annual General Meeting 2024 has ended.Amendment of the Articles of AssociationDue to the amendments made to Chapter 5 of the Finnish Companies Act  the Board of Directors proposes to the General Meeting that the General Meeting amends the company's Articles of Association to allow organising of a remote general meeting without a meeting venue as an alternative to a physical general meeting or a hybrid meeting. The purpose of the amendment is to facilitate the holding of a remote general meeting in unexpected or exceptional circumstances  however not limited to these situations. According to the Finnish Companies Act  a shareholder must be able to exercise their rights fully at a remote general meeting in the same way as at a traditional general meeting held physically. The amendments do not prevent the holding of physical or hybrid meetings. The venues for physical general meetings will be defined in the same context.In accordance with the proposal of the Board of Directors  Article 5 of the company's Articles of Association shall be amended as follows:""5 Â§ Right to attend the General Meeting and the venue of the General MeetingTo participate in the General Meeting  a shareholder must notify the company of their attendance by the deadline specified in the invitation to the meeting. The deadline for registration may not be earlier than ten days before the General Meeting.The General Meeting can be held in Helsinki  Espoo  or Vantaa. The Board of Directors may decide that the General Meeting shall be held without a meeting venue so that the shareholders exercise their right to decide during the meeting in full and in a timely manner by means of a telecommunication connection and a technical aid (remote meeting).""Authorising the Board of Directors to decide on issue of shares or special rights entitling to shares referred to in Chapter 10 of the Companies Act in one or several tranchesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to issue shares  or special rights entitling to shares referred to in Chapter 10 of the Companies Act  as follows:A maximum amount of 7 238 000 shares can be issued based on this authorisation  which corresponds to approximately 10% of all shares in the company.The Board of Directors is authorised to decide on all terms for issues of shares and of special rights entitling to shares. The authorisation concerns the issuance of new shares. Issues of shares or of special rights entitling to shares can be carried out in deviation from the shareholders' pre-emptive subscription right to the companyâ€™s shares (directed share issue).The Board of Directors has the right to use this authorisation  among other things  to strengthen the company's capital base  for the company's share-based incentive scheme  acquisitions and/or other corporate transactions.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to issue shares given by the Annual General Meeting on 6 April 2022.Authorising the Board of Directors to decide on acquisition of own sharesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to decide on the acquisition of 500 000 shares at a maximum  corresponding to approximately 0.7% of the total number of shares in the company.The company's own shares may be acquired in one or several tranches using the unrestricted equity of the company.The company's own shares may be acquired at a price formed in public trading on the date of the acquisition  or at a price otherwise prevailing on the market. The company's own shares may be acquired in a proportion other than that of the shares held by the shareholders (directed acquisition).The company's own shares may be acquired to be used in the company's share-based incentive schemes and/or for the remuneration of the members of the Board of Directors  for further transfer  retention  or cancellation.The Board of Directors is authorised to decide on all additional terms concerning the acquisition of the company's own shares.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to purchase the company's own shares given by the Annual General Meeting on 6 April 2022.Authorising the Board of Directors to decide to divest the companyâ€™s own sharesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to decide on divesting own shares held by the company  as follows.Based on the authorisation  a maximum of 500 000 shares may be divested.Board of Directors is authorised to decide on all additional terms concerning the divestment of the company's own shares. The divestment of the company's own shares can be carried out in deviation from the shareholdersâ€™ pre-emptive subscription rights to shares in the company (directed share issue)  e.g. for implementing the company's incentive programs and for remuneration  including divesting the company's own shares to board members for payment of board remuneration.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to divest the company's own shares given by the Annual General Meeting on 6 April 2022.Aktia Bank PlcFurther information:Lotta BorgstrÃ¶m  Director  Investor Relations and Communications  tel. +358 10 247 6838  lotta.borgstrom (at) aktia.fiDistribution:Nasdaq Helsinki LtdMass mediawww.aktia.comAktia is a Finnish asset manager  bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in Helsinki  Turku  Tampere  Vaasa and Oulu regions. Our award-winning asset management business sells investment funds internationally. We employ approximately 900 people around Finland. Aktia's assets under management (AuM) on 31 December 2022 amounted to EUR 13.5 billion  and the balance sheet total was EUR 12.4 billion. Aktia's shares are listed on Nasdaq Helsinki Ltd (AKTIA). aktia.com.",neutral,0.0,1.0,0.0,neutral,0.03,0.96,0.01,True,English,"['Aktia Bank Plc', 'Annual General Meeting', ""Directors' proposals"", 'Board', 'Aktia Bank Plc Stock Exchange Release', 'separate Stock Exchange Release', 'Stock Exchange Building', 'Euroclear Finland Ltd', 'KPMG Oy Ab', 'authorised public accountants', 'Marcus TÃ¶tterman', 'Annual General Meeting', 'traditional general meeting', 'Finnish Companies Act', 'remote general meeting', 'The General Meeting', 'physical general meetings', 'consolidated financial statements', ""Directors' Audit Committee"", 'Directorsâ€™ Audit Committee', 'The Remuneration Report', ""Shareholders' Nomination Board"", 'remote meeting', 'hybrid meetings', 'financial year', 'meeting venue', 'detailed information', 'balance sheet', 'record date', 'governing bodies', 'reasonable invoice', 'M.Sc.', 'exceptional circumstances', 'same way', 'same context', 'timely manner', 'telecommunication connection', 'technical aid', 'several tranches', 'maximum amount', 'The Board', 'special rights', 'dividend payment', ""Directors' proposals"", 'February', '8.10 a', 'company', '5 April', 'Fabianinkatu', 'Helsinki', 'invitation', 'registration', 'attendance', 'addition', 'number', 'members', 'election', '31 January', 'Adoption', 'auditor', 'Resolution', 'use', 'profit', 'register', '18 April', 'accordance', 'rules', '15 March', 'Story', 'recommendation', 'firm', 'Econ.', 'APA', 'charge', 'office', 'Amendment', 'Articles', 'Association', 'Chapter', 'organising', 'alternative', 'purpose', 'holding', 'unexpected', 'situations', 'venues', 'Â§ Right', 'deadline', 'Espoo', 'Vantaa', 'full', 'means', 'issue', 'shares', 'one', 'authorisation', 'terms', 'issuance', 'new', '4.00', '2022']",2023-02-17,2023-02-18,finance.yahoo.com
18691,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/IANTE-INVESTMENTS-SOCIMI-107634495/news/Iante-Investments-SOCIMI-S-A-Certificate-of-the-Extraordinary-GSM-ndash-Capital-increase-and-oth-43020229/?utm_medium=RSS&utm_content=20230217,Iante Investments SOCIMI S A : Certificate of the Extraordinary GSM â€“ Capital increase and other agreements 10.02.2023 17-02-2023,"(marketscreener.com)   CERTIFICATE OF THE MINUTES OF THE   EXTRAORDINARY AND UNIVERSAL GENERAL SHAREHOLDERS' MEETING OF THE COMPANY   ""IANTE INVESTMENTS SOCIMI  S.A.""   Mr. DÃ¡maso RiaÃ±o LÃ³pez  in his position as Secretary Non-Director of the Board â€¦","""Article 5.- Capital.The share capital  which is totally subscribed and paid-up  is set at NINE MILLION EIGHT HUNDREDAND TWENTY-THREE THOUSAND THREE HUNDRED WITH SIXTY-THREE EUROS (EUR 9 823 363.00). Said capital is divided into NINE MILLION EIGHT HUNDRED AND TWENTY-THREE THOUSAND THREE HUNDRED WITH SIXTY-THREE (9 823 363.00) shares of ONE EURO (EUR 1.00) face value per share  represented via nominative shares  all of the same kind and series.Maintaining the book entries of the shares shall correspond to Euroclear France  S.A. (Euroclear) and its affiliated entities.""Second.- Recording of the ownership of the new shares recently issued.Similarly  by virtue of articles 314 of the Spanish Corporation Law and 198.4.1 of the Spanish Commercial Registry Regulation  the Universal General Shareholders' Meeting states for the record that in the Shares Registry Book of the Company  appears the ownership of the new 253 636 shares created as consequence of the previous agreement of capital increase.Third.- Granting of specific authorization to execute the preceding agreements.The Universal General Shareholders' Meeting unanimously agree to confer an express authorization as broad and wide as legally required  in favour of the management body as well as any attorney of the Company entitled to execute its corporate resolutions according to article 108(3) of the Spanish Companies' House Regulation; so that any of them  acting jointly and severally  may appear before a Notary Public of their choice and thus execute the preceding corporate resolutions; being them all furthermore entitled to enter into as many documents and perform as many actions as may be required when filing them  where applicable  with the relevant Companies' House; and to remedy any defects that may be rated by the Registrar  whether verbally or in writing  and that may be remedied  notwithstanding the possibility to partially record these resolutions  if any  all in accordance with the provisions of articles 62 and 63 of the Spanish Companies' House Regulation.And there being no other decisions to be recorded  these minutes are drawn up  which  once read  are approved unanimously and signed by the Secretary  with the approval of the Chairman  in the place and date of the header.For such purposes  this certificate is issued by the Secretary Non-Director  after approval by the Chairman of the Board of Directors  in Madrid on February 14th  2023.",neutral,0.0,1.0,0.0,negative,0.07,0.31,0.62,True,English,"['Iante Investments SOCIMI S A', 'Extraordinary GSM', 'Capital increase', 'other agreements', 'Certificate', ""The Universal General Shareholders' Meeting"", 'NINE MILLION EIGHT HUNDRED', 'Spanish Commercial Registry Regulation', ""Spanish Companies' House Regulation"", ""relevant Companies' House"", 'Spanish Corporation Law', 'TWENTY-THREE THOUSAND THREE', 'Shares Registry Book', 'preceding corporate resolutions', 'book entries', 'preceding agreements', 'ONE EURO', 'same kind', 'S.A.', 'affiliated entities', 'previous agreement', 'specific authorization', 'express authorization', 'management body', 'Notary Public', 'many documents', 'many actions', 'other decisions', 'nominative shares', 'new shares', 'new 253,636 shares', 'SIXTY-THREE EUROS', 'Euroclear France', 'capital increase', 'Secretary Non-Director', 'share capital', '3.00) shares', 'Article', 'value', 'series', 'Recording', 'ownership', 'virtue', 'Company', 'consequence', 'Granting', 'favour', 'attorney', 'choice', 'defects', 'Registrar', 'writing', 'possibility', 'accordance', 'provisions', 'minutes', 'approval', 'Chairman', 'place', 'date', 'header', 'purposes', 'certificate', 'Board', 'Directors', 'Madrid', 'February']",2023-02-17,2023-02-18,marketscreener.com
18692,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610347/0/en/Board-of-Directors-proposals-to-Aktia-Bank-Plc-s-Annual-General-Meeting-2023.html,Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023,Aktia Bank PlcÂ  Â  Â  Â  Â  Â  Â  Â Â Stock Exchange ReleaseÂ Â Â Â Â Â Â Â  17 February 2023 atÂ 8.10 a.m.    Board of Directors' proposals to Aktia Bank Plcâ€™s Annual......,"English Finnish SwedishAktia Bank PlcStock Exchange Release17 February 2023 at 8.10 a.m.Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023The Board of Directors of Aktia Bank Plc (hereinafter ""Aktia"" or ""company"") has decided that the Annual General Meeting will be held on 5 April 2023 at 4.00 pm at Stock Exchange Building  Fabianinkatu 14 in Helsinki.The company will publish the invitation to the Annual General Meeting separately later. The invitation will contain more detailed information on registration and attendance at the General Meeting.In addition to the proposals set forth by the Board of Directors below  the proposals of the Shareholders' Nomination Board for the Annual General Meeting 2023 concerning the number of members and election of the Board of Directors and the remuneration of the Board of Directors have been published in a separate Stock Exchange Release on 31 January 2023.Adoption of the financial statements and the consolidated financial statementsThe Board of Directors proposes that the Annual General Meeting will decide on confirming the financial statements. The companyâ€™s auditor has recommended confirming the financial statements.Resolution on the use of the profit shown in the balance sheet and the payment of dividendThe Board of Directors proposes that a dividend of EUR 0.43 per share shall be paid for the financial year 2022.Shareholders registered in the register of shareholders of the company maintained by Euroclear Finland Ltd on the record date for the dividend payment 11 April 2023 are entitled to the dividend. The Board of Directors proposes that the dividend shall be paid out on 18 April 2023 in accordance with the rules of Euroclear Finland Ltd.Aktia Bank Plc's Remuneration Report for 2022The Board of Directors proposes to the Annual General Meeting that the Remuneration Report for the companyâ€™s governing bodies be confirmed. The Remuneration Report is expected to be published on or about 15 March 2023.Resolution on the auditor's remunerationThe Board of Directors proposes  based on the recommendation of the Board of Directors' Audit Committee  that remuneration shall be paid to the auditor against the auditorâ€™s reasonable invoice.Election of the auditorThe Board of Directors proposes  based on the recommendation of the Board of Directorsâ€™ Audit Committee  that KPMG Oy Ab  a firm of authorised public accountants  shall be elected as auditor  with Marcus TÃ¶tterman  M.Sc. (Econ.)  APA  as auditor-in-charge for a term of office beginning when the Annual General Meeting 2023 is closed and continuing up until the Annual General Meeting 2024 has ended.Amendment of the Articles of AssociationDue to the amendments made to Chapter 5 of the Finnish Companies Act  the Board of Directors proposes to the General Meeting that the General Meeting amends the company's Articles of Association to allow organising of a remote general meeting without a meeting venue as an alternative to a physical general meeting or a hybrid meeting. The purpose of the amendment is to facilitate the holding of a remote general meeting in unexpected or exceptional circumstances  however not limited to these situations. According to the Finnish Companies Act  a shareholder must be able to exercise their rights fully at a remote general meeting in the same way as at a traditional general meeting held physically. The amendments do not prevent the holding of physical or hybrid meetings. The venues for physical general meetings will be defined in the same context.In accordance with the proposal of the Board of Directors  Article 5 of the company's Articles of Association shall be amended as follows:""5 Â§ Right to attend the General Meeting and the venue of the General MeetingTo participate in the General Meeting  a shareholder must notify the company of their attendance by the deadline specified in the invitation to the meeting. The deadline for registration may not be earlier than ten days before the General Meeting.The General Meeting can be held in Helsinki  Espoo  or Vantaa. The Board of Directors may decide that the General Meeting shall be held without a meeting venue so that the shareholders exercise their right to decide during the meeting in full and in a timely manner by means of a telecommunication connection and a technical aid (remote meeting).""Authorising the Board of Directors to decide on issue of shares or special rights entitling to shares referred to in Chapter 10 of the Companies Act in one or several tranchesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to issue shares  or special rights entitling to shares referred to in Chapter 10 of the Companies Act  as follows:A maximum amount of 7 238 000 shares can be issued based on this authorisation  which corresponds to approximately 10% of all shares in the company.The Board of Directors is authorised to decide on all terms for issues of shares and of special rights entitling to shares. The authorisation concerns the issuance of new shares. Issues of shares or of special rights entitling to shares can be carried out in deviation from the shareholders' pre-emptive subscription right to the companyâ€™s shares (directed share issue).The Board of Directors has the right to use this authorisation  among other things  to strengthen the company's capital base  for the company's share-based incentive scheme  acquisitions and/or other corporate transactions.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to issue shares given by the Annual General Meeting on 6 April 2022.Authorising the Board of Directors to decide on acquisition of own sharesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to decide on the acquisition of 500 000 shares at a maximum  corresponding to approximately 0.7% of the total number of shares in the company.The company's own shares may be acquired in one or several tranches using the unrestricted equity of the company.The company's own shares may be acquired at a price formed in public trading on the date of the acquisition  or at a price otherwise prevailing on the market. The company's own shares may be acquired in a proportion other than that of the shares held by the shareholders (directed acquisition).The company's own shares may be acquired to be used in the company's share-based incentive schemes and/or for the remuneration of the members of the Board of Directors  for further transfer  retention  or cancellation.The Board of Directors is authorised to decide on all additional terms concerning the acquisition of the company's own shares.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to purchase the company's own shares given by the Annual General Meeting on 6 April 2022.Authorising the Board of Directors to decide to divest the companyâ€™s own sharesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to decide on divesting own shares held by the company  as follows.Based on the authorisation  a maximum of 500 000 shares may be divested.Board of Directors is authorised to decide on all additional terms concerning the divestment of the company's own shares. The divestment of the company's own shares can be carried out in deviation from the shareholdersâ€™ pre-emptive subscription rights to shares in the company (directed share issue)  e.g. for implementing the company's incentive programs and for remuneration  including divesting the company's own shares to board members for payment of board remuneration.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to divest the company's own shares given by the Annual General Meeting on 6 April 2022.Aktia Bank PlcFurther information:Lotta BorgstrÃ¶m  Director  Investor Relations and Communications  tel. +358 10 247 6838  lotta.borgstrom (at) aktia.fiDistribution:Nasdaq Helsinki LtdMass mediawww.aktia.comAktia is a Finnish asset manager  bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in Helsinki  Turku  Tampere  Vaasa and Oulu regions. Our award-winning asset management business sells investment funds internationally. We employ approximately 900 people around Finland. Aktia's assets under management (AuM) on 31 December 2022 amounted to EUR 13.5 billion  and the balance sheet total was EUR 12.4 billion. Aktia's shares are listed on Nasdaq Helsinki Ltd (AKTIA). aktia.com.",neutral,0.0,1.0,0.0,neutral,0.02,0.98,0.0,True,English,"['Aktia Bank Plc', 'Annual General Meeting', ""Directors' proposals"", 'Board', 'Aktia Bank Plc Stock Exchange Release', 'separate Stock Exchange Release', 'Stock Exchange Building', 'English Finnish Swedish', 'Euroclear Finland Ltd', 'KPMG Oy Ab', 'authorised public accountants', 'Marcus TÃ¶tterman', 'Annual General Meeting', 'traditional general meeting', 'Finnish Companies Act', 'remote general meeting', 'The General Meeting', 'physical general meetings', 'consolidated financial statements', ""Directors' Audit Committee"", 'Directorsâ€™ Audit Committee', 'The Remuneration Report', ""Shareholders' Nomination Board"", 'remote meeting', 'hybrid meetings', 'financial year', 'meeting venue', 'detailed information', 'balance sheet', 'record date', 'governing bodies', 'reasonable invoice', 'M.Sc.', 'exceptional circumstances', 'same way', 'same context', 'timely manner', 'telecommunication connection', 'technical aid', 'several tranches', 'maximum amount', 'The Board', 'special rights', 'dividend payment', 'new shares', ""Directors' proposals"", '7,238,000 shares', 'February', '8.10 a', 'company', '5 April', 'Fabianinkatu', 'Helsinki', 'invitation', 'registration', 'attendance', 'addition', 'number', 'members', 'election', '31 January', 'Adoption', 'auditor', 'Resolution', 'use', 'profit', 'register', '18 April', 'accordance', 'rules', '15 March', 'recommendation', 'firm', 'Econ.', 'APA', 'charge', 'office', 'Amendment', 'Articles', 'Association', 'Chapter', 'organising', 'alternative', 'purpose', 'holding', 'unexpected', 'situations', 'venues', 'Â§ Right', 'deadline', 'Espoo', 'Vantaa', 'means', 'issue', 'one', 'authorisation', 'terms', 'issuance', '4.00', '2022']",2023-02-17,2023-02-18,globenewswire.com
18693,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/AKTIA-PANKKI-OYJ-42765428/news/Board-of-Directors-proposals-to-Aktia-Bank-Plc-s-Annual-General-Meeting-2023-43013769/?utm_medium=RSS&utm_content=20230217,Board of Directors' proposals to Aktia Bank Plc's Annual General Meeting 2023,(marketscreener.com) Aktia Bank PlcÂ  Â  Â  Â  Â  Â  Â  Â Â Stock Exchange ReleaseÂ Â Â Â Â Â Â Â  17 February 2023 atÂ 8.10 a.m. Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023 The Board of Directors of Aktia Bank Plc has decided that the Annual â€¦,"Aktia Bank PlcStock Exchange Release17 February 2023 at 8.10 a.m.Board of Directors' proposals to Aktia Bank Plcâ€™s Annual General Meeting 2023The Board of Directors of Aktia Bank Plc (hereinafter ""Aktia"" or ""company"") has decided that the Annual General Meeting will be held on 5 April 2023 at 4.00 pm at Stock Exchange Building  Fabianinkatu 14 in Helsinki.The company will publish the invitation to the Annual General Meeting separately later. The invitation will contain more detailed information on registration and attendance at the General Meeting.In addition to the proposals set forth by the Board of Directors below  the proposals of the Shareholders' Nomination Board for the Annual General Meeting 2023 concerning the number of members and election of the Board of Directors and the remuneration of the Board of Directors have been published in a separate Stock Exchange Release on 31 January 2023.Adoption of the financial statements and the consolidated financial statementsThe Board of Directors proposes that the Annual General Meeting will decide on confirming the financial statements. The companyâ€™s auditor has recommended confirming the financial statements.Resolution on the use of the profit shown in the balance sheet and the payment of dividendThe Board of Directors proposes that a dividend of EUR 0.43 per share shall be paid for the financial year 2022.Shareholders registered in the register of shareholders of the company maintained by Euroclear Finland Ltd on the record date for the dividend payment 11 April 2023 are entitled to the dividend. The Board of Directors proposes that the dividend shall be paid out on 18 April 2023 in accordance with the rules of Euroclear Finland Ltd.Aktia Bank Plc's Remuneration Report for 2022The Board of Directors proposes to the Annual General Meeting that the Remuneration Report for the companyâ€™s governing bodies be confirmed. The Remuneration Report is expected to be published on or about 15 March 2023.Resolution on the auditor's remunerationThe Board of Directors proposes  based on the recommendation of the Board of Directors' Audit Committee  that remuneration shall be paid to the auditor against the auditorâ€™s reasonable invoice.Election of the auditorThe Board of Directors proposes  based on the recommendation of the Board of Directorsâ€™ Audit Committee  that KPMG Oy Ab  a firm of authorised public accountants  shall be elected as auditor  with Marcus TÃ¶tterman  M.Sc. (Econ.)  APA  as auditor-in-charge for a term of office beginning when the Annual General Meeting 2023 is closed and continuing up until the Annual General Meeting 2024 has ended.Amendment of the Articles of AssociationDue to the amendments made to Chapter 5 of the Finnish Companies Act  the Board of Directors proposes to the General Meeting that the General Meeting amends the company's Articles of Association to allow organising of a remote general meeting without a meeting venue as an alternative to a physical general meeting or a hybrid meeting. The purpose of the amendment is to facilitate the holding of a remote general meeting in unexpected or exceptional circumstances  however not limited to these situations. According to the Finnish Companies Act  a shareholder must be able to exercise their rights fully at a remote general meeting in the same way as at a traditional general meeting held physically. The amendments do not prevent the holding of physical or hybrid meetings. The venues for physical general meetings will be defined in the same context.In accordance with the proposal of the Board of Directors  Article 5 of the company's Articles of Association shall be amended as follows:""5 Â§ Right to attend the General Meeting and the venue of the General MeetingTo participate in the General Meeting  a shareholder must notify the company of their attendance by the deadline specified in the invitation to the meeting. The deadline for registration may not be earlier than ten days before the General Meeting.The General Meeting can be held in Helsinki  Espoo  or Vantaa. The Board of Directors may decide that the General Meeting shall be held without a meeting venue so that the shareholders exercise their right to decide during the meeting in full and in a timely manner by means of a telecommunication connection and a technical aid (remote meeting).""Authorising the Board of Directors to decide on issue of shares or special rights entitling to shares referred to in Chapter 10 of the Companies Act in one or several tranchesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to issue shares  or special rights entitling to shares referred to in Chapter 10 of the Companies Act  as follows:A maximum amount of 7 238 000 shares can be issued based on this authorisation  which corresponds to approximately 10% of all shares in the company.The Board of Directors is authorised to decide on all terms for issues of shares and of special rights entitling to shares. The authorisation concerns the issuance of new shares. Issues of shares or of special rights entitling to shares can be carried out in deviation from the shareholders' pre-emptive subscription right to the companyâ€™s shares (directed share issue).The Board of Directors has the right to use this authorisation  among other things  to strengthen the company's capital base  for the company's share-based incentive scheme  acquisitions and/or other corporate transactions.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to issue shares given by the Annual General Meeting on 6 April 2022.Authorising the Board of Directors to decide on acquisition of own sharesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to decide on the acquisition of 500 000 shares at a maximum  corresponding to approximately 0.7% of the total number of shares in the company.The company's own shares may be acquired in one or several tranches using the unrestricted equity of the company.The company's own shares may be acquired at a price formed in public trading on the date of the acquisition  or at a price otherwise prevailing on the market. The company's own shares may be acquired in a proportion other than that of the shares held by the shareholders (directed acquisition).The company's own shares may be acquired to be used in the company's share-based incentive schemes and/or for the remuneration of the members of the Board of Directors  for further transfer  retention  or cancellation.The Board of Directors is authorised to decide on all additional terms concerning the acquisition of the company's own shares.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to purchase the company's own shares given by the Annual General Meeting on 6 April 2022.Authorising the Board of Directors to decide to divest the companyâ€™s own sharesThe Board of Directors proposes that the General Meeting authorises the Board of Directors to decide on divesting own shares held by the company  as follows.Based on the authorisation  a maximum of 500 000 shares may be divested.Board of Directors is authorised to decide on all additional terms concerning the divestment of the company's own shares. The divestment of the company's own shares can be carried out in deviation from the shareholdersâ€™ pre-emptive subscription rights to shares in the company (directed share issue)  e.g. for implementing the company's incentive programs and for remuneration  including divesting the company's own shares to board members for payment of board remuneration.The authorisation is effective for 18 months from the resolution by the General Meeting and revokes the authorisation to divest the company's own shares given by the Annual General Meeting on 6 April 2022.Aktia Bank PlcFurther information:Lotta BorgstrÃ¶m  Director  Investor Relations and Communications  tel. +358 10 247 6838  lotta.borgstrom (at) aktia.fiDistribution:Nasdaq Helsinki LtdMass mediawww.aktia.comAktia is a Finnish asset manager  bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in Helsinki  Turku  Tampere  Vaasa and Oulu regions. Our award-winning asset management business sells investment funds internationally. We employ approximately 900 people around Finland. Aktia's assets under management (AuM) on 31 December 2022 amounted to EUR 13.5 billion  and the balance sheet total was EUR 12.4 billion. Aktia's shares are listed on Nasdaq Helsinki Ltd (AKTIA). aktia.com.",neutral,0.0,1.0,0.0,neutral,0.02,0.97,0.01,True,English,"['Aktia Bank Plc', 'Annual General Meeting', ""Directors' proposals"", 'Board', 'Aktia Bank Plc Stock Exchange Release', 'separate Stock Exchange Release', 'Stock Exchange Building', 'Euroclear Finland Ltd', 'KPMG Oy Ab', 'authorised public accountants', 'Marcus TÃ¶tterman', 'Annual General Meeting', 'traditional general meeting', 'Finnish Companies Act', 'remote general meeting', 'The General Meeting', 'physical general meetings', 'consolidated financial statements', ""Directors' Audit Committee"", 'Directorsâ€™ Audit Committee', 'The Remuneration Report', ""Shareholders' Nomination Board"", 'remote meeting', 'hybrid meetings', 'financial year', 'meeting venue', 'detailed information', 'balance sheet', 'record date', 'governing bodies', 'reasonable invoice', 'M.Sc.', 'exceptional circumstances', 'same way', 'same context', 'timely manner', 'telecommunication connection', 'technical aid', 'several tranches', 'maximum amount', 'The Board', 'special rights', 'dividend payment', 'new shares', ""Directors' proposals"", '7,238,000 shares', 'February', '8.10 a', 'company', '5 April', 'Fabianinkatu', 'Helsinki', 'invitation', 'registration', 'attendance', 'addition', 'number', 'members', 'election', '31 January', 'Adoption', 'auditor', 'Resolution', 'use', 'profit', 'register', '18 April', 'accordance', 'rules', '15 March', 'recommendation', 'firm', 'Econ.', 'APA', 'charge', 'office', 'Amendment', 'Articles', 'Association', 'Chapter', 'organising', 'alternative', 'purpose', 'holding', 'unexpected', 'situations', 'venues', 'Â§ Right', 'deadline', 'Espoo', 'Vantaa', 'means', 'issue', 'one', 'authorisation', 'terms', 'issuance', '4.00', '2022']",2023-02-17,2023-02-18,marketscreener.com
18694,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/METSO-OUTOTEC-OYJ-1412510/news/Metso-Outotec-Oyj-Proposals-by-the-Shareholders-Nomination-Board-and-the-Board-of-Directors-43014255/?utm_medium=RSS&utm_content=20230217,Metso Outotec Oyj : Proposals by the Shareholders' Nomination Board and the Board of Directors,(marketscreener.com)   Annual General Meeting 2023   DECISION PROPOSALS TO THE ANNUAL GENERAL MEETING OF METSO OUTOTEC CORPORATION TO BE HELD ON   MAY 3  2023   Resolution on the use of the profit shown on the balance sheet and the payment of dividâ€¦,"Annual General Meeting 2023 DECISION PROPOSALS TO THE ANNUAL GENERAL MEETING (THE ""GENERAL MEETING"") OF METSO OUTOTEC CORPORATION (THE ""COMPANY"") TO BE HELD ON MAY 3  2023 Resolution on the use of the profit shown on the balance sheet and the payment of dividend (agenda item 8) The Board of Directors proposes to the General Meeting that a dividend of EUR 0.30 per share (in the aggregate approximately EUR 248 million based on the total number of outstanding shares of the Company at the time of the proposal) be paid based on the balance sheet to be adopted for the financial year January 1 - December 31  2022  and that the remaining part of the profit for the financial year be retained and carried further in unrestricted equity. The dividend shall be paid in two instalments as follows: The first dividend instalment of EUR 0.15 per share shall be paid to the shareholders who are registered as shareholders in the Company's register of shareholders as maintained by Euroclear Finland Oy on the dividend record date  May 5  2023. The Board of Directors proposes that the first dividend instalment be paid on May 12  2023.The second dividend instalment of EUR 0.15 per share shall be paid in November 2023 to the shareholders who are registered as shareholders in the Company's register of shareholders as maintained by Euroclear Finland Oy on the dividend record date. The Board of Directors shall resolve on the dividend record date and the date of payment of the second dividend instalment in its meeting agreed to be held on October 26  2023. Based on the current rules of the Finnish book-entry system  the dividend record date would be October 30  2023  and the date of payment November 6  2023. All the shares in the Company are entitled to a dividend with the exception of own shares held by the Company on the relevant dividend record date. Adoption of the Company's remuneration report for governing bodies (agenda item 10) The Board of Directors proposes to the General Meeting that it adopts  through an advisory resolution  the Company's remuneration report for governing bodies for the year 2022. The Company's remuneration report for governing bodies will be published by a stock exchange release and will also be made available on the Company's website at www.mogroup.com/agm no later than on March 24  2023. Resolution on the remuneration of the members of the Board of Directors (agenda item 11) The Shareholders' Nomination Board proposes to the General Meeting that the members of the Board of Directors and such Board members who will be elected to the committees of the Board be paid a fixed annual remuneration as follows: EUR 164 000 for the Chair of the Board of Directors (previously EUR 156 000)  EUR 85 000 for the Vice Chair of the Board of Directors (previously EUR 82 500) and EUR 69 000 for the other members of the Board of Directors each (previously EUR 67 000)  as well as an additional EUR 24 500 for the Chair of the Audit and Risk Committee (previously EUR 23 800)  an additional EUR 10 500 for the other members of the Audit and Risk Committee each (previously EUR 10 300)  an additional EUR 12 650 for the Chair of the Remuneration and HR Committee (previously EUR 12 400)  and an additional EUR 5 250 for the other members of the Remuneration and HR Committee each (previously EUR 5 150). The Shareholders' Nomination Board proposes to the General Meeting that  as a condition for the annual remuneration  the Board members be obliged  directly based on the General Meeting's decision  to use 20 or 40 percent of their fixed total annual remuneration for purchasing Metso Outotec shares from the market at a priceAnnual General Meeting 2023 formed in public trading  and that the purchase be carried out within two weeks from the publication of the interim report for January 1 - March 31  2023 on May 3  2023. The Shareholders' Nomination Board further proposes to the General Meeting that the members of the Board of Directors be paid the following meeting fees for attending the meetings of the Board and its committees: EUR 900 for meetings requiring travel within the Nordic countries  EUR 1 800 for meetings requiring travel within a continent  EUR 3 000 for meetings requiring intercontinental travel  and EUR 900 for meetings with remote attendance. Resolution on the number of members of the Board of Directors (agenda item 12) The Shareholders' Nomination Board proposes to the General Meeting that the number of members of the Board of Directors shall be nine (9) (last year: nine (9)). Election of members and Chair as well as Vice Chair of the Board of Directors (agenda item 13) The Shareholders' Nomination Board proposes to the General Meeting that the following current members of the Board of Directors be re-elected as Board members for the term ending at the closing of the Annual General Meeting 2024: Brian Beamish  Klaus CawÃ©n  Terhi KoipijÃ¤rvi  Ian W. Pearce  Emanuela Speranza  Kari Stadigh  and Arja Talma. Christer Gardell and Antti MÃ¤kinen have informed the Shareholders' Nomination Board that they will not be available for re-election. The Shareholders' Nomination Board proposes that Niko PakalÃ©n and Reima RytsÃ¶lÃ¤ be elected as new Board members for the term ending at the closing of the Annual General Meeting 2024. The Shareholders' Nomination Board further proposes that the General Meeting resolves to re-elect Kari Stadigh as the Chair of the Board of Directors and Klaus CawÃ©n as the Vice Chair of the Board of Directors for the term ending at the closing of the Annual General Meeting 2024. All the candidates have given their consent to be elected and have been assessed to be independent of the Company and its significant shareholders  except for Reima RytsÃ¶lÃ¤  who has been assessed to be independent of the Company but not independent of its significant shareholder. More information on the nominees is available on the Company's website at www.mogroup.com/agm. Resolution on the remuneration of the auditor (agenda item 14) On the recommendation of the Audit and Risk Committee  the Board of Directors proposes to the General Meeting that the Auditor's fees be paid according to the Auditor's reasonable invoice approved by the Company. Election of the auditor (agenda item 15) On the recommendation of the Audit and Risk Committee  the Board of Directors proposes to the General Meeting that authorized public accountants Ernst & Young Oy be re-elected as the Company's Auditor for a term ending at the closing of the Annual General Meeting 2024. Ernst & Young Oy has announced that Mikko JÃ¤rventausta  APA  would continue as the principally responsible auditor. Change of the Company's business name (agenda item 16) The Board of Directors proposes that Article 1 of the Articles of Association be amended to change the business name of the Company to ""Metso"". In its amended form  said provision of the Articles of Association would read as follows: ""1 Â§ Business name and domicileAnnual General Meeting 2023 The business name of the Company is Metso Oyj in Finnish and Metso Corporation in English. The domicile of the Company is Helsinki."" Amendment of Article 10 of the Articles of Association (agenda item 17) The Board of Directors proposes that Article 10 of the Articles of Association be amended to enable holding a general meeting entirely without a meeting venue as a so-called remote meeting in addition to the Company's domicile (Helsinki)  Espoo or Vantaa. In its amended form  said provision of the Articles of Association would read as follows: ""10 Â§ Time and place of the meeting and advance notice In order to attend the General Meeting a shareholder shall give an advance notice to the Company prior to the end of the advance notice period set out in the notice convening the meeting. The last day for advance notice may be assigned to be no earlier than ten days before the meeting and it may not be assigned to be on a Sunday  Saturday  Midsummer's Eve  Christmas Eve  New Year's Eve or any other public holiday. The General Meeting may be held in the domicile of the Company  Espoo or Vantaa. In addition  the Board of Directors may resolve on organizing the General Meeting without a meeting venue whereby the shareholders have the right to exercise their power of decision in full in real time during the meeting using telecommunication connection and technical means."" The proposal regarding the meeting venue is based on the changes to Chapter 5 of the Finnish Companies Act  including the possibility to arrange general meetings remotely. The legislative changes are based on the premise that  irrespective of the chosen general meeting format  shareholders' rights must not be compromised and that all participating shareholders can exercise their shareholder rights in full in real time  including the right to present questions and vote. The possibility to organize general meetings remotely enables the Company to prepare for rapid changes in the Company's operating environment and society in general  which may be caused  for example  by pandemics. It is important that the Company has the necessary means to offer its shareholders the possibility to exercise their shareholder rights and resolve on any matters that are presented in a general meeting under any circumstances. In addition  the possibility to organize a general meeting remotely would enable the use of a more sustainable meeting form with a smaller carbon footprint. Authorizing the Board of Directors to resolve on the repurchase of the Company's own shares (agenda item 18) The Board of Directors proposes that the General Meeting authorizes the Board of Directors to resolve on the repurchase of an aggregate maximum of 82 000 000 of the Company's own shares. The proposed amount of shares corresponds to approximately 9.9 percent of all the current shares of the Company. However  the Company together with its subsidiaries cannot at any moment own more than 10 percent of all the shares of the Company. Own shares may be repurchased on the basis of this authorization only by using unrestricted equity. Own shares can be repurchased at a price formed in trading on regulated market on the date of the repurchase or otherwise at a price formed on the market. The Board of Directors is entitled to resolve how shares are repurchased. Own shares may be repurchased otherwise than in proportion to the shares held by the shareholders (directed repurchase). The authorization shall be in force until the closing of the Annual General Meeting 2024. Authorizing the Board of Directors to resolve on the issuance of shares and the issuance of special rights entitling to shares (agenda item 19) The Board of Directors proposes that the General Meeting authorizes the Board of Directors to resolve on the issuance of shares and the issuance of special rights entitling to shares referred to in Chapter 10  Section 1 of the Finnish Limited Liability Companies Act as follows: The number of shares to be issued on the basis of this",neutral,0.0,1.0,0.0,neutral,0.0,0.99,0.0,True,English,"['Metso Outotec Oyj', ""Shareholders' Nomination Board"", 'Proposals', 'Directors', 'relevant dividend record date', 'price Annual General Meeting', 'fixed total annual remuneration', ""The Shareholders' Nomination Board"", 'first dividend instalment', 'second dividend instalment', 'Euroclear Finland Oy', 'Finnish book-entry system', 'stock exchange release', 'Klaus CawÃ©n', 'Terhi KoipijÃ¤rvi', 'Ian W. Pearce', 'Antti MÃ¤kinen', 'fixed annual remuneration', 'following meeting fees', 'Metso Outotec shares', 'following current members', 'The Board', 'OUTOTEC CORPORATION', 'current rules', 'total number', 'The Company', 'balance sheet', 'remaining part', 'unrestricted equity', 'two instalments', 'remuneration report', 'governing bodies', 'Risk Committee', 'HR Committee', 'public trading', 'two weeks', 'interim report', 'Nordic countries', 'remote attendance', 'Brian Beamish', 'Emanuela Speranza', 'Kari Stadigh', 'Arja Talma', 'Christer Gardell', 'agenda item', 'outstanding shares', 'financial year', 'last year', 'other members', 'DECISION PROPOSALS', 'Board members', 'Vice Chair', 'intercontinental travel', 'advisory resolution', 'MAY', 'use', 'profit', 'payment', 'Directors', 'aggregate', 'time', 'December', 'register', 'November', 'October', 'exception', 'Adoption', 'website', 'March', 'committees', 'Audit', 'condition', '40 percent', 'market', 'purchase', 'publication', 'January', 'meetings', 'Election', 'term', 'closing', '20']",2023-02-17,2023-02-18,marketscreener.com
18695,Euroclear,NewsApi.org,https://www.prnewswire.com/news-releases/notice-convening-the-annual-general-meeting-2023-of-essity-aktiebolag-publ-301749900.html,Notice convening the Annual General Meeting 2023 of Essity Aktiebolag (publ),"STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- Notice is given to the shareholders of Essity Aktiebolag (publ) Reg. No. 556325-5511 (""Essity"") of the Annual General Meeting to be held on Wednesday  29 March 2023 at 3 p.m. at Stockholm Waterfront Congress Centre  Niâ€¦","STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- Notice is given to the shareholders of Essity Aktiebolag (publ) Reg. No. 556325-5511 (""Essity"") of the Annual General Meeting to be held on Wednesday  29 March 2023 at 3 p.m. at Stockholm Waterfront Congress Centre  Nils Ericsons Plan 4  Stockholm (registration from 2 p.m.)The shareholders also have the opportunity to exercise their voting rights by voting in advance (so-called postal voting) ahead of the Annual General Meeting. Shareholders may thereby choose to exercise their voting rights at the Annual General Meeting 2023 by attending in person  through a proxy or by advance voting as instructed below.A. Right to participate at the MeetingShareholders who wish to participate in the Annual General Meeting mustbe listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB as of Tuesday  21 March 2023 ; and; and give notice of its intention to participate in the Meeting in accordance with the instructions set out in section ""B. Notice of participation at the meeting venue in person or by proxy""no later than Thursday  23 March 2023   or by submitting its advance vote in accordance with the instructions under section ""C. Advance voting"" no later than Thursday  23 March 2023 .For shareholders who have their shares registered through a bank or other nominee  the following applies in order to be entitled to participate in the Meeting. In addition to giving notice of participation  such shareholder must re-register its shares in its own name so that the shareholder is listed in the presentation of the share register as of the record date Tuesday  21 March 2023. Such re-registration may be temporary (so-called voting rights registration)  and request for such voting rights registration shall be made to the nominee in accordance with the nominee's routines  at such a time in advance as decided by the nominee. Voting rights registration that has been made by the nominee no later than Thursday  23 March 2023  will be considered in the presentation of the share register.B. Notice of participation at the meeting venue in person or by proxyA person who wishes to participate at the meeting venue in person or by proxy must give notice to the company as instructed below:by telephone +46 8 402 90 80  weekdays between 8 a.m. and 5 p.m.    on the company website www.essity.com by mail to Essity Aktiebolag (publ)  ""Annual General Meeting""  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden   or  or by email to [email protected]Name  personal identity number/corporate registration number  address and telephone number  and number of accompanying persons (no more than two)  if any  should be stated when notification is given. Shareholders represented by proxy shall issue a dated written proxy for their representative signed by the shareholder. A proxy is valid one (1) year from its issue date or such longer period as set out in the proxy  however not more than five (5) years. Proxy forms are available upon request and on the company's website  www.essity.com. Anyone representing a legal entity must present a copy of the registration certificate or equivalent authorization document  not older than one (1) year  listing the authorized signatories. To facilitate registration at the Meeting  the proxy as well as the registration certificate and other authorization document should be sent to the company at the address stated above well in advance of the Meeting and no later than Thursday  23 March 2023.C. Advance votingShareholders may exercise their voting rights at the Annual General Meeting by voting in advance  so-called postal voting. A person who wishes to attend the meeting venue in person or by proxy must however give notice in accordance with the instructions under section ""B. Notice of participation at the meeting venue in person or by proxy"" above. This means that a notice of participation only through advance voting is not sufficient for shareholders who wish to attend the meeting venue.A special form must be used for the advance vote. The form is available on Essity's website  www.essity.com. Submission of the form in accordance with the instructions set out below is considered as notice of participation in the Annual General Meeting. The completed form must be received by Euroclear Sweden AB no later than Thursday  23 March 2023. The completed form may be sent to Essity Aktiebolag (publ)  ""Annual General Meeting""  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden. A completed form may also be submitted electronically. Electronic submission can be made either through verification with BankID in accordance with instructions at https://anmalan.vpc.se/euroclearproxy  or by sending the completed form by email to [email protected]. Electronic submission must be made no later than Thursday  23 March 2023.Shareholders may not provide specific instructions or conditions to the advance vote. If so  the entire advance vote is invalid. Further instructions and conditions can be found in the advance voting form.Shareholders submitting their advance vote by proxy must issue a dated written proxy for their representative signed by the shareholder  which must be enclosed with the advance voting form. A proxy is valid one (1) year from its issue date or such longer period as set out in the proxy  however not more than five (5) years. Proxy forms are available upon request and on the company's website  www.essity.com. If the shareholder is a legal entity  a registration certificate or equivalent authorization document  not older than one (1) year  listing the authorized signatories shall be appended to the advance voting form.Proposed agenda1. Election of Chairman of the Meeting.2. Preparation and approval of the voting list.3. Election of two persons to check the minutes.4. Determination of whether the Meeting has been duly convened.5. Approval of the agenda.6. Presentation of the annual report and the auditor's report and the consolidated financial statements and the auditor's report on the consolidated financial statements and the auditor's statement regarding whether the guidelines for remuneration for the senior management have been complied with.7. Resolutions ona. adoption of the income statement and balance sheet  and of the consolidated income statement and the consolidated balance sheet;b. appropriations of the company's earnings under the adopted balance sheet and record date for dividend; andc. discharge from personal liability of the Board of Directors and the President for 2022.8. Resolution on the number of directors and deputy directors.9. Resolution on the number of auditors and deputy auditors.10. Resolution on remuneration for the Board of Directors and the auditor.11. Election of directors and deputy directors.Re-election ofa. Ewa BjÃ¶rlingb. PÃ¤r Bomanc. Annemarie Gardshold. Magnus Grothe. TorbjÃ¶rn LÃ¶Ã¶ff. Bert Nordbergg. Barbara Milian ThoralfssonNew election ofh. Maria Carelli. Jan Gurander12. Election of Chairman of the Board of Directors.13. Election of auditors and deputy auditors.14. Resolution on approval of the Board's report on remuneration for the senior management.15. Resolution on cash-based incentive program.16. Resolution on authorisation for the Board of Directors to resolve ona. acquisition of own shares; andb. transfer of own shares on account of company acquisitions.Proposal for resolution under Item 1The Nomination Committee proposes attorney-at-law Carl SvernlÃ¶v as Chairman of the Meeting.Proposal for resolution under Item 2The voting list proposed to be approved is the voting list prepared by Euroclear Sweden AB on behalf of Essity  based on the Annual General Meeting's share register  shareholders having given notice of participation and being present at the meeting venue and received advance votes.Proposal for resolution under Item 7.bThe Board of Directors proposes a dividend for the financial year 2022 of SEK 7.25 per share. As record date for the dividend  the Board of Directors proposes Friday  31 March 2023. If the Meeting resolves in accordance with this proposal  the dividend is expected to be distributed by Euroclear Sweden AB on Wednesday  5 April 2023.Proposal for resolution under Item 8â€“13The Nomination Committee proposes the following:The number of directors shall be nine with no deputy director.The number of auditors shall be one with no deputy auditor.The remuneration to each director elected by the Annual General Meeting and who is not employed by the company shall amount to SEK 875 000 and the Chairman of the Board of Directors is to receive SEK 2 625 000 . Members of the Remuneration Committee are each to receive an additional remuneration of SEK 130 000   while the Chairman of the Remuneration Committee is to receive an additional remuneration of SEK 155 000 . Members of the Audit Committee are each to receive an additional remuneration of SEK 300 000   while the Chairman of the Audit Committee is to receive an additional remuneration of SEK 425 000 . Members of the Portfolio Development Committee are each to receive an additional remuneration of SEK 300 000   while the Chairman of the Portfolio Development Committee is to receive an additional remuneration of SEK 425 000 . Remuneration to the auditor is to be paid according to approved invoice.and the Chairman of the Board of Directors is to receive . Members of the Remuneration Committee are each to receive an additional remuneration of   while the Chairman of the Remuneration Committee is to receive an additional remuneration of . Members of the Audit Committee are each to receive an additional remuneration of   while the Chairman of the Audit Committee is to receive an additional remuneration of . Members of the Portfolio Development Committee are each to receive an additional remuneration of   while the Chairman of the Portfolio Development Committee is to receive an additional remuneration of . Remuneration to the auditor is to be paid according to approved invoice. Re-election of the directors Ewa BjÃ¶rling  PÃ¤r Boman  Annemarie Gardshol  Magnus Groth   TorbjÃ¶rn LÃ¶Ã¶f  Bert Nordberg and Barbara Milian Thoralfsson and new election of Maria Carell and Jan Gurander. BjÃ¸rn Gulden  Louise Svanberg and Lars Rebien SÃ¸rensen have declined re-election.Maria Carell  born 1973  has since 2017 been the President and CEO of RG  an esthetics and skincare specialized company based in Dallas  USA. She is a Swedish citizen and has lived in the USA since 2012. Maria Carell has a solid pharmaceutical and med-tech background including previous leading positions in i.a. Exeltis  Meda  Q-MED  Actavis  Novartis and Jensen-Cilag. She has served as a board member in several companies during the last 20 years but today only has a board assignment in RG Holdco. Maria Carell has a M.Sc. in Business Administration and Economics with focus on international business.Jan Gurander  born 1961  was during 2016-2022 deputy CEO in the Volvo Group and was also CFO for the Volvo Group during 2014-2018. He is a Swedish citizen. Jan Gurander has experience from leading positions in listed large international industrial companies and from the financial sector  such as MAN  Volvo Cars  Swedbank Robur  Scania and Investor. Today he has a board assignment in one listed company (Skanska)  where he is also serving as a member in all of the board committees. Jan Gurander has a M.Sc. in Business and Economics from Stockholm School of Economics.Re-election of PÃ¤r Boman as Chairman of the Board of Directors.Re-election of the registered accounting firm Ernst & Young AB  in accordance with the Audit Committee's recommendation  for the period until the end of the Annual General Meeting 2024. If elected  Ernst & Young AB has announced its appointment of Erik SandstrÃ¶m as auditor in charge.Proposal for resolution under Item 15The Board of Directors proposes that the Annual General Meeting 2023 resolves to approve a cash-based incentive program which is directed to senior management as well as certain other executives and key employees in Essity (the ""Program"") as follows. In order to encourage a common interest for the participants and the shareholders of long-term good return and the company's ability to recruit and retain key employees  the Board of Directors considers that the company shall have cash-based incentive programs. Such programs should be approved annually and have performance conditions related to (i) the relative value development of Essity's class B share  and (ii) reduction of greenhouse gas emissions. The Board of Directors also considers that there should be a requirement for the participants' own investment in Essity shares and that such shares should be held for a period of at least three years. It is noted that the Program is exclusively cash-based and does not result in any dilution or other impact on the rights of the shares.Essity has for a number of years resolved on similar cash-based programs  which are described in the company's Annual and Sustainability Report and in the remuneration report approved by the Annual General Meeting 2022. The Board of Directors' assessment is that these programs have worked very well.Against this background  the Board of Directors proposes that the Annual General Meeting 2023 resolves on a cash-based incentive program  as further described below.Principal terms and conditions of the ProgramThe proposed Program for 2023â€“2025 shall be based on the following principal terms and conditions.a. The Program is proposed to be open to senior management as well as certain other executives and key employees in the Essity group  a total of approximately 380 persons (the ""Participants"").b. The Participants shall have the opportunity  depending on satisfaction of certain performance conditions in accordance with paragraph (c) below  to obtain a cash remuneration (the ""Cash Remuneration"") after the end of a measurement period which covers the years 2023â€“2025 (the ""Measurement Period""). The Cash Remuneration for each Participant may not exceed a certain percentage of the Participant's fixed annual salary (gross) for 2025  as follows: (i) for the President  a maximum of 50 per cent  (ii) for other members of the senior management  a maximum of 80 per cent and (iii) for other Participants  a maximum of 50 per cent. The maximum variable remuneration level shall be determined per individual  taking into account the total remuneration in relation to the specific role  the local market  the terms of employment or the individual performance.c. Payment of the Cash Remuneration shall depend on the degree on satisfaction of the following performance conditions for the Program under the Measurement Period:i. A financial target consisting of the total shareholder return (""TSR"") on the company's class B share under the Measurement Period in relation to a benchmark group of other companies (the ""TSR Condition"").[1] The benchmark group shall to 60 per cent consist of companies which are comparable with the operations in the company's business area Consumer Goods and to 20 per cent each consist of companies that are comparable with the operations in the business area Health & Medical and Professional Hygiene  respectively.[2]A condition for payment is that the TSR of Essity's class B share is not lower than the weighted TSR outcome for the benchmark group under the Measurement Period (the ""TSR Minimum Level""). If the TSR Minimum Level is not reached  no payment of Cash Remuneration related to the TSR Condition will be made. For maximum payment (100 per cent)  it is required that the TSR of Essity's class B share exceeds the weighted TSR outcome for the Benchmark Group with at least 5 percentage points during the Measurement Period (the ""TSR Maximum Level""). Should the TSR of Essity's class B share be between the TSR Minimum Level and the TSR Maximum Level during the Measurement Period  a linear payment will be made.ii. A sustainability target related to the company's reduction of greenhouse gas emissions during the Measurement Period (the ""Sustainability Condition"").[3]A condition for payment of Cash Remuneration related to Sustainability Condition is that the company reduces greenhouse gas emissions during the Measurement Period by at least 7.5 per cent compared to the base year 2016 (the ""Sustainability Target""). If the Sustainability Target is reached  full payment of Cash Remuneration relating to the Sustainability Condition will be made. If the Sustainability Target is not reached  no payment relating to this target will be made.iii. The TSR Condition will be weighted 80 per cent and the Sustainability Condition 20 per cent  when payment of the Cash Remuneration is decided.d. Cash Remuneration will normally be paid only after the expiration of the Measurement Period and shall in general not qualify for the basis for pension computation.e. Participants shall normally be invited to the Program during the first year of the Program. A prerequisite for a Participant to be able to receive full Cash Remuneration  is that the Participant has been permanently employed withing the Essity group throughout the Measurement Period. If a Participant has commenced its employment within the Essity group during the Measurement Period  the payment of Cash Remuneration shall be made pro rata.f. Each Participant shall undertake  for as long as the Participant is employed within the Essity group  to acquire Essity shares for (i) the total paid net amount of the Cash Remuneration regarding senior management  and (ii) at least half the total paid net amount regarding other Participants  no later than 30 June 2026 (or as soon as possible thereafter if the Participant has been prevented from acquiring Essity shares at such time due to applicable insider rules)  and to retain such shares for a period of at least three years after the acquisition  with certain exemptions approved by the Board of Directors. If a Participant does not acquire or retain Essity shares in accordance with the above  the Participant's right to payment under future incentive programs to which the Participant has been invited to participate  shall lapse.g. If extraordinary changes in the Essity group or in the market occur which  in the opinion of the Board of Directors  would result in a situation where the conditions for Cash Remuneration under the Program become unreasonable  the Board of Directors shall be entitled to make adjustments to the Program  including  among other things  be entitled to resolve on a reduced right to Cash Remuneration  or that no Cash Remuneration shall be paid at all.h. The Board of Directors shall be authorized to establish the detailed terms and conditions for the Program. The Board of Directors may  in that regard  make necessary adjustments of these general terms and conditions due to changed circumstances or to satisfy certain regulations or market conditions outside Sweden.i. Participation in the Program presupposes that such participation is legally possible in the various jurisdictions concerned.Measurement Period and vesting periodThe Measurement Period for the performance conditions under the proposed Program will cover the financial years 2023â€“2025. The intention of the Board of Directors is that also future programs shall have a measurement period of three years. In order to receive full Cash Remuneration  employment within the Essity group throughout the vesting period is required. Further  the vesting period  which is three years  shall be combined with a requirement that the Participant must undertake to acquire and hold Essity shares for at least a three-year period after the acquisition  in accordance with above. Required long-term nature of the Program is achieved by the above stated requirements which totals six years.Costs for the Program  dilution  etc.The cost for the Program  including social security charges  including approximately 380 employees  amounts to a maximum of SEK 260 million assuming 100 per cent satisfaction of all of the performance conditions for all Participants in the Program. The cost of the Program amounts to a maximum of 1.7 per cent of Essity's total cost for salaries and remuneration  including social security charges.The Program is cash-based and does not entail any dilution for the company's shareholders. No hedging arrangements are intended to be made with regard to the Program's financial exposure.Preparations of the proposalThe proposed Program has been prepared by Essity's Remuneration Committee. The Remuneration Committee has presented documentation to the Board of Directors  whereafter the Board of Directors has resolved that the Program shall be referred to the Annual General Meeting 2023 for approval.Majority requirementsThe Annual General Meeting's resolution on approval of the Program requires a simple majority of the votes cast.Previous incentive programs in EssityThe company's other incentive programs are described more in detail in Essity's report on remuneration for 2022  which is included in the company's Annual and Sustainability Report 2022 and available on the company's website  www.essity.com.Proposal for resolution under Item 16The Board of Directors makes the assessment that it would be advantageous for the company to be able to adapt the capital structure and to be able to acquire own shares to be used as payment or financing on account of company acquisitions and thereby contribute to increased shareholder value. Hence  the Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to resolve on acquisition and transfer of own class B shares mainly as follows.a. Acquisition of own sharesAcquisition of class B shares shall be made on Nasdaq Stockholm at a price within the at each time prevailing price interval for the share on the marketplace  meaning the interval between the highest purchase price and the lowest selling price. Payment for the shares shall be made in cash. The authorisation may be utilised on one or several occasions until the Annual General Meeting 2024. A maximum of so many class B shares may be acquired that Essity's holding at each time amount to a maximum of 10 per cent of the total number of outstanding shares in Essity.The Board of Directors has issued a statement pursuant to Chapter 19  Section 22 of the Swedish Companies Act.b. Transfer of own shares on account of company acquisitionsTransfer of class B shares may be made on Nasdaq Stockholm  as well as outside of Nasdaq Stockholm  with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind or set-off rights. The shares may be used as payment upon acquisition of companies or businesses or as to finance acquisition of companies or businesses. Transfer may be made of the maximum number of shares held by Essity at the time of the Board of Directors' resolution. The authorisation may be utilized on one or several occasions until the Annual General Meeting 2024. Transfer upon acquisition of companies or businesses may be made at a minimum price per share corresponding to an amount in close connection with the price of the company's class B shares on Nasdaq Stockholm at the time of the decision of transfer. Transfers made on Nasdaq Stockholm to finance acquisition of companies or businesses may be made at a price within the each time prevailing price interval of the share.The purpose of the authorisation to acquire shares in the company is to be able to adapt the company's capital structure and to be able to use repurchased shares in connection with the potential company acquisitions and thereby contribute to increased shareholder value. The purpose of the authorisation to transfer own shares is to give the Board of Directors increased flexibility when financing company acquisitions. The reason for deviation from the shareholders' preferential rights is to create alternative forms of payment upon acquisition of companies or businesses.Majority requirementsThe Meeting's resolution under Item 16 requires that shareholders representing at least two-thirds of the votes cast as well as of the shares represented at the Meeting approve the resolution.The Nomination CommitteeThe Nomination Committee for the Annual General Meeting 2023 is composed of Helena Stjernholm  AB IndustrivÃ¤rden  the Chairman of the Nomination Committee  Anders Oscarsson  AMF and AMF Fonder  Ola Peter Krohn Gjessing  Norges Bank Investment Management  Marianne Nilsson  Swedbank Robur Fonder and PÃ¤r Boman  Chairman of the Board of Essity.Shares and votesThe total number of shares in the company amounts to 702 342 489 shares  of which 61 158 914 are class A shares and 641 183 575 are class B shares  representing a total of 1 252 772 715 votes. The class A share carries ten votes  and the class B share carries one vote. No shares are held by Essity. The information pertains to the circumstances as per the time of issuing this notice.Additional informationThe financial statements  the auditor's report  the Board of Directors' complete proposals including the Board of Directors' statements pursuant to Chapter 18  Section 4 and Chapter 19  Section 22 of the Swedish Companies Act  the Board of Directors' report on remuneration pursuant to Chapter 8  Section 53 a of the Swedish Companies Act  and the auditor's statement pursuant to Chapter 8  Section 54 of the Swedish Companies Act regarding the remuneration guidelines for the senior management  will be available at the company and on the company's website  www.essity.com  no later than Wednesday  8 March 2023. Information about the proposed board members and the proposed auditor  the Nomination Committee's statement  proxy forms  and forms for advance voting are available on the company's website  www.essity.com. The documents will be distributed free of charge to shareholders who so request and state their address and will be available at the General Meeting.The Board of Directors and the president shall  if any shareholder so requests and the Board of Directors believes that it can be done without material harm to the company  provide information regarding circumstances that may affect the assessment of an item on the agenda  and regarding circumstances that can affect the assessment of the company's or its subsidiaries' financial situation or the company's relation to other companies within the group.Processing of personal dataFor information on how your personal data is processed  please see https://www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdfStockholm in February 2023Essity Aktiebolag (publ)The Board of Directors[1] The calculation of TSR is done as follows. The volume weighted average price of the share during the fourth quarter 2022 is compared with the volume weighted average price of the share during the fourth quarter 2025  including dividend and other return.[2] When implementing the Program  the benchmark group comprises of the following companies. For Consumer Goods: Procter & Gamble  Kimberly-Clark  Unicharm and Ontex. For Health & Medical: Smith & Nephew  Convatec and Hartman. For Professional Hygiene: Kimberly-Clark  Ecolab and Diversey. Each company has the same significance within the respective business area. The benchmark group can be adjusted according to the Board of Directors' decision if the Board of Directors deems it appropriate.[3] The calculation of greenhouse gas emissions shall be based on the target adopted by the company according to Science Based Targets (SBTi) in Scope 1 and 2. The assessment shall be made on the basis of the actual greenhouse gas emissions within the specified classes during the Measurement Period  taking into account acquisitions or divestments made. For more information about SBTi and the company's target  see Essity's Annual and Sustainability report 2022  and www.essity.com/sustainability/why-we-do-it/science-based-targets/.For further information  please contact:Per Lorentz  Vice President Corporate Communications  +46 733 13 30 55  [email protected]Johan Karlsson  Vice President Investor Relations  +46 705 11 15 81  [email protected]The following files are available for download:https://mb.cision.com/Main/15798/3717980/1858340.pdf Notice convening the Annual General Meeting 2023 of Essity Aktiebolag (publ)SOURCE Essity",neutral,0.0,0.99,0.0,mixed,0.5,0.16,0.34,True,English,"['Annual General Meeting', 'Essity Aktiebolag', 'Notice', 'Stockholm Waterfront Congress Centre', 'Nils Ericsons Plan', 'P.O. Box', 'equivalent authorization document', 'other authorization document', 'Euroclear Sweden AB', 'personal identity number', 'Annual General Meeting', 'corporate registration number', 'C. Advance voting', 'entire advance vote', 'voting rights registration', 'postal voting', 'registration certificate', 'meeting venue', 'Reg. No.', 'share register', 'record date', 'Such re-registration', 'accompanying persons', 'issue date', 'longer period', 'five (5) years', 'legal entity', 'one (1) year', 'authorized signatories', 'anmalan.vpc', 'telephone number', 'other nominee', 'Electronic submission', 'Essity Aktiebolag', 'special form', 'completed form', 'specific instructions', 'Further instructions', 'written proxy', 'Proxy forms', 'company website', 'B. Notice', 'Feb.', 'shareholders', 'Wednesday', 'March', 'opportunity', 'A.', 'presentation', 'Tuesday', 'intention', 'accordance', 'section', 'participation', 'Thursday', 'shares', 'bank', 'order', 'addition', 'name', 'request', 'routines', 'time', '8 a', 'mail', 'publ', 'address', 'notification', 'dated', 'representative', 'Anyone', 'copy', 'verification', 'euroclearproxy', 'conditions', '3', '2']",2023-02-17,2023-02-18,prnewswire.com
18698,Euroclear,Twitter API,Twitter,NCUA rejects North Dakota credit unions' bid to recoup funds #AAA Websites Euroclear Fintech https://t.co/enkfhOrhUI #regtech,nan,NCUA rejects North Dakota credit unions' bid to recoup funds #AAA Websites Euroclear Fintech https://t.co/enkfhOrhUI #regtech,neutral,0.0,0.98,0.02,neutral,0.0,0.98,0.02,True,English,"[""North Dakota credit unions' bid"", 'NCUA', 'funds', ""North Dakota credit unions' bid"", 'NCUA', 'funds']",2023-02-17,2023-02-18,Unknown
18699,Euroclear,Twitter API,Twitter,Energy-sector lenders see enduring demand for fossil fuels #AAA Websites Euroclear Fintech https://t.co/MPNiwWu9Xe #regtech,nan,Energy-sector lenders see enduring demand for fossil fuels #AAA Websites Euroclear Fintech https://t.co/MPNiwWu9Xe #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Energy-sector lenders', 'enduring demand', 'fossil fuels', 'MPNiwWu9Xe', 'Energy-sector lenders', 'enduring demand', 'fossil fuels', 'MPNiwWu9Xe']",2023-02-17,2023-02-18,Unknown
18700,Euroclear,Twitter API,Twitter,@fuzed_ @EuroclearGroup @CEOAdam Iâ€™m trying to understand it all ðŸ˜©. Euroclear is in bed bed with Blackrock. All broâ€¦ https://t.co/wG50FJpKZs,nan,@fuzed_ @EuroclearGroup @CEOAdam Iâ€™m trying to understand it all ðŸ˜©. Euroclear is in bed bed with Blackrock. All broâ€¦ https://t.co/wG50FJpKZs,positive,0.52,0.29,0.19,positive,0.52,0.29,0.19,True,English,"['bed bed', 'EuroclearGroup', 'CEOAdam', 'Blackrock', 'bed bed', 'EuroclearGroup', 'CEOAdam', 'Blackrock']",2023-02-17,2023-02-18,Unknown
18701,Euroclear,Twitter API,Twitter,Huntington plans reorganization aimed at tapping wealth opportunities #AAA Websites Euroclear Fintech https://t.co/i9WuRmejyP #regtech,nan,Huntington plans reorganization aimed at tapping wealth opportunities #AAA Websites Euroclear Fintech https://t.co/i9WuRmejyP #regtech,neutral,0.12,0.88,0.0,neutral,0.12,0.88,0.0,True,English,"['wealth opportunities', 'Huntington', 'reorganization', 'Fintech', 'regtech', 'wealth opportunities', 'Huntington', 'reorganization', 'Fintech', 'regtech']",2023-02-17,2023-02-18,Unknown
18702,Euroclear,Twitter API,Twitter,Demystifying digital transformation #AAA Websites Euroclear Fintech https://t.co/od0lcfnoX3 #regtech,nan,Demystifying digital transformation #AAA Websites Euroclear Fintech https://t.co/od0lcfnoX3 #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['digital transformation', 'AAA Websites', 'digital transformation', 'AAA Websites']",2023-02-17,2023-02-18,Unknown
18703,Deutsche Boerse,NewsApi.org,https://www.investing.com/news/stock-market-news/in-comeback-commerzbank-to-join-germanys-dax-bluechip-index-3007457,In comeback  Commerzbank to join Germany's DAX blue-chip index By Reuters,In comeback  Commerzbank to join Germany's DAX blue-chip index,"Â© Reuters. FILE PHOTO: A company logo is pictured at the headquarters of Germany's Commerzbank AG in Frankfurt  Germany  February 13  2020. REUTERS/Ralph Orlowski/File PhotoUK100 -0.10% Add to/Remove from Watchlist DJI +0.39% Add to/Remove from Watchlist DE40 -0.33% Add to/Remove from Watchlist ALVG -1.85% Add to/Remove from Watchlist CBKG -1.04% Add to/Remove from Watchlist DB1Gn +0.18% Add to/Remove from Watchlist SIEGY -0.83% Add to/Remove from Watchlist CRZBY -0.33% Add to/Remove from Watchlist LIN -0.61% Add to/Remove from Watchlist VWAGY 0.00% Add to/Remove from Watchlist WCAGY 0.00% Add to/Remove from WatchlistFRANKFURT (Reuters) - Germany's Commerzbank (ETR: ) will rejoin the on Feb. 27  Deutsche Boerse (ETR: ) announced late on Friday  marking a comeback for Germany's No. 2 lender after it was removed from the club of blue-chip companies in 2018.The return to the index comes after Commerzbank launched a major overhaul two years ago that saw thousands of job cuts and branch closures that restored profitability.""This shows that we are on the right track with our restructuring - and spurs us on to continue with the same energy "" Commerzbank AG (OTC: ) said on Twitter in response to the announcement.GRAPHIC: Commerzbank shares - https://www.reuters.com/graphics/COMMERZBANK-CFO/klpygkxdxpg/chart.pngIn 2018  Commerzbank  still partly owned by the German government after a bailout  was expelled from the DAX index to make room for a rising technology star  underscoring the declining fortunes of the nation's top banks.But that star was Wirecard AG (OTC: )  a payments company that collapsed in 2020 after a years-long fraud was exposed  embarrassing the German government and staining the nation's reputation as a safe haven investment.Following Wirecard's demise  Deutsche Boerse AG  which compiles the DAX index  revamped it to include 40 companies  rather than the previous 30  and made membership criteria tougher.Since its founding in 1988  the DAX has been Germany's answer to the in New York and the in London  with its members forming the corporate elite in one of the world's largest economies.Other members include Siemens AG (OTC: )  Volkswagen AG (OTC: )  and Allianz (ETR: ) SE.Commerzbank will replace Linde (NYSE: ) Plc  which is giving up its listing in Germany.",neutral,0.0,1.0,0.0,negative,0.0,0.11,0.89,True,English,"['DAX blue-chip index', 'comeback', 'Commerzbank', 'Germany', 'Reuters', 'Ralph Orlowski/File Photo UK100', 'safe haven investment', 'rising technology star', 'Deutsche Boerse AG', 'Siemens AG', 'Volkswagen AG', 'company logo', 'No. 2 lender', 'major overhaul', 'job cuts', 'branch closures', 'right track', 'same energy', 'German government', 'declining fortunes', 'top banks', 'payments company', 'years-long fraud', 'membership criteria', 'New York', 'corporate elite', 'largest economies', 'Watchlist DJI', 'Watchlist ALVG', 'Watchlist CBKG', 'Watchlist DB1Gn', 'Watchlist SIEGY', 'Watchlist CRZBY', 'Watchlist LIN', 'Watchlist VWAGY', 'Watchlist WCAGY', 'Wirecard AG', 'Commerzbank AG', 'blue-chip companies', 'Other members', 'Commerzbank shares', 'DAX index', '40 companies', 'Reuters', 'headquarters', 'Germany', 'Frankfurt', 'February', 'Feb.', 'ETR', 'Friday', 'comeback', 'club', 'return', 'thousands', 'profitability', 'restructuring', 'Twitter', 'response', 'announcement', 'GRAPHIC', 'COMMERZBANK-CFO', 'bailout', 'room', 'nation', 'OTC', 'reputation', 'demise', 'previous', 'founding', 'answer', 'London', 'world', 'Allianz', 'Linde', 'NYSE', 'Plc', 'listing', 'Â©']",2023-02-17,2023-02-18,investing.com
18704,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/COMMERZBANK-AG-13057331/news/In-comeback-Commerzbank-to-join-Germany-s-DAX-blue-chip-index-43022345/?utm_medium=RSS&utm_content=20230217,In comeback  Commerzbank to join Germany's DAX blue-chip index,(marketscreener.com) Germany's Commerzbank will rejoin the DAX index on Feb. 27  Deutsche Boerse announced late on Friday  marking a comeback for Germany's No. 2 lender after it was removed from the club of blue-chip companies in 2018.https://www.marketscreenâ€¦,"The return to the index comes after Commerzbank launched a major overhaul two years ago that saw thousands of job cuts and branch closures that restored profitability.""This shows that we are on the right track with our restructuring - and spurs us on to continue with the same energy "" Commerzbank AG said on Twitter in response to the announcement.In 2018  Commerzbank  still partly owned by the German government after a bailout  was expelled from the DAX index to make room for a rising technology star  underscoring the declining fortunes of the nation's top banks.But that star was Wirecard AG  a payments company that collapsed in 2020 after a years-long fraud was exposed  embarrassing the German government and staining the nation's reputation as a safe haven investment.Following Wirecard's demise  Deutsche Boerse AG  which compiles the DAX index  revamped it to include 40 companies  rather than the previous 30  and made membership criteria tougher.Since its founding in 1988  the DAX has been Germany's answer to the Dow Jones Industrial Average in New York and the FTSE in London  with its members forming the corporate elite in one of the world's largest economies.Other members include Siemens AG  Volkswagen AG  and Allianz SE.Commerzbank will replace Linde Plc  which is giving up its listing in Germany.(Reporting by Tom Sims; editing by Chris Reese and Jonathan Oatis)",neutral,0.0,1.0,0.0,negative,0.0,0.06,0.94,True,English,"['DAX blue-chip index', 'comeback', 'Commerzbank', 'Germany', 'Dow Jones Industrial Average', 'safe haven investment', 'Deutsche Boerse AG', 'rising technology star', 'Siemens AG', 'Volkswagen AG', 'major overhaul', 'job cuts', 'branch closures', 'right track', 'same energy', 'German government', 'declining fortunes', 'top banks', 'payments company', 'years-long fraud', 'membership criteria', 'New York', 'corporate elite', 'largest economies', 'Allianz SE', 'Linde Plc', 'Tom Sims', 'Chris Reese', 'Jonathan Oatis', 'Wirecard AG', 'Other members', 'Commerzbank AG', 'DAX index', 'return', 'thousands', 'profitability', 'restructuring', 'Twitter', 'response', 'announcement', 'bailout', 'room', 'nation', 'reputation', 'demise', '40 companies', 'previous', 'founding', 'Germany', 'answer', 'FTSE', 'London', 'world', 'listing']",2023-02-17,2023-02-18,marketscreener.com
18705,Deutsche Boerse,NewsApi.org,https://www.fxempire.com/news/article/in-comeback-commerzbank-to-join-germanys-dax-blue-chip-index-1288233,In comeback  Commerzbank to join Germanyâ€™s DAX blue-chip index,FRANKFURT (Reuters) -   Germany&#039;s Commerzbank will rejoin the DAX index on Feb. 27  Deutsche Boerse announced late on Friday  marking a comeback for Germany&#039;s No. 2 lender after it was removed from the club of blue-chip companies in 2018.,â€œThis shows that we are on the right track with our restructuring â€“ and spurs us on to continue with the same energy â€ Commerzbank AG said on Twitter in response to the announcement.In 2018  Commerzbank  still partly owned by the German government after a bailout  was expelled from the DAX index to make room for a rising technology star  underscoring the declining fortunes of the nationâ€™s top banks.But that star was Wirecard AG  a payments company that collapsed in 2020 after a years-long fraud was exposed  embarrassing the German government and staining the nationâ€™s reputation as a safe haven investment.Following Wirecardâ€™s demise  Deutsche Boerse AG  which compiles the DAX index  revamped it to include 40 companies  rather than the previous 30  and made membership criteria tougher.Since its founding in 1988  the DAX has been Germanyâ€™s answer to the Dow Jones Industrial Average in New York and the FTSE in London  with its members forming the corporate elite in one of the worldâ€™s largest economies.Other members include Siemens AG  Volkswagen AG  and Allianz SE.Commerzbank will replace Linde Plc  which is giving up its listing in Germany.(Reporting by Tom Sims; editing by Chris Reese and Jonathan Oatis),neutral,0.01,0.99,0.0,mixed,0.2,0.14,0.66,True,English,"['DAX blue-chip index', 'comeback', 'Commerzbank', 'Germany', 'Dow Jones Industrial Average', 'safe haven investment', 'Deutsche Boerse AG', 'rising technology star', 'Siemens AG', 'Volkswagen AG', 'right track', 'same energy', 'German government', 'declining fortunes', 'top banks', 'payments company', 'years-long fraud', 'membership criteria', 'New York', 'corporate elite', 'largest economies', 'Allianz SE', 'Linde Plc', 'Tom Sims', 'Chris Reese', 'Jonathan Oatis', 'Wirecard AG', 'DAX index', 'Commerzbank AG', 'Other members', 'restructuring', 'Twitter', 'response', 'announcement', 'bailout', 'room', 'nation', 'reputation', 'demise', '40 companies', 'previous', 'founding', 'Germany', 'answer', 'FTSE', 'London', 'world', 'listing']",2023-02-17,2023-02-18,fxempire.com
18707,Deutsche Boerse,Twitter API,Twitter,We're excited to announce #GoogleCloud's partnership with Deutsche BÃ¶rse to enhance  economize  and concentrate Deuâ€¦ https://t.co/bMOXqNJzo5,nan,We're excited to announce #GoogleCloud's partnership with Deutsche BÃ¶rse to enhance  economize  and concentrate Deuâ€¦ https://t.co/bMOXqNJzo5,positive,0.73,0.27,0.0,positive,0.73,0.27,0.0,True,English,"['Deutsche BÃ¶rse', 'partnership', 'Deutsche BÃ¶rse', 'partnership']",2023-02-17,2023-02-18,Unknown
18708,Deutsche Boerse,Twitter API,Twitter,@TintinCapital yea. the website is super good. a joke what Nasdaq or Deutsche BÃ¶rse is offering compared to this poâ€¦ https://t.co/Bla6lbZOCw,nan,@TintinCapital yea. the website is super good. a joke what Nasdaq or Deutsche BÃ¶rse is offering compared to this poâ€¦ https://t.co/Bla6lbZOCw,mixed,0.51,0.06,0.43,mixed,0.51,0.06,0.43,True,English,"['Deutsche BÃ¶rse', 'website', 'joke', 'Nasdaq', 'po', 'Bla6lbZOCw', 'Deutsche BÃ¶rse', 'website', 'joke', 'Nasdaq', 'po', 'Bla6lbZOCw']",2023-02-17,2023-02-18,Unknown
18709,EuroNext,NewsApi.org,https://finance.yahoo.com/news/evs-reports-2022-results-053000279.html,EVS REPORTS 2022 RESULTS,Publication on February 17  2023  before market openingRegulated information â€“ Press release annual resultsEVS Broadcast Equipment S.A.: Euronext Brussels...,"Publication on February 17  2023  before market openingRegulated information â€“ Press release annual resultsEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR)  Bloomberg (EVS BB)  Reuters (EVSB.BR)EVS reports 2022 resultsLiÃ¨ge  Belgium  February 17th  2023EVS delivers record revenue and order intake resultsThe results of 2022 are entirely supporting the growth ambitions of EVS. All the fundamentals for topline performance are strong: EVS realizes a record-high order intake and achieves a historical revenue number  despite the increased delivery terms in 2022. EVS is able to demonstrate a strong net profit result and as a consequence  realizes a solid Earnings Per Share.FY22 HighlightsRecord order intake at EUR 218 8 million  growing 46 5% YoY.Revenue performance in line with expectations at EUR 148 2 million  growing 7 7% vs. FY21 despite increased delivery terms announced early 2022 and despite reduced Big Event Rental (BER) activity. The growth is realized through strong growth in North America and in the MediaInfra solution.Controlled OPEX growth  in line with market expectations.Healthy net profit at EUR 31 3 million driven by a strong financial income performance and a one-off benefit in taxes  resulting in fully diluted earnings per share of EUR 2 29.2H22 HighlightsRecord order intake of EUR 130 1 million (including Big Tech 2022 contract).Revenue for the second half of 2022 at EUR 80 5 million  growing 6 1% compared to the same period last year. Big Event Rental revenue at EUR 4 2 million  down EUR 4 9 million compared to 2H21. Revenue excluding Big Event Rental at EUR 76 3 million  growing EUR 9 5 million.Net profit amounts to EUR 15 9 million  leading to fully diluted earnings per share of EUR 1 14.Outlook 2023The important order intake of 2022 has considerably fueled the order book to be delivered in future periods. The total order book at the end of 2022 is of EUR 141 8 million  growing 122% compared to last year. The order book reserved for 2023 is estimated at EUR 85 9 million  growing 68 4% compared to beginning of the year 2022.Based on the order book and current market dynamics  the revenue guidance for the year 2023 is set at EUR 145-155 million.The revenue range demonstrates the ambition of EVS to continue the organic growth  in a year with no Big Event Rental revenue.With the growth engine launched  the focus in 2023 for EVS will be on profitable growth.EVS plans no further growth in team members nor do we expect an increase in our capital expenditure envelope.We expect to pay out dividends in 2023 in line with our dividend policy  namely a base dividend per share of EUR 1 10.Story continuesKey figuresEUR millions  except earnings per share expressed in EUR 2H22 2H21 Variance FY22 FY21 Variance Revenue 80 5 75 8 4 7 148 2 137 6 10 6 Gross profit 53 0 53 2 -0 2 98 8 95 8 3 0 Gross margin % 65 8% 70 3% -4 5 Pts 66 7% 69 6% -2 9 Pts Operating profit â€“ EBIT 16 0 21 7 -5 7 31 7 37 1 -5 4 Operating margin â€“ EBIT % 19 9% 28 6% -8 7 Pts 21 4% 27 0% -5 6 Pts Net profit (Group share) 15 9 19 3 -3 5 31 3 34 9 -3 6 Fully diluted EPS (Group share) 1 14 1 42 -0 28 2 29 2 57 -0 28CommentsSerge Van Herck  CEO comments:â€œIâ€™m proud to say that 2022 was again quite a successful year for EVS. Our PlayForward strategy  as defined at the end of 2019  is starting to deliver the expected growth momentum.In 2022  we had a second record year in a row  with strong growth in revenues  order intake  and team member size. We showed significant growth in North America  announced our largest contract ever in August with the ""Big Tech 22 contractâ€ worth over 50MioUSD  and successfully fought against inflation and component shortages throughout the year.We feel we are winning market share in our Live Audience Business and protecting our position in the Live Service Providers markets. We successfully supported many of our customers in delivering the live TV production of major sports events in Asia  the Middle East  and North America.The growth of our team is clearly unlocking our sustainable growth ambitions. Our strong employer branding has enabled us to successfully hire strong talent across the world. Our team member engagement survey shows again further improvements compared to the years before  resulting in our recent â€œTop Employerâ€ certification.We are making good progress in our vision of developing a strong ecosystem relying on our VIA platform as we are successfully moving from product to solution sales. Our introduction of Artificial Intelligence (AI) in XtraMotion is a revolution in the industry and it represents a major differentiator.The Axon acquisition in May 2020 has translated into our Media Infrastructure revenue growth and positively contributes to our bottom line  demonstrating our capability to execute successfully large acquisitions. We have also launched our new ERP and upgraded our VIA Portal applications such as our customer ticketing system to support our long-term growth ambitions.In line with our commitments  we continued to deliver strong dividends for our shareholders. Our sustainability strategy has started to deliver strong results aligned with our customerâ€™s expectations  and resulting in good ESG ratings like the Ecovadis Silver medal. We completed our first carbon footprint analysis: this will be a critical management tool for taking the right sustainability decisions in the future.In conclusion  our PlayForward strategy  is clearly being appreciated by our customers and channel partners. This is helping us to get back into growth mode. While economic market conditions remain very challenging with high inflation  component shortages and with the war in Ukraine  we feel that our customers increasingly appreciate the reliability  performance and innovative edge of our solutions and services.Our ambition for the next years is to continue to deliver growth on both our top and bottomline. We are convinced that by focusing on cost control we will be able to deliver upon this promise.â€Commenting on the results and the outlook  Veerle De Wit  CFO  said:â€œOur 2022 revenue results clearly demonstrate our ability to achieve organic growth. Even despite increased delivery terms  announced early 2022  and with a declining Big Event Rental revenue  we are able to realize a strong top line performance. All indicators lead us to conclude that this organic growth is here to stay: the revenue performance  together with the strong secured revenue position for 2023  are a solid basis to continue our growth path.Being a company in growth mode  means that the necessary resources need to be invested to support this growth: 2022 has been a year where we invested in additional resources  in new product developments  and in the back-bone of our operations. This backbone  a globally released new ERP system  has allowed us to optimize our processes and refine our cost control. As a result  the granularity of our reporting is improving  which has led to a decision to write off EUR 0 7 million of Bill of Material costs in 4Q22.Our operational expenses grew in a controlled way. Control over our spending patterns remains an attention point for 2023  especially in the current volatile market.Thanks to sound treasury management and tax benefits  we are able to generate a strong Net Profit worth EUR 31 3 million  driving a diluted Earnings Per Share of EUR 2 29.Our balance sheet also remains healthy with a very low debt level and a sound cash position. Our cash position is declining throughout 2022  as a consequence of high dividends paid  and as a consequence on increased Net Working Capital requirements. The impact on Net Working Capital is temporary: the implementation of the new ERP system has created a delay in invoicing in the fourth quarter â€“ the quarter with the highest volume â€“ resulting in a large volume of receivables not due at the end of 2022. This is a temporary effect  that will normalize early in 2023  as soon as the invoices become due.Based on the strong results for the year 2022  we are able to maintain our dividend policy defined earlier in 2022.â€Market & customersThe record high numbers in terms of revenues  order intake and order book translate the market traction that EVS is living. Our main growth drivers are North America and Media Infrastructure. The performance of our MediaInfra solution clearly demonstrates the power of our acquisition strategy. It is the fruit of our investment in Axon in 2020  and this acquisition demonstrates its return on investment 2 years later.The high order intake is also thanks to our biggest contract signed in the history of EVS: our Big Tech 2022. This contract proved an exceptional milestone in the history of EVS. This contract is a 10-year agreement that covers the delivery of EVSâ€™ live production  replay and highlight solutions LiveCeptionÂ®  combined with a long-term services level agreement. The contract provides our US based customer access to the latest technology innovations for the next 10 years  a full upgrade of its installed base  a predictable operational spend and an ease of operations.2022 was a year with important Big Events  that EVS was able to support successfully. New solutions  like MediaHub and MediaInfra Strada  were introduced in our Big Event Rental business with success.Market conditions have been challenging throughout the year  with volatile interest rates  inflation and a continued erratic components market. This volatile market has urged EVS to implement a systemic price increase policy. Twice a year the sales prices are evaluated based on the underlying cost for components and inflation of labour cost. EVS has introduced 2 price increases in 2022: a first one in February 2022  and a second one in September 2022. The price increase policy aims to guarantee the overall profitability of the solutions of EVS.The erratic components market also forced EVS to extend its delivery periods early 2022 and to change the supply chain approach. However  as most components suffer longer lead-times  EVS has pro-actively invested in inventory to ensure these delivery terms are met.EVS has received many awards in 2022  and this for different business dimensions. Ranging from technology awards (Neuron Protect Best of Show Award at the NAB Show)  to Wallonia International Business Awards  to IABM Environmental Sustainability award  to Top Employer Certification 2023.Three years after the PLAYForward strategic exercise that has moved the focus from products to solutions  we can confidently say that this solution driven approach is highly appreciated by our customers and contributes to the differentiation reflected in the order book.TechnologiesDuring 2022  new generation of AI products did surface on the market. EVS continues to invest in the development of specific machine learning algorithms for broadcast specific components and also integrates in parallel existing AI technologies or libraries inside the solution portfolio or the workflows deployed for our customers.EVS also further developed and evangelized this year the concept of â€œBalanced computingâ€ as the best distribution of the computing workload between on-prem  datacenter and public cloud based on the economic benefits and the technical constraints for a specific workflow. This concept has been well received by the market where some players start to discover the limitations in terms of feature and the significant impact on Total Cost of Ownership for the production of premium events.EVS also currently invests in the development of important solution components that will be later embraced in the different solutions. Thanks to the capability to track the benefits brought by these components in the future  these developments are activated. These developments will contribute to the future sustainable growth of EVS.Corporate topics2022 marks the moment where the Axon acquisition really starts to pay off for EVS. The initial assumptions made in terms of greographical expansion of the market are becoming a reality. Also the developments made to ensure end-to-end integration with EVS products demonstrate the complementarity of this company within the EVS portfolio. It comforts us in our Acquisition strategy and our ability to integrate companies.One of the axes of the PLAYforward strategy is improving our internal way of working. As a company we want to ensure that we have efficient processes in place that promote end-to-end collabration across all our departments. Having an efficient operational back-bone is important in that context. In October 2022  EVS launched a new global ERP system to ensure optimimal functioning of our company. The launch was a success and did not cause any major business interruption: shipping  production and support were active as of day 1. We now have a solid base to continously optimize our processes and ensure an optimal team member and customer experience.Speaking about improved processes  2022 is also the year where we first implemented a systemic listprice adjustment. The market conditions require a clear methodology to offset the impact of rising component prices and increasing inflation over labour costs. EVS now evaluates the need for price adjustments twice a year to protect the margin generation of the company.2022 is also the year where we continue to expand our sustainability efforts in terms of ESG. After a first hollistic report published in 2021  we continue to structure our efforts in terms of sustainability. Our current ESG strategy and reporting has already received postive feedback from the market: we received a silver medal from Ecovadis  obtained encouriging score from other rating companies and recently obtained the certification of Top Employer for 2023. By the end of 2022  we also realized our first EVS Carbon Footprint analysis: it provides us not only insight on our direct and indirect CO2 emissions  but most importantly  helps us to define our roadmap to reduce our carbon footprint in the future.EVS also reinvented the way it collaborates with its channel partners. A structured channel partner program has been developed  focused on sustainable relationships with partners more than on opportunistic market responses  starting to develop certification paths and clear objectives. This program allows EVS to reach a broader set of clients and even penetrate new markets.Being a company in growth mode  EVS further invested in additional team members. Additional resources were primarily allocated to support and operations roles  as to fuel our future growth  and some research and development resources  as to staff some important developments ensuring future growth. Thanks to a strong employer branding  EVS was able to attract this high number of talents in a relatively short time frame.Also to support our future growth ambition  EVS further strengthened its leadership team  early 2022. A new CTO  Alex Redfern  was welcomed and Xavier Orri was named EVP of Projects & Operations.Revenue in 2H22 and FY22In 2H22  EVS revenue reached EUR 80 5 million: an increase of EUR 4 7 million or 6 2% compared to 2H21  despite a drop of EUR 4 2 million on Big Event Rentals.At constant currency  revenue decreased by 1.6% YoY.Revenue â€“ EUR millions 2H22 2H21 2H22/2H21 Total reported 80 5 75 8 6 0% Total at constant currency 74 7 75 8 -1.6% Total at constant currency and excluding big event rentals 70 5 66 8 5.6%For the full year 2022  EVS revenue reached EUR 148 2 million: an increase of EUR 10 6 million or 7 7% compared to 2021  despite a drop of EUR 3 7 million on Big Event Rentals and despite an increased delivery term announced early 2022. This performance demonstrates the organic growth realized in 2022.At constant currency  revenue increased by 3 5% YoY.Revenue â€“ EUR millions FY22 FY21 FY22/FY21 Total reported 148 158 137 578 7 7% Total at constant currency 142 382 137 578 3.5% Total at constant currency and excluding big event rentals 132 532 124 044 6.8%Currency fluctuations primarily impact EVS revenues by the EUR/USD conversion  which can have a significant impact on our results even if EUR/USD fluctuations also impact the cost of our US operations and partially our cost of goods sold.In the second half of the year  (excl. Big Event Rentals) LSP represented 40% (31% in 2H21) of the revenue  LAB 55% (57% in 2H21).Geographically  revenues (excl. Big Event Rentals) are distributed in 2H22 as follows:Europe  Middle East and Africa (EMEA): EUR 39 1 million (EUR 31 7 million in 2H21)Americas (NALA): EUR 25 9 million (EUR 21 7 million in 2H21)Asia & Pacific (APAC): EUR 11 3 million (EUR 13 4 million in 2H21)  impacted by the slowdown in the region following COVID implications (primarily in China). The order intake for APAC in 2H22 do recomfort us that this trend can be reversed.Overall 2022 resultsConsolidated gross margin was at 66 7% for FY22  compared to 69 6% in FY21 (-2 9 Pts) explained by different drivers:Important investments in the operations & support department to ensure we continue to deliver quality support all over the world  in line with our growth patterns (representing -1 4 Pts)Impact of the change in solution mix is representing -1.1 Pts following the relative weight of Media Infrastructure in the overall portfolio.Write-off worth EUR 0 7 million linked to bill of material costs  following more granuler inventory reporting thanks to optimized processes in our new ERP (-0 4 Pts)In order to maintain gross profit levels  the impact of cost price increases and inflation have been systematically modeled by corresponding sales price increases. This has resulted primarily in improved margins for our Media Infrastructure and MediaCeption solutions.Operating expenses increased by 11% YoY (remaining below the guidance provided) explained by inflation on labour cost and energy prices and post-COVID spending patterns impacting spend for travel  marketing  â€¦ EVS did also invest in additional Research & Development resources in 2022  both through internal engagements as well as external contracts. These additional resources were staffed on 2 important developments  recognized as intangible assets in 2022. The associated spend was therefore capitalised on the balance sheet.Overall EBIT performance is of EUR 31 7 million  generating an EBIT margin of 21 4%.The net profit ends at EUR 31 3 million benefiting from a strong financial income following pro-active cash flow management and low income taxes (EUR 1 4 million compared to EUR 2 8 million last year) resulting from an excess in tax paid in 2021 and various tax latencies linked to prior years.The net profit leads to a fully diluted earnings per share of EUR 2 29 (versus EUR 2 57 in 2021).Overall second half 2022 resultsThe gross profit margin in 2H22 was of 65 9% compared to 70 3% in the same period last year. The drop is a consequence of lesser revenue from Big Event Rentals and a higher weight of Media Infrastructure solution in the overall mix. In addition  the impact of the hirings done in 2022 to ensure continued quality operations and support affect the comparison.Operating expenses grew 13.8% in 2H22  compared to the same period last year and are a reflection of post-COVID spending patterns and impact of inflation.The 2H22 EBIT margin was 19 8%  compared to 28 6% in 2H21: the EBIT margin is dropping primarily following investments in the past 12 months to support our growth pattern.The Group net profit amounted to EUR 15 9 million in 2H22  compared to EUR 19 3 million in 2H21. Fully diluted earnings per share amounted to EUR 1 14 in 2H22 compared to EUR 1 42 in 2H21.Team membersAt the end of 2022  EVS employed 613 team members (FTE). This is an increase by 62 team members compared to the end of 2021 (551 FTE). This increase in team members reflects our continued investments in the growth of EVS. We expect no further growth of our team member base in 2023  and we will ensure that we balance the priorities of EVS with the existing workforce.Balance sheet and cash flow statementEVS continues to have a strong balance sheet with net cash position of EUR 33 8 million with low debt level (of which EUR 12 5 million related to IFRS 16) resulting in a total equity representing 75 4% of the total balance sheet as of the end of 2022. The decrease in cash and cash equivalents (EUR -23 1 million) compared to end of 2021 is mainly driven by the dividends paid in May and November (including exceptional additional dividend)  combined with the increase in working capital requirements at the end of 2022.The working capital requirements are growing  primarily linked to growing trade receivables. The trade receivables evolve largely in line with our overall sales volumes. 71% of our trade receivables is not due at year-end  with a large volume of invoices issued in the second half of the fourth quarter  given a temporary hold of invoicing operations after the Go-Live of our new ERP system. We expect these trade receivales to restore in 1Q23. A sound cash position remains a priority for EVS.Other intangible assets include the costs for internal development capitalized during 2022 according to IAS 38 (Intangible assets).Lands and building mainly include the headquarters in LiÃ¨ge as well as the right of use for the offices abroad (IFRS16).Inventories amount to EUR 28 8 million  an increase of EUR 2 8 million compared to the beginning of the year as a reflection of a pro-active supply chain management to ensure we systematically meet our customersâ€™ delivery terms.Liabilities include EUR 15 3 million of financial debt (including long term and short-term portion)  mainly related to the lease liabilities for EUR 12 5 million and borrowings for EUR 2 8 million. Long-term provisions include the provision for technical warranty on EVS products for labor and parts. Other amounts payable mainly represent deferred income and advance payments received from customers on contracts in progress.Net cash from operating activities amounts to EUR 11 0 million for the full year 2022  compared to EUR 38 7 million in 2021. The decrease is mainly driven by higher working capital requirements resulting from higher trade receivables (as described above) and lower trade payables  combined with lower net profit. On December 31  2022  cash and cash equivalents total EUR 49 1 million  compared to EUR 72 1 million at the end of 2021. The decrease is mainly driven by lower cash from operating activities  combined with the increase of the net cash used in investing activities mainly due to the investments in intangible and tangible assets (specifically in the internal development of intangible assets) together with the increase of the net cash used in financing activities following the higher amount of dividends distributed during 2022  including the exceptional dividend.At the end of December 2022  there were 14.327.024 EVS shares outstanding  of which 908.014 were owned by the company. At the same date  492.975 warrants were outstanding with average exercise price of EUR 16 95 and maturities between October 2026 and September 2028.Corporate updateThere has been no further change to the composition of the Board of Directors since the last General Assembly on May 17th during which the shareholders had appointed two new directors  FrÃ©dÃ©ric Vincent and Marco Miserez  both for a period of 4 years. The Board of Directors is currently composed of seven directors:Johan Deschuyffeleer   independent director & President (representing The House of Value BVBA);Michel Counson   managing director;Martin De Prycker   independent director (representing InnoConsult BVBA);Chantal De Vrieze   independent director (representing 7 Capital SRL);FrÃ©dÃ©ric Vincent   independent director;Marco Miserez   independent director; andAnne Cambier  independent director (representing Accompany You SRL)GlossaryTerm Definition Secured revenue Revenue already recognized as well as open orders on hand that will be recognized as revenue in the fiscal year Order book <date> Revenues planned to be recognized after the <date> based on current orders. LAB market pillar LAB â€“ Live Audience BusinessRevenue from customers leveraging EVS products and solutions to create content for their own purposeThis market pillar covers the following types of customers: Broadcasters  Stadium  House of Worship  Corporate Media Centers  Sports organizations  Government & institutions  University & Colleges LSP market pillar LSP â€“ Live Service ProvidersRevenue from customers leveraging EVS products and solutions to serve â€œLAB customersâ€This market pillar covers the following types of customers: Rental & facilities companies  Production companies  Freelance operators  Technology partners & system integrators buying for their own purpose BER market pillar BER â€“ Big Event RentalRevenue from major non-yearly big event rental.This market pillar covers the following types of customers: host broadcasters for major events.In case of discrepancies between the English and the French Version  the English Version prevails.Conference callEVS will hold a conference call in English today at 3.30 pm CET for financial analysts and institutional investors. Other interested parties may join the call in a listen-only mode. The presentation used during the conference call will be available shortly before the call on the EVS website.Participants must register for the conference using the link provided below. Upon registering  each participant will be provided with Participant Dial In Numbers  Direct Event Passcode and unique Registrant ID.1. Online registration: https://register.vevent.com/register/BIe156e14a79604a6984c8fb06a38e3c272. Webcast Player URL: https://edge.media-server.com/mmc/p/yzt4d6v8Corporate CalendarMay 16th  2023: General AssemblyMay 17th  2023: Q1 2023 Trading updateAugust 18th  2023: H1 2023 resultsNovember 17th  2023: Q3 2023 Trading updateFor more information  please contact:VEERLE DE WITEVS Broadcast Equipment S.A.  Liege Science Park  13 rue du Bois Saint-Jean  B-4102 Seraing  BelgiumTel: +32 4 361 70 00 | E-mail: corpcom@evs.com | Website: www.evs.comForward Looking StatementsThis press release contains forward-looking statements with respect to the business  financial condition  and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs of EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements  the companyâ€™s concentration on one industry  decline in demand for the companyâ€™s products and those of its affiliates  inability to timely develop and introduce new technologies  products and applications  and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.About EVSEVS is globally recognized as leader in live video technology for broadcast and new media productions. Our passion and purpose are to help our clients craft immersive stories that trigger the best return on emotion. Through a wide range of products and solutions  we deliver the most gripping live sports images  buzzing entertainment shows and breaking news content to billions of viewers every day â€“ and in real-time.The company is headquartered in Belgium with around 620 employees in offices in Europe  the Middle East  Asia and North America  and provides sales and technical support to more than 100 countries. EVS is a public company traded on Euronext Brussels: EVS  ISIN: BE0003820371. For more information  please visit www.evs.com.Condensed Interim Consolidated financial informationANNEX 1: condensed consolidated income statement(EUR thousands) Notes FY22 FY21 2H22 2H21 Revenue 5.3 148.158 137.578 80.486 75.799 Cost of sales -49.314 -41.764 -27.473 -22.543 Gross profit 98.844 95.814 53.013 53.256 Gross margin % 66 7% 69 6% 65 9% 70 3% Selling and administrative expenses -39.815 -32.392 -22.532 -17.555 Research and development expenses -26.267 -27.088 -14.368 -14.867 Other income 200 1.108 150 1.057 Other expenses -607 -114 -121 -71 Profit-sharing plan and warrants -643 -232 -169 -107 Operating profit (EBIT) 31.712 37.096 15.973 21.713 Operating margin (EBIT) % 21 4% 27 0% 19 8% 28 6% Interest revenue on loans and deposits 106 51 76 -17 Interest charges -912 -893 -439 -446 Other net financial income / (expenses) 5.6 1.793 1.254 -146 932 Share in the result of the enterprise accounted for using the equity method 67 193 -10 -20 Profit before taxes (PBT) 32.766 37.701 15.454 22.162 Income taxes 5.7 -1.422 -2.797 442 -2.853 Net profit 31.344 34.904 15.896 19.309 Attributable to : Non-controlling interest - - - - Share of the Group 31.344 34.904 15.896 19.309 EARNINGS PER SHARE (in number of shares and in EUR) FY22 FY21 2H22 2H21 Weighted average number of subscribed shares for the period less treasury shares 13.411.972 13.400.624 13.419.010 13.401.884 Weighted average fully diluted number of shares 13.681.084 13.587.624 13.768.895 13.588.884 Basic earnings â€“ share of the Group 2 34 2 60 1 19 1 44 Fully diluted earnings â€“ share of the Group (1) 2 29 2 57 1 14 1 42 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (EUR thousands) FY22 FY21 2H22 2H21 Net profit 31.344 34.904 15.896 19.309 Other comprehensive income of the period Currency translation differences 324 475 -231 276 Total of recyclable elements 324 475 -231 276 Difference on opening 460 - 460 - Gains / (losses) on remeasurement of defined benefit obligations  net of tax 1.373 -412 440 -412 Total of non-recyclable elements  net of tax 1.833 -412 900 -412 Total other comprehensive income of the period  net of tax 2.157 63 669 -136 Total comprehensive income for the period 33.501 34.967 16.565 19.173 Attributable to : Non controlling interest - - - - Share of the Group 33.501 34.967 16.565 19.173(1) The diluted earnings per share does include:187.000 warrants attributed in October 2020  of which 154.250 are outstanding with an exercise price below the share price and with maturity in October 2026; 158.600 warrants attributed in June 2021  of which 155.350 are outstanding with an exercise price below the share price and with maturity in June 2027; and 183.375 warrants attributed in September 2022  all outstanding and with a maturity in September 2028.ANNEX 2: condensed statement of financial position (balance sheet)ASSETS(EUR thousands) Notes Dec 31  2022 Dec 31  2021 Non-current assets: Goodwill 2.832 2.832 Other intangible assets 5.10 13.215 6.113 Lands and buildings 5.11 50.543 52.673 Other tangible assets 5.11 4.691 4.307 Investment accounted for using equity method 1.922 1.920 Other amounts receivables 3.647 2.408 Deferred tax assets 4.622 5.933 Financial assets 512 404 Total non-current assets 81.984 76.590 Current assets: Inventories 28.786 25.951 Trade receivables 61.655 38.924 Other amounts receivable  deferred charges and accrued income 11.566 6.417 Financial assets 174 201 Cash and cash equivalents 49.051 72.144 Total current assets 151.232 143.637 Total assets 233.216 220.227EQUITY AND LIABILITIES(EUR thousands) Notes Dec 31  2022 Dec 31  2021 Equity: Capital 8.772 8.772 Reserves 183.390 170.570 Treasury shares -17.447 -17.776 Total consolidated reserves 165.943 152.794 Translation differences 1.075 751 Equity  attributable to the owners of the parent 175.790 162.317 Non-controlling interest - - Total equity 5.4 175.790 162.317 Provisions 1.637 1.502 Deferred taxes liabilities 10 11 Financial debts 5.12 11.528 13.554 Other debts 5.13 120 1.825 Non-current liabilities 13.295 16.892 Financial debts 5.12 3.750 3.728 Trade payables 9.207 10.497 Amounts payable regarding remuneration and social security 11.219 10.658 Income tax payable 1.959 2.586 Other amounts payable  advances received  accrued charges and deferred income 5.6 17.996 13.549 Current liabilities 44.131 41.018 Total equity and liabilities 233.216 220.227ANNEX 3: condensed statement of cash flows(EUR thousands) Notes FY22 FY21 Cash flows from operating activities Net profit  share of the Group 31.344 34.904 Adjustment for: - Depreciation and write-offs on fixed assets 6.738 7.015 - Profit-sharing plan and warrants 5.4 642 232 - Provisions 212 417 - Income tax expense (+) / Income (-) 1.422 2.797 - Net financial expense (+) / income (-) -987 -412 - Share of the result of entities accounted for under the equity method -67 -193 Adjustment for changes in working capital items: - Inventories -2.834 -3.372 - Trade receivables -23.970 -10.061 - Other amounts receivable  deferred charges and accrued income -3.889 -430 - Trade payables -1.290 4.722 - Amounts payable regarding remuneration and social security 541 3.653 - Other amounts payable  advances received  accrued charges  and deferred income 4.776 -263 - Conversion differences 803 813 Cash generated from operations 13.441 39.822 Income taxes received / (paid) 5.7 -2.469 -1.112 Net cash from operating activities 10.972 38.710 Cash flows from investing activities Purchase of intangible assets -8.770 -234 Purchase of tangible assets (lands and building and other tangible assets) -1.101 -1.357 Other financial assets -102 3 Net cash used in investing activities -9.973 -1.588 Cash flows from financing activities Reimbursement of borrowings 5.12 -1.095 -1.086 Payment of lease liabilities -2.828 -3.417 Interests paid -688 -566 Interests received 75 13 Dividend received from investee 64 - Dividend paid -20.112 -13.400 Net cash used in financing activities -24.584 -18.456 Net increase / decrease in cash and cash equivalents -23.585 18.666 Net foreign exchange difference 492 810 Cash and cash equivalents at beginning of period 72.144 52.668 Cash and cash equivalents at end of period 49.051 72.144ANNEX 4: condensed statement of change in equity(EUR thousands) Capital Reserves Treasury shares Currency translation differences Equity share of the Group Non-controlling interest Total equity Balance as per January 1  2021 8.772 149.309 -17.835 276 140.522 - 140.522 Profit or loss 34.904 34.904 34.904 Other comprehensive income -412 475 63 63 Total comprehensive income for the period 34.492 475 34.967 34.967 Share-based payments 232 232 232 Operations with treasury shares 59 59 59 Final dividend -6.699 -6.699 -6.699 Interim dividend -6.701 -6.701 -6.701 Other allocation -63 -63 -63 Balance as per December 31  2021 8.772 170.570 -17.776 751 162.317 - 162.317(EUR thousands) Capital Reserves Treasury shares Currency translation differences Equity share of the Group Non-controlling interest Total equity Balance as per January 1  2022 8.772 170.570 -17.776 751 162.317 - 162.317 Profit or loss 31.344 31.344 31.344 Other comprehensive income 1.833 324 2.157 2.157 Total comprehensive income for the period 33.117 324 33.501 33.501 Share-based payments 581 581 581 Operations with treasury shares -329 329 - - Final dividend -13.402 -13.402 -13.402 Interim dividend -6.710 -6.710 -6.710 Other allocation -497 -497 -497 Balance as per December 31  2022 8.772 183.390 -17.447 1.075 175.790 - 175.790ANNEX 5: notes to the consolidated financial statementsNOTE 5.1: BASIS OF PREPARATION OF THE FINANCIAL STATEMENTSThe consolidated financial statements of EVS Group for the 12 month-period ended December 31  2022  are established and presented in accordance with the International Financial Reporting Standards (IFRS)  as adopted for use in the European Union. The accounting framework and standards adopted by the European Commission can be accessed through the following link on the website: http://ec.europa.eu/finance/company-reporting/index_en.htm.The condensed interim financial statements of the Group for the 12 month-period ending December 31  2022  were authorized for issue by the Board of Directors on February 16  2023. This interim report only provides an explanation of events and transactions that are significant to an understanding of the changes in financial position and reporting since the last annual reporting period and should therefore be read in conjunction with the full 2022 consolidated financial statements from which these condensed financial statements have been derived and which are planned to be published on EVS Groupâ€™s website by April 14  2023. The interim condensed financial statements are prepared on a going concern basis.NOTE 5.2.1: SIGNIFICANT ACCOUNTING POLICIES AND METHODSThese condensed interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting  as issued by the IASB  and as adopted by the EU. The accounting policies and methods adopted for the preparation of the company's IFRS consolidated financial statements are consistent with those applied in the 2021 consolidated financial statements. The companyâ€™s IFRS accounting policies and methods are available in the 2021 annual report on www.evs.com  except for the accounting policy on intangible assets which include the capitalization of development cost for the first time (see note 5.10) as well as the new  amended or revised IFRS standards and IFRIC Interpretations that have been in effect since January 1  2022. The adoption of these new  amended or revised pronouncements did not have a significant impact on the consolidated financial statements of the Group.NOTE 5.2.2: JUDGMENTS AND ESTIMATESImpacts of current market volatility and macroeconomic developmentsThe impacts of the current market volatility and macroeconomic developments were taken into account by the company to assess potential effects on EVSâ€™s financial performance and the valuation of its assets and liabilities. In particular  key assumptions used in the calculation of the pension obligations have been reviewed to ensure a proper valuation as per 31 December 2022. Also  the key assumptions that are used for estimating the recoverable amounts of cash generating units in the context of goodwill impairment test reflect latest market conditions for interest rates and weighted average cost of capitalEstimation of useful life and residual valueProperty  Plant and Equipment are depreciated using a straight-line method to allocate their depreciable amount on a systematic basis over their useful life. For the headquarter building in LiÃ¨ge  the depreciable amount is the cost less its estimated residual value. Useful life and residual value of an asset is estimated on a realistic basis based on the experience of the Group with similar assets and reviewed on a regular basis. The effect of changes in useful life are recognized prospectively.Functional currency of the Group entitiesThe individual financial statements of each subsidiary are prepared in the currency of the primary economic environment in which the entity operates. When the factors set out by IAS 21 to determine the functional currency are mixed and the functional currency is not obvious  management judgment is used to determine which functional currency most faithfully represents the economic effects of its underlying transactions  events and conditions. The functional currency of the EVS Group entities is EUR except for the US entity EVS Inc. for which US Dollar is assessed by management to be the functional currency.Claims and contingent liabilitiesRelated to claims and contingencies  judgement is necessary in assessing the existence of an obligation resulting from a past event  in assessing the probability of an economic outflow  and in quantifying the probable outcome of economic resources. This judgment is reviewed when new information becomes available and often with support of internal and external expert advice.Impact of the war in Ukraine on our activitiesGiven the nature and location of its operations and the fact that EVS does not currently have activities in Russia nor in Ukraine or with Russian companies  The Company does not foresee a direct impact of the Ukrainian conflict on its business.NOTE 5.3: SEGMENT REPORTINGFrom an operational point of view  the company is vertically integrated with the majority of its staff located in the headquarters in Belgium  including the R&D  production  marketing and administration departments. Therefore the majority of investments and costs are located at the level of the Belgian parent company. Resources securing the customer facing interactions such as sales  operations and support profiles are primarily hired within the respective regions. The foreign subsidiaries are primarily sales and representative offices. The Chief Operating Decision Maker  being the Executive Committee  reviews the operating results  operating plans  and makes resource allocation decisions on a company-wide basis. Revenue related to products of the same nature (digital broadcast production equipment) are realized by commercial polyvalent teams. The companyâ€™s internal reporting is the reflection of the above-mentioned operational organization and is characterized by the strong integration of the activities of the company.By consequence  the company is composed of one segment according to the IFRS 8 definition  and the consolidated income statement of the Group reflects this unique segment. All long-term assets are located in the parent company EVS Broadcast Equipment SA in Belgium.The company provides one class of business defined as solutions based on tapeless workflows with a consistent modular architecture. There are no other significant classes of business  either singularly or in aggregate. Identical modules can meet the needs of different markets  and our customers themselves are often multi-markets. Providing information for each module is therefore not relevant for EVS.At the geographical level  our activities are divided into the following regions: Asia-Pacific (â€œAPACâ€)  Europe  Middle East and Africa (â€œEMEAâ€)  and America (â€œNALAâ€). This division follows the organization of the commercial and support services within the Group  which operates worldwide. A fourth region is dedicated to the worldwide events (â€œbig event rentalsâ€).The company provides additional information with a presentation of the revenue by market pillar: â€œLive Service providerâ€  â€œLive Audience Businessâ€ and â€œBig Event Rentalsâ€ for rental contracts relating to the big sporting events.Finally  sales are presented by nature: systems and services.5.3.1. INFORMATION ON REVENUE BY DESTINATIONRevenue can be presented by Market Pillar: â€œLive Service providerâ€  â€œLive Audience Businessâ€ and â€œBig event rentalsâ€. Maintenance and after sale service are included in the complete solution proposed to the clients.Revenue (EUR thousands) 2H22 2H21 % 2H22/2H21 Live Audience Business 45.147 42.986 5 0% Live Service Provider 31.151 23.888 30 4% Big event rentals 4.187 9.021 -53 6% Total Revenue 80.486 75.894 6 0%Revenue (EUR thousands) FY22 FY21 % FY22/FY21 Live Audience Business 71.438 72.259 -1 1% Live Service Provider 66.869 51.785 29 1% Big event rentals 9.850 13.534 -27 2% Total Revenue 148.158 137.578 7 7%5.3.2. INFORMATION ON REVENUE BY GEOGRAPHICAL AREAActivities are divided in three regions: Asia-Pacific (â€œAPACâ€)  Europe  Middle East and Africa (â€œEMEAâ€)  and â€œAmericasâ€. Aside of them  we also identify the â€œbig event rentalsâ€.Revenue for the YTD period (EUR thousands) APACexcl. events EMEAexcl. events Americasexcl. events Big eventrentals TOTAL 2H22 revenue 11.278 39.107 25.914 4.187 80.486 Evolution versus 2H21 (%) -15 8% 23 4% 19 4% -53 9% 6 0% Variation versus 2H21 (%) at constant currency -15 8% 23 4% -7 2% -53 9% -1 6% 2H21 revenue 13.401 31.696 21.706 9.021 75.894Revenue for the YTD period (EUR thousands) APACexcl. events EMEAexcl. events Americasexcl. events Big eventrentals TOTAL FY22 revenue 18.952 67.764 51.592 9.850 148.158 Evolution versus FY21 (%) -17 9% 6 8% 37 6% -27 2% 7 7% Variation versus FY21 (%) at constant currency -17 9% 6 8% 22 2% -27 2% 3 5% FY21 revenue 23.077 63.468 37.499 13.534 137.578Revenue realized in Belgium (the country of origin of the company) with external clients represent less than 5% of the total revenue for the period. In the last 12 months  the Group realized significant revenue with external clients (according to the definition of IFRS 8) in one country: The United States (Americas)  EUR 38 1 million in the last 12 months.5.3.3. INFORMATION ON REVENUE BY NATURERevenue can be presented by nature: systems and services.Revenue (EUR thousands) 2H22 2H21 % 2H22/2H21 Sale of Equipment 64.226 58.524 10 3% Other services 16.259 17.610 -7 7% Total Revenue 80.486 75.894 6 0%Revenue (EUR thousands) FY22 FY21 % FY22/FY21 Sale of Equipment 118.015 106.416 10 9% Other services 30.142 31.162 -3 3% Total Revenue 148.158 137.578 7 7%Other services include the advice  installations  project management  rentals  training  maintenance  and distant support. Work in progress (â€œWIPâ€) contracts are included in both categories.5.3.4. INFORMATION ON IMPORTANT CLIENTSOver the last 12 months  no external client of the company represented more than 10% of the revenue (similar in 2021).NOTE 5.4: EQUITY SECURITIESThe variance in number of treasury shares and outstanding warrants in the period is as follows:2022 2021 Number of own shares at January 1 925.140 928.207 Acquisition of own shares on the market - - Sale of own shares on the market - - Allocation to Employees Profit Sharing Plans -17.126 -3.067 Sale related to Employee Stock Option Plan (ESOP) and other transactions - - Number of own shares at December 31 908.014 925.140 Outstanding warrants at December 31 492.975 456.432In 2022  the Group did not repurchase own shares on the stock market. No shares were used to satisfy the exercise of warrants by employees.The Ordinary General Meeting of shareholders of May 17  2022 approved the allocation of 17.126 shares to EVS employees (grant of 56 shares to each staff member in proportion to their effective or assimilated time of occupation in 2021) as a reward for their contribution to the Group successes. The expense recorded in the consolidated income statement amounts to EUR 329k in 2022.NOTE 5.5: DIVIDENDSThe Ordinary General Meeting of May 17  2022  approved the payment of a total gross dividend of EUR 1.50 per share for the year 2021  which includes EUR 0.50 per share exceptional dividend to honor past commitments on dividend payout.For the year 2022  an interim dividend of EUR 0.50 per share was paid in November 2022. Full year dividend of EUR 1 60 per share will be proposed to the Ordinary General Meeting of shareholders  which also includes EUR 0.50 per share exceptional dividend to honor past commitments on dividend payout.(EUR thousands  gross) # Coupon Declaration date 2022 2021 - Final dividend for 2020(EUR 0 50 per share excl. treasury shares) 30 May 2021 - 6.699 - Interim dividend for 2021(EUR 0 50 per share excl. treasury shares) 31 Nov. 2021 - 6.701 - Final dividend for 2021 (incl. exceptional dividend)(EUR 1 00 per share excl. treasury shares) 32 May 2022 13.402 - Interim dividend for 2022(EUR 0 50 per share excl. treasury shares) 33 Nov. 2022 6.710 Total paid dividends 20.112 13.400A new dividend guidance for upcoming years has been issued early 2022 and is as follows*:In â‚¬ per share per fiscal year 2022 2023 2024 Base dividend 1 10 1 10 1 10 Exceptional additional dividend 0 50 0 00 0 00 Total dividend 1 60 1 10 1 10*subject to market conditions and to the approval of the Ordinary General Meeting of ShareholdersNOTE 5.6: OTHER NET FINANCIAL INCOME / (EXPENSES)(EUR thousands) FY22 FY21 - Exchange results 1.393 1.117 - Fair value variation of financial instruments 324 -7 - Other financial results 76 144 Other net financial income / (expenses) 1.793 1.254The functional currency of EVS Broadcast Equipment SA as well as all subsidiaries is the Euro  except for EVS Inc. subsidiary in the USA whose functional currency is the US dollar. Entity Axon Digital Design LTD. in the UK changed functional currency from GBP to EUR starting as of July 1st 2022  following updated Management assesment driven by new implementation of EUR invoicing at the affiliate. The presentation currency of the consolidated financial statements of EVS Group is the Euro. For more information on exchange rates  see also the note 5.9. The favourable exchange result is mainly explained by the appreciation of USD vs. EUR in the period.The estimated fair values of the financial assets and liabilities are equal to their fair book values in the balance sheet.Since 2022  EVS systematically measures the Groupâ€™s anticipated exposure to transactional exchange risk  mainly relating to the EUR/USD risk. Given the Group has a long position in USD and based on revenue forecasts  EVS hedges future USD net inflows through forward or option foreign exchange contracts. The change in the fair value of the foreign exchange contracts is recorded directly to the income statement since the Group does not apply hedge accounting on these transactions. The valuation techniques used are mainly based on spot rates  forward rates and interest rate curves.On December 31  2022  the Group holds EUR/USD FX forward and option contracts for a total notional amount of USD 34 0 million with monthly maturities between January 2023 and June 2024. The fair value of those financial instruments on December 31  2022 amounts to EUR 0 3 million.NOTE 5.7: INCOME TAX EXPENSE(EUR thousands) FY22 FY21 - Current tax expense -569 -1.245 - Deferred tax expense -853 -1.552 Income tax expense -1.422 -2.797Income tax expense amounts to EUR 1 4 million for the full year 2022  compared to EUR 2 8 million in 2021. The decrease is mainly explained by lower taxable profit  tax relief of EUR 0 6 million received in December 2022 and decrease of the deferred tax expenses due to lower consumption of recoverable tax latencies (EUR 1 2 million in 2022 compared to 8 6 million in 2021).The effective tax rate for the period ended on December 31  2022 is 4 3%  compared to 7 5% in 2021.NOTE 5.8: HEADCOUNT(in full time equivalents) At December 31 2022 613 2021 551 Variation +62NOTE 5.9: EXCHANGE RATESThe main exchange rates that influence the consolidated financial accounts are USD/EUR and GBP/EUR which were considered as follows:Exchange rate USD/EUR Average FY At December 31 2022 1 0537 1 0666 2021 1 1830 1 1326 Variation -10 9% -5 8%Exchange rate GBP/EUR Average FY At December 31 2022 0 8527 0 8869 2021 0 8599 0 8403 Variation -0 7% 5 5%NOTE 5.10: INTANGIBLE ASSETSDuring 2022  intangible assets increased by EUR 7 1 million due to capitalization of internal development costs of EUR 8 4 million less depreciations of EUR 1 3 million.The capitalized costs during 2022 include mainly the internal personnel costs and external consultantsâ€™ costs. These costs are only related to the development phase of 2 important projects that should secure future growth for EVS.At the beginning of the period  the Group identified internal development projects  that for the first time of EVS Broadcast Equipmentâ€™s history fulfilled all the conditions to be capitalized according to IAS 38 Intangible assets. This ability arises after the implementation of extensive business cases  where R&D together with the solutions and sales departments perform an end-to-end exercise whereby objectives  costs  market analysis and return are clearly identified.These internal development projects consist of software that will be commercialized at the end of the development period (expected return on investment is scheduled for 2024). These 2 projects complement the PLAYForward strategy of the Group. The progress of these internal developments is monitored frequently as to ensure the future economic benefit remains assured.We refer to H1 2022 press release for the update of the accounting policy 2.11 related to the intagible assets applicable as of fiscal year 2022 and that replaces the accounting policy disclosed in 2021 annual report.NOTE 5.11: TANGIBLE ASSETSThe decrease of lands and buildings of EUR -2 1 million during 2022 is mainly explained by the depreciation of the period partially offset by investments in progress of EUR 0 5 million. The increase in other tangible assets of EUR 0 4 million is mainly driven by investments in office and IT equipment of EUR 1 1 million  net of the depreciation of the year of EUR 0 7 million.NOTE 5.12: FINANCIAL LIABILITIES(EUR thousands) 2022 2021 Long term financial debts Bank loans 1.675 2.779 Long term lease liabilities 9.853 10.775 Amount due within 12 months (shown under current liabilities) Bank loans 1.105 1.095 Short term lease liabilities 2.645 2.633 Total financial debt (short and long-term) 15.278 17.282 The total financial debt is repayable as follows: - within one year 3.750 3.728 - after one year but no more than five 8.676 9.673 - more than five years 2.852 3.881In June 2020  a loan of EUR 5 5 million was put in place with BNP Paribas Fortis to partially finance the acquisition of Axon. The repayment schedule foresees first repayment of EUR 0 6 million in 2020 and annual installments of EUR 1 1 million between 2021 and 2024  with final repayment of EUR 0 6 million in 2025 at loan maturity.For full year 2022  lease liabilities variation includes repayment of EUR 2 5 million  excluding interest of EUR 0 4 million.In June 2020  a roll over credit line of EUR 5 0 million was put in place with Belfius bank to partially finance the acquisition of Axon. This amortizing credit line will end at the latest on 30/06/2025. As of this date  EVS has not used this credit facility.NOTE 5.13: OTHER LIABILITIES - PENSIONOther long-term liabilities mainly correspond to pension obligations. Changes recorded in 2022 in the Belgian pension defined benefit obligation and fair value of plan assets were as follows:(EUR thousands) 2022 2021 Defined benefit obligation Fair value of plan assets Net defined benefit liability Defined benefit obligation Fair value of plan assets Net defined benefit liability As of January 1 10.587 -8.762 1.825 8.670 -7.686 984 Service cost 1.156 1.156 1.398 1.398 Administrative costs 28 28 18 18 Net interest expenses 120 -106 14 41 -38 3 Sub-total included in profit or loss 1.276 -78 1.198 1.439 -20 1.419 Benefits paid -179 179 0 -141 141 0 Return on plan assets -153 -153 -106 -106 Actuarial changes (assumptions) of which: Arising from changes in demographic assumptions 235 235 0 Arising from changes in financial assumptions -1.349 -1.349 -1.172 -1.172 Arising from experience adjustments -367 -350 -717 1.791 -69 1.722 Sub-total included in OCI -1.481 -350 -1.831 619 -69 550 Contributions by employer -1.078 -1.078 -1.128 -1.128 As of December 31 10.203 -10.089 114 10.587 -8.762 1.825The decrease in the net defined benefit liability of EUR -1 7 million is mainly driven by actuarial changes included in OCI arising from changes in financial assumptions of EUR -1 3 million (mainly increase in discount rate from 1 15% to 3 80%) and from experience adjustments of EUR -0 7 million  combined with employer contributions in the period of EUR -1 1 million and partially offset by service cost recorded in income statement of EUR 1 2 million.The main assumptions used for the actuarial valuation are as follows:Salary increase for financial year 2022 of 14 5% (5 7% in 2021)Discount rate p.a. of 3 8% (1 15% in 2021)Long term salary increase (inflation included) p.a. of 2 4% (2 1% in 2021)NOTE 5.14: FINANCIAL RISK MANAGEMENT POLICIESThe Group enters into derivative transactions  principally forward and option currency contracts  with the purpose to secure its sales and purchases in foreign currencies against negative variations of these currencies. The Group has transactional currency exposure arising from sales or purchases by operating entities in currencies other than the Groupâ€™s functional currency. Foreign currency risk is described in note 5.14.1.The Groupâ€™s main financial instruments  other than derivatives  comprise bank loans  finance leases  cash and short-term deposits. The purpose of these financial instruments is to raise finance for the Groupâ€™s operations. The Group has other financial instruments such as trade debtors and trade creditors  which arise directly from its operations. The Groupâ€™s policy is  and has always been  that no trading in financial instruments shall be undertaken. Credit risk is described in note 5.14.2.5.14.1 FOREIGN CURRENCY RISKSince 2022  EVS systematically measures the Groupâ€™s anticipated exposure to transactional exchange risk over six to eighteen months. In its current structure  the Groupâ€™s exposure is mainly linked to the EUR/USD risk. The Group invoices all clients in Euro  except in the United States where invoices are denominated in USD. Since the majority of operating expenses are denominated in Euro  the Group has a long position in USD  i.e. all of the Groupâ€™s activities generate globally a positive net cash flow in USD.On the basis of the forecasts and according to the market conditions  the Group hedges a portion of the exchange rate risk on estimated net future flows  mainly through foreign exchange forward and option contracts. EVS does not apply hedge accounting according to IAS 39 for those transactions.Foreign exchange contracts are revalued at each closing date at their market value. The generated exchange rate profit or loss is recorded in the â€œOther net financial income/(charges)â€ account in the consolidated income statement. The valuation techniques used are mainly based on spot rates  forward rates and interest rate curves. Details of fair value at closing date are presented in note 5.6.5.14.2 CREDIT RISKCredit exposure is controlled and reviewed regularly by the management.Trade receivables consist of a large number of customers  spread across many geographical areas. The evolution of the credit risk is monitored permanently. As of December 31  2022  it is assumed that the carrying amounts of those trade receivables are the most appropriate estimate to the fair value of those assets.The credit risk on financial instruments is contained as it is spread over a selection of different counterparties which are financial institutions with high credit ratings assigned by international credit rating agencies.As of December 31  2022  the maximum amount the Group could have to pay if guarantees are called on is EUR 0 8 million (similar to EUR 0 8 million in December 2021).NOTE 5.15: SUBSEQUENT EVENTSThere are no subsequent events that may have a material impact on the condensed financial statements of the Group.NOTE 5.16: RISK AND UNCERTAINTIESInvesting in the stock of EVS involves risks and uncertainties. The risks and uncertainties relating to the current year are similar to the risks and uncertainties that have been identified by the management of the company and that are listed in the management report of the annual report (available at www.evs.com).In terms of new risks arising since the last annual report we highlight the macro-economic environment that drives energy prices  components prices and labour cost to higher levels. EVS closely monitors the developments in this area and pro-actively takes actions to keep these rising costs under control or to minimize their effect on the profitability of the company. We also reiterate the potential impacts following the war in Ukraine. The company continues to comply with the sanction screening in vigor.Certification of responsible personsSerge Van Herck  CEO*Veerle De Wit  CFO*Certify that  based on their knowledge a) the condensed financial statements  prepared in accordance with the International Financial Reporting Standards (IFRS) adopted by the European Union  fairly present in all material respects the financial condition and results of operations of the issuer and the companies included in the consolidation b) the Directorsâ€™ report fairly presents the important events and related parties transactions of 2022  including their impact on the condensed financial statements  and a description of the existing risks and uncertainties for the remaining months of the fiscal year.* acting on behalf of a BVExternal AuditorThe condensed consolidated financial statements of EVS Broadcast SA for the year ending December 31  2022 were authorized of issue in accordance with a resolution of the Board of Directors on February 16  2023. EY rÃ©viseurs dâ€™Entreprises represented by Carlo-SÃ©bastien dâ€™Addario has confirmed that their audit procedures  which have been substantially completed  have not revealed any material adjustments which would have to be made to the accounting information included in this press release. The complete audit report related to the audit of the consolidated financial statements will be shown in 2022 annual report that will be published in April 2023.Attachment",neutral,0.0,1.0,0.0,mixed,0.66,0.16,0.18,True,English,"['EVS REPORTS 2022 RESULTS', '2H21 Variance FY22 FY21 Variance Revenue', 'Big Event Rental (BER) activity', 'EVS Broadcast Equipment S.A.', 'recent â€œTop Employerâ€ certification', 'Live Service Providers markets', 'Comments Serge Van Herck', 'Big Event Rental revenue', 'team member engagement survey', 'strong financial income performance', 'Media Infrastructure revenue growth', 'strong net profit result', 'Live Audience Business', 'live TV production', 'Big Tech 2022 contract', 'Big Tech 22 contract', 'strong employer branding', 'capital expenditure envelope', 'team member size', 'The Axon acquisition', 'customer ticketing system', 'historical revenue number', 'major sports events', 'VIA Portal applications', 'record-high order intake', 'important order intake', 'Healthy net profit', 'current market dynamics', 'Record order intake', 'expected growth momentum', 'total order book', 'sustainable growth ambitions', 'long-term growth ambitions', 'order intake results', 'second record year', 'FY22 Highlights', 'record revenue', 'Revenue performance', 'CEO comments', 'strong growth', 'revenue guidance', 'revenue range', 'strong talent', 'strong ecosystem', 'topline performance', 'largest contract', 'second half', 'team members', '10,6 Gross profit', 'Operating profit', 'VIA platform', 'major differentiator', 'market opening', 'OPEX growth', 'organic growth', 'growth engine', 'profitable growth', 'significant growth', 'Regulated information', 'Press release', 'Euronext Brussels', 'LiÃ¨ge', 'delivery terms', 'North America', 'MediaInfra solution', 'one-off benefit', '2H22 Highlights', 'same period', 'future periods', 'base dividend', 'Key figures', 'Operating margin', 'PlayForward strategy', 'component shortages', 'Middle East', 'good progress', 'solution sales', 'Artificial Intelligence', 'large acquisitions', 'new ERP', 'annual results', 'market expectations', 'market share', 'last year', 'successful year', 'EVS BB', 'Group share', 'solid Earnings', 'bottom line', '2022 results', 'Publication', 'February', 'Bloomberg', 'Reuters', 'Belgium', 'fundamentals', 'consequence', 'taxes', 'Outlook', 'beginning', 'focus', 'increase', 'dividends', 'policy', 'Story', 'EBIT', 'EPS', 'revenues', 'August', 'inflation', 'position', 'customers', 'Asia', 'world', 'improvements', 'years', 'vision', 'introduction', 'XtraMotion', 'revolution', 'industry', 'May', 'capability', 'commitments']",2023-02-17,2023-02-18,finance.yahoo.com
18711,EuroNext,NewsApi.org,https://finance.yahoo.com/news/pfizer-valneva-issue-phase-3-060000447.html,Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15,New York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer...,"VALNEVANew York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy  safety and immunogenicity of an investigational Lyme disease vaccine candidate  VLA15. These study participants  representing approximately half of the total recruited participants in the trial  are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator. The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event.GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. These standards are designed to put participantsâ€™ interests first and ensure high scientific integrity. Once Pfizer learned of potential violations of GCP  it conducted a thorough review of the operations and data collection at the clinical trial sites run by the third party and followed standard operating safeguards to determine the correct course of action.The clinical trial remains ongoing with other sites not operated by the third party  and Pfizer continues to enroll new participants at those sites. The companies intend to work with regulatory authorities  and as previously announced 1 2 aim for Pfizer to potentially submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025  pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan.Participants are being notified and Pfizer has also notified the FDA  other regulatory agencies and the independent Institutional Review Board for this study.Integrity of data collected in clinical trials is critical to provide evidence and confidence in a potential vaccine or medicineâ€™s safety and efficacy. Pfizer and Valneva are committed to collecting robust data needed for potential regulatory submission of VLA15. While VLA15 is still under investigation  to date the companies have been encouraged by the data from the Phase 2 clinical studies  which demonstrated strong immunogenicity and acceptable safety and tolerability profiles.2-4About VLA15VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi  the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. Blocking OspA inhibits the bacteriumâ€™s ability to leave the tick and infect humans. The vaccine covers the six most common OspA serotypes expressed by the Borrelia burgdorferi sensu lato species that are prevalent in North America and Europe. VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA15  with updates to the terms within this agreement made in June 2022.5 6 The program was granted Fast Track designation by the U.S. FDA in July 2017.7About Lyme DiseaseLyme disease is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks.8 It is considered the most common vector-borne illness in the Northern Hemisphere.9 While the true incidence of Lyme disease is unknown  it is estimated to annually affect approximately 476 000 people in the United States and 130 000 people in Europe.10 11 Early symptoms of Lyme disease (such as a gradually expanding erythematous rash called Erythema migrans or more nonspecific symptoms like fatigue  fever  headache  mild stiff neck  arthralgia or myalgia) are often overlooked or misinterpreted. Left untreated  the disease can disseminate and cause more serious complications affecting the joints (arthritis)  the heart (carditis) or the nervous system.12 The medical need for vaccination against Lyme disease is steadily increasing as the geographic footprint of the disease widens.10About Pfizer: Breakthroughs That Change Patientsâ€™ LivesAt Pfizer  we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality  safety and value in the discovery  development and manufacture of health care products  including innovative medicines and vaccines. Every day  Pfizer colleagues work across developed and emerging markets to advance wellness  prevention  treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies  we collaborate with health care providers  governments and local communities to support and expand access to reliable  affordable health care around the world. For more than 170 years  we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition  to learn more  please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News  LinkedIn  YouTube and like us on Facebook at Facebook.com/Pfizer.Pfizer Disclosure NoticeThe information contained in this release is as of February 17  2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.This release contains forward-looking information about an investigational Lyme disease vaccine candidate  VLA15  and a collaboration between Pfizer and Valneva for VLA15  including their potential benefits  VALOR  a Phase 3 clinical study investigating the efficacy  safety and immunogenicity of VLA15  and the timing of potential regulatory submissions  that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include  among other things  the uncertainties inherent in research and development  including the ability to meet anticipated clinical endpoints  commencement and/or completion dates for our clinical trials  regulatory submission dates  regulatory approval dates and/or launch dates  including uncertainties relating to the time needed to recruit and enroll participants  and accrue cases in the Phase 3 trial  and uncertainties relating to an agreement with regulatory authorities on any modifications to the clinical trial plan as needed  as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for VLA15; whether and when any such applications may be approved by regulatory authorities  which will depend on myriad factors  including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and  if approved  whether VLA15 will be commercially successful; decisions by regulatory authorities impacting labeling  manufacturing processes  safety and/or other matters that could affect the availability or commercial potential of VLA15; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; whether our collaboration with Valneva will be successful; uncertainties regarding the impact of COVID-19 on Pfizerâ€™s business  operations and financial results; and competitive developments.A further description of risks and uncertainties can be found in Pfizerâ€™s Annual Report on Form 10-K for the fiscal year ended December 31  2021 and in its subsequent reports on Form 10-Q  including in the sections thereof captioned â€œRisk Factorsâ€ and â€œForward-Looking Information and Factors That May Affect Future Resultsâ€  as well as in its subsequent reports on Form 8-K  all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.About Valneva SEValneva is a specialty vaccine company focused on the development  manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic  including candidates against the chikungunya virus and Lyme disease.Valneva Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva  including with respect to the progress and recruitment of clinical trials  discussions with regulatory agencies  modifications to clinical trial plans  results of clinical trials  and timing for filing for potential regulatory approval of product candidates. In addition  even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release  those results or developments of Valneva may not be sustained in the future. In some cases  you can identify forward-looking statements by words such as ""could "" ""should "" ""may "" ""expects "" ""anticipates "" ""believes "" ""intends "" ""estimates "" ""aims "" ""targets "" or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results  performance or achievements to be materially different from any future results  performance or achievement expressed or implied by these forward-looking statements. In particular  the expectations of Valneva could be affected by  among other things  uncertainties involved in the development and manufacture of vaccines  unexpected clinical trial results or delays  unexpected regulatory actions or delays  competition in general  currency fluctuations  the impact of the global and European credit crisis  and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties  there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release and disclaim any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events  or otherwise.Media ContactsPfizerMedia Relations:PfizerMediaRelations@pfizer.com212-733-1226Investor Relations:IR@pfizer.com212-733-4848ValnevaLaÃ«titia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 7099laetitia.bachelot-fontaine@valneva.comJoshua Drumm  Ph.D.VP Global Investor RelationsM +1 917 815 4520joshua.drumm@valneva.comReferencesPfizer. Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15. August 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease. Accessed: February 2023. Valneva. Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate. December 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-six-month-antibody-persistence. Accessed: February 2023 Valneva. Valneva Pfizer Report Positive Phase 2 Pediatric Data for Lyme Vaccine Candidate. April 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-report-positive-phase-2-pediatric-data-for-lyme-disease-vaccine-candidate/ Accessed: July 2022. Valneva. Valneva Pfizer Report Positive Phase 2 Data for Lyme Disease Vaccine Candidate. February 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-report-further-positive-phase-2-data-for-lyme-disease-vaccine-candidate/ Accessed: July 2022. Valneva. Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine  VLA15. April 2020. Available at: https://valneva.com/press-release/valneva-and-pfizer-announce-collaboration-to-co-develop-and-commercialize-lyme-disease-vaccine-vla15/ Accessed: July 2022 . Valneva. Valneva and Pfizer Enter into Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15. June 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-enter-into-an-equity-subscription-agreement-and-update-terms-of-collaboration-agreement-for-lyme-disease-vaccine-candidate-vla15/ Accessed: July 2022. Valneva. Valneva Receives FDA Fast track Designation for its Lyme Disease Vaccine Candidate VLA15. July 2017. Available at: https://valneva.com/press-release/valneva-receives-fda-fast-track-designation-for-its-lyme-disease-vaccine-candidate-vla15/ Accessed: July 2022. Stanek G  Wormser GP  Gray J  et al. Lyme borreliosis. Lancet. 2012; 4;379(9814):461-73. Gern L  Falco RC. Lyme disease. Rev Sci Tech. 2000 Apr;19(1):121-35. Center for Disease Control and Prevention. Lyme Disease. Data and Surveillance. April 2021. Available at: https://www.cdc.gov/lyme/datasurveillance/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Flyme%2Fstats%2Findex.html Accessed July 2022. Sykes RA  et al. An estimate of Lyme borreliosis incidence in Western Europe. Journal of Public Health 2017; 39(1): 74-81 Center for Disease Control and Prevention. Lyme Disease. Signs and Symptoms of Untreated Lyme disease. January 2021. Available at: https://www.cdc.gov/lyme/signs_symptoms/index.html Accessed July 2022.Attachment",neutral,0.0,0.97,0.03,mixed,0.23,0.06,0.71,True,English,"['Lyme Disease Vaccine Candidate VLA15', 'Valneva Issue Update', 'Phase 3 Clinical Trial', 'Pfizer', 'six most common OspA serotypes', 'Borrelia burgdorferi sensu lato species', 'investigational multivalent protein subunit vaccine', 'third-party clinical trial site operator', 'investigational Lyme disease vaccine candidate', 'independent Institutional Review Board', 'outer surface protein A', 'participant-reported adverse event', 'Biologics License Application', 'Marketing Authorisation Application', 'Fast Track designation', 'expanding erythematous rash', 'mild stiff neck', 'health care products', 'Good Clinical Practice', 'clinical trial plan', 'European Medicines Agency', 'strong immune response', 'standard operating safeguards', 'Borrelia burgdorferi bacteria', 'U.S. Food', 'high scientific integrity', 'potential regulatory submission', 'clinical trial sites', 'Phase 2 clinical studies', 'satisfactory safety profile', 'other regulatory agencies', 'scientific quality standard', 'Phase 3 clinical study', 'U.S. FDA', 'investigational vaccine', 'potential vaccine', 'thorough review', 'Phase 3 studies', 'other sites', 'clinical trials', 'clinical researchers', 'regulatory authorities', 'innovative medicines', 'clinical development', 'New York', 'Euronext Paris', 'significant percentage', 'Outdoor Recreationists', 'international ethical', 'third party', 'correct course', 'Drug Administration', 'successful completion', 'strong immunogenicity', 'tolerability profiles', 'North America', 'systemic infection', 'Ixodes ticks', 'vector-borne illness', 'Northern Hemisphere', 'true incidence', 'United States', 'Early symptoms', 'nonspecific symptoms', 'serious complications', 'nervous system', 'medical need', 'geographic footprint', 'global resources', 'emerging market', 'potential violations', 'study sponsor', 'safety concerns', 'acceptable safety', 'data collection', 'robust data', 'participantsâ€™ interests', 'new participants', 'Valneva SE', 'collaboration agreement', 'study participants', 'Pfizer Inc.', 'Pfizer colleagues', 'Saint-Herblain', 'France', 'February', 'PFE', 'Nasdaq', 'VLA', 'VALOR', 'efficacy', 'half', 'GCP', 'discontinuation', 'standards', 'operations', 'action', 'companies', 'MAA', 'modifications', 'evidence', 'confidence', 'mechanism', 'humans', 'pre-clinical', 'April', 'updates', 'terms', 'June', 'program', 'July', '476,000 people', '130,000 people', 'fatigue', 'fever', 'headache', 'arthralgia', 'myalgia', 'joints', 'arthritis', 'heart', 'carditis', 'vaccination', 'Breakthroughs', 'Lives', 'science', 'value', 'discovery', 'manufacture', 'vaccines']",2023-02-17,2023-02-18,finance.yahoo.com
18712,EuroNext,NewsApi.org,https://finance.yahoo.com/news/abivax-appoints-dr-sheldon-sloan-072000928.html,Abivax Appoints Dr. Sheldon Sloan  M.D.  as Chief Medical Officer,Abivax SA (Euronext Paris: FR0012333284 - ABVX)  a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune...,"Sheldon Sloan  M.D.  M. Bioethics  has a strong track record in product development and commercial launches in the pharmaceutical industry with a focus on Inflammatory Bowel DiseaseAs CMO of Abivax  Dr. Sloan will play a critical role in the successful conduct and completion of the ongoing Phase 3 global clinical program with obefazimod for the treatment of ulcerative colitis (UC)  as well as in the subsequent global submissions and commercial launch preparationsDr. Sloan will be based in the US  establishing an Abivax office on the US East CoastPARIS  FRANCE / ACCESSWIRE / February 17  2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX)  a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases  today announced the appointment of Dr. Sheldon Sloan  M.D.  M. Bioethics  as new Chief Medical Officer  effective on March 1  2023. Dr. Sloan brings over 30 years of experience in academia and the biopharmaceutical industry  with an extensive track record in the field of Gastroenterology and Inflammatory Bowel Disease (IBD). He has spent the last 25 years of his career in large pharmaceutical and biotech companies  including 15 years in leading positions at J&J  followed by Arena Pharmaceuticals and then Pfizer as Program Lead for Etrasimod UC. He successfully managed late-stage clinical trial programs  global submissions and product launches in the IBD field.""We are excited to welcome Sheldon at Abivax and to benefit from his vast experience to drive the clinical and medical strategy and development of our Company in the years to come  said Prof. Hartmut J. Ehrlich  M.D.  CEO of Abivax. ""His strong competencies will be particularly valuable to assist Abivax in conducting our ongoing Phase 3 clinical program with obefazimod for the treatment of UC patients. Further  Sheldon will be driving the strategy for future clinical development programs with obefazimod  first and foremost for Crohn's disease. The Abivax team is now very much looking forward to leveraging our competencies and efforts with Sheldon and to advancing obefazimod towards potential global licensing and to make the drug candidate quickly available to all the patients in need of new effective treatment options  if approved.""Story continuesPrior to joining Abivax  Dr. Sloan worked for Arena Pharmaceuticals and  after its acquisition  for Pfizer. He was Program Lead for Etrasimod UC  responsible for cross-functional leadership  planning and management  operational business process planning  and execution management of the Ulcerative Colitis program  including its global submission and launch. Before joining Arena Pharmaceuticals  Dr. Sloan held different leadership positions at J&J in Medical Affairs  R&D  and Science Policy. In his last position at J&J  he was Global Medical Affairs Leader for IBD  leading the global launch strategy and execution for Crohn's Disease and Ulcerative Colitis for Stelara. Dr. Sloan also has a strong track record in bioethics and has been involved on different levels in questions addressing bioethics issues including animal care and use and human subjects research. Dr. Sloan holds an M.D. from Rush Medical College  Chicago  USA  and a Master of Bioethics from the University of Pennsylvania  USA. He has authored a large number of scientific publications and abstracts and contributed to various books in the gastroenterology and immunology fields.Sheldon Sloan  M.D.  M. Bioethics  CMO of Abivax  commented: ""I am thrilled to join Abivax during these exciting and decisive times and to drive its late-stage clinical program with obefazimod for the treatment of UC through the pivotal studies and  if successful  towards global submissions and launch  if approved. I am excited to have the opportunity to contribute with my dedicated expertise in the IBD field to guide obefazimod through the medical  clinical and commercial steps and processes. I believe that this drug candidate could become a novel long-term therapy option addressing the still high unmet medical needs in the chronic inflammatory disease field and am committed to make sure its potential is fully realized for the benefit of the many patients suffering from IBD and other chronic inflammatory diseases.""*****About Abivax (www.abivax.com)Abivax is a Phase 3 clinical stage biotechnology company  focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax  founded by Truffle Capital  is listed on Euronext compartment B (ISIN: FR0012333284 - MnÃ©mo: ABVX). Based in Paris and Montpellier  Abivax's lead drug candidate  obefazimod (ABX464)  is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.ContactsAbivaxCommunicationsRegina Jehleregina.jehle@abivax.com+33 6 24 50 69 63InvestorsLifeSci AdvisorsLigia Vela-Reidlvela-reid@lifesciadvisors.com+44 7413 825310Press Relations & Investors EuropeMC Services AGAnne Henneckeanne.hennecke@mc-services.eu+49 211 529 252 22Public Relations FranceActifinGhislaine Gasparettoggasparetto@actifin.fr+33 6 21 10 49 24 Public Relations FrancePrimaticeThomas Roborel de Climensthomasdeclimens@primatice.com+33 6 78 12 97 95 Public Relations USARooney Partners LLCJeanene Timberlakejtimberlake@rooneypartners.com+1 646 770 8858DISCLAIMERThis press release contains forward-looking statements  forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax' management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks  contingencies and uncertainties  many of which are difficult to predict and generally beyond the control of Abivax  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. A description of these risks  contingencies and uncertainties can be found in the documents filed by the Company with the French AutoritÃ© des MarchÃ©s Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). These risks  contingencies and uncertainties include among other things  the uncertainties inherent in research and development  future clinical data and analysis  decisions by regulatory authorities  such as the FDA or the EMA  regarding whether and when to approve any drug  as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical  pharmacokinetic  carcinogenicity  toxicity  CMC and clinical data. Furthermore  these forward-looking statements  forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements  forecasts or estimates to reflect any subsequent changes that the Company becomes aware of  except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only  and the information contained herein does not constitute either an offer to sell  or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction  in particular in France. Similarly  it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives  financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.SOURCE: ABIVAXView source version on accesswire.com:https://www.accesswire.com/739772/Abivax-Appoints-Dr-Sheldon-Sloan-MD-as-Chief-Medical-Officer",neutral,0.0,1.0,0.0,mixed,0.71,0.16,0.13,True,English,"['Dr. Sheldon Sloan', 'Chief Medical Officer', 'M.D.', 'Abivax', 'Phase 3 clinical stage biotechnology company', 'ongoing Phase 3 global clinical program', 'novel long-term therapy option', 'Phase 3 clinical-stage biotechnology company', 'ongoing Phase 3 clinical program', 'new Chief Medical Officer', 'high unmet medical needs', 'late-stage clinical trial programs', 'operational business process planning', 'Prof. Hartmut J. Ehrlich', 'other chronic inflammatory diseases', 'future clinical development programs', 'new effective treatment options', 'Global Medical Affairs Leader', 'chronic inflammatory disease field', 'Phase 3 clinical trials', 'late-stage clinical program', 'extensive track record', 'human subjects research', 'Rush Medical College', 'Inflammatory Bowel Disease', 'strong track record', 'Euronext compartment B', 'subsequent global submissions', 'US East Coast', 'potential global licensing', 'Ulcerative Colitis program', 'different leadership positions', 'commercial launch preparations', 'The Abivax team', 'global launch strategy', 'lead drug candidate', 'medical, clinical', 'Dr. Sheldon Sloan', 'Program Lead', 'medical strategy', 'J&J', 'leading positions', 'cross-functional leadership', 'different levels', 'product development', 'commercial launches', 'commercial steps', 'Dr. Sloan', 'strong competencies', 'M.D.', 'pharmaceutical industry', 'critical role', 'successful conduct', 'immune system', 'large pharmaceutical', 'biotech companies', 'Arena Pharmaceuticals', 'product launches', 'R&D', 'Science Policy', 'last position', 'animal care', 'large number', 'scientific publications', 'various books', 'immunology fields', 'decisive times', 'pivotal studies', 'dedicated expertise', 'Truffle Capital', 'MnÃ©mo', 'More information', 'LifeSci Advisors', 'Ligia Vela-Reid', 'Press Relations', 'Euronext Paris', 'M. Bioethics', 'bioethics issues', 'IBD field', 'Etrasimod UC', 'vast experience', 'Regina Jehle', 'many patients', 'Abivax office', 'Abivax SA', 'Abivax Communications', 'last 25 years', 'UC patients', 'execution management', '30 years', '15 years', 'focus', 'CMO', 'completion', 'obefazimod', 'FRANCE', 'ACCESSWIRE', 'February', 'ABVX', 'therapeutics', 'appointment', 'March', 'academia', 'Gastroenterology', 'career', 'Pfizer', 'CEO', 'Crohn', 'efforts', 'Story', 'acquisition', 'Stelara', 'questions', 'use', 'Chicago', 'USA', 'Master', 'University', 'Pennsylvania', 'abstracts', 'exciting', 'opportunity', 'processes', 'benefit', 'Montpellier', 'Twitter', 'Contacts', 'Investors', 'lifesciadvisors']",2023-02-17,2023-02-18,finance.yahoo.com
18713,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bekaert-completion-share-buyback-program-071500854.html,Bekaert - Completion of the Share Buyback Program and Update on the Liquidity Agreement,Completion of the Share Buyback Program and Update on the Liquidity Agreement Period from 9 February 2023 to 15 February 2023 Share Buyback Program fully...,BekaertCompletion of the Share Buyback Program and Update on the Liquidity AgreementPeriod from 9 February 2023 to 15 February 2023Share Buyback Program fully implementedOn 25 February 2022   Bekaert announced a program (the â€œProgramâ€) to buy back own shares up to â‚¬ 120 million. The Program was split into four equal tranches of up to â‚¬ 30 million each.Bekaert announces today that it completed the fourth and last tranche of the Program. During the fourth tranche  which started on 18 November 2022 and ended on 13 February 2023  the company repurchased 820 929 ordinary shares for an aggregate consideration of â‚¬ 30 million. Under the full Program  the company repurchased 3 488 344 ordinary shares for an aggregate consideration of â‚¬ 117.3 million.As previously announced  the purpose of the Program is to reduce the issued share capital of the company and all shares repurchased as part of this arrangement will be cancelled. So far  1 449 409 treasury shares were cancelled. The balance of the repurchased shares (2 038 935 shares) will be cancelled before the end of February 2023.Bekaertâ€™s reference shareholder  Stichting Administratiekantoor Bekaert (STAK) and the parties acting in concert with the STAK  have confirmed that they will take appropriate measures so that their voting rights in Bekaertâ€™s share capital will not exceed the level they had at the start of the Program (i.e. 36.13%) by the end of February 2023.During the period from 9 February 2023 to 13 February 2023  Kepler Cheuvreux on behalf of Bekaert has bought 38 369 shares.The table below provides an overview of the transactions under the fourth tranche of the Program during the period from 9 February 2023 to 13 February 2023:Repurchase of shares Date Market Number of Shares Average Price paid (â‚¬) Highest Pricepaid (â‚¬) Lowest Pricepaid (â‚¬) TotalAmount (â‚¬) 9 February 2023 Euronext Brussels 6 345 40.24 40.48 39.80 255 323 MTF CBOE 3 952 40.21 40.44 39.78 158 910 MTF Turquoise 765 40.25 40.44 39.96 30 791 MTF Aquis 1 497 40.25 40.46 39.92 60 254 10 February 2023 Euronext Brussels 7 833 39.93 40.40 39.64 312 772 MTF CBOE 4 808 39.95 40.38 39.62 192 080 MTF Turquoise 889 39.96 40.36 39.76 35 524 MTF Aquis 1 893 39.96 40.38 39.62 75 644 13 February 2023 Euronext Brussels 7 725 39.74 39.90 39.60 306 992 MTF CBOE 2 662 39.76 39.90 39.64 105 841 MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” Total 38 369 39.98 40.48 38.86 1 534 131Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022   Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 2 400 shares during the period from 9 February 2023 to 15 February 2023 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 5 500 shares on Euronext Brussels.Story continuesThe tables below provide an overview of the transactions under the liquidity agreement during the period from 9 February 2023 to 15 February 2023:Purchase of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 9 February 2023 0 0.00 0.00 0.00 0 10 February 2023 400 39.90 39.90 39.90 15 960 13 February 2023 1 200 39.69 39.80 39.54 47 628 14 February 2023 800 39.45 39.50 39.40 31 560 15 February 2023 0 0.00 0.00 0.00 0 Total 2 400 â€” â€” â€” 95 148Sale of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 9 February 2023 1 900 40.15 40.40 39.80 0 10 February 2023 0 0.00 0.00 0.00 0 13 February 2023 0 0.00 0.00 0.00 0 14 February 2023 2 000 39.86 40.00 39.80 79 720 15 February 2023 1 600 40.20 40.40 39.90 64 320 Total 5 500 â€” â€” â€” 144 040The balance held by Bekaert under the liquidity agreement at the end of the period is 37 636 shares.On 15 February 2023 after closing of the market  Bekaert holds 4 750 289 own shares  or 8.05% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Attachment,neutral,0.01,0.99,0.0,positive,0.69,0.27,0.04,True,English,"['Share Buyback Program', 'Liquidity Agreement', 'Bekaert', 'Completion', 'Update', 'four equal tranches', 'investor relations pages', 'Stichting Administratiekantoor Bekaert', 'Share Buyback Program', 'Shares Average Price', 'Date Market Number', 'Liquidity Agreement Period', 'Date Number', 'share capital', 'Highest Price', 'Lowest Price', 'last tranche', 'aggregate consideration', 'reference shareholder', 'appropriate measures', 'voting rights', 'Kepler Cheuvreux', 'Euronext Brussels', 'MTF CBOE', 'MTF Turquoise', 'MTF Aquis', 'total number', 'fourth tranche', '820 929 ordinary shares', '3 488 344 ordinary shares', '1 449 409 treasury shares', 'outstanding shares', 'full Program', 'same period', 'Total Amount', '038 935 shares', '38 369 shares', '2 400 shares', '5 500 shares', '37 636 shares', 'Completion', 'Update', '9 February', '15 February', '25 February', '18 November', '13 February', 'company', 'purpose', 'part', 'arrangement', 'balance', 'end', 'STAK', 'concert', 'level', 'start', 'behalf', 'table', 'overview', 'transactions', 'Repurchase', '2 September', 'Story', '10 February', 'Sale', '14 February', 'closing', 'information', 'website', 'Attachment', '750 289']",2023-02-17,2023-02-18,finance.yahoo.com
18715,EuroNext,NewsApi.org,https://finance.yahoo.com/news/autoliv-board-directors-approves-renewal-203100757.html,Autoliv: Board of Directors approves renewal of EMTN Programme,"The Funding Committee of the Board of Directors of Autoliv  Inc. (NYSE: ALV) (SSE: ALIVsdb) (the ""Company"") approved on February 14  2023 the renewal for one...","STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- The Funding Committee of the Board of Directors of Autoliv  Inc. (NYSE: ALV) (SSE: ALIVsdb) (the ""Company"") approved on February 14  2023 the renewal for one year of its â‚¬3 000 000 000 guaranteed euro medium term note programme (the ""EMTN Programme"")  which was originally established on 11 April 2019.The renewal of the EMTN Programme will allow the Company to take advantage of the funding opportunities provided by the capital markets and institutional investors through the future issuance of notes (the ""Notes""). The Notes issued by the Company under the EMTN Programme will be unconditionally and irrevocably guaranteed by the Company's subsidiary  Autoliv ASP  Inc. (the ""Guarantor"").The base listing particulars dated February 17  2023 (the ""Base Listing Particulars"")  which has been prepared by the Company and the Guarantor in connection with the EMTN Programme  has been approved by Euronext Dublin and is available for viewing on the website of Euronext Dublin (http://www.ise.ie).InquiriesTreasury: Par-Ola Wirenlind  Tel +46 (0) 7 030 332 78Investors & Analysts: Anders Trapp  Tel +46 (0) 8 587 206 71Investors & Analysts: Henrik Kaar  Tel +46 (0)8 587 206 14Media: Gabriella Ekelund  Tel +46 (70) 612 64 24About AutolivAutoliv  Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies  we develop  manufacture and market protective systems  such as airbags  seatbelts  and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions  such as pedestrian protection  connected safety services and safety solutions for riders of powered two wheelers. At Autoliv  we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2022  our products saved close to 35 000 lives and reduced more than 450 000 injuries.Our close to 70 000 associates in 27 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation  research  and development at our 14 technical centers  with their 20 test tracks. Sales in 2022 amounted to US $ 8.8 billion. For more information go to www.autoliv.com.Story continuesImportant InformationNOTHING IN THIS COMMUNICATION CONSTITUTES AN OFFER TO SELL  OR THE SOLICITATION OF AN OFFER TO BUY  ANY SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES REFERRED TO IN THE BASE LISTING PARTICULARS (THE ""SECURITIES"") HAVE NOT BEEN  AND WILL NOT BE  REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933  AS AMENDED (THE ""SECURITIES ACT"")  OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES  AND THE SECURITIES MAY NOT BE OFFERED OR SOLD  DIRECTLY OR INDIRECTLY  WITHIN THE UNITED STATES OR TO  OR FOR THE ACCOUNT OR BENEFIT OF  U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) EXCEPT PURSUANT TO AN EXEMPTION FROM  OR IN A TRANSACTION NOT SUBJECT TO  THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.Safe Harbor StatementThis communication contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities  events or developments that Autoliv  Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations  various assumptions and data available from third parties.Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However  there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks  uncertainties and other factors which may cause actual future results  performance or achievements to differ materially from the future results  performance or achievements expressed in or implied by such forward-looking statements.Numerous risks  uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this communication or any other document  we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995  and we assume no obligation to update publicly or revise any such statements in light of new information or future events  except as required by law.The following files are available for download:https://mb.cision.com/Main/751/3718209/1858691.pdf Autoliv: Board of Directors approves renewal of EMTN Programme (PDF)CisionView original content:https://www.prnewswire.co.uk/news-releases/autoliv-board-of-directors-approves-renewal-of-emtn-programme-301750184.html",neutral,0.01,0.99,0.0,mixed,0.36,0.24,0.41,True,English,"['EMTN Programme', 'Autoliv', 'Board', 'Directors', 'renewal', 'â‚¬3,000,000,000 guaranteed euro medium term note programme', 'Private Securities Litigation Reform Act', 'UNITED STATES SECURITIES ACT', 'market protective systems', 'major automotive manufacturers', 'close to 70,000 associates', 'U.S. PERSONS', 'automotive safety systems', 'connected safety services', 'base listing particulars', 'Safe Harbor Statement', 'mobility safety solutions', 'The Funding Committee', 'Such forward-looking statements', 'actual future results', 'actual results', 'EMTN Programme', 'funding opportunities', 'leading solutions', 'SECURITIES LAWS', 'one year', 'capital markets', 'future issuance', 'Euronext Dublin', 'ise.ie', 'Inquiries Treasury', 'Par-Ola Wirenlind', 'Anders Trapp', 'Henrik Kaar', 'Gabriella Ekelund', 'Nasdaq Stockholm', 'ALIV.sdb', 'worldwide leader', 'group companies', 'steering wheels', 'two wheelers', '14 technical centers', '20 test tracks', 'OTHER JURISDICTION', 'REGISTRATION REQUIREMENTS', 'historical facts', 'third parties', 'good faith', 'reasonable basis', 'unknown risks', 'other factors', 'Numerous risks', 'other document', 'following files', 'original content', 'Important Information', 'new information', 'pedestrian protection', 'More Lives', 'APPLICABLE STATE', 'current expectations', 'various assumptions', 'future events', 'institutional investors', 'Autoliv ASP', '35,000 lives', 'Feb.', 'Board', 'Directors', 'Inc.', 'NYSE', 'ALV', 'SSE', 'ALIVsdb', 'Company', 'February', 'renewal', '11 April', 'advantage', 'notes', 'subsidiary', 'Guarantor', 'connection', 'website', 'Tel', 'Analysts', 'Media', 'airbags', 'seatbelts', 'riders', 'standards', 'products', '450,000 injuries', '27 countries', 'vision', 'quality', 'heart', 'everything', 'innovation', 'research', 'development', 'Sales', 'Story', 'COMMUNICATION', 'OFFER', 'SELL', 'SOLICITATION', 'BUY', 'ACCOUNT', 'BENEFIT', 'REGULATION', 'EXEMPTION', 'TRANSACTION', 'meaning', 'activities', 'management', 'data', 'assurance', 'uncertainties', 'performance', 'achievements', 'obligation', 'light', 'download', 'cision', 'Main', 'news-releases', 'emtn-programme', '46']",2023-02-17,2023-02-18,finance.yahoo.com
18716,EuroNext,NewsApi.org,https://finance.yahoo.com/news/dsm-delivery-shares-203000898.html,DSM - delivery of shares,Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital ...,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube AG (to be renamed DSM-Firmenich AG) for all the issued and outstanding ordinary shares in the capital of DSM (the Exchange Offer). This press release does not constitute an offer  or any solicitation of any offer  to buy or subscribe for any securities. This press release is not for general release  publication or distribution  in whole or in part  in or into  directly or indirectly  the United States or any other jurisdiction where such release  publication or distribution would violate applicable laws or regulations.HEERLEN  Netherlands  Feb. 17  2023 /PRNewswire/ -- Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.DSM Logo.Pursuant to commitments entered into prior to issuing the Offering Circular  DSM has on 17 February 2023  delivered 165 ordinary shares to employees in view of settling the exercise of an equivalent number of stock options granted under the respective DSM Incentive Plan (average exercise price â‚¬94.82). On the date hereof  the total number of issued and outstanding DSM ordinary shares is 173 126 125. As a consequence of the delivery included herein  the number of outstanding DSM ordinary shares increased by 0.0001%.DSMRoyal DSM is a global  purpose-led company in Health  Nutrition & Bioscience  applying science to improve the health of people  animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic  environmental and societal value for all its stakeholders â€“ customers  employees  shareholders  and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.Story continuesOr find us on:LinkedIn: http://www.linkedin.com/company/3108Twitter: http://www.twitter.com/DSMFacebook: http://www.facebook.com/DSMcompanyYouTube: http://www.youtube.com/user/dsmcompanyFor more informationDSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 email investor.relations@dsm.comForward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations  estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release  unless required by law. The English language version of the press release is leading.Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpgCisionView original content:https://www.prnewswire.co.uk/news-releases/dsm---delivery-of-shares-301750087.html,neutral,0.02,0.98,0.0,mixed,0.39,0.18,0.43,True,English,"['DSM', 'delivery', 'shares', 'DSM Media Relations Gareth Mead', 'DSM Investor Relations Dave Huizing', 'Koninklijke DSM N.V.', 'respective DSM Incentive Plan', 'Dutch public offer rules', 'outstanding DSM ordinary shares', 'outstanding ordinary shares', 'Public Takeover Bids', 'English language version', 'future (financial) performance', 'average exercise price', 'global, purpose-led company', '165 ordinary shares', 'treasury shares', 'Dutch Decree', 'actual performance', 'Royal DSM', 'Sections 13 paragraphs', 'biedingen Wft', 'Danube AG', 'Exchange Offer', 'United States', 'other jurisdiction', 'applicable laws', 'Offering Circular', 'share units', 'stock options', 'brighter lives', 'biggest challenges', 'economic, environmental', 'societal value', 'Euronext Amsterdam', 'current expectations', 'many factors', 'original content', 'press release', 'general release', 'DSM Logo', 'equivalent number', 'total number', 'Forward-looking statements', 'Such statements', 'More information', 'provisions', 'connection', 'capital', 'solicitation', 'securities', 'publication', 'distribution', 'part', 'regulations', 'HEERLEN', 'Netherlands', 'Feb.', '22 November', 'transactions', 'accordance', 'delivery', 'employees', 'view', 'vesting', 'commitments', '17 February', 'date', 'consequence', 'Health', 'Nutrition', 'Bioscience', 'people', 'animals', 'planet', 'products', 'solutions', 'world', 'stakeholders', 'customers', 'shareholders', 'society', 'Story', 'LinkedIn', 'Twitter', 'Facebook', 'DSMcompany', 'YouTube', 'position', 'estimates', 'projections', 'readers', 'risks', 'uncertainties', 'obligation', 'prnewswire', 'Cision', 'news-releases']",2023-02-17,2023-02-18,finance.yahoo.com
18717,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610339/0/en/EVS-REPORTS-2022-RESULTS.html,EVS REPORTS 2022 RESULTS,Publication on February 17  2023  before market openingRegulated information â€“ Press release annual resultsEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR)  Bloomberg (EVS BB)  Reuters (EVSB.BR),"English FrenchPublication on February 17  2023  before market openingRegulated information â€“ Press release annual resultsEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR)  Bloomberg (EVS BB)  Reuters (EVSB.BR)EVS reports 2022 resultsLiÃ¨ge  Belgium  February 17th  2023EVS delivers record revenue and order intake resultsThe results of 2022 are entirely supporting the growth ambitions of EVS. All the fundamentals for topline performance are strong: EVS realizes a record-high order intake and achieves a historical revenue number  despite the increased delivery terms in 2022. EVS is able to demonstrate a strong net profit result and as a consequence  realizes a solid Earnings Per Share.FY22 HighlightsRecord order intake at EUR 218 8 million  growing 46 5% YoY.Revenue performance in line with expectations at EUR 148 2 million  growing 7 7% vs. FY21 despite increased delivery terms announced early 2022 and despite reduced Big Event Rental (BER) activity. The growth is realized through strong growth in North America and in the MediaInfra solution.Controlled OPEX growth  in line with market expectations.Healthy net profit at EUR 31 3 million driven by a strong financial income performance and a one-off benefit in taxes  resulting in fully diluted earnings per share of EUR 2 29.2H22 HighlightsRecord order intake of EUR 130 1 million (including Big Tech 2022 contract).Revenue for the second half of 2022 at EUR 80 5 million  growing 6 1% compared to the same period last year. Big Event Rental revenue at EUR 4 2 million  down EUR 4 9 million compared to 2H21. Revenue excluding Big Event Rental at EUR 76 3 million  growing EUR 9 5 million.Net profit amounts to EUR 15 9 million  leading to fully diluted earnings per share of EUR 1 14.Outlook 2023The important order intake of 2022 has considerably fueled the order book to be delivered in future periods. The total order book at the end of 2022 is of EUR 141 8 million  growing 122% compared to last year. The order book reserved for 2023 is estimated at EUR 85 9 million  growing 68 4% compared to beginning of the year 2022.Based on the order book and current market dynamics  the revenue guidance for the year 2023 is set at EUR 145-155 million.The revenue range demonstrates the ambition of EVS to continue the organic growth  in a year with no Big Event Rental revenue.With the growth engine launched  the focus in 2023 for EVS will be on profitable growth.EVS plans no further growth in team members nor do we expect an increase in our capital expenditure envelope.We expect to pay out dividends in 2023 in line with our dividend policy  namely a base dividend per share of EUR 1 10.Key figuresEUR millions  except earnings per share expressed in EUR 2H22 2H21 Variance FY22 FY21 Variance Revenue 80 5 75 8 4 7 148 2 137 6 10 6 Gross profit 53 0 53 2 -0 2 98 8 95 8 3 0 Gross margin % 65 8% 70 3% -4 5 Pts 66 7% 69 6% -2 9 Pts Operating profit â€“ EBIT 16 0 21 7 -5 7 31 7 37 1 -5 4 Operating margin â€“ EBIT % 19 9% 28 6% -8 7 Pts 21 4% 27 0% -5 6 Pts Net profit (Group share) 15 9 19 3 -3 5 31 3 34 9 -3 6 Fully diluted EPS (Group share) 1 14 1 42 -0 28 2 29 2 57 -0 28CommentsSerge Van Herck  CEO comments:â€œIâ€™m proud to say that 2022 was again quite a successful year for EVS. Our PlayForward strategy  as defined at the end of 2019  is starting to deliver the expected growth momentum.In 2022  we had a second record year in a row  with strong growth in revenues  order intake  and team member size. We showed significant growth in North America  announced our largest contract ever in August with the ""Big Tech 22 contractâ€ worth over 50MioUSD  and successfully fought against inflation and component shortages throughout the year.We feel we are winning market share in our Live Audience Business and protecting our position in the Live Service Providers markets. We successfully supported many of our customers in delivering the live TV production of major sports events in Asia  the Middle East  and North America.The growth of our team is clearly unlocking our sustainable growth ambitions. Our strong employer branding has enabled us to successfully hire strong talent across the world. Our team member engagement survey shows again further improvements compared to the years before  resulting in our recent â€œTop Employerâ€ certification.We are making good progress in our vision of developing a strong ecosystem relying on our VIA platform as we are successfully moving from product to solution sales. Our introduction of Artificial Intelligence (AI) in XtraMotion is a revolution in the industry and it represents a major differentiator.The Axon acquisition in May 2020 has translated into our Media Infrastructure revenue growth and positively contributes to our bottom line  demonstrating our capability to execute successfully large acquisitions. We have also launched our new ERP and upgraded our VIA Portal applications such as our customer ticketing system to support our long-term growth ambitions.In line with our commitments  we continued to deliver strong dividends for our shareholders. Our sustainability strategy has started to deliver strong results aligned with our customerâ€™s expectations  and resulting in good ESG ratings like the Ecovadis Silver medal. We completed our first carbon footprint analysis: this will be a critical management tool for taking the right sustainability decisions in the future.In conclusion  our PlayForward strategy  is clearly being appreciated by our customers and channel partners. This is helping us to get back into growth mode. While economic market conditions remain very challenging with high inflation  component shortages and with the war in Ukraine  we feel that our customers increasingly appreciate the reliability  performance and innovative edge of our solutions and services.Our ambition for the next years is to continue to deliver growth on both our top and bottomline. We are convinced that by focusing on cost control we will be able to deliver upon this promise.â€Commenting on the results and the outlook  Veerle De Wit  CFO  said:â€œOur 2022 revenue results clearly demonstrate our ability to achieve organic growth. Even despite increased delivery terms  announced early 2022  and with a declining Big Event Rental revenue  we are able to realize a strong top line performance. All indicators lead us to conclude that this organic growth is here to stay: the revenue performance  together with the strong secured revenue position for 2023  are a solid basis to continue our growth path.Being a company in growth mode  means that the necessary resources need to be invested to support this growth: 2022 has been a year where we invested in additional resources  in new product developments  and in the back-bone of our operations. This backbone  a globally released new ERP system  has allowed us to optimize our processes and refine our cost control. As a result  the granularity of our reporting is improving  which has led to a decision to write off EUR 0 7 million of Bill of Material costs in 4Q22.Our operational expenses grew in a controlled way. Control over our spending patterns remains an attention point for 2023  especially in the current volatile market.Thanks to sound treasury management and tax benefits  we are able to generate a strong Net Profit worth EUR 31 3 million  driving a diluted Earnings Per Share of EUR 2 29.Our balance sheet also remains healthy with a very low debt level and a sound cash position. Our cash position is declining throughout 2022  as a consequence of high dividends paid  and as a consequence on increased Net Working Capital requirements. The impact on Net Working Capital is temporary: the implementation of the new ERP system has created a delay in invoicing in the fourth quarter â€“ the quarter with the highest volume â€“ resulting in a large volume of receivables not due at the end of 2022. This is a temporary effect  that will normalize early in 2023  as soon as the invoices become due.Based on the strong results for the year 2022  we are able to maintain our dividend policy defined earlier in 2022.â€Market & customersThe record high numbers in terms of revenues  order intake and order book translate the market traction that EVS is living. Our main growth drivers are North America and Media Infrastructure. The performance of our MediaInfra solution clearly demonstrates the power of our acquisition strategy. It is the fruit of our investment in Axon in 2020  and this acquisition demonstrates its return on investment 2 years later.The high order intake is also thanks to our biggest contract signed in the history of EVS: our Big Tech 2022. This contract proved an exceptional milestone in the history of EVS. This contract is a 10-year agreement that covers the delivery of EVSâ€™ live production  replay and highlight solutions LiveCeptionÂ®  combined with a long-term services level agreement. The contract provides our US based customer access to the latest technology innovations for the next 10 years  a full upgrade of its installed base  a predictable operational spend and an ease of operations.2022 was a year with important Big Events  that EVS was able to support successfully. New solutions  like MediaHub and MediaInfra Strada  were introduced in our Big Event Rental business with success.Market conditions have been challenging throughout the year  with volatile interest rates  inflation and a continued erratic components market. This volatile market has urged EVS to implement a systemic price increase policy. Twice a year the sales prices are evaluated based on the underlying cost for components and inflation of labour cost. EVS has introduced 2 price increases in 2022: a first one in February 2022  and a second one in September 2022. The price increase policy aims to guarantee the overall profitability of the solutions of EVS.The erratic components market also forced EVS to extend its delivery periods early 2022 and to change the supply chain approach. However  as most components suffer longer lead-times  EVS has pro-actively invested in inventory to ensure these delivery terms are met.EVS has received many awards in 2022  and this for different business dimensions. Ranging from technology awards (Neuron Protect Best of Show Award at the NAB Show)  to Wallonia International Business Awards  to IABM Environmental Sustainability award  to Top Employer Certification 2023.Three years after the PLAYForward strategic exercise that has moved the focus from products to solutions  we can confidently say that this solution driven approach is highly appreciated by our customers and contributes to the differentiation reflected in the order book.TechnologiesDuring 2022  new generation of AI products did surface on the market. EVS continues to invest in the development of specific machine learning algorithms for broadcast specific components and also integrates in parallel existing AI technologies or libraries inside the solution portfolio or the workflows deployed for our customers.EVS also further developed and evangelized this year the concept of â€œBalanced computingâ€ as the best distribution of the computing workload between on-prem  datacenter and public cloud based on the economic benefits and the technical constraints for a specific workflow. This concept has been well received by the market where some players start to discover the limitations in terms of feature and the significant impact on Total Cost of Ownership for the production of premium events.EVS also currently invests in the development of important solution components that will be later embraced in the different solutions. Thanks to the capability to track the benefits brought by these components in the future  these developments are activated. These developments will contribute to the future sustainable growth of EVS.Corporate topics2022 marks the moment where the Axon acquisition really starts to pay off for EVS. The initial assumptions made in terms of greographical expansion of the market are becoming a reality. Also the developments made to ensure end-to-end integration with EVS products demonstrate the complementarity of this company within the EVS portfolio. It comforts us in our Acquisition strategy and our ability to integrate companies.One of the axes of the PLAYforward strategy is improving our internal way of working. As a company we want to ensure that we have efficient processes in place that promote end-to-end collabration across all our departments. Having an efficient operational back-bone is important in that context. In October 2022  EVS launched a new global ERP system to ensure optimimal functioning of our company. The launch was a success and did not cause any major business interruption: shipping  production and support were active as of day 1. We now have a solid base to continously optimize our processes and ensure an optimal team member and customer experience.Speaking about improved processes  2022 is also the year where we first implemented a systemic listprice adjustment. The market conditions require a clear methodology to offset the impact of rising component prices and increasing inflation over labour costs. EVS now evaluates the need for price adjustments twice a year to protect the margin generation of the company.2022 is also the year where we continue to expand our sustainability efforts in terms of ESG. After a first hollistic report published in 2021  we continue to structure our efforts in terms of sustainability. Our current ESG strategy and reporting has already received postive feedback from the market: we received a silver medal from Ecovadis  obtained encouriging score from other rating companies and recently obtained the certification of Top Employer for 2023. By the end of 2022  we also realized our first EVS Carbon Footprint analysis: it provides us not only insight on our direct and indirect CO2 emissions  but most importantly  helps us to define our roadmap to reduce our carbon footprint in the future.EVS also reinvented the way it collaborates with its channel partners. A structured channel partner program has been developed  focused on sustainable relationships with partners more than on opportunistic market responses  starting to develop certification paths and clear objectives. This program allows EVS to reach a broader set of clients and even penetrate new markets.Being a company in growth mode  EVS further invested in additional team members. Additional resources were primarily allocated to support and operations roles  as to fuel our future growth  and some research and development resources  as to staff some important developments ensuring future growth. Thanks to a strong employer branding  EVS was able to attract this high number of talents in a relatively short time frame.Also to support our future growth ambition  EVS further strengthened its leadership team  early 2022. A new CTO  Alex Redfern  was welcomed and Xavier Orri was named EVP of Projects & Operations.Revenue in 2H22 and FY22In 2H22  EVS revenue reached EUR 80 5 million: an increase of EUR 4 7 million or 6 2% compared to 2H21  despite a drop of EUR 4 2 million on Big Event Rentals.At constant currency  revenue decreased by 1.6% YoY.Revenue â€“ EUR millions 2H22 2H21 2H22/2H21 Total reported 80 5 75 8 6 0% Total at constant currency 74 7 75 8 -1.6% Total at constant currency and excluding big event rentals 70 5 66 8 5.6%For the full year 2022  EVS revenue reached EUR 148 2 million: an increase of EUR 10 6 million or 7 7% compared to 2021  despite a drop of EUR 3 7 million on Big Event Rentals and despite an increased delivery term announced early 2022. This performance demonstrates the organic growth realized in 2022.At constant currency  revenue increased by 3 5% YoY.Revenue â€“ EUR millions FY22 FY21 FY22/FY21 Total reported 148 158 137 578 7 7% Total at constant currency 142 382 137 578 3.5% Total at constant currency and excluding big event rentals 132 532 124 044 6.8%Currency fluctuations primarily impact EVS revenues by the EUR/USD conversion  which can have a significant impact on our results even if EUR/USD fluctuations also impact the cost of our US operations and partially our cost of goods sold.In the second half of the year  (excl. Big Event Rentals) LSP represented 40% (31% in 2H21) of the revenue  LAB 55% (57% in 2H21).Geographically  revenues (excl. Big Event Rentals) are distributed in 2H22 as follows:Europe  Middle East and Africa (EMEA): EUR 39 1 million (EUR 31 7 million in 2H21)EUR 39 1 million (EUR 31 7 million in 2H21) Americas (NALA): EUR 25 9 million (EUR 21 7 million in 2H21)EUR 25 9 million (EUR 21 7 million in 2H21) Asia & Pacific (APAC): EUR 11 3 million (EUR 13 4 million in 2H21)  impacted by the slowdown in the region following COVID implications (primarily in China). The order intake for APAC in 2H22 do recomfort us that this trend can be reversed.Overall 2022 resultsConsolidated gross margin was at 66 7% for FY22  compared to 69 6% in FY21 (-2 9 Pts) explained by different drivers:Important investments in the operations & support department to ensure we continue to deliver quality support all over the world  in line with our growth patterns (representing -1 4 Pts)Impact of the change in solution mix is representing -1.1 Pts following the relative weight of Media Infrastructure in the overall portfolio.Write-off worth EUR 0 7 million linked to bill of material costs  following more granuler inventory reporting thanks to optimized processes in our new ERP (-0 4 Pts)In order to maintain gross profit levels  the impact of cost price increases and inflation have been systematically modeled by corresponding sales price increases. This has resulted primarily in improved margins for our Media Infrastructure and MediaCeption solutions.Operating expenses increased by 11% YoY (remaining below the guidance provided) explained by inflation on labour cost and energy prices and post-COVID spending patterns impacting spend for travel  marketing  â€¦ EVS did also invest in additional Research & Development resources in 2022  both through internal engagements as well as external contracts. These additional resources were staffed on 2 important developments  recognized as intangible assets in 2022. The associated spend was therefore capitalised on the balance sheet.Overall EBIT performance is of EUR 31 7 million  generating an EBIT margin of 21 4%.The net profit ends at EUR 31 3 million benefiting from a strong financial income following pro-active cash flow management and low income taxes (EUR 1 4 million compared to EUR 2 8 million last year) resulting from an excess in tax paid in 2021 and various tax latencies linked to prior years.The net profit leads to a fully diluted earnings per share of EUR 2 29 (versus EUR 2 57 in 2021).Overall second half 2022 resultsThe gross profit margin in 2H22 was of 65 9% compared to 70 3% in the same period last year. The drop is a consequence of lesser revenue from Big Event Rentals and a higher weight of Media Infrastructure solution in the overall mix. In addition  the impact of the hirings done in 2022 to ensure continued quality operations and support affect the comparison.Operating expenses grew 13.8% in 2H22  compared to the same period last year and are a reflection of post-COVID spending patterns and impact of inflation.The 2H22 EBIT margin was 19 8%  compared to 28 6% in 2H21: the EBIT margin is dropping primarily following investments in the past 12 months to support our growth pattern.The Group net profit amounted to EUR 15 9 million in 2H22  compared to EUR 19 3 million in 2H21. Fully diluted earnings per share amounted to EUR 1 14 in 2H22 compared to EUR 1 42 in 2H21.Team membersAt the end of 2022  EVS employed 613 team members (FTE). This is an increase by 62 team members compared to the end of 2021 (551 FTE). This increase in team members reflects our continued investments in the growth of EVS. We expect no further growth of our team member base in 2023  and we will ensure that we balance the priorities of EVS with the existing workforce.Balance sheet and cash flow statementEVS continues to have a strong balance sheet with net cash position of EUR 33 8 million with low debt level (of which EUR 12 5 million related to IFRS 16) resulting in a total equity representing 75 4% of the total balance sheet as of the end of 2022. The decrease in cash and cash equivalents (EUR -23 1 million) compared to end of 2021 is mainly driven by the dividends paid in May and November (including exceptional additional dividend)  combined with the increase in working capital requirements at the end of 2022.The working capital requirements are growing  primarily linked to growing trade receivables. The trade receivables evolve largely in line with our overall sales volumes. 71% of our trade receivables is not due at year-end  with a large volume of invoices issued in the second half of the fourth quarter  given a temporary hold of invoicing operations after the Go-Live of our new ERP system. We expect these trade receivales to restore in 1Q23. A sound cash position remains a priority for EVS.Other intangible assets include the costs for internal development capitalized during 2022 according to IAS 38 (Intangible assets).Lands and building mainly include the headquarters in LiÃ¨ge as well as the right of use for the offices abroad (IFRS16).Inventories amount to EUR 28 8 million  an increase of EUR 2 8 million compared to the beginning of the year as a reflection of a pro-active supply chain management to ensure we systematically meet our customersâ€™ delivery terms.Liabilities include EUR 15 3 million of financial debt (including long term and short-term portion)  mainly related to the lease liabilities for EUR 12 5 million and borrowings for EUR 2 8 million. Long-term provisions include the provision for technical warranty on EVS products for labor and parts. Other amounts payable mainly represent deferred income and advance payments received from customers on contracts in progress.Net cash from operating activities amounts to EUR 11 0 million for the full year 2022  compared to EUR 38 7 million in 2021. The decrease is mainly driven by higher working capital requirements resulting from higher trade receivables (as described above) and lower trade payables  combined with lower net profit. On December 31  2022  cash and cash equivalents total EUR 49 1 million  compared to EUR 72 1 million at the end of 2021. The decrease is mainly driven by lower cash from operating activities  combined with the increase of the net cash used in investing activities mainly due to the investments in intangible and tangible assets (specifically in the internal development of intangible assets) together with the increase of the net cash used in financing activities following the higher amount of dividends distributed during 2022  including the exceptional dividend.At the end of December 2022  there were 14.327.024 EVS shares outstanding  of which 908.014 were owned by the company. At the same date  492.975 warrants were outstanding with average exercise price of EUR 16 95 and maturities between October 2026 and September 2028.Corporate updateThere has been no further change to the composition of the Board of Directors since the last General Assembly on May 17th during which the shareholders had appointed two new directors  FrÃ©dÃ©ric Vincent and Marco Miserez  both for a period of 4 years. The Board of Directors is currently composed of seven directors:Johan Deschuyffeleer   independent director & President (representing The House of Value BVBA);  independent director & President (representing The House of Value BVBA); Michel Counson   managing director;  managing director; Martin De Prycker   independent director (representing InnoConsult BVBA);  independent director (representing InnoConsult BVBA); Chantal De Vrieze   independent director (representing 7 Capital SRL);  independent director (representing 7 Capital SRL); FrÃ©dÃ©ric Vincent   independent director;  independent director; Marco Miserez   independent director; and  independent director; and Anne Cambier  independent director (representing Accompany You SRL)GlossaryTerm Definition Secured revenue Revenue already recognized as well as open orders on hand that will be recognized as revenue in the fiscal year Order book <date> Revenues planned to be recognized after the <date> based on current orders. LAB market pillar LAB â€“ Live Audience BusinessRevenue from customers leveraging EVS products and solutions to create content for their own purposeThis market pillar covers the following types of customers: Broadcasters  Stadium  House of Worship  Corporate Media Centers  Sports organizations  Government & institutions  University & Colleges LSP market pillar LSP â€“ Live Service ProvidersRevenue from customers leveraging EVS products and solutions to serve â€œLAB customersâ€This market pillar covers the following types of customers: Rental & facilities companies  Production companies  Freelance operators  Technology partners & system integrators buying for their own purpose BER market pillar BER â€“ Big Event RentalRevenue from major non-yearly big event rental.This market pillar covers the following types of customers: host broadcasters for major events.In case of discrepancies between the English and the French Version  the English Version prevails.Conference callEVS will hold a conference call in English today at 3.30 pm CET for financial analysts and institutional investors. Other interested parties may join the call in a listen-only mode. The presentation used during the conference call will be available shortly before the call on the EVS website.Participants must register for the conference using the link provided below. Upon registering  each participant will be provided with Participant Dial In Numbers  Direct Event Passcode and unique Registrant ID.1. Online registration: https://register.vevent.com/register/BIe156e14a79604a6984c8fb06a38e3c272. Webcast Player URL: https://edge.media-server.com/mmc/p/yzt4d6v8Corporate CalendarMay 16th  2023: General AssemblyMay 17th  2023: Q1 2023 Trading updateAugust 18th  2023: H1 2023 resultsNovember 17th  2023: Q3 2023 Trading updateFor more information  please contact:VEERLE DE WITEVS Broadcast Equipment S.A.  Liege Science Park  13 rue du Bois Saint-Jean  B-4102 Seraing  BelgiumTel: +32 4 361 70 00 | E-mail: corpcom@evs.com | Website: www.evs.comForward Looking StatementsThis press release contains forward-looking statements with respect to the business  financial condition  and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs of EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements  the companyâ€™s concentration on one industry  decline in demand for the companyâ€™s products and those of its affiliates  inability to timely develop and introduce new technologies  products and applications  and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.About EVSEVS is globally recognized as leader in live video technology for broadcast and new media productions. Our passion and purpose are to help our clients craft immersive stories that trigger the best return on emotion. Through a wide range of products and solutions  we deliver the most gripping live sports images  buzzing entertainment shows and breaking news content to billions of viewers every day â€“ and in real-time.The company is headquartered in Belgium with around 620 employees in offices in Europe  the Middle East  Asia and North America  and provides sales and technical support to more than 100 countries. EVS is a public company traded on Euronext Brussels: EVS  ISIN: BE0003820371. For more information  please visit www.evs.com.Condensed Interim Consolidated financial informationANNEX 1: condensed consolidated income statement(EUR thousands) Notes FY22 FY21 2H22 2H21 Revenue 5.3 148.158 137.578 80.486 75.799 Cost of sales -49.314 -41.764 -27.473 -22.543 Gross profit 98.844 95.814 53.013 53.256 Gross margin % 66 7% 69 6% 65 9% 70 3% Selling and administrative expenses -39.815 -32.392 -22.532 -17.555 Research and development expenses -26.267 -27.088 -14.368 -14.867 Other income 200 1.108 150 1.057 Other expenses -607 -114 -121 -71 Profit-sharing plan and warrants -643 -232 -169 -107 Operating profit (EBIT) 31.712 37.096 15.973 21.713 Operating margin (EBIT) % 21 4% 27 0% 19 8% 28 6% Interest revenue on loans and deposits 106 51 76 -17 Interest charges -912 -893 -439 -446 Other net financial income / (expenses) 5.6 1.793 1.254 -146 932 Share in the result of the enterprise accounted for using the equity method 67 193 -10 -20 Profit before taxes (PBT) 32.766 37.701 15.454 22.162 Income taxes 5.7 -1.422 -2.797 442 -2.853 Net profit 31.344 34.904 15.896 19.309 Attributable to : Non-controlling interest - - - - Share of the Group 31.344 34.904 15.896 19.309 EARNINGS PER SHARE (in number of shares and in EUR) FY22 FY21 2H22 2H21 Weighted average number of subscribed shares for the period less treasury shares 13.411.972 13.400.624 13.419.010 13.401.884 Weighted average fully diluted number of shares 13.681.084 13.587.624 13.768.895 13.588.884 Basic earnings â€“ share of the Group 2 34 2 60 1 19 1 44 Fully diluted earnings â€“ share of the Group (1) 2 29 2 57 1 14 1 42 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (EUR thousands) FY22 FY21 2H22 2H21 Net profit 31.344 34.904 15.896 19.309 Other comprehensive income of the period Currency translation differences 324 475 -231 276 Total of recyclable elements 324 475 -231 276 Difference on opening 460 - 460 - Gains / (losses) on remeasurement of defined benefit obligations  net of tax 1.373 -412 440 -412 Total of non-recyclable elements  net of tax 1.833 -412 900 -412 Total other comprehensive income of the period  net of tax 2.157 63 669 -136 Total comprehensive income for the period 33.501 34.967 16.565 19.173 Attributable to : Non controlling interest - - - - Share of the Group 33.501 34.967 16.565 19.173(1) The diluted earnings per share does include:187.000 warrants attributed in October 2020  of which 154.250 are outstanding with an exercise price below the share price and with maturity in October 2026; 158.600 warrants attributed in June 2021  of which 155.350 are outstanding with an exercise price below the share price and with maturity in June 2027; and 183.375 warrants attributed in September 2022  all outstanding and with a maturity in September 2028.ANNEX 2: condensed statement of financial position (balance sheet)ASSETS(EUR thousands) Notes Dec 31  2022 Dec 31  2021 Non-current assets: Goodwill 2.832 2.832 Other intangible assets 5.10 13.215 6.113 Lands and buildings 5.11 50.543 52.673 Other tangible assets 5.11 4.691 4.307 Investment accounted for using equity method 1.922 1.920 Other amounts receivables 3.647 2.408 Deferred tax assets 4.622 5.933 Financial assets 512 404 Total non-current assets 81.984 76.590 Current assets: Inventories 28.786 25.951 Trade receivables 61.655 38.924 Other amounts receivable  deferred charges and accrued income 11.566 6.417 Financial assets 174 201 Cash and cash equivalents 49.051 72.144 Total current assets 151.232 143.637 Total assets 233.216 220.227EQUITY AND LIABILITIES(EUR thousands) Notes Dec 31  2022 Dec 31  2021 Equity: Capital 8.772 8.772 Reserves 183.390 170.570 Treasury shares -17.447 -17.776 Total consolidated reserves 165.943 152.794 Translation differences 1.075 751 Equity  attributable to the owners of the parent 175.790 162.317 Non-controlling interest - - Total equity 5.4 175.790 162.317 Provisions 1.637 1.502 Deferred taxes liabilities 10 11 Financial debts 5.12 11.528 13.554 Other debts 5.13 120 1.825 Non-current liabilities 13.295 16.892 Financial debts 5.12 3.750 3.728 Trade payables 9.207 10.497 Amounts payable regarding remuneration and social security 11.219 10.658 Income tax payable 1.959 2.586 Other amounts payable  advances received  accrued charges and deferred income 5.6 17.996 13.549 Current liabilities 44.131 41.018 Total equity and liabilities 233.216 220.227ANNEX 3: condensed statement of cash flows(EUR thousands) Notes FY22 FY21 Cash flows from operating activities Net profit  share of the Group 31.344 34.904 Adjustment for: - Depreciation and write-offs on fixed assets 6.738 7.015 - Profit-sharing plan and warrants 5.4 642 232 - Provisions 212 417 - Income tax expense (+) / Income (-) 1.422 2.797 - Net financial expense (+) / income (-) -987 -412 - Share of the result of entities accounted for under the equity method -67 -193 Adjustment for changes in working capital items: - Inventories -2.834 -3.372 - Trade receivables -23.970 -10.061 - Other amounts receivable  deferred charges and accrued income -3.889 -430 - Trade payables -1.290 4.722 - Amounts payable regarding remuneration and social security 541 3.653 - Other amounts payable  advances received  accrued charges  and deferred income 4.776 -263 - Conversion differences 803 813 Cash generated from operations 13.441 39.822 Income taxes received / (paid) 5.7 -2.469 -1.112 Net cash from operating activities 10.972 38.710 Cash flows from investing activities Purchase of intangible assets -8.770 -234 Purchase of tangible assets (lands and building and other tangible assets) -1.101 -1.357 Other financial assets -102 3 Net cash used in investing activities -9.973 -1.588 Cash flows from financing activities Reimbursement of borrowings 5.12 -1.095 -1.086 Payment of lease liabilities -2.828 -3.417 Interests paid -688 -566 Interests received 75 13 Dividend received from investee 64 - Dividend paid -20.112 -13.400 Net cash used in financing activities -24.584 -18.456 Net increase / decrease in cash and cash equivalents -23.585 18.666 Net foreign exchange difference 492 810 Cash and cash equivalents at beginning of period 72.144 52.668 Cash and cash equivalents at end of period 49.051 72.144ANNEX 4: condensed statement of change in equity(EUR thousands) Capital Reserves Treasury shares Currency translation differences Equity share of the Group Non-controlling interest Total equity Balance as per January 1  2021 8.772 149.309 -17.835 276 140.522 - 140.522 Profit or loss 34.904 34.904 34.904 Other comprehensive income -412 475 63 63 Total comprehensive income for the period 34.492 475 34.967 34.967 Share-based payments 232 232 232 Operations with treasury shares 59 59 59 Final dividend -6.699 -6.699 -6.699 Interim dividend -6.701 -6.701 -6.701 Other allocation -63 -63 -63 Balance as per December 31  2021 8.772 170.570 -17.776 751 162.317 - 162.317(EUR thousands) Capital Reserves Treasury shares Currency translation differences Equity share of the Group Non-controlling interest Total equity Balance as per January 1  2022 8.772 170.570 -17.776 751 162.317 - 162.317 Profit or loss 31.344 31.344 31.344 Other comprehensive income 1.833 324 2.157 2.157 Total comprehensive income for the period 33.117 324 33.501 33.501 Share-based payments 581 581 581 Operations with treasury shares -329 329 - - Final dividend -13.402 -13.402 -13.402 Interim dividend -6.710 -6.710 -6.710 Other allocation -497 -497 -497 Balance as per December 31  2022 8.772 183.390 -17.447 1.075 175.790 - 175.790ANNEX 5: notes to the consolidated financial statementsNOTE 5.1: BASIS OF PREPARATION OF THE FINANCIAL STATEMENTSThe consolidated financial statements of EVS Group for the 12 month-period ended December 31  2022  are established and presented in accordance with the International Financial Reporting Standards (IFRS)  as adopted for use in the European Union. The accounting framework and standards adopted by the European Commission can be accessed through the following link on the website: http://ec.europa.eu/finance/company-reporting/index_en.htm.The condensed interim financial statements of the Group for the 12 month-period ending December 31  2022  were authorized for issue by the Board of Directors on February 16  2023. This interim report only provides an explanation of events and transactions that are significant to an understanding of the changes in financial position and reporting since the last annual reporting period and should therefore be read in conjunction with the full 2022 consolidated financial statements from which these condensed financial statements have been derived and which are planned to be published on EVS Groupâ€™s website by April 14  2023. The interim condensed financial statements are prepared on a going concern basis.NOTE 5.2.1: SIGNIFICANT ACCOUNTING POLICIES AND METHODSThese condensed interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting  as issued by the IASB  and as adopted by the EU. The accounting policies and methods adopted for the preparation of the company's IFRS consolidated financial statements are consistent with those applied in the 2021 consolidated financial statements. The companyâ€™s IFRS accounting policies and methods are available in the 2021 annual report on www.evs.com  except for the accounting policy on intangible assets which include the capitalization of development cost for the first time (see note 5.10) as well as the new  amended or revised IFRS standards and IFRIC Interpretations that have been in effect since January 1  2022. The adoption of these new  amended or revised pronouncements did not have a significant impact on the consolidated financial statements of the Group.NOTE 5.2.2: JUDGMENTS AND ESTIMATESImpacts of current market volatility and macroeconomic developmentsThe impacts of the current market volatility and macroeconomic developments were taken into account by the company to assess potential effects on EVSâ€™s financial performance and the valuation of its assets and liabilities. In particular  key assumptions used in the calculation of the pension obligations have been reviewed to ensure a proper valuation as per 31 December 2022. Also  the key assumptions that are used for estimating the recoverable amounts of cash generating units in the context of goodwill impairment test reflect latest market conditions for interest rates and weighted average cost of capitalEstimation of useful life and residual valueProperty  Plant and Equipment are depreciated using a straight-line method to allocate their depreciable amount on a systematic basis over their useful life. For the headquarter building in LiÃ¨ge  the depreciable amount is the cost less its estimated residual value. Useful life and residual value of an asset is estimated on a realistic basis based on the experience of the Group with similar assets and reviewed on a regular basis. The effect of changes in useful life are recognized prospectively.Functional currency of the Group entitiesThe individual financial statements of each subsidiary are prepared in the currency of the primary economic environment in which the entity operates. When the factors set out by IAS 21 to determine the functional currency are mixed and the functional currency is not obvious  management judgment is used to determine which functional currency most faithfully represents the economic effects of its underlying transactions  events and conditions. The functional currency of the EVS Group entities is EUR except for the US entity EVS Inc. for which US Dollar is assessed by management to be the functional currency.Claims and contingent liabilitiesRelated to claims and contingencies  judgement is necessary in assessing the existence of an obligation resulting from a past event  in assessing the probability of an economic outflow  and in quantifying the probable outcome of economic resources. This judgment is reviewed when new information becomes available and often with support of internal and external expert advice.Impact of the war in Ukraine on our activitiesGiven the nature and location of its operations and the fact that EVS does not currently have activities in Russia nor in Ukraine or with Russian companies  The Company does not foresee a direct impact of the Ukrainian conflict on its business.NOTE 5.3: SEGMENT REPORTINGFrom an operational point of view  the company is vertically integrated with the majority of its staff located in the headquarters in Belgium  including the R&D  production  marketing and administration departments. Therefore the majority of investments and costs are located at the level of the Belgian parent company. Resources securing the customer facing interactions such as sales  operations and support profiles are primarily hired within the respective regions. The foreign subsidiaries are primarily sales and representative offices. The Chief Operating Decision Maker  being the Executive Committee  reviews the operating results  operating plans  and makes resource allocation decisions on a company-wide basis. Revenue related to products of the same nature (digital broadcast production equipment) are realized by commercial polyvalent teams. The companyâ€™s internal reporting is the reflection of the above-mentioned operational organization and is characterized by the strong integration of the activities of the company.By consequence  the company is composed of one segment according to the IFRS 8 definition  and the consolidated income statement of the Group reflects this unique segment. All long-term assets are located in the parent company EVS Broadcast Equipment SA in Belgium.The company provides one class of business defined as solutions based on tapeless workflows with a consistent modular architecture. There are no other significant classes of business  either singularly or in aggregate. Identical modules can meet the needs of different markets  and our customers themselves are often multi-markets. Providing information for each module is therefore not relevant for EVS.At the geographical level  our activities are divided into the following regions: Asia-Pacific (â€œAPACâ€)  Europe  Middle East and Africa (â€œEMEAâ€)  and America (â€œNALAâ€). This division follows the organization of the commercial and support services within the Group  which operates worldwide. A fourth region is dedicated to the worldwide events (â€œbig event rentalsâ€).The company provides additional information with a presentation of the revenue by market pillar: â€œLive Service providerâ€  â€œLive Audience Businessâ€ and â€œBig Event Rentalsâ€ for rental contracts relating to the big sporting events.Finally  sales are presented by nature: systems and services.5.3.1. INFORMATION ON REVENUE BY DESTINATIONRevenue can be presented by Market Pillar: â€œLive Service providerâ€  â€œLive Audience Businessâ€ and â€œBig event rentalsâ€. Maintenance and after sale service are included in the complete solution proposed to the clients.Revenue (EUR thousands) 2H22 2H21 % 2H22/2H21 Live Audience Business 45.147 42.986 5 0% Live Service Provider 31.151 23.888 30 4% Big event rentals 4.187 9.021 -53 6% Total Revenue 80.486 75.894 6 0%Revenue (EUR thousands) FY22 FY21 % FY22/FY21 Live Audience Business 71.438 72.259 -1 1% Live Service Provider 66.869 51.785 29 1% Big event rentals 9.850 13.534 -27 2% Total Revenue 148.158 137.578 7 7%5.3.2. INFORMATION ON REVENUE BY GEOGRAPHICAL AREAActivities are divided in three regions: Asia-Pacific (â€œAPACâ€)  Europe  Middle East and Africa (â€œEMEAâ€)  and â€œAmericasâ€. Aside of them  we also identify the â€œbig event rentalsâ€.Revenue for the YTD period (EUR thousands) APACexcl. events EMEAexcl. events Americasexcl. events Big eventrentals TOTAL 2H22 revenue 11.278 39.107 25.914 4.187 80.486 Evolution versus 2H21 (%) -15 8% 23 4% 19 4% -53 9% 6 0% Variation versus 2H21 (%) at constant currency -15 8% 23 4% -7 2% -53 9% -1 6% 2H21 revenue 13.401 31.696 21.706 9.021 75.894Revenue for the YTD period (EUR thousands) APACexcl. events EMEAexcl. events Americasexcl. events Big eventrentals TOTAL FY22 revenue 18.952 67.764 51.592 9.850 148.158 Evolution versus FY21 (%) -17 9% 6 8% 37 6% -27 2% 7 7% Variation versus FY21 (%) at constant currency -17 9% 6 8% 22 2% -27 2% 3 5% FY21 revenue 23.077 63.468 37.499 13.534 137.578Revenue realized in Belgium (the country of origin of the company) with external clients represent less than 5% of the total revenue for the period. In the last 12 months  the Group realized significant revenue with external clients (according to the definition of IFRS 8) in one country: The United States (Americas)  EUR 38 1 million in the last 12 months.5.3.3. INFORMATION ON REVENUE BY NATURERevenue can be presented by nature: systems and services.Revenue (EUR thousands) 2H22 2H21 % 2H22/2H21 Sale of Equipment 64.226 58.524 10 3% Other services 16.259 17.610 -7 7% Total Revenue 80.486 75.894 6 0%Revenue (EUR thousands) FY22 FY21 % FY22/FY21 Sale of Equipment 118.015 106.416 10 9% Other services 30.142 31.162 -3 3% Total Revenue 148.158 137.578 7 7%Other services include the advice  installations  project management  rentals  training  maintenance  and distant support. Work in progress (â€œWIPâ€) contracts are included in both categories.5.3.4. INFORMATION ON IMPORTANT CLIENTSOver the last 12 months  no external client of the company represented more than 10% of the revenue (similar in 2021).NOTE 5.4: EQUITY SECURITIESThe variance in number of treasury shares and outstanding warrants in the period is as follows:2022 2021 Number of own shares at January 1 925.140 928.207 Acquisition of own shares on the market - - Sale of own shares on the market - - Allocation to Employees Profit Sharing Plans -17.126 -3.067 Sale related to Employee Stock Option Plan (ESOP) and other transactions - - Number of own shares at December 31 908.014 925.140 Outstanding warrants at December 31 492.975 456.432In 2022  the Group did not repurchase own shares on the stock market. No shares were used to satisfy the exercise of warrants by employees.The Ordinary General Meeting of shareholders of May 17  2022 approved the allocation of 17.126 shares to EVS employees (grant of 56 shares to each staff member in proportion to their effective or assimilated time of occupation in 2021) as a reward for their contribution to the Group successes. The expense recorded in the consolidated income statement amounts to EUR 329k in 2022.NOTE 5.5: DIVIDENDSThe Ordinary General Meeting of May 17  2022  approved the payment of a total gross dividend of EUR 1.50 per share for the year 2021  which includes EUR 0.50 per share exceptional dividend to honor past commitments on dividend payout.For the year 2022  an interim dividend of EUR 0.50 per share was paid in November 2022. Full year dividend of EUR 1 60 per share will be proposed to the Ordinary General Meeting of shareholders  which also includes EUR 0.50 per share exceptional dividend to honor past commitments on dividend payout.(EUR thousands  gross) # Coupon Declaration date 2022 2021 - Final dividend for 2020(EUR 0 50 per share excl. treasury shares) 30 May 2021 - 6.699 - Interim dividend for 2021(EUR 0 50 per share excl. treasury shares) 31 Nov. 2021 - 6.701 - Final dividend for 2021 (incl. exceptional dividend)(EUR 1 00 per share excl. treasury shares) 32 May 2022 13.402 - Interim dividend for 2022(EUR 0 50 per share excl. treasury shares) 33 Nov. 2022 6.710 Total paid dividends 20.112 13.400A new dividend guidance for upcoming years has been issued early 2022 and is as follows*:In â‚¬ per share per fiscal year 2022 2023 2024 Base dividend 1 10 1 10 1 10 Exceptional additional dividend 0 50 0 00 0 00 Total dividend 1 60 1 10 1 10*subject to market conditions and to the approval of the Ordinary General Meeting of ShareholdersNOTE 5.6: OTHER NET FINANCIAL INCOME / (EXPENSES)(EUR thousands) FY22 FY21 - Exchange results 1.393 1.117 - Fair value variation of financial instruments 324 -7 - Other financial results 76 144 Other net financial income / (expenses) 1.793 1.254The functional currency of EVS Broadcast Equipment SA as well as all subsidiaries is the Euro  except for EVS Inc. subsidiary in the USA whose functional currency is the US dollar. Entity Axon Digital Design LTD. in the UK changed functional currency from GBP to EUR starting as of July 1st 2022  following updated Management assesment driven by new implementation of EUR invoicing at the affiliate. The presentation currency of the consolidated financial statements of EVS Group is the Euro. For more information on exchange rates  see also the note 5.9. The favourable exchange result is mainly explained by the appreciation of USD vs. EUR in the period.The estimated fair values of the financial assets and liabilities are equal to their fair book values in the balance sheet.Since 2022  EVS systematically measures the Groupâ€™s anticipated exposure to transactional exchange risk  mainly relating to the EUR/USD risk. Given the Group has a long position in USD and based on revenue forecasts  EVS hedges future USD net inflows through forward or option foreign exchange contracts. The change in the fair value of the foreign exchange contracts is recorded directly to the income statement since the Group does not apply hedge accounting on these transactions. The valuation techniques used are mainly based on spot rates  forward rates and interest rate curves.On December 31  2022  the Group holds EUR/USD FX forward and option contracts for a total notional amount of USD 34 0 million with monthly maturities between January 2023 and June 2024. The fair value of those financial instruments on December 31  2022 amounts to EUR 0 3 million.NOTE 5.7: INCOME TAX EXPENSE(EUR thousands) FY22 FY21 - Current tax expense -569 -1.245 - Deferred tax expense -853 -1.552 Income tax expense -1.422 -2.797Income tax expense amounts to EUR 1 4 million for the full year 2022  compared to EUR 2 8 million in 2021. The decrease is mainly explained by lower taxable profit  tax relief of EUR 0 6 million received in December 2022 and decrease of the deferred tax expenses due to lower consumption of recoverable tax latencies (EUR 1 2 million in 2022 compared to 8 6 million in 2021).The effective tax rate for the period ended on December 31  2022 is 4 3%  compared to 7 5% in 2021.NOTE 5.8: HEADCOUNT(in full time equivalents) At December 31 2022 613 2021 551 Variation +62NOTE 5.9: EXCHANGE RATESThe main exchange rates that influence the consolidated financial accounts are USD/EUR and GBP/EUR which were considered as follows:Exchange rate USD/EUR Average FY At December 31 2022 1 0537 1 0666 2021 1 1830 1 1326 Variation -10 9% -5 8%Exchange rate GBP/EUR Average FY At December 31 2022 0 8527 0 8869 2021 0 8599 0 8403 Variation -0 7% 5 5%NOTE 5.10: INTANGIBLE ASSETSDuring 2022  intangible assets increased by EUR 7 1 million due to capitalization of internal development costs of EUR 8 4 million less depreciations of EUR 1 3 million.The capitalized costs during 2022 include mainly the internal personnel costs and external consultantsâ€™ costs. These costs are only related to the development phase of 2 important projects that should secure future growth for EVS.At the beginning of the period  the Group identified internal development projects  that for the first time of EVS Broadcast Equipmentâ€™s history fulfilled all the conditions to be capitalized according to IAS 38 Intangible assets. This ability arises after the implementation of extensive business cases  where R&D together with the solutions and sales departments perform an end-to-end exercise whereby objectives  costs  market analysis and return are clearly identified.These internal development projects consist of software that will be commercialized at the end of the development period (expected return on investment is scheduled for 2024). These 2 projects complement the PLAYForward strategy of the Group. The progress of these internal developments is monitored frequently as to ensure the future economic benefit remains assured.We refer to H1 2022 press release for the update of the accounting policy 2.11 related to the intagible assets applicable as of fiscal year 2022 and that replaces the accounting policy disclosed in 2021 annual report.NOTE 5.11: TANGIBLE ASSETSThe decrease of lands and buildings of EUR -2 1 million during 2022 is mainly explained by the depreciation of the period partially offset by investments in progress of EUR 0 5 million. The increase in other tangible assets of EUR 0 4 million is mainly driven by investments in office and IT equipment of EUR 1 1 million  net of the depreciation of the year of EUR 0 7 million.NOTE 5.12: FINANCIAL LIABILITIES(EUR thousands) 2022 2021 Long term financial debts Bank loans 1.675 2.779 Long term lease liabilities 9.853 10.775 Amount due within 12 months (shown under current liabilities) Bank loans 1.105 1.095 Short term lease liabilities 2.645 2.633 Total financial debt (short and long-term) 15.278 17.282 The total financial debt is repayable as follows: - within one year 3.750 3.728 - after one year but no more than five 8.676 9.673 - more than five years 2.852 3.881In June 2020  a loan of EUR 5 5 million was put in place with BNP Paribas Fortis to partially finance the acquisition of Axon. The repayment schedule foresees first repayment of EUR 0 6 million in 2020 and annual installments of EUR 1 1 million between 2021 and 2024  with final repayment of EUR 0 6 million in 2025 at loan maturity.For full year 2022  lease liabilities variation includes repayment of EUR 2 5 million  excluding interest of EUR 0 4 million.In June 2020  a roll over credit line of EUR 5 0 million was put in place with Belfius bank to partially finance the acquisition of Axon. This amortizing credit line will end at the latest on 30/06/2025. As of this date  EVS has not used this credit facility.NOTE 5.13: OTHER LIABILITIES - PENSIONOther long-term liabilities mainly correspond to pension obligations. Changes recorded in 2022 in the Belgian pension defined benefit obligation and fair value of plan assets were as follows:(EUR thousands) 2022 2021 Defined benefit obligation Fair value of plan assets Net defined benefit liability Defined benefit obligation Fair value of plan assets Net defined benefit liability As of January 1 10.587 -8.762 1.825 8.670 -7.686 984 Service cost 1.156 1.156 1.398 1.398 Administrative costs 28 28 18 18 Net interest expenses 120 -106 14 41 -38 3 Sub-total included in profit or loss 1.276 -78 1.198 1.439 -20 1.419 Benefits paid -179 179 0 -141 141 0 Return on plan assets -153 -153 -106 -106 Actuarial changes (assumptions) of which: Arising from changes in demographic assumptions 235 235 0 Arising from changes in financial assumptions -1.349 -1.349 -1.172 -1.172 Arising from experience adjustments -367 -350 -717 1.791 -69 1.722 Sub-total included in OCI -1.481 -350 -1.831 619 -69 550 Contributions by employer -1.078 -1.078 -1.128 -1.128 As of December 31 10.203 -10.089 114 10.587 -8.762 1.825The decrease in the net defined benefit liability of EUR -1 7 million is mainly driven by actuarial changes included in OCI arising from changes in financial assumptions of EUR -1 3 million (mainly increase in discount rate from 1 15% to 3 80%) and from experience adjustments of EUR -0 7 million  combined with employer contributions in the period of EUR -1 1 million and partially offset by service cost recorded in income statement of EUR 1 2 million.The main assumptions used for the actuarial valuation are as follows:Salary increase for financial year 2022 of 14 5% (5 7% in 2021)Discount rate p.a. of 3 8% (1 15% in 2021)Long term salary increase (inflation included) p.a. of 2 4% (2 1% in 2021)NOTE 5.14: FINANCIAL RISK MANAGEMENT POLICIESThe Group enters into derivative transactions  principally forward and option currency contracts  with the purpose to secure its sales and purchases in foreign currencies against negative variations of these currencies. The Group has transactional currency exposure arising from sales or purchases by operating entities in currencies other than the Groupâ€™s functional currency. Foreign currency risk is described in note 5.14.1.The Groupâ€™s main financial instruments  other than derivatives  comprise bank loans  finance leases  cash and short-term deposits. The purpose of these financial instruments is to raise finance for the Groupâ€™s operations. The Group has other financial instruments such as trade debtors and trade creditors  which arise directly from its operations. The Groupâ€™s policy is  and has always been  that no trading in financial instruments shall be undertaken. Credit risk is described in note 5.14.2.5.14.1 FOREIGN CURRENCY RISKSince 2022  EVS systematically measures the Groupâ€™s anticipated exposure to transactional exchange risk over six to eighteen months. In its current structure  the Groupâ€™s exposure is mainly linked to the EUR/USD risk. The Group invoices all clients in Euro  except in the United States where invoices are denominated in USD. Since the majority of operating expenses are denominated in Euro  the Group has a long position in USD  i.e. all of the Groupâ€™s activities generate globally a positive net cash flow in USD.On the basis of the forecasts and according to the market conditions  the Group hedges a portion of the exchange rate risk on estimated net future flows  mainly through foreign exchange forward and option contracts. EVS does not apply hedge accounting according to IAS 39 for those transactions.Foreign exchange contracts are revalued at each closing date at their market value. The generated exchange rate profit or loss is recorded in the â€œOther net financial income/(charges)â€ account in the consolidated income statement. The valuation techniques used are mainly based on spot rates  forward rates and interest rate curves. Details of fair value at closing date are presented in note 5.6.5.14.2 CREDIT RISKCredit exposure is controlled and reviewed regularly by the management.Trade receivables consist of a large number of customers  spread across many geographical areas. The evolution of the credit risk is monitored permanently. As of December 31  2022  it is assumed that the carrying amounts of those trade receivables are the most appropriate estimate to the fair value of those assets.The credit risk on financial instruments is contained as it is spread over a selection of different counterparties which are financial institutions with high credit ratings assigned by international credit rating agencies.As of December 31  2022  the maximum amount the Group could have to pay if guarantees are called on is EUR 0 8 million (similar to EUR 0 8 million in December 2021).NOTE 5.15: SUBSEQUENT EVENTSThere are no subsequent events that may have a material impact on the condensed financial statements of the Group.NOTE 5.16: RISK AND UNCERTAINTIESInvesting in the stock of EVS involves risks and uncertainties. The risks and uncertainties relating to the current year are similar to the risks and uncertainties that have been identified by the management of the company and that are listed in the management report of the annual report (available at www.evs.com).In terms of new risks arising since the last annual report we highlight the macro-economic environment that drives energy prices  components prices and labour cost to higher levels. EVS closely monitors the developments in this area and pro-actively takes actions to keep these rising costs under control or to minimize their effect on the profitability of the company. We also reiterate the potential impacts following the war in Ukraine. The company continues to comply with the sanction screening in vigor.Certification of responsible personsSerge Van Herck  CEO*Veerle De Wit  CFO*Certify that  based on their knowledge a) the condensed financial statements  prepared in accordance with the International Financial Reporting Standards (IFRS) adopted by the European Union  fairly present in all material respects the financial condition and results of operations of the issuer and the companies included in the consolidation b) the Directorsâ€™ report fairly presents the important events and related parties transactions of 2022  including their impact on the condensed financial statements  and a description of the existing risks and uncertainties for the remaining months of the fiscal year.* acting on behalf of a BVExternal AuditorThe condensed consolidated financial statements of EVS Broadcast SA for the year ending December 31  2022 were authorized of issue in accordance with a resolution of the Board of Directors on February 16  2023. EY rÃ©viseurs dâ€™Entreprises represented by Carlo-SÃ©bastien dâ€™Addario has confirmed that their audit procedures  which have been substantially completed  have not revealed any material adjustments which would have to be made to the accounting information included in this press release. The complete audit report related to the audit of the consolidated financial statements will be shown in 2022 annual report that will be published in April 2023.Attachment",neutral,0.0,1.0,0.0,mixed,0.71,0.1,0.19,True,English,"['EVS REPORTS 2022 RESULTS', '2H21 Variance FY22 FY21 Variance Revenue', 'Big Event Rental (BER) activity', 'EVS Broadcast Equipment S.A', 'recent â€œTop Employerâ€ certification', 'Live Service Providers markets', 'Comments Serge Van Herck', 'Big Event Rental revenue', 'team member engagement survey', 'strong financial income performance', 'Media Infrastructure revenue growth', 'strong net profit result', 'Live Audience Business', 'live TV production', 'Big Tech 2022 contract', 'Big Tech 22 contract', 'strong employer branding', 'capital expenditure envelope', 'team member size', 'The Axon acquisition', 'customer ticketing system', 'historical revenue number', 'major sports events', 'VIA Portal applications', 'record-high order intake', 'important order intake', 'Healthy net profit', 'current market dynamics', 'Record order intake', 'expected growth momentum', 'total order book', 'sustainable growth ambitions', 'long-term growth ambitions', 'order intake results', 'second record year', 'FY22 Highlights', 'record revenue', 'Revenue performance', 'CEO comments', 'strong growth', 'revenue guidance', 'revenue range', 'strong talent', 'strong ecosystem', 'topline performance', 'largest contract', 'second half', 'team members', '10,6 Gross profit', 'Operating profit', 'VIA platform', 'major differentiator', 'market opening', 'OPEX growth', 'organic growth', 'growth engine', 'profitable growth', 'significant growth', 'English French', 'Regulated information', 'Press release', 'Euronext Brussels', 'LiÃ¨ge', 'delivery terms', 'North America', 'MediaInfra solution', 'one-off benefit', '2H22 Highlights', 'same period', 'future periods', 'base dividend', 'Key figures', 'Operating margin', 'PlayForward strategy', 'component shortages', 'Middle East', 'good progress', 'solution sales', 'Artificial Intelligence', 'large acquisitions', 'new ERP', 'annual results', 'market expectations', 'market share', 'last year', 'successful year', 'EVS BB', 'Group share', 'solid Earnings', 'bottom line', '2022 results', 'Publication', 'February', 'Bloomberg', 'Reuters', 'Belgium', 'fundamentals', 'consequence', 'taxes', 'Outlook', 'beginning', 'focus', 'increase', 'dividends', 'policy', 'EBIT', 'EPS', 'revenues', 'August', 'inflation', 'position', 'customers', 'Asia', 'world', 'improvements', 'years', 'vision', 'introduction', 'XtraMotion', 'revolution', 'industry', 'May', 'capability', 'commitments']",2023-02-17,2023-02-18,globenewswire.com
18718,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-eur-nav-063000154.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 16 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 27.2139 Â£ 23.9792 Estimated MTD return -0.18 % -0.13 % Estimated YTD return -2.00 % -1.83 % Estimated ITD return 172.14 % 139.79 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -18.42 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.76 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 238.7094 Class GBP A Shares (estimated) Â£ 127.9798The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.Story continuesFor further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.16,0.84,True,English,"['BGHL', 'EUR', 'NAV', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Euro Shares Sterling Shares', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'A N/A Range', 'Sterling Shares Shares', 'GAVAUDAN HOLDING LIMITED', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', '800 N/A Shares', 'The Shares', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Emmanuel Gavaudan', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'Number', 'Outstanding', 'respect', 'role', 'Story', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-17,2023-02-18,finance.yahoo.com
18719,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-gbp-nav-063000206.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 16 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 27.2139 Â£ 23.9792 Estimated MTD return -0.18 % -0.13 % Estimated YTD return -2.00 % -1.83 % Estimated ITD return 172.14 % 139.79 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -18.42 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.76 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 238.7094 Class GBP A Shares (estimated) Â£ 127.9798The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.Story continuesFor further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.16,0.84,True,English,"['BGHL', 'GBP', 'NAV', 'The Class B Euro Shares', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'A N/A Average Price', 'Euro Shares Sterling Shares', 'London Stock Exchange plc', 'Class GBP A Shares', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'A N/A Range', 'Sterling Shares Shares', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', '800 N/A Shares', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'Number', 'Outstanding', 'respect', 'role', 'Story', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-17,2023-02-18,finance.yahoo.com
18720,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/EVS-BROADCAST-EQUIPMENT-S-5999/news/EVS-REPORTS-2022-RESULTS-43013564/?utm_medium=RSS&utm_content=20230217,EVS REPORTS 2022 RESULTS,(marketscreener.com) Publication on February 17  2023  before market openingRegulated information â€“ Press release annual resultsEVS Broadcast Equipment S.A.: Euronext Brussels   Bloomberg   Reuters EVS reports 2022 results LiÃ¨ge  Belgium  February 17th  2023 â€¦,"EVS REPORTS 2022 RESULTS 02/17/2023 | 12:31am EST Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields Publication on February 17  2023  before market openingRegulated information â€“ Press release annual resultsEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR)  Bloomberg (EVS BB)  Reuters (EVSB.BR) EVS reports 2022 results LiÃ¨ge  Belgium  February 17th  2023 EVS delivers record revenue and order intake results The results of 2022 are entirely supporting the growth ambitions of EVS. All the fundamentals for topline performance are strong: EVS realizes a record-high order intake and achieves a historical revenue number  despite the increased delivery terms in 2022. EVS is able to demonstrate a strong net profit result and as a consequence  realizes a solid Earnings Per Share. FY22 Highlights Record order intake at EUR 218 8 million  growing 46 5% YoY.Revenue performance in line with expectations at EUR 148 2 million  growing 7 7% vs. FY21 despite increased delivery terms announced early 2022 and despite reduced Big Event Rental (BER) activity. The growth is realized through strong growth in North America and in the MediaInfra solution.Controlled OPEX growth  in line with market expectations.Healthy net profit at EUR 31 3 million driven by a strong financial income performance and a one-off benefit in taxes  resulting in fully diluted earnings per share of EUR 2 29. 2H22 Highlights Record order intake of EUR 130 1 million (including Big Tech 2022 contract).Revenue for the second half of 2022 at EUR 80 5 million  growing 6 1% compared to the same period last year. Big Event Rental revenue at EUR 4 2 million  down EUR 4 9 million compared to 2H21. Revenue excluding Big Event Rental at EUR 76 3 million  growing EUR 9 5 million.Net profit amounts to EUR 15 9 million  leading to fully diluted earnings per share of EUR 1 14.Outlook 2023 The important order intake of 2022 has considerably fueled the order book to be delivered in future periods. The total order book at the end of 2022 is of EUR 141 8 million  growing 122% compared to last year. The order book reserved for 2023 is estimated at EUR 85 9 million  growing 68 4% compared to beginning of the year 2022.Based on the order book and current market dynamics  the revenue guidance for the year 2023 is set at EUR 145-155 million.The revenue range demonstrates the ambition of EVS to continue the organic growth  in a year with no Big Event Rental revenue.With the growth engine launched  the focus in 2023 for EVS will be on profitable growth.EVS plans no further growth in team members nor do we expect an increase in our capital expenditure envelope.We expect to pay out dividends in 2023 in line with our dividend policy  namely a base dividend per share of EUR 1 10. Key figures EUR millions  except earnings per share expressed in EUR 2H22 2H21 Variance FY22 FY21 Variance Revenue 80 5 75 8 4 7 148 2 137 6 10 6 Gross profit 53 0 53 2 -0 2 98 8 95 8 3 0 Gross margin % 65 8% 70 3% -4 5 Pts 66 7% 69 6% -2 9 Pts Operating profit â€“ EBIT 16 0 21 7 -5 7 31 7 37 1 -5 4 Operating margin â€“ EBIT % 19 9% 28 6% -8 7 Pts 21 4% 27 0% -5 6 Pts Net profit (Group share) 15 9 19 3 -3 5 31 3 34 9 -3 6 Fully diluted EPS (Group share) 1 14 1 42 -0 28 2 29 2 57 -0 28 Comments Serge Van Herck  CEO comments: â€œIâ€™m proud to say that 2022 was again quite a successful year for EVS. Our PlayForward strategy  as defined at the end of 2019  is starting to deliver the expected growth momentum. In 2022  we had a second record year in a row  with strong growth in revenues  order intake  and team member size. We showed significant growth in North America  announced our largest contract ever in August with the ""Big Tech 22 contractâ€ worth over 50MioUSD  and successfully fought against inflation and component shortages throughout the year. We feel we are winning market share in our Live Audience Business and protecting our position in the Live Service Providers markets. We successfully supported many of our customers in delivering the live TV production of major sports events in Asia  the Middle East  and North America. The growth of our team is clearly unlocking our sustainable growth ambitions. Our strong employer branding has enabled us to successfully hire strong talent across the world. Our team member engagement survey shows again further improvements compared to the years before  resulting in our recent â€œTop Employerâ€ certification. We are making good progress in our vision of developing a strong ecosystem relying on our VIA platform as we are successfully moving from product to solution sales. Our introduction of Artificial Intelligence (AI) in XtraMotion is a revolution in the industry and it represents a major differentiator. The Axon acquisition in May 2020 has translated into our Media Infrastructure revenue growth and positively contributes to our bottom line  demonstrating our capability to execute successfully large acquisitions. We have also launched our new ERP and upgraded our VIA Portal applications such as our customer ticketing system to support our long-term growth ambitions. In line with our commitments  we continued to deliver strong dividends for our shareholders. Our sustainability strategy has started to deliver strong results aligned with our customerâ€™s expectations  and resulting in good ESG ratings like the Ecovadis Silver medal. We completed our first carbon footprint analysis: this will be a critical management tool for taking the right sustainability decisions in the future. In conclusion  our PlayForward strategy  is clearly being appreciated by our customers and channel partners. This is helping us to get back into growth mode. While economic market conditions remain very challenging with high inflation  component shortages and with the war in Ukraine  we feel that our customers increasingly appreciate the reliability  performance and innovative edge of our solutions and services. Our ambition for the next years is to continue to deliver growth on both our top and bottomline. We are convinced that by focusing on cost control we will be able to deliver upon this promise.â€ Commenting on the results and the outlook  Veerle De Wit  CFO  said: â€œOur 2022 revenue results clearly demonstrate our ability to achieve organic growth. Even despite increased delivery terms  announced early 2022  and with a declining Big Event Rental revenue  we are able to realize a strong top line performance. All indicators lead us to conclude that this organic growth is here to stay: the revenue performance  together with the strong secured revenue position for 2023  are a solid basis to continue our growth path. Being a company in growth mode  means that the necessary resources need to be invested to support this growth: 2022 has been a year where we invested in additional resources  in new product developments  and in the back-bone of our operations. This backbone  a globally released new ERP system  has allowed us to optimize our processes and refine our cost control. As a result  the granularity of our reporting is improving  which has led to a decision to write off EUR 0 7 million of Bill of Material costs in 4Q22. Our operational expenses grew in a controlled way. Control over our spending patterns remains an attention point for 2023  especially in the current volatile market. Thanks to sound treasury management and tax benefits  we are able to generate a strong Net Profit worth EUR 31 3 million  driving a diluted Earnings Per Share of EUR 2 29. Our balance sheet also remains healthy with a very low debt level and a sound cash position. Our cash position is declining throughout 2022  as a consequence of high dividends paid  and as a consequence on increased Net Working Capital requirements. The impact on Net Working Capital is temporary: the implementation of the new ERP system has created a delay in invoicing in the fourth quarter â€“ the quarter with the highest volume â€“ resulting in a large volume of receivables not due at the end of 2022. This is a temporary effect  that will normalize early in 2023  as soon as the invoices become due. Based on the strong results for the year 2022  we are able to maintain our dividend policy defined earlier in 2022.â€ Market & customers The record high numbers in terms of revenues  order intake and order book translate the market traction that EVS is living. Our main growth drivers are North America and Media Infrastructure. The performance of our MediaInfra solution clearly demonstrates the power of our acquisition strategy. It is the fruit of our investment in Axon in 2020  and this acquisition demonstrates its return on investment 2 years later. The high order intake is also thanks to our biggest contract signed in the history of EVS: our Big Tech 2022. This contract proved an exceptional milestone in the history of EVS. This contract is a 10-year agreement that covers the delivery of EVSâ€™ live production  replay and highlight solutions LiveCeptionÂ®  combined with a long-term services level agreement. The contract provides our US based customer access to the latest technology innovations for the next 10 years  a full upgrade of its installed base  a predictable operational spend and an ease of operations. 2022 was a year with important Big Events  that EVS was able to support successfully. New solutions  like MediaHub and MediaInfra Strada  were introduced in our Big Event Rental business with success. Market conditions have been challenging throughout the year  with volatile interest rates  inflation and a continued erratic components market. This volatile market has urged EVS to implement a systemic price increase policy. Twice a year the sales prices are evaluated based on the underlying cost for components and inflation of labour cost. EVS has introduced 2 price increases in 2022: a first one in February 2022  and a second one in September 2022. The price increase policy aims to guarantee the overall profitability of the solutions of EVS. The erratic components market also forced EVS to extend its delivery periods early 2022 and to change the supply chain approach. However  as most components suffer longer lead-times  EVS has pro-actively invested in inventory to ensure these delivery terms are met. EVS has received many awards in 2022  and this for different business dimensions. Ranging from technology awards (Neuron Protect Best of Show Award at the NAB Show)  to Wallonia International Business Awards  to IABM Environmental Sustainability award  to Top Employer Certification 2023. Three years after the PLAYForward strategic exercise that has moved the focus from products to solutions  we can confidently say that this solution driven approach is highly appreciated by our customers and contributes to the differentiation reflected in the order book. Technologies During 2022  new generation of AI products did surface on the market. EVS continues to invest in the development of specific machine learning algorithms for broadcast specific components and also integrates in parallel existing AI technologies or libraries inside the solution portfolio or the workflows deployed for our customers. EVS also further developed and evangelized this year the concept of â€œBalanced computingâ€ as the best distribution of the computing workload between on-prem  datacenter and public cloud based on the economic benefits and the technical constraints for a specific workflow. This concept has been well received by the market where some players start to discover the limitations in terms of feature and the significant impact on Total Cost of Ownership for the production of premium events. EVS also currently invests in the development of important solution components that will be later embraced in the different solutions. Thanks to the capability to track the benefits brought by these components in the future  these developments are activated. These developments will contribute to the future sustainable growth of EVS. Corporate topics 2022 marks the moment where the Axon acquisition really starts to pay off for EVS. The initial assumptions made in terms of greographical expansion of the market are becoming a reality. Also the developments made to ensure end-to-end integration with EVS products demonstrate the complementarity of this company within the EVS portfolio. It comforts us in our Acquisition strategy and our ability to integrate companies. One of the axes of the PLAYforward strategy is improving our internal way of working. As a company we want to ensure that we have efficient processes in place that promote end-to-end collabration across all our departments. Having an efficient operational back-bone is important in that context. In October 2022  EVS launched a new global ERP system to ensure optimimal functioning of our company. The launch was a success and did not cause any major business interruption: shipping  production and support were active as of day 1. We now have a solid base to continously optimize our processes and ensure an optimal team member and customer experience. Speaking about improved processes  2022 is also the year where we first implemented a systemic listprice adjustment. The market conditions require a clear methodology to offset the impact of rising component prices and increasing inflation over labour costs. EVS now evaluates the need for price adjustments twice a year to protect the margin generation of the company. 2022 is also the year where we continue to expand our sustainability efforts in terms of ESG. After a first hollistic report published in 2021  we continue to structure our efforts in terms of sustainability. Our current ESG strategy and reporting has already received postive feedback from the market: we received a silver medal from Ecovadis  obtained encouriging score from other rating companies and recently obtained the certification of Top Employer for 2023. By the end of 2022  we also realized our first EVS Carbon Footprint analysis: it provides us not only insight on our direct and indirect CO2 emissions  but most importantly  helps us to define our roadmap to reduce our carbon footprint in the future. EVS also reinvented the way it collaborates with its channel partners. A structured channel partner program has been developed  focused on sustainable relationships with partners more than on opportunistic market responses  starting to develop certification paths and clear objectives. This program allows EVS to reach a broader set of clients and even penetrate new markets. Being a company in growth mode  EVS further invested in additional team members. Additional resources were primarily allocated to support and operations roles  as to fuel our future growth  and some research and development resources  as to staff some important developments ensuring future growth. Thanks to a strong employer branding  EVS was able to attract this high number of talents in a relatively short time frame. Also to support our future growth ambition  EVS further strengthened its leadership team  early 2022. A new CTO  Alex Redfern  was welcomed and Xavier Orri was named EVP of Projects & Operations. Revenue in 2H22 and FY22 In 2H22  EVS revenue reached EUR 80 5 million: an increase of EUR 4 7 million or 6 2% compared to 2H21  despite a drop of EUR 4 2 million on Big Event Rentals. At constant currency  revenue decreased by 1.6% YoY. Revenue â€“ EUR millions 2H22 2H21 2H22/2H21 Total reported 80 5 75 8 6 0% Total at constant currency 74 7 75 8 -1.6% Total at constant currency and excluding big event rentals 70 5 66 8 5.6% For the full year 2022  EVS revenue reached EUR 148 2 million: an increase of EUR 10 6 million or 7 7% compared to 2021  despite a drop of EUR 3 7 million on Big Event Rentals and despite an increased delivery term announced early 2022. This performance demonstrates the organic growth realized in 2022. At constant currency  revenue increased by 3 5% YoY. Revenue â€“ EUR millions FY22 FY21 FY22/FY21 Total reported 148 158 137 578 7 7% Total at constant currency 142 382 137 578 3.5% Total at constant currency and excluding big event rentals 132 532 124 044 6.8% Currency fluctuations primarily impact EVS revenues by the EUR/USD conversion  which can have a significant impact on our results even if EUR/USD fluctuations also impact the cost of our US operations and partially our cost of goods sold. In the second half of the year  (excl. Big Event Rentals) LSP represented 40% (31% in 2H21) of the revenue  LAB 55% (57% in 2H21). Geographically  revenues (excl. Big Event Rentals) are distributed in 2H22 as follows: Europe  Middle East and Africa (EMEA): EUR 39 1 million (EUR 31 7 million in 2H21)EUR 39 1 million (EUR 31 7 million in 2H21) Americas (NALA): EUR 25 9 million (EUR 21 7 million in 2H21)EUR 25 9 million (EUR 21 7 million in 2H21) Asia & Pacific (APAC): EUR 11 3 million (EUR 13 4 million in 2H21)  impacted by the slowdown in the region following COVID implications (primarily in China). The order intake for APAC in 2H22 do recomfort us that this trend can be reversed.Overall 2022 results Consolidated gross margin was at 66 7% for FY22  compared to 69 6% in FY21 (-2 9 Pts) explained by different drivers: Important investments in the operations & support department to ensure we continue to deliver quality support all over the world  in line with our growth patterns (representing -1 4 Pts)Impact of the change in solution mix is representing -1.1 Pts following the relative weight of Media Infrastructure in the overall portfolio.Write-off worth EUR 0 7 million linked to bill of material costs  following more granuler inventory reporting thanks to optimized processes in our new ERP (-0 4 Pts)In order to maintain gross profit levels  the impact of cost price increases and inflation have been systematically modeled by corresponding sales price increases. This has resulted primarily in improved margins for our Media Infrastructure and MediaCeption solutions. Operating expenses increased by 11% YoY (remaining below the guidance provided) explained by inflation on labour cost and energy prices and post-COVID spending patterns impacting spend for travel  marketing  â€¦ EVS did also invest in additional Research & Development resources in 2022  both through internal engagements as well as external contracts. These additional resources were staffed on 2 important developments  recognized as intangible assets in 2022. The associated spend was therefore capitalised on the balance sheet. Overall EBIT performance is of EUR 31 7 million  generating an EBIT margin of 21 4%. The net profit ends at EUR 31 3 million benefiting from a strong financial income following pro-active cash flow management and low income taxes (EUR 1 4 million compared to EUR 2 8 million last year) resulting from an excess in tax paid in 2021 and various tax latencies linked to prior years. The net profit leads to a fully diluted earnings per share of EUR 2 29 (versus EUR 2 57 in 2021). Overall second half 2022 results The gross profit margin in 2H22 was of 65 9% compared to 70 3% in the same period last year. The drop is a consequence of lesser revenue from Big Event Rentals and a higher weight of Media Infrastructure solution in the overall mix. In addition  the impact of the hirings done in 2022 to ensure continued quality operations and support affect the comparison. Operating expenses grew 13.8% in 2H22  compared to the same period last year and are a reflection of post-COVID spending patterns and impact of inflation. The 2H22 EBIT margin was 19 8%  compared to 28 6% in 2H21: the EBIT margin is dropping primarily following investments in the past 12 months to support our growth pattern. The Group net profit amounted to EUR 15 9 million in 2H22  compared to EUR 19 3 million in 2H21. Fully diluted earnings per share amounted to EUR 1 14 in 2H22 compared to EUR 1 42 in 2H21. Team members At the end of 2022  EVS employed 613 team members (FTE). This is an increase by 62 team members compared to the end of 2021 (551 FTE). This increase in team members reflects our continued investments in the growth of EVS. We expect no further growth of our team member base in 2023  and we will ensure that we balance the priorities of EVS with the existing workforce. Balance sheet and cash flow statement EVS continues to have a strong balance sheet with net cash position of EUR 33 8 million with low debt level (of which EUR 12 5 million related to IFRS 16) resulting in a total equity representing 75 4% of the total balance sheet as of the end of 2022. The decrease in cash and cash equivalents (EUR -23 1 million) compared to end of 2021 is mainly driven by the dividends paid in May and November (including exceptional additional dividend)  combined with the increase in working capital requirements at the end of 2022. The working capital requirements are growing  primarily linked to growing trade receivables. The trade receivables evolve largely in line with our overall sales volumes. 71% of our trade receivables is not due at year-end  with a large volume of invoices issued in the second half of the fourth quarter  given a temporary hold of invoicing operations after the Go-Live of our new ERP system. We expect these trade receivales to restore in 1Q23. A sound cash position remains a priority for EVS. Other intangible assets include the costs for internal development capitalized during 2022 according to IAS 38 (Intangible assets). Lands and building mainly include the headquarters in LiÃ¨ge as well as the right of use for the offices abroad (IFRS16). Inventories amount to EUR 28 8 million  an increase of EUR 2 8 million compared to the beginning of the year as a reflection of a pro-active supply chain management to ensure we systematically meet our customersâ€™ delivery terms. Liabilities include EUR 15 3 million of financial debt (including long term and short-term portion)  mainly related to the lease liabilities for EUR 12 5 million and borrowings for EUR 2 8 million. Long-term provisions include the provision for technical warranty on EVS products for labor and parts. Other amounts payable mainly represent deferred income and advance payments received from customers on contracts in progress. Net cash from operating activities amounts to EUR 11 0 million for the full year 2022  compared to EUR 38 7 million in 2021. The decrease is mainly driven by higher working capital requirements resulting from higher trade receivables (as described above) and lower trade payables  combined with lower net profit. On December 31  2022  cash and cash equivalents total EUR 49 1 million  compared to EUR 72 1 million at the end of 2021. The decrease is mainly driven by lower cash from operating activities  combined with the increase of the net cash used in investing activities mainly due to the investments in intangible and tangible assets (specifically in the internal development of intangible assets) together with the increase of the net cash used in financing activities following the higher amount of dividends distributed during 2022  including the exceptional dividend. At the end of December 2022  there were 14.327.024 EVS shares outstanding  of which 908.014 were owned by the company. At the same date  492.975 warrants were outstanding with average exercise price of EUR 16 95 and maturities between October 2026 and September 2028. Corporate update There has been no further change to the composition of the Board of Directors since the last General Assembly on May 17th during which the shareholders had appointed two new directors  FrÃ©dÃ©ric Vincent and Marco Miserez  both for a period of 4 years. The Board of Directors is currently composed of seven directors: Johan Deschuyffeleer   independent director & President (representing The House of Value BVBA);  independent director & President (representing The House of Value BVBA); Michel Counson   managing director;  managing director; Martin De Prycker   independent director (representing InnoConsult BVBA);  independent director (representing InnoConsult BVBA); Chantal De Vrieze   independent director (representing 7 Capital SRL);  independent director (representing 7 Capital SRL); FrÃ©dÃ©ric Vincent   independent director;  independent director; Marco Miserez   independent director; and  independent director; and Anne Cambier  independent director (representing Accompany You SRL)Glossary Term Definition Secured revenue Revenue already recognized as well as open orders on hand that will be recognized as revenue in the fiscal year Order book <date> Revenues planned to be recognized after the <date> based on current orders. LAB market pillar LAB â€“ Live Audience BusinessRevenue from customers leveraging EVS products and solutions to create content for their own purposeThis market pillar covers the following types of customers: Broadcasters  Stadium  House of Worship  Corporate Media Centers  Sports organizations  Government & institutions  University & Colleges LSP market pillar LSP â€“ Live Service ProvidersRevenue from customers leveraging EVS products and solutions to serve â€œLAB customersâ€This market pillar covers the following types of customers: Rental & facilities companies  Production companies  Freelance operators  Technology partners & system integrators buying for their own purpose BER market pillar BER â€“ Big Event RentalRevenue from major non-yearly big event rental.This market pillar covers the following types of customers: host broadcasters for major events. In case of discrepancies between the English and the French Version  the English Version prevails. Conference call EVS will hold a conference call in English today at 3.30 pm CET for financial analysts and institutional investors. Other interested parties may join the call in a listen-only mode. The presentation used during the conference call will be available shortly before the call on the EVS website. Participants must register for the conference using the link provided below. Upon registering  each participant will be provided with Participant Dial In Numbers  Direct Event Passcode and unique Registrant ID. 1. Online registration: https://register.vevent.com/register/BIe156e14a79604a6984c8fb06a38e3c27 2. Webcast Player URL: https://edge.media-server.com/mmc/p/yzt4d6v8 Corporate Calendar May 16th  2023: General Assembly May 17th  2023: Q1 2023 Trading update August 18th  2023: H1 2023 results November 17th  2023: Q3 2023 Trading update For more information  please contact: VEERLE DE WIT EVS Broadcast Equipment S.A.  Liege Science Park  13 rue du Bois Saint-Jean  B-4102 Seraing  Belgium Tel: +32 4 361 70 00 | E-mail: corpcom@evs.com | Website: www.evs.com Forward Looking Statements This press release contains forward-looking statements with respect to the business  financial condition  and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs of EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements  the companyâ€™s concentration on one industry  decline in demand for the companyâ€™s products and those of its affiliates  inability to timely develop and introduce new technologies  products and applications  and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. About EVS EVS is globally recognized as leader in live video technology for broadcast and new media productions. Our passion and purpose are to help our clients craft immersive stories that trigger the best return on emotion. Through a wide range of products and solutions  we deliver the most gripping live sports images  buzzing entertainment shows and breaking news content to billions of viewers every day â€“ and in real-time. The company is headquartered in Belgium with around 620 employees in offices in Europe  the Middle East  Asia and North America  and provides sales and technical support to more than 100 countries. EVS is a public company traded on Euronext Brussels: EVS  ISIN: BE0003820371. For more information  please visit www.evs.com.Condensed Interim Consolidated financial information ANNEX 1: condensed consolidated income statement (EUR thousands) Notes FY22 FY21 2H22 2H21 Revenue 5.3 148.158 137.578 80.486 75.799 Cost of sales -49.314 -41.764 -27.473 -22.543 Gross profit 98.844 95.814 53.013 53.256 Gross margin % 66 7% 69 6% 65 9% 70 3% Selling and administrative expenses -39.815 -32.392 -22.532 -17.555 Research and development expenses -26.267 -27.088 -14.368 -14.867 Other income 200 1.108 150 1.057 Other expenses -607 -114 -121 -71 Profit-sharing plan and warrants -643 -232 -169 -107 Operating profit (EBIT) 31.712 37.096 15.973 21.713 Operating margin (EBIT) % 21 4% 27 0% 19 8% 28 6% Interest revenue on loans and deposits 106 51 76 -17 Interest charges -912 -893 -439 -446 Other net financial income / (expenses) 5.6 1.793 1.254 -146 932 Share in the result of the enterprise accounted for using the equity method 67 193 -10 -20 Profit before taxes (PBT) 32.766 37.701 15.454 22.162 Income taxes 5.7 -1.422 -2.797 442 -2.853 Net profit 31.344 34.904 15.896 19.309 Attributable to : Non-controlling interest - - - - Share of the Group 31.344 34.904 15.896 19.309 EARNINGS PER SHARE (in number of shares and in EUR) FY22 FY21 2H22 2H21 Weighted average number of subscribed shares for the period less treasury shares 13.411.972 13.400.624 13.419.010 13.401.884 Weighted average fully diluted number of shares 13.681.084 13.587.624 13.768.895 13.588.884 Basic earnings â€“ share of the Group 2 34 2 60 1 19 1 44 Fully diluted earnings â€“ share of the Group (1) 2 29 2 57 1 14 1 42 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (EUR thousands) FY22 FY21 2H22 2H21 Net profit 31.344 34.904 15.896 19.309 Other comprehensive income of the period Currency translation differences 324 475 -231 276 Total of recyclable elements 324 475 -231 276 Difference on opening 460 - 460 - Gains / (losses) on remeasurement of defined benefit obligations  net of tax 1.373 -412 440 -412 Total of non-recyclable elements  net of tax 1.833 -412 900 -412 Total other comprehensive income of the period  net of tax 2.157 63 669 -136 Total comprehensive income for the period 33.501 34.967 16.565 19.173 Attributable to : Non controlling interest - - - - Share of the Group 33.501 34.967 16.565 19.173 (1) The diluted earnings per share does include: 187.000 warrants attributed in October 2020  of which 154.250 are outstanding with an exercise price below the share price and with maturity in October 2026; 158.600 warrants attributed in June 2021  of which 155.350 are outstanding with an exercise price below the share price and with maturity in June 2027; and 183.375 warrants attributed in September 2022  all outstanding and with a maturity in September 2028. ANNEX 2: condensed statement of financial position (balance sheet) ASSETS(EUR thousands) Notes Dec 31  2022 Dec 31  2021 Non-current assets: Goodwill 2.832 2.832 Other intangible assets 5.10 13.215 6.113 Lands and buildings 5.11 50.543 52.673 Other tangible assets 5.11 4.691 4.307 Investment accounted for using equity method 1.922 1.920 Other amounts receivables 3.647 2.408 Deferred tax assets 4.622 5.933 Financial assets 512 404 Total non-current assets 81.984 76.590 Current assets: Inventories 28.786 25.951 Trade receivables 61.655 38.924 Other amounts receivable  deferred charges and accrued income 11.566 6.417 Financial assets 174 201 Cash and cash equivalents 49.051 72.144 Total current assets 151.232 143.637 Total assets 233.216 220.227 EQUITY AND LIABILITIES(EUR thousands) Notes Dec 31  2022 Dec 31  2021 Equity: Capital 8.772 8.772 Reserves 183.390 170.570 Treasury shares -17.447 -17.776 Total consolidated reserves 165.943 152.794 Translation differences 1.075 751 Equity  attributable to the owners of the parent 175.790 162.317 Non-controlling interest - - Total equity 5.4 175.790 162.317 Provisions 1.637 1.502 Deferred taxes liabilities 10 11 Financial debts 5.12 11.528 13.554 Other debts 5.13 120 1.825 Non-current liabilities 13.295 16.892 Financial debts 5.12 3.750 3.728 Trade payables 9.207 10.497 Amounts payable regarding remuneration and social security 11.219 10.658 Income tax payable 1.959 2.586 Other amounts payable  advances received  accrued charges and deferred income 5.6 17.996 13.549 Current liabilities 44.131 41.018 Total equity and liabilities 233.216 220.227 ANNEX 3: condensed statement of cash flows (EUR thousands) Notes FY22 FY21 Cash flows from operating activities Net profit  share of the Group 31.344 34.904 Adjustment for: - Depreciation and write-offs on fixed assets 6.738 7.015 - Profit-sharing plan and warrants 5.4 642 232 - Provisions 212 417 - Income tax expense (+) / Income (-) 1.422 2.797 - Net financial expense (+) / income (-) -987 -412 - Share of the result of entities accounted for under the equity method -67 -193 Adjustment for changes in working capital items: - Inventories -2.834 -3.372 - Trade receivables -23.970 -10.061 - Other amounts receivable  deferred charges and accrued income -3.889 -430 - Trade payables -1.290 4.722 - Amounts payable regarding remuneration and social security 541 3.653 - Other amounts payable  advances received  accrued charges  and deferred income 4.776 -263 - Conversion differences 803 813 Cash generated from operations 13.441 39.822 Income taxes received / (paid) 5.7 -2.469 -1.112 Net cash from operating activities 10.972 38.710 Cash flows from investing activities Purchase of intangible assets -8.770 -234 Purchase of tangible assets (lands and building and other tangible assets) -1.101 -1.357 Other financial assets -102 3 Net cash used in investing activities -9.973 -1.588 Cash flows from financing activities Reimbursement of borrowings 5.12 -1.095 -1.086 Payment of lease liabilities -2.828 -3.417 Interests paid -688 -566 Interests received 75 13 Dividend received from investee 64 - Dividend paid -20.112 -13.400 Net cash used in financing activities -24.584 -18.456 Net increase / decrease in cash and cash equivalents -23.585 18.666 Net foreign exchange difference 492 810 Cash and cash equivalents at beginning of period 72.144 52.668 Cash and cash equivalents at end of period 49.051 72.144 ANNEX 4: condensed statement of change in equity (EUR thousands) Capital Reserves Treasury shares Currency translation differences Equity share of the Group Non-controlling interest Total equity Balance as per January 1  2021 8.772 149.309 -17.835 276 140.522 - 140.522 Profit or loss 34.904 34.904 34.904 Other comprehensive income -412 475 63 63 Total comprehensive income for the period 34.492 475 34.967 34.967 Share-based payments 232 232 232 Operations with treasury shares 59 59 59 Final dividend -6.699 -6.699 -6.699 Interim dividend -6.701 -6.701 -6.701 Other allocation -63 -63 -63 Balance as per December 31  2021 8.772 170.570 -17.776 751 162.317 - 162.317 (EUR thousands) Capital Reserves Treasury shares Currency translation differences Equity share of the Group Non-controlling interest Total equity Balance as per January 1  2022 8.772 170.570 -17.776 751 162.317 - 162.317 Profit or loss 31.344 31.344 31.344 Other comprehensive income 1.833 324 2.157 2.157 Total comprehensive income for the period 33.117 324 33.501 33.501 Share-based payments 581 581 581 Operations with treasury shares -329 329 - - Final dividend -13.402 -13.402 -13.402 Interim dividend -6.710 -6.710 -6.710 Other allocation -497 -497 -497 Balance as per December 31  2022 8.772 183.390 -17.447 1.075 175.790 - 175.790 ANNEX 5: notes to the consolidated financial statements NOTE 5.1: BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS The consolidated financial statements of EVS Group for the 12 month-period ended December 31  2022  are established and presented in accordance with the International Financial Reporting Standards (IFRS)  as adopted for use in the European Union. The accounting framework and standards adopted by the European Commission can be accessed through the following link on the website: http://ec.europa.eu/finance/company-reporting/index_en.htm. The condensed interim financial statements of the Group for the 12 month-period ending December 31  2022  were authorized for issue by the Board of Directors on February 16  2023. This interim report only provides an explanation of events and transactions that are significant to an understanding of the changes in financial position and reporting since the last annual reporting period and should therefore be read in conjunction with the full 2022 consolidated financial statements from which these condensed financial statements have been derived and which are planned to be published on EVS Groupâ€™s website by April 14  2023. The interim condensed financial statements are prepared on a going concern basis. NOTE 5.2.1: SIGNIFICANT ACCOUNTING POLICIES AND METHODS These condensed interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting  as issued by the IASB  and as adopted by the EU. The accounting policies and methods adopted for the preparation of the company's IFRS consolidated financial statements are consistent with those applied in the 2021 consolidated financial statements. The companyâ€™s IFRS accounting policies and methods are available in the 2021 annual report on www.evs.com  except for the accounting policy on intangible assets which include the capitalization of development cost for the first time (see note 5.10) as well as the new  amended or revised IFRS standards and IFRIC Interpretations that have been in effect since January 1  2022. The adoption of these new  amended or revised pronouncements did not have a significant impact on the consolidated financial statements of the Group. NOTE 5.2.2: JUDGMENTS AND ESTIMATES Impacts of current market volatility and macroeconomic developmentsThe impacts of the current market volatility and macroeconomic developments were taken into account by the company to assess potential effects on EVSâ€™s financial performance and the valuation of its assets and liabilities. In particular  key assumptions used in the calculation of the pension obligations have been reviewed to ensure a proper valuation as per 31 December 2022. Also  the key assumptions that are used for estimating the recoverable amounts of cash generating units in the context of goodwill impairment test reflect latest market conditions for interest rates and weighted average cost of capital Estimation of useful life and residual valueProperty  Plant and Equipment are depreciated using a straight-line method to allocate their depreciable amount on a systematic basis over their useful life. For the headquarter building in LiÃ¨ge  the depreciable amount is the cost less its estimated residual value. Useful life and residual value of an asset is estimated on a realistic basis based on the experience of the Group with similar assets and reviewed on a regular basis. The effect of changes in useful life are recognized prospectively. Functional currency of the Group entitiesThe individual financial statements of each subsidiary are prepared in the currency of the primary economic environment in which the entity operates. When the factors set out by IAS 21 to determine the functional currency are mixed and the functional currency is not obvious  management judgment is used to determine which functional currency most faithfully represents the economic effects of its underlying transactions  events and conditions. The functional currency of the EVS Group entities is EUR except for the US entity EVS Inc. for which US Dollar is assessed by management to be the functional currency. Claims and contingent liabilitiesRelated to claims and contingencies  judgement is necessary in assessing the existence of an obligation resulting from a past event  in assessing the probability of an economic outflow  and in quantifying the probable outcome of economic resources. This judgment is reviewed when new information becomes available and often with support of internal and external expert advice. Impact of the war in Ukraine on our activitiesGiven the nature and location of its operations and the fact that EVS does not currently have activities in Russia nor in Ukraine or with Russian companies  The Company does not foresee a direct impact of the Ukrainian conflict on its business. NOTE 5.3: SEGMENT REPORTING From an operational point of view  the company is vertically integrated with the majority of its staff located in the headquarters in Belgium  including the R&D  production  marketing and administration departments. Therefore the majority of investments and costs are located at the level of the Belgian parent company. Resources securing the customer facing interactions such as sales  operations and support profiles are primarily hired within the respective regions. The foreign subsidiaries are primarily sales and representative offices. The Chief Operating Decision Maker  being the Executive Committee  reviews the operating results  operating plans  and makes resource allocation decisions on a company-wide basis. Revenue related to products of the same nature (digital broadcast production equipment) are realized by commercial polyvalent teams. The companyâ€™s internal reporting is the reflection of the above-mentioned operational organization and is characterized by the strong integration of the activities of the company. By consequence  the company is composed of one segment according to the IFRS 8 definition  and the consolidated income statement of the Group reflects this unique segment. All long-term assets are located in the parent company EVS Broadcast Equipment SA in Belgium. The company provides one class of business defined as solutions based on tapeless workflows with a consistent modular architecture. There are no other significant classes of business  either singularly or in aggregate. Identical modules can meet the needs of different markets  and our customers themselves are often multi-markets. Providing information for each module is therefore not relevant for EVS. At the geographical level  our activities are divided into the following regions: Asia-Pacific (â€œAPACâ€)  Europe  Middle East and Africa (â€œEMEAâ€)  and America (â€œNALAâ€). This division follows the organization of the commercial and support services within the Group  which operates worldwide. A fourth region is dedicated to the worldwide events (â€œbig event rentalsâ€). The company provides additional information with a presentation of the revenue by market pillar: â€œLive Service providerâ€  â€œLive Audience Businessâ€ and â€œBig Event Rentalsâ€ for rental contracts relating to the big sporting events. Finally  sales are presented by nature: systems and services. 5.3.1. INFORMATION ON REVENUE BY DESTINATION Revenue can be presented by Market Pillar: â€œLive Service providerâ€  â€œLive Audience Businessâ€ and â€œBig event rentalsâ€. Maintenance and after sale service are included in the complete solution proposed to the clients. Revenue (EUR thousands) 2H22 2H21 % 2H22/2H21 Live Audience Business 45.147 42.986 5 0% Live Service Provider 31.151 23.888 30 4% Big event rentals 4.187 9.021 -53 6% Total Revenue 80.486 75.894 6 0% Revenue (EUR thousands) FY22 FY21 % FY22/FY21 Live Audience Business 71.438 72.259 -1 1% Live Service Provider 66.869 51.785 29 1% Big event rentals 9.850 13.534 -27 2% Total Revenue 148.158 137.578 7 7% 5.3.2. INFORMATION ON REVENUE BY GEOGRAPHICAL AREA Activities are divided in three regions: Asia-Pacific (â€œAPACâ€)  Europe  Middle East and Africa (â€œEMEAâ€)  and â€œAmericasâ€. Aside of them  we also identify the â€œbig event rentalsâ€. Revenue for the YTD period (EUR thousands) APACexcl. events EMEAexcl. events Americasexcl. events Big eventrentals TOTAL 2H22 revenue 11.278 39.107 25.914 4.187 80.486 Evolution versus 2H21 (%) -15 8% 23 4% 19 4% -53 9% 6 0% Variation versus 2H21 (%) at constant currency -15 8% 23 4% -7 2% -53 9% -1 6% 2H21 revenue 13.401 31.696 21.706 9.021 75.894 Revenue for the YTD period (EUR thousands) APACexcl. events EMEAexcl. events Americasexcl. events Big eventrentals TOTAL FY22 revenue 18.952 67.764 51.592 9.850 148.158 Evolution versus FY21 (%) -17 9% 6 8% 37 6% -27 2% 7 7% Variation versus FY21 (%) at constant currency -17 9% 6 8% 22 2% -27 2% 3 5% FY21 revenue 23.077 63.468 37.499 13.534 137.578 Revenue realized in Belgium (the country of origin of the company) with external clients represent less than 5% of the total revenue for the period. In the last 12 months  the Group realized significant revenue with external clients (according to the definition of IFRS 8) in one country: The United States (Americas)  EUR 38 1 million in the last 12 months. 5.3.3. INFORMATION ON REVENUE BY NATURE Revenue can be presented by nature: systems and services. Revenue (EUR thousands) 2H22 2H21 % 2H22/2H21 Sale of Equipment 64.226 58.524 10 3% Other services 16.259 17.610 -7 7% Total Revenue 80.486 75.894 6 0% Revenue (EUR thousands) FY22 FY21 % FY22/FY21 Sale of Equipment 118.015 106.416 10 9% Other services 30.142 31.162 -3 3% Total Revenue 148.158 137.578 7 7% Other services include the advice  installations  project management  rentals  training  maintenance  and distant support. Work in progress (â€œWIPâ€) contracts are included in both categories.5.3.4. INFORMATION ON IMPORTANT CLIENTS Over the last 12 months  no external client of the company represented more than 10% of the revenue (similar in 2021). NOTE 5.4: EQUITY SECURITIES The variance in number of treasury shares and outstanding warrants in the period is as follows: 2022 2021 Number of own shares at January 1 925.140 928.207 Acquisition of own shares on the market - - Sale of own shares on the market - - Allocation to Employees Profit Sharing Plans -17.126 -3.067 Sale related to Employee Stock Option Plan (ESOP) and other transactions - - Number of own shares at December 31 908.014 925.140 Outstanding warrants at December 31 492.975 456.432 In 2022  the Group did not repurchase own shares on the stock market. No shares were used to satisfy the exercise of warrants by employees. The Ordinary General Meeting of shareholders of May 17  2022 approved the allocation of 17.126 shares to EVS employees (grant of 56 shares to each staff member in proportion to their effective or assimilated time of occupation in 2021) as a reward for their contribution to the Group successes. The expense recorded in the consolidated income statement amounts to EUR 329k in 2022. NOTE 5.5: DIVIDENDS The Ordinary General Meeting of May 17  2022  approved the payment of a total gross dividend of EUR 1.50 per share for the year 2021  which includes EUR 0.50 per share exceptional dividend to honor past commitments on dividend payout. For the year 2022  an interim dividend of EUR 0.50 per share was paid in November 2022. Full year dividend of EUR 1 60 per share will be proposed to the Ordinary General Meeting of shareholders  which also includes EUR 0.50 per share exceptional dividend to honor past commitments on dividend payout. (EUR thousands  gross) # Coupon Declaration date 2022 2021 - Final dividend for 2020(EUR 0 50 per share excl. treasury shares) 30 May 2021 - 6.699 - Interim dividend for 2021(EUR 0 50 per share excl. treasury shares) 31 Nov. 2021 - 6.701 - Final dividend for 2021 (incl. exceptional dividend)(EUR 1 00 per share excl. treasury shares) 32 May 2022 13.402 - Interim dividend for 2022(EUR 0 50 per share excl. treasury shares) 33 Nov. 2022 6.710 Total paid dividends 20.112 13.400 A new dividend guidance for upcoming years has been issued early 2022 and is as follows*: In â‚¬ per share per fiscal year 2022 2023 2024 Base dividend 1 10 1 10 1 10 Exceptional additional dividend 0 50 0 00 0 00 Total dividend 1 60 1 10 1 10 *subject to market conditions and to the approval of the Ordinary General Meeting of Shareholders NOTE 5.6: OTHER NET FINANCIAL INCOME / (EXPENSES) (EUR thousands) FY22 FY21 - Exchange results 1.393 1.117 - Fair value variation of financial instruments 324 -7 - Other financial results 76 144 Other net financial income / (expenses) 1.793 1.254 The functional currency of EVS Broadcast Equipment SA as well as all subsidiaries is the Euro  except for EVS Inc. subsidiary in the USA whose functional currency is the US dollar. Entity Axon Digital Design LTD. in the UK changed functional currency from GBP to EUR starting as of July 1st 2022  following updated Management assesment driven by new implementation of EUR invoicing at the affiliate. The presentation currency of the consolidated financial statements of EVS Group is the Euro. For more information on exchange rates  see also the note 5.9. The favourable exchange result is mainly explained by the appreciation of USD vs. EUR in the period. The estimated fair values of the financial assets and liabilities are equal to their fair book values in the balance sheet. Since 2022  EVS systematically measures the Groupâ€™s anticipated exposure to transactional exchange risk  mainly relating to the EUR/USD risk. Given the Group has a long position in USD and based on revenue forecasts  EVS hedges future USD net inflows through forward or option foreign exchange contracts. The change in the fair value of the foreign exchange contracts is recorded directly to the income statement since the Group does not apply hedge accounting on these transactions. The valuation techniques used are mainly based on spot rates  forward rates and interest rate curves. On December 31  2022  the Group holds EUR/USD FX forward and option contracts for a total notional amount of USD 34 0 million with monthly maturities between January 2023 and June 2024. The fair value of those financial instruments on December 31  2022 amounts to EUR 0 3 million. NOTE 5.7: INCOME TAX EXPENSE (EUR thousands) FY22 FY21 - Current tax expense -569 -1.245 - Deferred tax expense -853 -1.552 Income tax expense -1.422 -2.797 Income tax expense amounts to EUR 1 4 million for the full year 2022  compared to EUR 2 8 million in 2021. The decrease is mainly explained by lower taxable profit  tax relief of EUR 0 6 million received in December 2022 and decrease of the deferred tax expenses due to lower consumption of recoverable tax latencies (EUR 1 2 million in 2022 compared to 8 6 million in 2021). The effective tax rate for the period ended on December 31  2022 is 4 3%  compared to 7 5% in 2021. NOTE 5.8: HEADCOUNT (in full time equivalents) At December 31 2022 613 2021 551 Variation +62 NOTE 5.9: EXCHANGE RATES The main exchange rates that influence the consolidated financial accounts are USD/EUR and GBP/EUR which were considered as follows: Exchange rate USD/EUR Average FY At December 31 2022 1 0537 1 0666 2021 1 1830 1 1326 Variation -10 9% -5 8% Exchange rate GBP/EUR Average FY At December 31 2022 0 8527 0 8869 2021 0 8599 0 8403 Variation -0 7% 5 5% NOTE 5.10: INTANGIBLE ASSETS During 2022  intangible assets increased by EUR 7 1 million due to capitalization of internal development costs of EUR 8 4 million less depreciations of EUR 1 3 million. The capitalized costs during 2022 include mainly the internal personnel costs and external consultantsâ€™ costs. These costs are only related to the development phase of 2 important projects that should secure future growth for EVS. At the beginning of the period  the Group identified internal development projects  that for the first time of EVS Broadcast Equipmentâ€™s history fulfilled all the conditions to be capitalized according to IAS 38 Intangible assets. This ability arises after the implementation of extensive business cases  where R&D together with the solutions and sales departments perform an end-to-end exercise whereby objectives  costs  market analysis and return are clearly identified. These internal development projects consist of software that will be commercialized at the end of the development period (expected return on investment is scheduled for 2024). These 2 projects complement the PLAYForward strategy of the Group. The progress of these internal developments is monitored frequently as to ensure the future economic benefit remains assured. We refer to H1 2022 press release for the update of the accounting policy 2.11 related to the intagible assets applicable as of fiscal year 2022 and that replaces the accounting policy disclosed in 2021 annual report. NOTE 5.11: TANGIBLE ASSETS The decrease of lands and buildings of EUR -2 1 million during 2022 is mainly explained by the depreciation of the period partially offset by investments in progress of EUR 0 5 million. The increase in other tangible assets of EUR 0 4 million is mainly driven by investments in office and IT equipment of EUR 1 1 million  net of the depreciation of the year of EUR 0 7 million. NOTE 5.12: FINANCIAL LIABILITIES (EUR thousands) 2022 2021 Long term financial debts Bank loans 1.675 2.779 Long term lease liabilities 9.853 10.775 Amount due within 12 months (shown under current liabilities) Bank loans 1.105 1.095 Short term lease liabilities 2.645 2.633 Total financial debt (short and long-term) 15.278 17.282 The total financial debt is repayable as follows: - within one year 3.750 3.728 - after one year but no more than five 8.676 9.673 - more than five years 2.852 3.881 In June 2020  a loan of EUR 5 5 million was put in place with BNP Paribas Fortis to partially finance the acquisition of Axon. The repayment schedule foresees first repayment of EUR 0 6 million in 2020 and annual installments of EUR 1 1 million between 2021 and 2024  with final repayment of EUR 0 6 million in 2025 at loan maturity. For full year 2022  lease liabilities variation includes repayment of EUR 2 5 million  excluding interest of EUR 0 4 million. In June 2020  a roll over credit line of EUR 5 0 million was put in place with Belfius bank to partially finance the acquisition of Axon. This amortizing credit line will end at the latest on 30/06/2025. As of this date  EVS has not used this credit facility. NOTE 5.13: OTHER LIABILITIES - PENSION Other long-term liabilities mainly correspond to pension obligations. Changes recorded in 2022 in the Belgian pension defined benefit obligation and fair value of plan assets were as follows: (EUR thousands) 2022 2021 Defined benefit obligation Fair value of plan assets Net defined benefit liability Defined benefit obligation Fair value of plan assets Net defined benefit liability As of January 1 10.587 -8.762 1.825 8.670 -7.686 984 Service cost 1.156 1.156 1.398 1.398 Administrative costs 28 28 18 18 Net interest expenses 120 -106 14 41 -38 3 Sub-total included in profit or loss 1.276 -78 1.198 1.439 -20 1.419 Benefits paid -179 179 0 -141 141 0 Return on plan assets -153 -153 -106 -106 Actuarial changes (assumptions) of which: Arising from changes in demographic assumptions 235 235 0 Arising from changes in financial assumptions -1.349 -1.349 -1.172 -1.172 Arising from experience adjustments -367 -350 -717 1.791 -69 1.722 Sub-total included in OCI -1.481 -350 -1.831 619 -69 550 Contributions by employer -1.078 -1.078 -1.128 -1.128 As of December 31 10.203 -10.089 114 10.587 -8.762 1.825 The decrease in the net defined benefit liability of EUR -1 7 million is mainly driven by actuarial changes included in OCI arising from changes in financial assumptions of EUR -1 3 million (mainly increase in discount rate from 1 15% to 3 80%) and from experience adjustments of EUR -0 7 million  combined with employer contributions in the period of EUR -1 1 million and partially offset by service cost recorded in income statement of EUR 1 2 million. The main assumptions used for the actuarial valuation are as follows: Salary increase for financial year 2022 of 14 5% (5 7% in 2021)Discount rate p.a. of 3 8% (1 15% in 2021)Long term salary increase (inflation included) p.a. of 2 4% (2 1% in 2021)NOTE 5.14: FINANCIAL RISK MANAGEMENT POLICIES The Group enters into derivative transactions  principally forward and option currency contracts  with the purpose to secure its sales and purchases in foreign currencies against negative variations of these currencies. The Group has transactional currency exposure arising from sales or purchases by operating entities in currencies other than the Groupâ€™s functional currency. Foreign currency risk is described in note 5.14.1. The Groupâ€™s main financial instruments  other than derivatives  comprise bank loans  finance leases  cash and short-term deposits. The purpose of these financial instruments is to raise finance for the Groupâ€™s operations. The Group has other financial instruments such as trade debtors and trade creditors  which arise directly from its operations. The Groupâ€™s policy is  and has always been  that no trading in financial instruments shall be undertaken. Credit risk is described in note 5.14.2. 5.14.1 FOREIGN CURRENCY RISK Since 2022  EVS systematically measures the Groupâ€™s anticipated exposure to transactional exchange risk over six to eighteen months. In its current structure  the Groupâ€™s exposure is mainly linked to the EUR/USD risk. The Group invoices all clients in Euro  except in the United States where invoices are denominated in USD. Since the majority of operating expenses are denominated in Euro  the Group has a long position in USD  i.e. all of the Groupâ€™s activities generate globally a positive net cash flow in USD. On the basis of the forecasts and according to the market conditions  the Group hedges a portion of the exchange rate risk on estimated net future flows  mainly through foreign exchange forward and option contracts. EVS does not apply hedge accounting according to IAS 39 for those transactions. Foreign exchange contracts are revalued at each closing date at their market value. The generated exchange rate profit or loss is recorded in the â€œOther net financial income/(charges)â€ account in the consolidated income statement. The valuation techniques used are mainly based on spot rates  forward rates and interest rate curves. Details of fair value at closing date are presented in note 5.6. 5.14.2 CREDIT RISK Credit exposure is controlled and reviewed regularly by the management. Trade receivables consist of a large number of customers  spread across many geographical areas. The evolution of the credit risk is monitored permanently. As of December 31  2022  it is assumed that the carrying amounts of those trade receivables are the most appropriate estimate to the fair value of those assets. The credit risk on financial instruments is contained as it is spread over a selection of different counterparties which are financial institutions with high credit ratings assigned by international credit rating agencies. As of December 31  2022  the maximum amount the Group could have to pay if guarantees are called on is EUR 0 8 million (similar to EUR 0 8 million in December 2021). NOTE 5.15: SUBSEQUENT EVENTS There are no subsequent events that may have a material impact on the condensed financial statements of the Group. NOTE 5.16: RISK AND UNCERTAINTIES Investing in the stock of EVS involves risks and uncertainties. The risks and uncertainties relating to the current year are similar to the risks and uncertainties that have been identified by the management of the company and that are listed in the management report of the annual report (available at www.evs.com). In terms of new risks arising since the last annual report we highlight the macro-economic environment that drives energy prices  components prices and labour cost to higher levels. EVS closely monitors the developments in this area and pro-actively takes actions to keep these rising costs under control or to minimize their effect on the profitability of the company. We also reiterate the potential impacts following the war in Ukraine. The company continues to comply with the sanction screening in vigor. Certification of responsible persons Serge Van Herck  CEO*Veerle De Wit  CFO* Certify that  based on their knowledge  a) the condensed financial statements  prepared in accordance with the International Financial Reporting Standards (IFRS) adopted by the European Union  fairly present in all material respects the financial condition and results of operations of the issuer and the companies included in the consolidation  b) the Directorsâ€™ report fairly presents the important events and related parties transactions of 2022  including their impact on the condensed financial statements  and a description of the existing risks and uncertainties for the remaining months of the fiscal year. * acting on behalf of a BV External Auditor The condensed consolidated financial statements of EVS Broadcast SA for the year ending December 31  2022 were authorized of issue in accordance with a resolution of the Board of Directors on February 16  2023. EY rÃ©viseurs dâ€™Entreprises represented by Carlo-SÃ©bastien dâ€™Addario has confirmed that their audit procedures  which have been substantially completed  have not revealed any material adjustments which would have to be made to the accounting information included in this press release. The complete audit report related to the audit of the consolidated financial statements will be shown in 2022 annual report that will be published in April 2023. Attachment Press release in PDF formatAll news about EVS BROADCAST EQUIPMENT SA 02/17 Evs reports 2022 results GL 02/17 EVS Broadcast Equipment SA Reports Earnings Results for the Full Year Ended December 31.. CI 02/16 Evs Broadcast Equipment : The press release PU 02/02 Evs Full Year 2022 Results to be Announced on Friday 17 February 2023 GL 02/02 Evs Full Year 2022 Results to be Announced on Friday 17 February 2023 AQ 02/02 Evs Broadcast Equipment : The conference call details PU 2022 LucidLink and EVS Partner to Cloud Enable Live Sports  Entertainment  and Breaking News.. CI 2022 Evs Broadcast Equipment : launches IPD-VIA Create web-based editing application PU 2022 Evs Broadcast Equipment : ProSiebenSat.1 Media SE trusts EVS for live production  replays .. PU 2022 EVS BROADCAST EQUIPMENT SA : Ex-dividend day for interim divi.. FA",neutral,0.0,1.0,0.0,mixed,0.71,0.16,0.13,True,English,"['EVS REPORTS 2022 RESULTS', '2H21 Variance FY22 FY21 Variance Revenue', 'Big Event Rental (BER) activity', 'EVS Broadcast Equipment S.A.', '2H22 Highlights Record order intake', 'recent â€œTop Employerâ€ certification', 'Live Service Providers markets', 'Big Event Rental revenue', 'team member engagement survey', 'strong financial income performance', 'Media Infrastructure revenue growth', 'strong net profit result', 'Live Audience Business', 'live TV production', 'Big Tech 2022 contract', 'Big Tech 22 contract', 'strong employer branding', 'multiple email addresses', 'capital expenditure envelope', 'Serge Van Herck', 'team member size', 'The Axon acquisition', 'historical revenue number', 'record-high order intake', 'important order intake', 'major sports events', 'VIA Portal ap', 'Healthy net profit', 'current market dynamics', 'total order book', 'sustainable growth ambitions', 'second record year', 'record revenue', 'Revenue performance', 'revenue guidance', 'revenue range', 'strong growth', 'strong talent', 'strong ecosystem', 'topline performance', 'largest contract', 'second half', 'team members', '6 Gross profit', 'Operating profit', 'VIA platform', 'major differentiator', 'market opening', 'fields Publication', 'Regulated information', 'Press release', 'Euronext Brussels', 'EVSB.BR', 'LiÃ¨ge', 'delivery terms', 'North America', 'MediaInfra solution', 'OPEX growth', 'one-off benefit', 'same period', 'future periods', 'organic growth', 'growth engine', 'profitable growth', 'base dividend', 'Key figures', '3,0 Gross margin', 'Operating margin', 'PlayForward strategy', 'growth momentum', 'significant growth', 'component shortages', 'Middle East', 'good progress', 'solution sales', 'Artificial Intelligence', 'large acquisitions', 'new ERP', 'market expectations', 'market share', 'last year', 'successful year', 'EVS REPORTS', 'EVS.BR', 'EVS BB', 'First name', 'Group share', 'solid Earnings', 'bottom line', 'annual results', '2022 results', 'commas', 'Message', 'February', 'Bloomberg', 'Reuters', 'Belgium', 'fundamentals', 'consequence', 'taxes', 'Outlook', 'beginning', 'focus', 'increase', 'dividends', 'policy', 'Pts', 'EBIT', 'EPS', 'Comments', 'CEO', 'revenues', 'August', '50MioUSD', 'inflation', 'position', 'customers', 'Asia', 'world', 'improvements', 'years', 'vision', 'introduction', 'XtraMotion', 'revolution', 'industry', 'May', 'capability', '10']",2023-02-17,2023-02-18,marketscreener.com
18721,EuroNext,NewsApi.org,https://biztoc.com/x/9476fc444ea9e7c4,Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15,New York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.Sâ€¦,New York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinicalâ€¦This story appeared on valneva.com   2023-02-17.,neutral,0.0,0.97,0.03,neutral,0.0,0.97,0.02,True,English,"['Lyme Disease Vaccine Candidate VLA15', 'Valneva Issue Update', 'Phase 3 Clinical Trial', 'Pfizer', 'New York', 'Valneva SE', 'Euronext Paris', 'study sponsor', 'significant percentage', 'U.S.', 'Outdoor Recreationists', 'valneva.com', 'Pfizer Inc.', 'Saint-Herblain', 'France', 'February', 'NYSE', 'PFE', 'Nasdaq', 'VLA', 'participants', 'Vaccine', 'Lyme', 'VALOR', 'Phase', 'story']",2023-02-17,2023-02-18,biztoc.com
18722,EuroNext,NewsApi.org,https://www.hospitalitynet.org/news/4115017.html,Accor: TÃ¼rkiye and Syria - Situation Update,On the 6th of February  a devastating earthquake struck TÃ¼rkiye and Syria. In this time of immense sadness and difficulty  Accor stands in solidarity with the people of TÃ¼rkiye and Syria  as well as the search and rescue teams and humanitarian workers who havâ€¦,On the 6th of February  a devastating earthquake struck TÃ¼rkiye and Syria. In this time of immense sadness and difficulty  Accor stands in solidarity with the people of TÃ¼rkiye and Syria  as well as the search and rescue teams and humanitarian workers who have rushed to the earthquake impact site.Accor supports the communities in which our teams live and work  to ensure they have the means to recover and rebuild their lives. As such  several initiatives have already been deployed:Offering temporary accommodation for first responders and earthquake victims at properties located within proximity of the affected areasHousing of team members with damaged residences at our properties with their loved onesHotels in TÃ¼rkiye are donating their supplies of linen  towels  and food products to the Turkey Hotel AssociationAccor Heartist Solidarity  our endowment fund  is partnering with the UNHCR  the UN Refugee Agency (UNHCR) to collect employeesâ€™ donations that will be topped-up by AccorAccor continues to monitor the situation closely and will take a medium to long term approach to our support for the country  establishing a roadmap of priorities and ways in which we can continue our ongoing efforts.We would like to thank all our team members on the ground for their outstanding efforts towards not only guests  but the community overall. Our warmest heartfelt thoughts go to all those affected by this tragic event.About Accor  a world-leading hospitality groupAccor is a world leading hospitality group consisting of 5 300 properties and 10 000 food and beverage venues throughout 110 countries. The group has one of the industry's most diverse and fully-integrated hospitality ecosystems encompassing more than 40 luxury  premium  midscale and economy hotel brands  entertainment and nightlife venues  restaurants and bars  branded private residences  shared accommodation properties  concierge services  co-working spaces and more. Accor's unmatched position in lifestyle hospitality â€“ one of the fastest growing categories in the industry â€“ is led by Ennismore  a joint venture  which Accor holds a majority shareholding. Ennismore is a creative hospitality company with a global collective of entrepreneurial and founder-built brands with purpose at their heart. Accor boasts an unrivalled portfolio of distinctive brands and more than 230 000 team members worldwide. Members benefit from the company's comprehensive loyalty program â€“ ALL - Accor Live Limitless â€“ a daily lifestyle companion that provides access to a wide variety of rewards  services and experiences. Through its global sustainability commitments (such as achieving Net Zero Carbon emissions by 2050  global elimination of single use plastics in its hotels' guest experience  etc.)  Accor Solidarity  RiiSE and ALL Heartist Fund initiatives  the Group is focused on driving positive action through business ethics  responsible tourism  environmental sustainability  community engagement  diversity and inclusivity. Founded in 1967  Accor SA is headquartered in France and publicly listed on the Euronext Paris Stock Exchange (ISIN code: FR0000120404) and on the OTC Market (Ticker: ACCYY) in the United States. For more information visit group.accor.com  or follow Accor on Twitter  Facebook  LinkedIn  and Instagram.,neutral,0.0,0.99,0.01,mixed,0.48,0.09,0.44,True,English,"['TÃ¼rkiye', 'Situation Update', 'Accor', 'Syria', 'Net Zero Carbon emissions', 'Euronext Paris Stock Exchange', 'ALL Heartist Fund initiatives', 'world leading hospitality group', 'Turkey Hotel Association', 'UN Refugee Agency', 'long term approach', 'warmest heartfelt thoughts', 'comprehensive loyalty program', 'single use plastics', 'daily lifestyle companion', 'earthquake impact site', 'economy hotel brands', ""hotels' guest experience"", 'global sustainability commitments', 'world-leading hospitality group', 'creative hospitality company', 'Accor Heartist Solidarity', 'lifestyle hospitality', 'several initiatives', 'endowment fund', 'hospitality ecosystems', 'environmental sustainability', 'devastating earthquake', 'earthquake victims', 'global collective', 'founder-built brands', 'distinctive brands', 'global elimination', 'TÃ¼rkiye', 'immense sadness', 'humanitarian workers', 'temporary accommodation', 'first responders', 'affected areas', 'loved ones', 'employeesâ€™ donations', 'medium to', 'ongoing efforts', 'outstanding efforts', 'tragic event', 'beverage venues', 'nightlife venues', 'working spaces', 'unmatched position', 'growing categories', 'joint venture', 'majority shareholding', 'unrivalled portfolio', 'wide variety', 'positive action', 'business ethics', 'responsible tourism', 'ISIN code', 'OTC Market', 'United States', 'team members', 'rescue teams', 'food products', 'private residences', 'concierge services', 'community engagement', 'Accor Live', 'Accor Solidarity', 'Accor SA', 'accommodation properties', '10,000 food', '5,300 properties', '6th', 'February', 'Syria', 'time', 'difficulty', 'people', 'search', 'communities', 'means', 'lives', 'proximity', 'Housing', 'supplies', 'linen', 'towels', 'UNHCR', 'situation', 'support', 'country', 'roadmap', 'priorities', 'ways', 'ground', 'guests', '110 countries', 'industry', 'diverse', 'midscale', 'entertainment', 'restaurants', 'bars', 'fastest', 'Ennismore', 'purpose', 'access', 'rewards', 'experiences', 'RiiSE', 'diversity', 'inclusivity', 'France', 'Ticker', 'ACCYY', 'information', 'Twitter', 'Facebook', 'LinkedIn', 'Instagram']",2023-02-17,2023-02-18,hospitalitynet.org
18723,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/VAN-DE-VELDE-NV-6022/news/Van-de-Velde-Acquisition-of-treasury-shares-43021341/?utm_medium=RSS&utm_content=20230217,Van de Velde : Acquisition of treasury shares,(marketscreener.com)   17.02.2023 - 18h00 Regulated information   Acquisition of treasury shares   In order to reduce the excess cash of the company and possibly cancel all or part of the purchased shares  the Board of Directors of Van de Velde NV proâ€¦,17.02.2023 - 18h00 Regulated informationAcquisition of treasury sharesIn order to reduce the excess cash of the company and possibly cancel all or part of the purchased shares  the Board of Directors of Van de Velde NV proceeded with the purchase of shares on the market of Euronext Brussels. The following treasury shares have been acquired during the period of 8 February 2023 until and including 16 February 2023:Transaction Date Number of shares Average price Minimum price Maximum price (â‚¬/share) (â‚¬/share) (â‚¬/share) 08/02/2023 600 31 75 31 75 31 75 09/02/2023 1.094 31 81 31 75 31 85 10/02/2023 1.082 31 47 31 45 31 50 13/02/2023 1.223 31 67 31 65 31 70 14/02/2023 246 31 35 31 35 31 35 15/02/2023 1.651 31 32 31 30 31 35 16/02/2023 374 31 20 31 20 31 25Total number of shares = 6.270. Average price = 31 54 â‚¬/share. Total amount = 197.734 45 â‚¬.The authorization to acquire own shares was granted to the Board of Directors on 11 December 2019 during the extraordinary meeting of shareholders.On 16 February 2023  363.548 own shares are held by Van de Velde NV  including the 11 000 shares that were already purchased in the context of a stock option plan. This represents 2 7 per cent of the total number of shares of Van de Velde NV.Van de Velde creates fashionable lingerie of superior quality with its premium  complementary brands PrimaDonna  Marie Jo and Andres Sarda. We believe in 'Shaping the bodies and minds of women': we want to make a difference in women's lives with our beautiful and perfectly fitting lingerie  by lifting their self-confidence and self-image. For us  an impeccable in-store service is key  an approach which we have consolidated in our Lingerie Styling Concept.We work in close partnership with 3 600 independent lingerie boutiques worldwide. In addition  we have our own retail network with retail brands Rigby & Peller and Lincherie. Our geographical center of gravity is Europe and North America. Van de Velde employs almost 1 500 employees and is listed on Euronext Brussels.CONTACTSFor more information  contact:Van de Velde NV - Lageweg 4 - 9260 Schellebelle - +32 (0)9 365 21 00 - www.vandevelde.euKarel Verlinde CommV always represented by Karel VerlindeChief Executive OfficerVan de Velde NV - Lageweg 4 - 9260 Schellebelle - Belgium - T. +32 9 365 21 00 - www.vandevelde.eu - info@vandevelde.eu,neutral,0.01,0.99,0.0,positive,0.8,0.19,0.01,True,English,"['Van de Velde', 'treasury shares', 'Acquisition', 'Chief Executive Officer Van de Velde NV', 'Average price Minimum price', 'stock option plan', 'premium, complementary brands', 'Lingerie Styling Concept', '3,600 independent lingerie boutiques', 'Karel Verlinde CommV', 'following treasury shares', 'Maximum price', 'fashionable lingerie', 'fitting lingerie', 'retail brands', 'excess cash', 'Euronext Brussels', 'Transaction Date', 'Total amount', 'extraordinary meeting', '2,7 per cent', 'superior quality', 'Marie Jo', 'Andres Sarda', 'store service', 'close partnership', 'retail network', 'geographical center', 'North America', 'Total number', 'Regulated information', '11,000 shares', 'Acquisition', 'order', 'company', 'Board', 'Directors', 'purchase', 'market', 'period', '8 February', '16 February', 'authorization', '11 December', 'shareholders', 'context', 'PrimaDonna', 'bodies', 'minds', 'women', 'difference', 'lives', 'beautiful', 'perfectly', 'self-confidence', 'self-image', 'impeccable', 'approach', 'addition', 'Rigby', 'Peller', 'Lincherie', 'gravity', 'Europe', '1,500 employees', 'CONTACTS', 'Lageweg', '9260 Schellebelle', 'Belgium', 'T.', 'vandevelde', '363.548', '32']",2023-02-17,2023-02-18,marketscreener.com
18724,EuroNext,NewsApi.org,https://finance.yahoo.com/news/nokia-announces-final-results-tender-123000750.html,Nokia Announces Final Results for its Tender Offers and the New Notes Issue,Nokia CorporationStock Exchange Release17 February 2023 at 14:30 EET NOT FOR RELEASE  PUBLICATION OR DISTRIBUTION IN OR INTO  OR TO ANY PERSON LOCATED OR...,"Nokia OyjNokia CorporationStock Exchange Release17 February 2023 at 14:30 EETNOT FOR RELEASE  PUBLICATION OR DISTRIBUTION IN OR INTO  OR TO ANY PERSON LOCATED OR RESIDENT IN OR AT ANY ADDRESS IN  THE UNITED STATES OF AMERICA  ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO  THE U.S. VIRGIN ISLANDS  GUAM  AMERICAN SAMOA  WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS)  ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO.Nokia Announces Final Results for its Tender Offers and the New Notes IssueEspoo  Finland â€“ Nokia Corporation (â€œNokiaâ€)  announced on 9 February 2023 that it has separately invited holders of each Series of the Notes (as defined below) issued under Nokia's EUR 5 000 000 000 Euro Medium Term Note Programme (each such invitation a â€œTender Offerâ€ and  together  the â€œTender Offersâ€) to tender their EUR 750 000 000 2.000 per cent. Notes due 15 March 2024 (the â€œ2024 Notesâ€)  EUR 500 000 000 2.375 per cent. Notes due 15 May 2025 (the â€œ2025 Notesâ€) and EUR 750 000 000 2.000 per cent. Notes due 11 March 2026 (the â€œ2026 Notesâ€ and  together with the 2024 Notes and the 2025 Notes  the ""Notes"" and each a ""Seriesâ€) for purchase for cash up to the Maximum Acceptance Amount (as defined in the Tender Offer Memorandum).The Tender Offers were made on the terms and subject to the conditions set out in the tender offer memorandum dated 9 February 2023 (the â€œTender Offer Memorandumâ€). Capitalised terms not defined herein have the meaning ascribed to them in the Tender Offer Memorandum.The Expiration Deadline for the Tender Offers was 4.00 p.m. (London time) on 16 February 2023.Nokia hereby informs Noteholders that set out in the table below is: (i) each Series Acceptance Amount; (ii) the aggregate nominal amount of Notes tendered for purchase pursuant to each Tender Offer; (iii) each Purchase Yield; (iv) each Interpolated Mid-Swap Rate; (v) each Purchase Price; (vi) the pro-ration factor that will be applied to valid tenders of Notes of each Series; and (vii) the aggregate nominal amount of each Series of the Notes that remain outstanding following settlement of the Tender Offers.Story continuesNotes ISIN / Common Code Purchase Spread Interpolated Mid-Swap Rate Purchase Yield Purchase Price Aggregate nominal amount tendered for purchase Series Acceptance Amount Pro-ration Factor Aggregate nominal amount that remain outstanding following settlement 2024 Notes XS1577731604 / 157773160 -35 bps 3.588% 3.238%% 98.728% EUR 372 472 000 EUR 372 472 000 100% EUR 377 528 000 2025 Notes XS2171759256 / 217175925 +5 bps 3.530% 3.580% 97.456% EUR 207 843 000 EUR 207 843 000 100% EUR 292 157 000 2026 Notes XS1960685383 / 196068538 +25 bps 3.395% 3.645% 95.331% EUR 256 879 000 EUR 119 685 000 approximately 43.513% EUR 630 315 000The Final Acceptance Amount is EUR 700 000 000.Nokia will also pay Accrued Interest in respect of the Notes purchased pursuant to the Tender Offers.On 10 February 2023  Nokia priced a new issue of â‚¬500 000 000 4.375 per cent. Notes due 21 August 2031 (the â€œNew Notesâ€). Application will be made for the New Notes to be admitted to listing and trading on Euronext Dublin.The New Financing Condition has been satisfied  subject to the issuance of the New Notes. The New Notes have been priced and a subscription agreement between Nokia and the joint bookrunners named therein for the purchase of  and subscription for  the New Notes has been signed and remains in full force and effect as of the date hereof.The Settlement Date for the Tender Offers and the New Notes is expected to be 21 February 2023.Notes purchased by Nokia pursuant to the Tender Offers will be immediately cancelled. Notes which have not been validly submitted and accepted for purchase pursuant to the Tender Offers will remain outstanding after the Settlement Date.The Tender Offers have now expired and no further Notes can be tendered for purchase.Joint Dealer ManagersBofA Securities SA  Citigroup Global Markets Limited  Deutsche Bank Aktiengesellschaft and UniCredit Bank AG (the â€œJoint Dealer Managersâ€) are acting as Joint Dealer Managers for the Tender Offers. Investors with questions may contact the Joint Dealer Managers at the addresses and numbers shown below.BofA Securities SA Citigroup Global Markets Limited 51  rue La BoÃ©tie75008 ParisFrance Citigroup CentreCanada SquareCanary WharfLondon E14 5LBUnited Kingdom Tel.: +33 1 877 01057Attn.: Liability Management GroupEmail: DG.LM-EMEA@bofa.com Tel: +44 20 7986 8969Attn.: Liability Management GroupEmail: liabilitymanagement.europe@citi.com Deutsche Bank Aktiengesellschaft UniCredit Bank AG Mainzer Landstr. 11-1760329 Frankfurt am MainGermany UniCredit Bank AGArabellastraÃŸe 1281925 MunichGermany Tel: +44 207 545 8011Attn.: Liability Management GroupTel: +39 02 8862 0581Attn.: Liability ManagementEmail: corporate.lm@unicredit.deCopies of the Tender Offer Memorandum can be requested from the Tender Agent  Kroll Issuer Services Limited  at: +44 20 7704 0880 or at nokia@is.kroll.com .DISCLAIMERThis announcement must be read in conjunction with the Tender Offer Memorandum. No offer or invitation to acquire any securities is being made pursuant to this announcement. The distribution of this announcement and the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this announcement and/or the Tender Offer Memorandum comes are required by each of Nokia  the Dealer Managers and the Tender Agent to inform themselves about  and to observe  any such restrictions.About NokiaAt Nokia  we create technology that helps the world act together.As a trusted partner for critical networks  we are committed to innovation and technology leadership across mobile  fixed and cloud networks. We create value with intellectual property and long-term research  led by the award-winning Nokia Bell Labs.Adhering to high standards of integrity and security  we help build the capabilities needed for a more productive  sustainable and inclusive world.Inquiries:NokiaCommunicationsPhone: +358 10 448 4900Email: press.services@nokia.comMaria Vaismaa  Global Head of Public RelationsNokiaInvestor RelationsPhone: +358 40 803 4080Email: investor.relations@nokia.comForward-looking statementsCertain statements herein that are not historical facts are forward-looking statements. These forward-looking statements reflect Nokia's current expectations and views of future developments and include statements regarding: A) expectations  plans  benefits or outlook related to our strategies  product launches  growth management  sustainability and other ESG targets  operational key performance indicators and decisions on market exits; B) expectations  plans or benefits related to future performance of our businesses (including the expected impact  timing and duration of COVID-19 and the general macroeconomic conditions on our businesses  our supply chain and our customersâ€™ businesses) and any future dividends and other distributions of profit; C) expectations and targets regarding financial performance and results of operations  including market share  prices  net sales  income  margins  cash flows  the timing of receivables  operating expenses  provisions  impairments  taxes  currency exchange rates  hedging  investment funds  inflation  product cost reductions  competitiveness  revenue generation in any specific region  and licensing income and payments; D) ability to execute  expectations  plans or benefits related to changes in organisational structure and operating model; E) impact on revenue with respect to litigation/renewal discussions; and F) any statements preceded by or including ""continue""  â€œbelieveâ€  â€œcommitâ€  â€œestimateâ€  â€œexpectâ€  â€œaimâ€  â€œinfluenceâ€  ""willâ€ or similar expressions. These forward-looking statements are subject to a number of risks and uncertainties  many of which are beyond our control  which could cause our actual results to differ materially from such statements. These statements are based on managementâ€™s best assumptions and beliefs in light of the information currently available to them. These forward-looking statements are only predictions based upon our current expectations and views of future events and developments and are subject to risks and uncertainties that are difficult to predict because they relate to events and depend on circumstances that will occur in the future.",neutral,0.01,0.99,0.0,mixed,0.25,0.2,0.55,True,English,"['New Notes Issue', 'Final Results', 'Tender Offers', 'Nokia', 'purchase Series Acceptance Amount Pro-ration Factor Aggregate nominal amount', 'Nokia Oyj Nokia Corporation Stock Exchange Release', '5,000,000,000 Euro Medium Term Note Programme', 'Mid-Swap Rate Purchase Yield Purchase Price', 'UniCredit Bank AG Mainzer Landstr.', 'THE U.S. VIRGIN ISLANDS', 'rue La BoÃ©tie', 'Citigroup Global Markets Limited', 'The Final Acceptance Amount', 'Germany UniCredit Bank AG', 'The New Financing Condition', 'Maximum Acceptance Amount', 'Interpolated Mid-Swap Rate', 'NORTHERN MARIANA ISLANDS', 'U.S. PERSON', 'France Citigroup Centre', 'Deutsche Bank Aktiengesellschaft', 'Common Code Purchase', 'The Expiration Deadline', 'Joint Dealer Managers', 'Liability Management Group', 'Tender Offer Memorandum', 'EUR 750,000,000 2.000 per cent', 'BofA Securities SA', 'The Tender Offers', 'The New Notes', 'The Settlement Date', 'New Notes Issue', 'Final Results', 'new issue', 'joint bookrunners', 'SECURITIES ACT', 'UNITED STATES', 'PUERTO RICO', 'AMERICAN SAMOA', 'valid tenders', 'Accrued Interest', 'Euronext Dublin', 'full force', 'Canada Square', 'Canary Wharf', 'United Kingdom', 'ArabellastraÃŸe', 'Capitalised terms', 'London time', 'subscription agreement', 'Notes ISIN', '2024 Notes XS1577731604', 'Notes XS2171759256', '2025 Notes', '2026 Notes', '17 February', '14:30 EET', 'DISTRIBUTION', 'INTO', 'ADDRESS', 'POSSESSIONS', 'GUAM', 'WAKE', 'DISTRICT', 'COLUMBIA', 'REGULATION', 'JURISDICTION', 'Espoo', 'Finland', '9 February', 'holders', 'invitation', 'cash', 'conditions', 'meaning', '16 February', 'table', 'Story', 'respect', '10 February', 'Application', 'trading', 'issuance', 'effect', 'Investors', 'questions', 'numbers', 'Paris', 'Attn.', 'Email', 'DG.', 'LM-EMEA', 'Frankfurt', 'Munich', 'Tel', 'Copies', '4.00', '44']",2023-02-17,2023-02-18,finance.yahoo.com
18725,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BEKAERT-NV-5971/news/Bekaert-Completion-of-the-Share-Buyback-Program-and-Update-on-the-Liquidity-Agreement-43014236/?utm_medium=RSS&utm_content=20230217,Bekaert - Completion of the Share Buyback Program and Update on the Liquidity Agreement,(marketscreener.com) Â  Â  Â  Â  Completion of the Share Buyback Program and Update on the Liquidity Agreement Period from 9Â February 2023 to 15Â February 2023 Share Buyback Program fully implementedOn 25 February 2022  Bekaert announced a program to buy back own â€¦,Completion of the Share Buyback Program and Update on the Liquidity AgreementPeriod from 9 February 2023 to 15 February 2023Share Buyback Program fully implementedOn 25 February 2022   Bekaert announced a program (the â€œProgramâ€) to buy back own shares up to â‚¬ 120 million. The Program was split into four equal tranches of up to â‚¬ 30 million each.Bekaert announces today that it completed the fourth and last tranche of the Program. During the fourth tranche  which started on 18 November 2022 and ended on 13 February 2023  the company repurchased 820 929 ordinary shares for an aggregate consideration of â‚¬ 30 million. Under the full Program  the company repurchased 3 488 344 ordinary shares for an aggregate consideration of â‚¬ 117.3 million.As previously announced  the purpose of the Program is to reduce the issued share capital of the company and all shares repurchased as part of this arrangement will be cancelled. So far  1 449 409 treasury shares were cancelled. The balance of the repurchased shares (2 038 935 shares) will be cancelled before the end of February 2023.Bekaertâ€™s reference shareholder  Stichting Administratiekantoor Bekaert (STAK) and the parties acting in concert with the STAK  have confirmed that they will take appropriate measures so that their voting rights in Bekaertâ€™s share capital will not exceed the level they had at the start of the Program (i.e. 36.13%) by the end of February 2023.During the period from 9 February 2023 to 13 February 2023  Kepler Cheuvreux on behalf of Bekaert has bought 38 369 shares.The table below provides an overview of the transactions under the fourth tranche of the Program during the period from 9 February 2023 to 13 February 2023:Repurchase of shares Date Market Number of Shares Average Price paid (â‚¬) Highest Pricepaid (â‚¬) Lowest Pricepaid (â‚¬) TotalAmount (â‚¬) 9 February 2023 Euronext Brussels 6 345 40.24 40.48 39.80 255 323 MTF CBOE 3 952 40.21 40.44 39.78 158 910 MTF Turquoise 765 40.25 40.44 39.96 30 791 MTF Aquis 1 497 40.25 40.46 39.92 60 254 10 February 2023 Euronext Brussels 7 833 39.93 40.40 39.64 312 772 MTF CBOE 4 808 39.95 40.38 39.62 192 080 MTF Turquoise 889 39.96 40.36 39.76 35 524 MTF Aquis 1 893 39.96 40.38 39.62 75 644 13 February 2023 Euronext Brussels 7 725 39.74 39.90 39.60 306 992 MTF CBOE 2 662 39.76 39.90 39.64 105 841 MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” Total 38 369 39.98 40.48 38.86 1 534 131Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022   Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 2 400 shares during the period from 9 February 2023 to 15 February 2023 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 5 500 shares on Euronext Brussels.The tables below provide an overview of the transactions under the liquidity agreement during the period from 9 February 2023 to 15 February 2023:Purchase of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 9 February 2023 0 0.00 0.00 0.00 0 10 February 2023 400 39.90 39.90 39.90 15 960 13 February 2023 1 200 39.69 39.80 39.54 47 628 14 February 2023 800 39.45 39.50 39.40 31 560 15 February 2023 0 0.00 0.00 0.00 0 Total 2 400 â€” â€” â€” 95 148Sale of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 9 February 2023 1 900 40.15 40.40 39.80 0 10 February 2023 0 0.00 0.00 0.00 0 13 February 2023 0 0.00 0.00 0.00 0 14 February 2023 2 000 39.86 40.00 39.80 79 720 15 February 2023 1 600 40.20 40.40 39.90 64 320 Total 5 500 â€” â€” â€” 144 040The balance held by Bekaert under the liquidity agreement at the end of the period is 37 636 shares.On 15 February 2023 after closing of the market  Bekaert holds 4 750 289 own shares  or 8.05% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Attachment,neutral,0.01,0.99,0.0,neutral,0.03,0.95,0.02,True,English,"['Share Buyback Program', 'Liquidity Agreement', 'Bekaert', 'Completion', 'Update', 'four equal tranches', 'investor relations pages', 'Stichting Administratiekantoor Bekaert', 'Share Buyback Program', 'Shares Average Price', 'Date Market Number', 'Liquidity Agreement Period', 'Date Number', 'share capital', 'Highest Price', 'Lowest Price', 'last tranche', 'aggregate consideration', 'reference shareholder', 'appropriate measures', 'voting rights', 'Kepler Cheuvreux', 'Euronext Brussels', 'MTF CBOE', 'MTF Turquoise', 'MTF Aquis', 'total number', 'fourth tranche', '820 929 ordinary shares', '3 488 344 ordinary shares', '1 449 409 treasury shares', 'outstanding shares', 'full Program', 'same period', 'Total Amount', '038 935 shares', '38 369 shares', '2 400 shares', '5 500 shares', '37 636 shares', 'Completion', 'Update', '9 February', '15 February', '25 February', '18 November', '13 February', 'company', 'purpose', 'part', 'arrangement', 'balance', 'end', 'STAK', 'concert', 'level', 'start', 'behalf', 'table', 'overview', 'transactions', 'Repurchase', '2 September', '10 February', 'Sale', '14 February', 'closing', 'information', 'website', 'Attachment', '750 289']",2023-02-17,2023-02-18,marketscreener.com
18726,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610373/0/en/Bekaert-Completion-of-the-Share-Buyback-Program-and-Update-on-the-Liquidity-Agreement.html,Bekaert - Completion of the Share Buyback Program and Update on the Liquidity Agreement,Completion of the Share Buyback Program and Update on the Liquidity Agreement    Period from 9Â February 2023 to 15Â February 2023    Share......,English Dutch FrenchCompletion of the Share Buyback Program and Update on the Liquidity AgreementPeriod from 9 February 2023 to 15 February 2023Share Buyback Program fully implementedOn 25 February 2022   Bekaert announced a program (the â€œProgramâ€) to buy back own shares up to â‚¬ 120 million. The Program was split into four equal tranches of up to â‚¬ 30 million each.Bekaert announces today that it completed the fourth and last tranche of the Program. During the fourth tranche  which started on 18 November 2022 and ended on 13 February 2023  the company repurchased 820 929 ordinary shares for an aggregate consideration of â‚¬ 30 million. Under the full Program  the company repurchased 3 488 344 ordinary shares for an aggregate consideration of â‚¬ 117.3 million.As previously announced  the purpose of the Program is to reduce the issued share capital of the company and all shares repurchased as part of this arrangement will be cancelled. So far  1 449 409 treasury shares were cancelled. The balance of the repurchased shares (2 038 935 shares) will be cancelled before the end of February 2023.Bekaertâ€™s reference shareholder  Stichting Administratiekantoor Bekaert (STAK) and the parties acting in concert with the STAK  have confirmed that they will take appropriate measures so that their voting rights in Bekaertâ€™s share capital will not exceed the level they had at the start of the Program (i.e. 36.13%) by the end of February 2023.During the period from 9 February 2023 to 13 February 2023  Kepler Cheuvreux on behalf of Bekaert has bought 38 369 shares.The table below provides an overview of the transactions under the fourth tranche of the Program during the period from 9 February 2023 to 13 February 2023:Repurchase of shares Date Market Number of Shares Average Price paid (â‚¬) Highest Pricepaid (â‚¬) Lowest Pricepaid (â‚¬) TotalAmount (â‚¬) 9 February 2023 Euronext Brussels 6 345 40.24 40.48 39.80 255 323 MTF CBOE 3 952 40.21 40.44 39.78 158 910 MTF Turquoise 765 40.25 40.44 39.96 30 791 MTF Aquis 1 497 40.25 40.46 39.92 60 254 10 February 2023 Euronext Brussels 7 833 39.93 40.40 39.64 312 772 MTF CBOE 4 808 39.95 40.38 39.62 192 080 MTF Turquoise 889 39.96 40.36 39.76 35 524 MTF Aquis 1 893 39.96 40.38 39.62 75 644 13 February 2023 Euronext Brussels 7 725 39.74 39.90 39.60 306 992 MTF CBOE 2 662 39.76 39.90 39.64 105 841 MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” Total 38 369 39.98 40.48 38.86 1 534 131Liquidity agreementIn relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 2 September 2022   Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 2 400 shares during the period from 9 February 2023 to 15 February 2023 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 5 500 shares on Euronext Brussels.The tables below provide an overview of the transactions under the liquidity agreement during the period from 9 February 2023 to 15 February 2023:Purchase of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 9 February 2023 0 0.00 0.00 0.00 0 10 February 2023 400 39.90 39.90 39.90 15 960 13 February 2023 1 200 39.69 39.80 39.54 47 628 14 February 2023 800 39.45 39.50 39.40 31 560 15 February 2023 0 0.00 0.00 0.00 0 Total 2 400 â€” â€” â€” 95 148Sale of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 9 February 2023 1 900 40.15 40.40 39.80 0 10 February 2023 0 0.00 0.00 0.00 0 13 February 2023 0 0.00 0.00 0.00 0 14 February 2023 2 000 39.86 40.00 39.80 79 720 15 February 2023 1 600 40.20 40.40 39.90 64 320 Total 5 500 â€” â€” â€” 144 040The balance held by Bekaert under the liquidity agreement at the end of the period is 37 636 shares.On 15 February 2023 after closing of the market  Bekaert holds 4 750 289 own shares  or 8.05% of the total number of the outstanding shares.This information is also made available on the investor relations pages of our website.Attachment,neutral,0.01,0.99,0.0,positive,0.62,0.37,0.01,True,English,"['Share Buyback Program', 'Liquidity Agreement', 'Bekaert', 'Completion', 'Update', 'English Dutch French', 'four equal tranches', 'investor relations pages', 'Stichting Administratiekantoor Bekaert', 'Share Buyback Program', 'Shares Average Price', 'Date Market Number', 'Liquidity Agreement Period', 'Date Number', 'share capital', 'Highest Price', 'Lowest Price', 'last tranche', 'aggregate consideration', 'reference shareholder', 'appropriate measures', 'voting rights', 'Kepler Cheuvreux', 'Euronext Brussels', 'MTF CBOE', 'MTF Turquoise', 'MTF Aquis', 'total number', 'fourth tranche', '820 929 ordinary shares', '3 488 344 ordinary shares', '1 449 409 treasury shares', 'outstanding shares', 'full Program', 'same period', 'Total Amount', '038 935 shares', '38 369 shares', '2 400 shares', '5 500 shares', '37 636 shares', 'Completion', 'Update', '9 February', '15 February', '25 February', '18 November', '13 February', 'company', 'purpose', 'part', 'arrangement', 'balance', 'end', 'STAK', 'concert', 'level', 'start', 'behalf', 'table', 'overview', 'transactions', 'Repurchase', '2 September', '10 February', 'Sale', '14 February', 'closing', 'information', 'website', 'Attachment', '750 289']",2023-02-17,2023-02-18,globenewswire.com
18727,EuroNext,NewsApi.org,https://www.marketscreener.com/news/latest/Galp-planning-to-sell-10-stake-in-Mozambique-gas-project-report--43014600/?utm_medium=RSS&utm_content=20230217,Galp planning to sell 10% stake in Mozambique gas project - report,(marketscreener.com) Portugal's Galp Energia has mandated Bank of America to prepare a sale of its 10% stake in a multibillion-dollar natural gas project in Mozambique's Rovuma basin  the Negocios newspaper said on Thursday  citing an unidentified source linkâ€¦,There would be no lack of interest in Galp's stake as the war in Ukraine had increased the appetite for gas from international companies  the report said.Galp declined to comment.The energy company holds a 10% stake in a consortium exploring for natural gas in Rovuma's Area 4  in the northern Mozambique region of Cabo Delgado  which has been the target of attacks by militants.The main shareholder with a 70% stake is Mozambique Rovuma Venture  comprising Exxon Mobil Corp  Italy's ENI and China National Petroleum Corporation (CNPC). Korea's Kogas and Mozambique's National Hydrocarbons Company ENH have 10% each.Galp announced a deal on Monday to sell its upstream business in Angola to SOMOIL for about $830 million. Its Angolan output comes from mature fields with declining production while its main upstream business is in Brazil.Galp shares were up 1% at 11.815 euros($12.61) on Euronext Lisbon in afternoon trading.($1 = 0.9373 euros)(Reporting by Sergio Goncalves; Editing by Andrei Khalip and Mike Harrison),neutral,0.0,0.99,0.0,negative,0.0,0.01,0.99,True,English,"['Mozambique gas project', 'Galp', '10% stake', 'report', 'China National Petroleum Corporation', 'Exxon Mobil Corp', 'National Hydrocarbons Company', 'northern Mozambique region', 'main upstream business', 'Mozambique Rovuma Venture', 'energy company', 'main shareholder', 'international companies', 'Cabo Delgado', 'Angolan output', 'mature fields', 'declining production', 'Euronext Lisbon', 'afternoon trading', 'Sergio Goncalves', 'Andrei Khalip', 'Mike Harrison', 'natural gas', 'Galp shares', 'lack', 'interest', 'stake', 'war', 'Ukraine', 'appetite', 'report', 'consortium', 'Area', 'target', 'attacks', 'militants', 'Italy', 'ENI', 'CNPC', 'Korea', 'Kogas', 'ENH', 'deal', 'Monday', 'SOMOIL', 'Brazil', '11.815 euros', '0.9373 euros', 'Editing']",2023-02-17,2023-02-18,marketscreener.com
18728,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SARTORIUS-STEDIM-BIOTECH-27471609/news/Sartorius-Stedim-Biotech-SA-Information-on-Document-Availability-43014443/?utm_medium=RSS&utm_content=20230217,Sartorius Stedim Biotech SA: Information on Document Availability,(marketscreener.com) Sartorius Stedim Biotech SASartorius Stedim Biotech SA: Information on Document Availability 17-Feb-2023 / 08:41 CET/CESTDissemination of a French Regulatory News  transmitted by EQS Group.The issuer is solely responsible for theâ€¦,Sartorius Stedim Biotech SASartorius Stedim Biotech SA: Information on Document Availability17-Feb-2023 / 08:41 CET/CESTDissemination of a French Regulatory News  transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.Aubagne  February 17  2023 Sartorius Stedim Biotech: Information on Document Availability Sartorius Stedim Biotech Groupâ€™s Universal Registration Document 2022 is now available at: https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/news-financial-publications It contains the following information: - Business development for fiscal 2022 and the 2023 forecast for the Sartorius Stedim Biotech Group - Consolidated financial statements for the year ended December 31  2022 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider  the company helps its customers to manufacture biotech medications safely  rapidly and economically. Headquartered in Aubagne  France  the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe  North America and Asia and an international network of sales companies  Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2022  the company employed roughly 12 000 people  and earned sales revenue of around 3.5 billion euros.ContactPetra Kirchhoff; Head of Corporate Communications and Investor Relations Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com Follow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn. Regulatory filing PDF fileFile: Sartorius Stedim Biotech S.A. - Information on Document Availability,neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.0,True,English,"['Sartorius Stedim Biotech SA', 'Document Availability', 'Information', 'Sartorius Stedim Biotech Sartorius Stedim Biotech', 'Regulatory filing PDF file File', 'Sartorius Stedim Biotech S.A.', 'Sartorius Stedim Biotech Group', 'French Regulatory News', 'total solutions provider', 'R&D sites', 'leading international partner', 'Universal Registration Document', 'biotech medications', 'EQS Group', 'The Group', 'international network', 'Document Availability', 'Business development', 'financial statements', 'biopharmaceutical industry', 'Euronext Paris', 'North America', 'sales companies', 'global reach', 'double digits', 'complementary technologies', 'sales revenue', '3.5 billion euros', 'Corporate Communications', 'Investor Relations', 'Petra Kirchhoff', 'following information', 'CEST', 'Dissemination', 'issuer', 'content', 'announcement', 'Aubagne', 'investor-relations', 'sartorius-stedim-biotech', 'fiscal 2022', '2023 forecast', 'year', 'profile', 'company', 'customers', 'France', 'shares', 'manufacturing', 'Europe', 'Asia', 'portfolio', 'acquisitions', '12,000 people', 'Contact', 'Head', 'Phone', 'Twitter', 'Sartorius_Group', 'LinkedIn', '08']",2023-02-17,2023-02-18,marketscreener.com
18729,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/OXURION-NV-29715/news/Oxurion-Receives-Transparency-Notifications-from-Negma-Group-43021665/?utm_medium=RSS&utm_content=20230217,Oxurion Receives Transparency Notifications from Negma Group,(marketscreener.com) Oxurion Receives Transparency Notifications from Negma Group Leuven  BELGIUM  Boston  MA  US â€“ February 17  2022 â€“ 7.00 PM CET Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with câ€¦,"Oxurion Receives Transparency Notifications from Negma GroupLeuven  BELGIUM  Boston  MA  US â€“ February 17  2022 â€“ 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with clinical stage assets in vascular retinal disorders  today announced that  pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:Oxurion received a transparency notification on February 14  2023 from Negma Group Ltd. indicating that as of February 9  2023  it held no shares of the then outstanding 493 468 012 shares  and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1Oxurion received a transparency notification on February 13  2023 from Negma Group Ltd. indicating that as of February 8  2023  it held 15 503 696 shares of the then outstanding 493 468 012 shares  and therefore crossed above the threshold (3%) by virtue of acquisition of voting securities. See Annex 2About OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered â€œforward-lookingâ€. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companyâ€™s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10"" tom.graney@oxurion.comMichael DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.comU SConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com________1. Article 14  first paragraph  of the Law of 2 May 2007 on disclosure of major holdings.ANNEX 1ANNEX 2Attachments",neutral,0.01,0.99,0.0,mixed,0.22,0.23,0.55,True,English,"['Transparency Notifications', 'Negma Group', 'Oxurion', 'applicable U.S. state securities laws', 'Tom Graney Chief Executive Officer', 'potent plasma kallikrein inhibitor', 'U.S. Securities Act', 'Chief Business Officer', 'next generation standard', 'Negma Group Ltd.', 'diabetic macular edema', 'potential new standard', 'Mary T. Conway', 'Belgian Transparency legislation1', 'Negma Group Leuven', 'clinical stage assets', 'U S', 'vascular retinal disorders', 'Such forward-looking statements', 'CET Oxurion NV', 'care ophthalmic therapies', 'voting securities', 'Conway Communications', 'new information', 'Transparency Notifications', 'Euronext Brussels', 'leading cause', 'working-age people', 'other conditions', 'important role', 'successful development', 'novel therapeutic', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'Annual Report', 'United States', 'first paragraph', 'major holdings', 'More information', 'Important information', 'Additional information', 'biopharmaceutical company', 'The Company', 'outstanding 493,468,012 shares', 'vision loss', 'various risks', 'ICR Westwicke', 'Christopher Brinzey', 'ANNEX 2 Attachments', 'Michael Dillen', 'DME patients', '15,503,696 shares', 'Annex 1', 'BELGIUM', 'Boston', 'February', 'threshold', 'virtue', 'disposal', 'acquisition', 'treatment', 'THR-149', 'uncertainties', 'assurance', 'obligation', 'offer', 'invitation', 'sale', 'purchase', 'jurisdiction', 'registration', 'compliance', 'exemption', 'accordance', 'Tel', 'Article', '2 May', 'disclosure', '7.00', '32']",2023-02-17,2023-02-18,marketscreener.com
18730,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610346/0/en/Pfizer-and-Valneva-Issue-Update-on-Phase-3-Clinical-Trial-Evaluating-Lyme-Disease-Vaccine-Candidate-VLA15.html,Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15,New York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.Sâ€¦,"English FrenchNew York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy  safety and immunogenicity of an investigational Lyme disease vaccine candidate  VLA15. These study participants  representing approximately half of the total recruited participants in the trial  are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator. The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event.GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. These standards are designed to put participantsâ€™ interests first and ensure high scientific integrity. Once Pfizer learned of potential violations of GCP  it conducted a thorough review of the operations and data collection at the clinical trial sites run by the third party and followed standard operating safeguards to determine the correct course of action.The clinical trial remains ongoing with other sites not operated by the third party  and Pfizer continues to enroll new participants at those sites. The companies intend to work with regulatory authorities  and as previously announced 1 2 aim for Pfizer to potentially submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025  pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan.Participants are being notified and Pfizer has also notified the FDA  other regulatory agencies and the independent Institutional Review Board for this study.Integrity of data collected in clinical trials is critical to provide evidence and confidence in a potential vaccine or medicineâ€™s safety and efficacy. Pfizer and Valneva are committed to collecting robust data needed for potential regulatory submission of VLA15. While VLA15 is still under investigation  to date the companies have been encouraged by the data from the Phase 2 clinical studies  which demonstrated strong immunogenicity and acceptable safety and tolerability profiles.2-4About VLA15VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi  the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. Blocking OspA inhibits the bacteriumâ€™s ability to leave the tick and infect humans. The vaccine covers the six most common OspA serotypes expressed by the Borrelia burgdorferi sensu lato species that are prevalent in North America and Europe. VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA15  with updates to the terms within this agreement made in June 2022.5 6 The program was granted Fast Track designation by the U.S. FDA in July 2017.7About Lyme DiseaseLyme disease is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks.8 It is considered the most common vector-borne illness in the Northern Hemisphere.9 While the true incidence of Lyme disease is unknown  it is estimated to annually affect approximately 476 000 people in the United States and 130 000 people in Europe.10 11 Early symptoms of Lyme disease (such as a gradually expanding erythematous rash called Erythema migrans or more nonspecific symptoms like fatigue  fever  headache  mild stiff neck  arthralgia or myalgia) are often overlooked or misinterpreted. Left untreated  the disease can disseminate and cause more serious complications affecting the joints (arthritis)  the heart (carditis) or the nervous system.12 The medical need for vaccination against Lyme disease is steadily increasing as the geographic footprint of the disease widens.10About Pfizer: Breakthroughs That Change Patientsâ€™ LivesAt Pfizer  we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality  safety and value in the discovery  development and manufacture of health care products  including innovative medicines and vaccines. Every day  Pfizer colleagues work across developed and emerging markets to advance wellness  prevention  treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies  we collaborate with health care providers  governments and local communities to support and expand access to reliable  affordable health care around the world. For more than 170 years  we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition  to learn more  please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News  LinkedIn  YouTube and like us on Facebook at Facebook.com/Pfizer.Pfizer Disclosure NoticeThe information contained in this release is as of February 17  2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.This release contains forward-looking information about an investigational Lyme disease vaccine candidate  VLA15  and a collaboration between Pfizer and Valneva for VLA15  including their potential benefits  VALOR  a Phase 3 clinical study investigating the efficacy  safety and immunogenicity of VLA15  and the timing of potential regulatory submissions  that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include  among other things  the uncertainties inherent in research and development  including the ability to meet anticipated clinical endpoints  commencement and/or completion dates for our clinical trials  regulatory submission dates  regulatory approval dates and/or launch dates  including uncertainties relating to the time needed to recruit and enroll participants  and accrue cases in the Phase 3 trial  and uncertainties relating to an agreement with regulatory authorities on any modifications to the clinical trial plan as needed  as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for VLA15; whether and when any such applications may be approved by regulatory authorities  which will depend on myriad factors  including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and  if approved  whether VLA15 will be commercially successful; decisions by regulatory authorities impacting labeling  manufacturing processes  safety and/or other matters that could affect the availability or commercial potential of VLA15; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; whether our collaboration with Valneva will be successful; uncertainties regarding the impact of COVID-19 on Pfizerâ€™s business  operations and financial results; and competitive developments.A further description of risks and uncertainties can be found in Pfizerâ€™s Annual Report on Form 10-K for the fiscal year ended December 31  2021 and in its subsequent reports on Form 10-Q  including in the sections thereof captioned â€œRisk Factorsâ€ and â€œForward-Looking Information and Factors That May Affect Future Resultsâ€  as well as in its subsequent reports on Form 8-K  all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.About Valneva SEValneva is a specialty vaccine company focused on the development  manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic  including candidates against the chikungunya virus and Lyme disease.Valneva Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva  including with respect to the progress and recruitment of clinical trials  discussions with regulatory agencies  modifications to clinical trial plans  results of clinical trials  and timing for filing for potential regulatory approval of product candidates. In addition  even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release  those results or developments of Valneva may not be sustained in the future. In some cases  you can identify forward-looking statements by words such as ""could "" ""should "" ""may "" ""expects "" ""anticipates "" ""believes "" ""intends "" ""estimates "" ""aims "" ""targets "" or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results  performance or achievements to be materially different from any future results  performance or achievement expressed or implied by these forward-looking statements. In particular  the expectations of Valneva could be affected by  among other things  uncertainties involved in the development and manufacture of vaccines  unexpected clinical trial results or delays  unexpected regulatory actions or delays  competition in general  currency fluctuations  the impact of the global and European credit crisis  and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties  there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release and disclaim any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events  or otherwise.Media ContactsPfizerMedia Relations:PfizerMediaRelations@pfizer.com212-733-1226Investor Relations:IR@pfizer.com212-733-4848ValnevaLaÃ«titia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 7099laetitia.bachelot-fontaine@valneva.comJoshua Drumm  Ph.D.VP Global Investor RelationsM +1 917 815 4520joshua.drumm@valneva.comReferencesPfizer. Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15. August 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease. Accessed: February 2023. Valneva. Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate. December 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-six-month-antibody-persistence. Accessed: February 2023 Valneva. Valneva Pfizer Report Positive Phase 2 Pediatric Data for Lyme Vaccine Candidate. April 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-report-positive-phase-2-pediatric-data-for-lyme-disease-vaccine-candidate/ Accessed: July 2022. Valneva. Valneva Pfizer Report Positive Phase 2 Data for Lyme Disease Vaccine Candidate. February 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-report-further-positive-phase-2-data-for-lyme-disease-vaccine-candidate/ Accessed: July 2022. Valneva. Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine  VLA15. April 2020. Available at: https://valneva.com/press-release/valneva-and-pfizer-announce-collaboration-to-co-develop-and-commercialize-lyme-disease-vaccine-vla15/ Accessed: July 2022 . Valneva. Valneva and Pfizer Enter into Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15. June 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-enter-into-an-equity-subscription-agreement-and-update-terms-of-collaboration-agreement-for-lyme-disease-vaccine-candidate-vla15/ Accessed: July 2022. Valneva. Valneva Receives FDA Fast track Designation for its Lyme Disease Vaccine Candidate VLA15. July 2017. Available at: https://valneva.com/press-release/valneva-receives-fda-fast-track-designation-for-its-lyme-disease-vaccine-candidate-vla15/ Accessed: July 2022. Stanek G  Wormser GP  Gray J  et al. Lyme borreliosis. Lancet. 2012; 4;379(9814):461-73. Gern L  Falco RC. Lyme disease. Rev Sci Tech. 2000 Apr;19(1):121-35. Center for Disease Control and Prevention. Lyme Disease. Data and Surveillance. April 2021. Available at: https://www.cdc.gov/lyme/datasurveillance/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Flyme%2Fstats%2Findex.html Accessed July 2022. Sykes RA  et al. An estimate of Lyme borreliosis incidence in Western Europe. Journal of Public Health 2017; 39(1): 74-81 Center for Disease Control and Prevention. Lyme Disease. Signs and Symptoms of Untreated Lyme disease. January 2021. Available at: https://www.cdc.gov/lyme/signs_symptoms/index.html Accessed July 2022.Attachment",neutral,0.0,0.97,0.03,mixed,0.23,0.06,0.71,True,English,"['Lyme Disease Vaccine Candidate VLA15', 'Valneva Issue Update', 'Phase 3 Clinical Trial', 'Pfizer', 'six most common OspA serotypes', 'Borrelia burgdorferi sensu lato species', 'investigational multivalent protein subunit vaccine', 'third-party clinical trial site operator', 'investigational Lyme disease vaccine candidate', 'independent Institutional Review Board', 'outer surface protein A', 'participant-reported adverse event', 'Biologics License Application', 'Marketing Authorisation Application', 'Fast Track designation', 'expanding erythematous rash', 'mild stiff neck', 'health care products', 'Good Clinical Practice', 'clinical trial plan', 'European Medicines Agency', 'strong immune response', 'standard operating safeguards', 'Borrelia burgdorferi bacteria', 'U.S. Food', 'high scientific integrity', 'potential regulatory submission', 'clinical trial sites', 'Phase 2 clinical studies', 'satisfactory safety profile', 'other regulatory agencies', 'scientific quality standard', 'Phase 3 clinical study', 'U.S. FDA', 'investigational vaccine', 'potential vaccine', 'thorough review', 'Phase 3 studies', 'other sites', 'clinical trials', 'clinical researchers', 'regulatory authorities', 'innovative medicines', 'clinical development', 'English French', 'New York', 'Euronext Paris', 'significant percentage', 'Outdoor Recreationists', 'international ethical', 'third party', 'correct course', 'Drug Administration', 'successful completion', 'strong immunogenicity', 'tolerability profiles', 'North America', 'systemic infection', 'Ixodes ticks', 'vector-borne illness', 'Northern Hemisphere', 'true incidence', 'United States', 'Early symptoms', 'nonspecific symptoms', 'serious complications', 'nervous system', 'medical need', 'geographic footprint', 'global resources', 'potential violations', 'study sponsor', 'safety concerns', 'acceptable safety', 'data collection', 'robust data', 'participantsâ€™ interests', 'new participants', 'Valneva SE', 'collaboration agreement', 'study participants', 'Pfizer Inc.', 'Pfizer colleagues', 'Saint-Herblain', 'France', 'February', 'PFE', 'Nasdaq', 'VLA', 'VALOR', 'half', 'GCP', 'discontinuation', 'standards', 'operations', 'action', 'companies', 'MAA', 'modifications', 'evidence', 'confidence', 'efficacy', 'mechanism', 'humans', 'pre-clinical', 'April', 'updates', 'terms', 'June', 'program', 'July', '476,000 people', '130,000 people', 'fatigue', 'fever', 'headache', 'arthralgia', 'myalgia', 'joints', 'arthritis', 'heart', 'carditis', 'vaccination', 'Breakthroughs', 'Lives', 'science', 'value', 'discovery', 'manufacture', 'vaccines']",2023-02-17,2023-02-18,globenewswire.com
18731,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610930/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-NEGMA.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA   Negma Group Investment Ltd. has converted 320......,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMANegma Group Investment Ltd. has converted 320 convertible bonds in Oxurion resulting in a EUR 800 000 capital increase. This is part of Negma Group Investment Ltd.â€™s EUR 15 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US â€“ February 17  2023 â€“ 07.00 PM CET â€“ In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the â€œCompanyâ€ or â€œOxurionâ€)  announces the below information  following the issuance of (i) 34 246 575 new ordinary shares on February 13  2023  for a total amount of EUR 400 000  as the result of the conversion of 160 class B convertible bonds  and (ii) 36 496 350 new ordinary shares on February 15  2023  for a total amount of EUR 400 000  as the result of the conversion of 160 class B convertible bonds  pursuant to the Capital Commitment entered into with Negma Group Investment Ltd.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 564 210 937  outstanding ordinary shares carrying voting rights (compared to 493 468 012 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 77 506 161.32 Total number of securities with voting rights (all ordinary shares) 564 210 937 Total number of ordinary shares (= denominator) 564 210 937 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 694 000 subscription rights (â€œSRsâ€) issued on November 20  2017  entitling their holders to subscribe to a total number of 694 000 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);976 874 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 976 874 securities carrying voting rights (all ordinary shares);534 688 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 534 688 securities carrying voting rights (all ordinary shares);582 248 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 582 248 securities carrying voting rights (all ordinary shares);80 convertible bonds issued on January 25  2023  entitling their holder (Negma Group Investment Ltd.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group Investment Ltd. on August 26  2021  and the addenda thereto dated September 2  2022 and January 25  2023; and100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021.ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered â€œforward-lookingâ€. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companyâ€™s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMichaÃ«l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com1 Press release Oxurion  06/04/2021  Press release Oxurion  02/09/2022 and Press release Oxurion  25/01/2023Attachments,neutral,0.0,1.0,0.0,mixed,0.37,0.26,0.37,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'NEGMA', 'potent plasma kallikrein inhibitor', 'Negma Group Investment Ltd.', 'EUR 15 million Capital Commitment1', '160 class B convertible bonds', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'potential new standard', 'EUR 800,000 capital increase', 'Kreos Capital VI', 'potential market opportunities', 'care ophthalmic therapies', 'Such forward-looking statements', '34,246,575 new ordinary shares', '36,496,350 new ordinary shares', '564,210,937, outstanding ordinary shares', '493,468,012 outstanding ordinary shares', 'Israel) L.P.', '320 convertible bonds', '80 convertible bonds', '100 convertible bonds', 'Share capital', 'regulated market', 'drug candidate', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'various risks', 'Voting Rights', '694,000 subscription rights', 'Total Number', 'updated information', 'More information', 'Important information', 'subscription agreement', 'vision loss', 'novel therapeutic', 'biopharmaceutical company', 'The Company', 'other conditions', 'Conversion Notice', 'Oxurion NV', 'DME patients', 'Denominator', 'back', 'eye', 'Leuven', 'BELGIUM', 'Boston', 'February', '07.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'result', 'completion', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'January', 'terms', 'August', 'addenda', 'UK', 'Cayman', 'Limited', 'treatment', 'THR-149', 'uncertainties', 'assurance']",2023-02-17,2023-02-18,globenewswire.com
18732,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/AUTOLIV-INC-11628/news/Autoliv-Board-of-Directors-approves-renewal-of-EMTN-Programme-43022105/?utm_medium=RSS&utm_content=20230217,Autoliv: Board of Directors approves renewal of EMTN Programme,(marketscreener.com) STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- The Funding Committee of the Board of Directors of Autoliv  Inc. approved on February 14  2023 the renewal for one year of its â‚¬3 000 000 000 guaranteed euro medium term note programme   which waâ€¦,"STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- The Funding Committee of the Board of Directors of Autoliv  Inc. (NYSE: ALV) (SSE: ALIVsdb) (the ""Company"") approved on February 14  2023 the renewal for one year of its â‚¬3 000 000 000 guaranteed euro medium term note programme (the ""EMTN Programme"")  which was originally established on 11 April 2019.The renewal of the EMTN Programme will allow the Company to take advantage of the funding opportunities provided by the capital markets and institutional investors through the future issuance of notes (the ""Notes""). The Notes issued by the Company under the EMTN Programme will be unconditionally and irrevocably guaranteed by the Company's subsidiary  Autoliv ASP  Inc. (the ""Guarantor"").The base listing particulars dated February 17  2023 (the ""Base Listing Particulars"")  which has been prepared by the Company and the Guarantor in connection with the EMTN Programme  has been approved by Euronext Dublin and is available for viewing on the website of Euronext Dublin (http://www.ise.ie).InquiriesTreasury: Par-Ola Wirenlind  Tel +46 (0) 7 030 332 78Investors & Analysts: Anders Trapp  Tel +46 (0) 8 587 206 71Investors & Analysts: Henrik Kaar  Tel +46 (0)8 587 206 14Media: Gabriella Ekelund  Tel +46 (70) 612 64 24About AutolivAutoliv  Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies  we develop  manufacture and market protective systems  such as airbags  seatbelts  and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions  such as pedestrian protection  connected safety services and safety solutions for riders of powered two wheelers. At Autoliv  we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2022  our products saved close to 35 000 lives and reduced more than 450 000 injuries.Our close to 70 000 associates in 27 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation  research  and development at our 14 technical centers  with their 20 test tracks. Sales in 2022 amounted to US $ 8.8 billion. For more information go to www.autoliv.com.Important InformationNOTHING IN THIS COMMUNICATION CONSTITUTES AN OFFER TO SELL  OR THE SOLICITATION OF AN OFFER TO BUY  ANY SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES REFERRED TO IN THE BASE LISTING PARTICULARS (THE ""SECURITIES"") HAVE NOT BEEN  AND WILL NOT BE  REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933  AS AMENDED (THE ""SECURITIES ACT"")  OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES  AND THE SECURITIES MAY NOT BE OFFERED OR SOLD  DIRECTLY OR INDIRECTLY  WITHIN THE UNITED STATES OR TO  OR FOR THE ACCOUNT OR BENEFIT OF  U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) EXCEPT PURSUANT TO AN EXEMPTION FROM  OR IN A TRANSACTION NOT SUBJECT TO  THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.Safe Harbor StatementThis communication contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities  events or developments that Autoliv  Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations  various assumptions and data available from third parties.Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However  there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks  uncertainties and other factors which may cause actual future results  performance or achievements to differ materially from the future results  performance or achievements expressed in or implied by such forward-looking statements.Numerous risks  uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this communication or any other document  we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995  and we assume no obligation to update publicly or revise any such statements in light of new information or future events  except as required by law.The following files are available for download:https://mb.cision.com/Main/751/3718209/1858691.pdf Autoliv: Board of Directors approves renewal of EMTN Programme (PDF)View original content: https://www.prnewswire.com/news-releases/autoliv-board-of-directors-approves-renewal-of-emtn-programme-301750181.htmlSOURCE Autoliv",neutral,0.01,0.99,0.0,mixed,0.57,0.03,0.4,True,English,"['EMTN Programme', 'Autoliv', 'Board', 'Directors', 'renewal', 'â‚¬3,000,000,000 guaranteed euro medium term note programme', 'Private Securities Litigation Reform Act', 'UNITED STATES SECURITIES ACT', 'market protective systems', 'major automotive manufacturers', 'close to 70,000 associates', 'U.S. PERSONS', 'automotive safety systems', 'connected safety services', 'base listing particulars', 'Safe Harbor Statement', 'LOCAL SECURITIES LAWS', 'The Funding Committee', 'mobility safety solutions', 'Such forward-looking statements', 'actual future results', 'actual results', 'EMTN Programme', 'funding opportunities', 'leading solutions', 'one year', 'capital markets', 'future issuance', 'Euronext Dublin', 'ise.ie', 'Inquiries Treasury', 'Par-Ola Wirenlind', 'Anders Trapp', 'Henrik Kaar', 'Gabriella Ekelund', 'Nasdaq Stockholm', 'ALIV.sdb', 'worldwide leader', 'group companies', 'steering wheels', 'two wheelers', '14 technical centers', '20 test tracks', 'OTHER JURISDICTION', 'REGISTRATION REQUIREMENTS', 'historical facts', 'third parties', 'good faith', 'reasonable basis', 'unknown risks', 'other factors', 'Numerous risks', 'other document', 'following files', 'original content', 'Important Information', 'new information', 'pedestrian protection', 'More Lives', 'APPLICABLE STATE', 'current expectations', 'various assumptions', 'future events', 'institutional investors', 'Autoliv ASP', 'SOURCE Autoliv', '35,000 lives', 'Feb.', 'Board', 'Directors', 'Inc.', 'NYSE', 'ALV', 'SSE', 'ALIVsdb', 'Company', 'February', 'renewal', '11 April', 'advantage', 'notes', 'subsidiary', 'Guarantor', 'connection', 'website', 'Tel', 'Analysts', 'Media', 'airbags', 'seatbelts', 'riders', 'standards', 'products', '450,000 injuries', '27 countries', 'vision', 'quality', 'heart', 'everything', 'innovation', 'research', 'development', 'Sales', 'COMMUNICATION', 'OFFER', 'SELL', 'SOLICITATION', 'BUY', 'ACCOUNT', 'BENEFIT', 'REGULATION', 'EXEMPTION', 'TRANSACTION', 'meaning', 'activities', 'management', 'data', 'assurance', 'uncertainties', 'performance', 'achievements', 'obligation', 'light', 'download', 'cision', 'Main', 'emtn-programme', '46']",2023-02-17,2023-02-18,marketscreener.com
18734,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ABIVAX-22387984/news/Abivax-appoints-Dr-Sheldon-Sloan-M-D-as-Chief-Medical-Officer-43014097/?utm_medium=RSS&utm_content=20230217,Abivax appoints Dr. Sheldon Sloan  M.D.  as Chief Medical Officer,(marketscreener.com) EQS-News: ABIVAX / Key word: PersonnelAbivax appoints Dr. Sheldon Sloan  M.D.  as Chief Medical Officer 17.02.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax appâ€¦,EQS-News: ABIVAX / Key word(s): PersonnelAbivax appoints Dr. Sheldon Sloan  M.D.  as Chief Medical Officer17.02.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax appoints Dr. Sheldon Sloan  M.D.  as Chief Medical OfficerSheldon Sloan  M.D.  M. Bioethics  has a strong track record in product development and commercial launches in the pharmaceutical industry with a focus on Inflammatory Bowel DiseaseAs CMO of Abivax  Dr. Sloan will play a critical role in the successful conduct and completion of the ongoing Phase 3 global clinical program with obefazimod for the treatment of ulcerative colitis (UC)  as well as in the subsequent global submissions and commercial launch preparationsDr. Sloan will be based in the US  establishing an Abivax office on the US East CoastPARIS  France  February 17  2023 â€“ 08:00 a.m. (CET) â€“ Abivax SA (Euronext Paris: FR0012333284 â€“ ABVX)  a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases  today announced the appointment of Dr. Sheldon Sloan  M.D.  M. Bioethics  as new Chief Medical Officer  effective on March 1  2023. Dr. Sloan brings over 30 years of experience in academia and the biopharmaceutical industry  with an extensive track record in the field of Gastroenterology and Inflammatory Bowel Disease (IBD). He has spent the last 25 years of his career in large pharmaceutical and biotech companies  including 15 years in leading positions at J&J  followed by Arena Pharmaceuticals and then Pfizer as Program Lead for Etrasimod UC. He successfully managed late-stage clinical trial programs  global submissions and product launches in the IBD field.â€œWe are excited to welcome Sheldon at Abivax and to benefit from his vast experience to drive the clinical and medical strategy and development of our Company in the years to come  said Prof. Hartmut J. Ehrlich  M.D.  CEO of Abivax. â€œHis strong competencies will be particularly valuable to assist Abivax in conducting our ongoing Phase 3 clinical program with obefazimod for the treatment of UC patients. Further  Sheldon will be driving the strategy for future clinical development programs with obefazimod  first and foremost for Crohnâ€™s disease. The Abivax team is now very much looking forward to leveraging our competencies and efforts with Sheldon and to advancing obefazimod towards potential global licensing and to make the drug candidate quickly available to all the patients in need of new effective treatment options  if approved.â€Prior to joining Abivax  Dr. Sloan worked for Arena Pharmaceuticals and  after its acquisition  for Pfizer. He was Program Lead for Etrasimod UC  responsible for cross-functional leadership  planning and management  operational business process planning  and execution management of the Ulcerative Colitis program  including its global submission and launch. Before joining Arena Pharmaceuticals  Dr. Sloan held different leadership positions at J&J in Medical Affairs  R&D  and Science Policy. In his last position at J&J  he was Global Medical Affairs Leader for IBD  leading the global launch strategy and execution for Crohnâ€™s Disease and Ulcerative Colitis for Stelara. Dr. Sloan also has a strong track record in bioethics and has been involved on different levels in questions addressing bioethics issues including animal care and use and human subjects research. Dr. Sloan holds an M.D. from Rush Medical College  Chicago  USA  and a Master of Bioethics from the University of Pennsylvania  USA. He has authored a large number of scientific publications and abstracts and contributed to various books in the gastroenterology and immunology fields.Sheldon Sloan  M.D.  M. Bioethics  CMO of Abivax  commented: â€œI am thrilled to join Abivax during these exciting and decisive times and to drive its late-stage clinical program with obefazimod for the treatment of UC through the pivotal studies and  if successful  towards global submissions and launch  if approved. I am excited to have the opportunity to contribute with my dedicated expertise in the IBD field to guide obefazimod through the medical  clinical and commercial steps and processes. I believe that this drug candidate could become a novel long-term therapy option addressing the still high unmet medical needs in the chronic inflammatory disease field and am committed to make sure its potential is fully realized for the benefit of the many patients suffering from IBD and other chronic inflammatory diseases.â€*****About Abivax (www.abivax.com)Abivax is a Phase 3 clinical stage biotechnology company  focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax  founded by Truffle Capital  is listed on Euronext compartment B (ISIN: FR0012333284 â€“ MnÃ©mo: ABVX). Based in Paris and Montpellier  Abivaxâ€™s lead drug candidate  obefazimod (ABX464)  is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.ContactsAbivaxCommunicationsRegina Jehleregina.jehle@abivax.com+33 6 24 50 69 63InvestorsLifeSci AdvisorsLigia Vela-Reidlvela-reid@lifesciadvisors.com+44 7413 825310Press Relations & Investors EuropeMC Services AGAnne Henneckeanne.hennecke@mc-services.eu+49 211 529 252 22Public Relations FranceActifinGhislaine Gasparettoggasparetto@actifin.fr+33 6 21 10 49 24 Public Relations FrancePrimaticeThomas Roborel de Climensthomasdeclimens@primatice.com+33 6 78 12 97 95 Public Relations USARooney Partners LLCJeanene Timberlakejtimberlake@rooneypartners.com+1 646 770 8858DISCLAIMERThis press release contains forward-looking statements  forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivaxâ€™ management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks  contingencies and uncertainties  many of which are difficult to predict and generally beyond the control of Abivax  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. A description of these risks  contingencies and uncertainties can be found in the documents filed by the Company with the French AutoritÃ© des MarchÃ©s Financiers pursuant to its legal obligations including its registration document (Document dâ€™Enregistrement Universel). These risks  contingencies and uncertainties include among other things  the uncertainties inherent in research and development  future clinical data and analysis  decisions by regulatory authorities  such as the FDA or the EMA  regarding whether and when to approve any drug  as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical  pharmacokinetic  carcinogenicity  toxicity  CMC and clinical data. Furthermore  these forward-looking statements  forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements  forecasts or estimates to reflect any subsequent changes that the Company becomes aware of  except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only  and the information contained herein does not constitute either an offer to sell  or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction  in particular in France. Similarly  it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives  financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.,neutral,0.0,0.99,0.0,mixed,0.66,0.15,0.19,True,English,"['Dr. Sheldon Sloan', 'Chief Medical Officer', 'M.D.', 'Abivax', 'Phase 3 clinical stage biotechnology company', 'ongoing Phase 3 global clinical program', 'Phase 3 clinical-stage biotechnology company', 'novel long-term therapy option', 'ongoing Phase 3 clinical program', 'high unmet medical needs', 'late-stage clinical trial programs', 'operational business process planning', 'Prof. Hartmut J. Ehrlich', 'other chronic inflammatory diseases', 'future clinical development programs', 'new Chief Medical Officer', 'new effective treatment options', 'Global Medical Affairs Leader', 'chronic inflammatory disease field', 'Phase 3 clinical trials', 'late-stage clinical program', 'extensive track record', 'human subjects research', 'Rush Medical College', 'Inflammatory Bowel Disease', 'strong track record', 'Euronext compartment B', 'subsequent global submissions', 'US East Coast', 'potential global licensing', 'Ulcerative Colitis program', 'different leadership positions', 'commercial launch preparations', 'The Abivax team', 'global launch strategy', 'lead drug candidate', 'Dr. Sheldon Sloan', 'medical, clinical', 'Program Lead', 'medical strategy', 'J&J', 'Dr. Sloan', 'leading positions', 'cross-functional leadership', 'different levels', 'product development', 'commercial launches', 'commercial steps', 'strong competencies', 'Key word', 'M.D.', 'pharmaceutical industry', 'critical role', 'successful conduct', 'immune system', 'large pharmaceutical', 'biotech companies', 'Arena Pharmaceuticals', 'product launches', 'R&D', 'Science Policy', 'last position', 'animal care', 'large number', 'scientific publications', 'various books', 'immunology fields', 'decisive times', 'pivotal studies', 'dedicated expertise', 'Truffle Capital', 'MnÃ©mo', 'Euronext Paris', 'M. Bioethics', 'bioethics issues', 'IBD field', 'Etrasimod UC', 'vast experience', 'many patients', 'last 25 years', 'Abivax office', 'Abivax SA', 'UC patients', '30 years', '15 years', 'EQS-News', 'Personnel', '00 CET', 'CEST', 'issuer', 'content', 'announcement', 'focus', 'CMO', 'completion', 'obefazimod', 'France', 'February', '08:00 a', 'ABVX', 'therapeutics', 'appointment', 'March', 'academia', 'Gastroenterology', 'career', 'Pfizer', 'CEO', 'Crohn', 'efforts', 'acquisition', 'management', 'execution', 'Stelara', 'questions', 'use', 'Chicago', 'USA', 'Master', 'University', 'Pennsylvania', 'abstracts', 'exciting', 'opportunity', 'processes', 'benefit', 'Montpellier', 'information']",2023-02-17,2023-02-18,marketscreener.com
18738,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ANTIN-INFRASTRUCTURE-PART-127080817/news/Antin-Infrastructure-Partners-S-A-invests-in-PearlX-an-innovative-US-smart-grid-infrastructure-pl-43013749/?utm_medium=RSS&utm_content=20230217,Antin Infrastructure Partners S A : invests in PearlX  an innovative US smart grid infrastructure platform,(marketscreener.com)  Antin invests in PearlX  an innovative US smart grid infrastructure platform  17 February 2023    PearlX marks the first investment in North America for Antin's NextGen platform and is positioned to play a key role in US decarbonizâ€¦,"17 February 2023PearlX marks the first investment in North America for Antin's NextGen platform and is positioned to play a key role in US decarbonization initiativesNew York  Paris  LondonAntin Infrastructure Partners announced today that it has invested in a majority stake in PearlX  an owner and operator of fully integrated smart grid infrastructure systems. PearlX provides an innovative solution that decarbonizes existing multi-family rental properties and provides residents with cheaper  cleaner  and more reliable energy.PearlX  founded by Michael Huerta and Peter Mendonez in 2019  is the first mover of scale of smart grid infrastructure in the US multi-family residential housing segment. Through a proven state-of-the-art solution combining rooftop solar panels  communal battery storage and community electrification  PearlX works with landlords to optimize their ""energy estate"". This provides renters with backup power and bill savings  and landlords with new income streams  community amenities and improved ESG performance.The investment will be deployed to scale up the team and platform  execute on a robust pipeline of solar and storage systems  and continue to expand electrification offerings to underserved multi-family rental communities in California  Texas  and across the US. As the first US investment of Antin's NextGen platform  PearlX joins a unique portfolio that includes SNRG  a UK-focused smart grid platform  and two European electric vehicle charging platforms  Power Dot and RAW Charging.Michael Huerta  PearlX co-founder and CEO stated: ""Antin's investment in PearlX along with our management team's experience in renewable energy and community solar provides a world-class foundation for our shared vision of smart grid infrastructure platforms. We are excited to partner with Antin to scale our solution and deliver cleaner  resilient  and more accessible energy solutions to additional middle-to-lower income rental communities.""Nathalie Kosciusko-Morizet and Rakesh Shankar  NextGen Partners at Antin commented: ""PearlX fully aligns with NextGen's mission of identifying and building tomorrow's sustainable and connected infrastructure landscape. We look forward to working with the exceptional PearlX team to further these important goals.""About PearlXPearlX is a smart-grid  clean electrification company that owns and operates renewable energy infrastructure. PearlX's mission is to provide energy accessibility  protection and affordability for multifamily renters across the United States. The company partners with multifamily landlords to deploy future-proof infrastructure and create economic benefits for communities. As families increasingly face climate-linked adversity including blackouts  higher temperatures and more extreme weather events  PearlX seeks to restore resilience and reliability.About Antin Infrastructure PartnersAntin Infrastructure Partners is a leading private equity firm focused on infrastructure. With over â‚¬30 billion in assets under management across its Flagship  Mid Cap and NextGen investment strategies  Antin targets investments in the energy and environment  digital  transport and social infrastructure sectors. With offices in Paris  London  New York  Singapore and Luxembourg  Antin employs approximately 200 professionals dedicated to growing  improving and transforming infrastructure businesses while delivering long-term value to portfolio companies and investors. Majority owned by its partners  Antin is listed on Euronext Paris (Ticker: ANTIN - ISIN: FR0014005AL0).Media ContactsAntin Infrastructure PartnersNicolle Graugnard  Communication DirectorEmail: nicolle.graugnard@antin-ip.comLudmilla Binet  Head of Shareholder RelationsEmail: ludmilla.binet@antin-ip.comBrunswickEmail: antinip@brunswickgroup.comTristan Roquet Montegon +33 (0) 6 37 00 52 57Gabriel JabÃ¨s +33 (0) 6 40 87 08 14PearlX InfrastructureJimmy Benjamin  Market Research and Development AssociateEmail: jkb@pearlxinfra.comIncus MediaEmail: miguel.afonso@incus-media.comMiguel Afonso +44 (0) 1737 215 200",neutral,0.01,0.99,0.0,positive,0.95,0.05,0.0,True,English,"['innovative US smart grid infrastructure platform', 'Antin Infrastructure Partners', 'S A', 'PearlX', 'two European electric vehicle charging platforms', 'US multi-family residential housing segment', 'integrated smart grid infrastructure systems', 'leading private equity firm', 'smart grid infrastructure platforms', 'existing multi-family rental properties', 'UK-focused smart grid platform', 'lower income rental communities', 'smart-grid, clean electrification company', 'multi-family rental communities', 'US decarbonization initiatives', 'extreme weather events', 'Tristan Roquet Montegon', 'Gabriel JabÃ¨s', 'connected infrastructure landscape', 'social infrastructure sectors', 'new income streams', 'communal battery storage', 'accessible energy solutions', 'rooftop solar panels', 'renewable energy infrastructure', 'first US investment', 'NextGen investment strategies', 'Antin Infrastructure Partners', 'exceptional PearlX team', 'storage systems', 'RAW Charging', 'future-proof infrastructure', 'infrastructure businesses', 'community electrification', 'electrification offerings', 'NextGen Partners', 'first investment', 'New York', 'first mover', 'NextGen platform', 'reliable energy', 'energy estate', 'energy accessibility', 'PearlX Infrastructure', 'North America', 'key role', 'Michael Huerta', 'Peter Mendonez', 'backup power', 'bill savings', 'community amenities', 'ESG performance', 'robust pipeline', 'unique portfolio', 'Power Dot', 'community solar', 'world-class foundation', 'Nathalie Kosciusko-Morizet', 'Rakesh Shankar', 'important goals', 'United States', 'economic benefits', 'climate-linked adversity', 'higher temperatures', 'Mid Cap', 'digital, transport', 'long-term value', 'portfolio companies', 'Communication Director', 'Shareholder Relations', 'Jimmy Benjamin', 'Market Research', 'Development Associate', 'miguel.afonso', 'Miguel Afonso', 'Media Contacts', 'Incus Media', 'majority stake', 'management team', 'multifamily renters', 'Nicolle Graugnard', 'Ludmilla Binet', 'innovative solution', 'multifamily landlords', 'Euronext Paris', 'February', 'London', 'owner', 'operator', 'residents', 'scale', 'California', 'Texas', 'SNRG', 'founder', 'CEO', 'experience', 'vision', 'additional', 'mission', 'tomorrow', 'sustainable', 'protection', 'affordability', 'families', 'blackouts', 'resilience', 'reliability', 'assets', 'Flagship', 'investments', 'environment', 'offices', 'Singapore', 'Luxembourg', '200 professionals', 'transforming', 'investors', 'Ticker', 'ISIN', 'Email', 'Head', 'Brunswick', 'jkb']",2023-02-17,2023-02-18,marketscreener.com
18740,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/dsm---delivery-of-shares-301750087.html,DSM - delivery of shares,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube Aâ€¦,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube AG (to be renamed DSM-Firmenich AG) for all the issued and outstanding ordinary shares in the capital of DSM (the Exchange Offer). This press release does not constitute an offer  or any solicitation of any offer  to buy or subscribe for any securities. This press release is not for general release  publication or distribution  in whole or in part  in or into  directly or indirectly  the United States or any other jurisdiction where such release  publication or distribution would violate applicable laws or regulations.HEERLEN  Netherlands  Feb. 17  2023 /PRNewswire/ -- Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.Pursuant to commitments entered into prior to issuing the Offering Circular  DSM has on 17 February 2023  delivered 165 ordinary shares to employees in view of settling the exercise of an equivalent number of stock options granted under the respective DSM Incentive Plan (average exercise price â‚¬94.82). On the date hereof  the total number of issued and outstanding DSM ordinary shares is 173 126 125. As a consequence of the delivery included herein  the number of outstanding DSM ordinary shares increased by 0.0001%.DSMRoyal DSM is a global  purpose-led company in Health  Nutrition & Bioscience  applying science to improve the health of people  animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic  environmental and societal value for all its stakeholders â€“ customers  employees  shareholders  and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.Or find us on:LinkedIn: http://www.linkedin.com/company/3108Twitter: http://www.twitter.com/DSMFacebook: http://www.facebook.com/DSMcompanyYouTube: http://www.youtube.com/user/dsmcompanyFor more informationDSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 email investor.relations@dsm.comForward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations  estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release  unless required by law. The English language version of the press release is leading.Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpgSOURCE Royal DSM,neutral,0.02,0.98,0.0,mixed,0.26,0.08,0.66,True,English,"['DSM', 'delivery', 'shares', 'DSM Media Relations Gareth Mead', 'DSM Investor Relations Dave Huizing', 'Koninklijke DSM N.V.', 'respective DSM Incentive Plan', 'Dutch public offer rules', 'outstanding DSM ordinary shares', 'outstanding ordinary shares', 'Public Takeover Bids', 'English language version', 'future (financial) performance', 'average exercise price', 'global, purpose-led company', 'SOURCE Royal DSM', '165 ordinary shares', 'treasury shares', 'Dutch Decree', 'actual performance', 'Sections 13 paragraphs', 'biedingen Wft', 'Danube AG', 'Exchange Offer', 'United States', 'other jurisdiction', 'applicable laws', 'Offering Circular', 'share units', 'stock options', 'brighter lives', 'biggest challenges', 'economic, environmental', 'societal value', 'Euronext Amsterdam', 'current expectations', 'many factors', 'press release', 'general release', 'equivalent number', 'total number', 'Forward-looking statements', 'Such statements', 'More information', 'provisions', 'connection', 'capital', 'solicitation', 'securities', 'publication', 'distribution', 'part', 'regulations', 'HEERLEN', 'Netherlands', 'Feb.', '22 November', 'transactions', 'accordance', 'delivery', 'employees', 'view', 'vesting', 'commitments', '17 February', 'date', 'consequence', 'Health', 'Nutrition', 'Bioscience', 'people', 'animals', 'planet', 'products', 'solutions', 'world', 'stakeholders', 'customers', 'shareholders', 'society', 'LinkedIn', 'Twitter', 'Facebook', 'DSMcompany', 'YouTube', 'position', 'estimates', 'projections', 'readers', 'risks', 'uncertainties', 'obligation', 'Logo']",2023-02-17,2023-02-18,prnewswire.co.uk
18753,EuroNext,Twitter API,Twitter,@galeone_matteo equity options market maker on Euronext Amsterdam,nan,@galeone_matteo equity options market maker on Euronext Amsterdam,neutral,0.0,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['galeone_matteo equity options market maker', 'Euronext Amsterdam', 'galeone_matteo equity options market maker', 'Euronext Amsterdam']",2023-02-17,2023-02-18,Unknown
18754,EuroNext,Twitter API,Twitter,Euronext wheat prices pause after volatile week https://t.co/iv36LM98K9 #news #stocks,nan,Euronext wheat prices pause after volatile week https://t.co/iv36LM98K9 #news #stocks,neutral,0.0,0.97,0.02,neutral,0.0,0.97,0.02,True,English,"['Euronext wheat prices', 'volatile week', 'news', 'stocks', 'Euronext wheat prices', 'volatile week', 'news', 'stocks']",2023-02-17,2023-02-18,Unknown
18755,EuroNext,Twitter API,Twitter,Other European stock markets mixed on Friday  02/17/2023: Euronext 100 -0.60% at 1 366.91  higher for the week  Eurâ€¦ https://t.co/BZFavFq406,nan,Other European stock markets mixed on Friday  02/17/2023: Euronext 100 -0.60% at 1 366.91  higher for the week  Eurâ€¦ https://t.co/BZFavFq406,neutral,0.1,0.89,0.01,neutral,0.1,0.89,0.01,True,English,"['Other European stock markets', 'Friday', 'Euronext', 'week', 'BZFavFq406', 'Other European stock markets', 'Friday', 'Euronext', 'week', 'BZFavFq406']",2023-02-17,2023-02-18,Unknown
18756,EuroNext,Twitter API,Twitter,UPDATE 1-Euronext wheat prices pause after volatile week https://t.co/iPFUDQCIjO [RTRS],nan,UPDATE 1-Euronext wheat prices pause after volatile week https://t.co/iPFUDQCIjO [RTRS],neutral,0.01,0.96,0.03,neutral,0.01,0.96,0.03,True,English,"['1-Euronext wheat prices', 'volatile week', 'UPDATE', 'pause', 'RTRS', '1-Euronext wheat prices', 'volatile week', 'UPDATE', 'pause', 'RTRS']",2023-02-17,2023-02-18,Unknown
18757,EuroNext,Twitter API,Twitter,Euronext wheat prices pause after volatile week https://t.co/OqrcYEwUyd [RTRS],nan,Euronext wheat prices pause after volatile week https://t.co/OqrcYEwUyd [RTRS],neutral,0.0,0.98,0.02,neutral,0.0,0.98,0.02,True,English,"['Euronext wheat prices', 'volatile week', 'OqrcYEwUyd', 'RTRS', 'Euronext wheat prices', 'volatile week', 'OqrcYEwUyd', 'RTRS']",2023-02-17,2023-02-18,Unknown
18761,Euroclear,NewsApi.org,https://finance.yahoo.com/news/notice-extraordinary-general-meeting-hilbert-082000936.html,Notice of Extraordinary General Meeting in Hilbert Group AB,Hilbert Group (STO:HILB-B)(FRA:999) The shareholders of Hilbert Group AB (publ) reg.no.,"STOCKHOLM  SWEDEN / ACCESSWIRE / February 17  2023 / Hilbert Group (STO:HILB-B)(FRA:999) The shareholders of Hilbert Group AB (publ) reg.no. 559105-2948 (""Hilbert Group"") are hereby summoned to an extraordinary general meeting (""EGM"") to be held on Monday  6 March 2023 at 10:00 AM in the office of Advokatfirman Nerpin  Birger Jarlsgatan 2  3rd floor in Stockholm.A. Entitlement to participation and notificationShareholders who wish to participate in the EGM must: (i) be recorded in the share register maintained by Euroclear Sweden AB (""Euroclear"") as of Friday  24 February 2023  and (ii) notify the company of their intention to participate in the EGM no later than Tuesday  28 February 2023. The notice may be done in writing by post to Hilbert Group AB  c/o Advokatfirman Nerpin  Mailbox 545  SE-114 11 Stockholm  or by e-mail to ir@hilbert.group  or by telephone to +46 8 502 353 00. When registering to attend  the shareholder must provide name  personal identity number or registration number  address  and telephone number  as well as the number of any advisors (no more than two).Shareholders whose shares are nominee-registered must temporarily re-register their shares in their own name in the shareholders' register maintained by Euroclear in order to participate in the EGM. Voting rights registrations made no later than the second banking day after the record date 24 February 2023 will be taken into account in the preparation of the share register. Shareholders must  in accordance with the respective nominee's routines  in due time before said date  request their nominee to carry out such voting rights registration.If the shareholder is represented by a proxy  a written and dated power of attorney  signed by the shareholder  is to be issued to the proxy. The power of attorney or any other documents of authorization  such as a copy of the registration certificate  is to be provided at the EGM. Any power of attorney or other document of authorization should also be enclosed in the notice to attend the EGM. A form of proxy is available on the company's website  www.hilbert.group.B. Shareholders' right to request informationThe board of directors and the CEO shall  if any shareholders so requests  and if the board of directors considers that it can be done without significant harm for the company  give information on circumstances that can affect the assessment of an item on the agenda and the company's relation to other group companies.C. Agenda for the meetingProposed agendaOpening of the meeting Election of the chairman of the meeting Drawing up and approval of the voting register Approval of the agenda Election of persons to attest the minutes Determination as to whether the meeting has been duly convened Approval of the board of directors' resolution on a directed issue of shares Election of new member of the Board and resolution on remuneration Closing of the meetingResolution proposalsHilbert Group announced on 14 February  2023  through a press release  that Hilbert Group had resolved to carry out a directed issue of B-shares and to raise a loan. It is proposed that Hilbert Group's CEO Niclas SandstrÃ¶m and Chief Risk Officer Hans-Peter Bermin should be entitled to participate in the new issue. This part of the new issue is submitted to the EGM for approval in accordance with the so called Lex Leo (Chapter 16 of the Swedish Companies Act). For more information about the new issue and the loan  refer to the press release which is available on Hilbert Group's website www.Hilbert.Group.Item 7 - Approval of the board of directors' resolution on a directed issue of sharesThe board of directors proposes the general meeting approves the board of directors' resolution on a directed issue of shares on the following terms and conditions.The company's share capital shall be increased by SEK 23 200.95 through the issuance of 464 019 B-shares. The right to subscribe for the new shares shall  with deviation from the shareholders' preferential right  be granted Hilbert Group's CEO Niclas SandstrÃ¶m (154 673 B-shares) and Hilbert Group's Chief Risk Officer Hans-Peter Bermin (309 346 B-shares). The subscription price shall be SEK 1.66 per share. The share premium shall be transferred to the unrestricted premium reserve. Subscription of the new shares shall be made on a separate subscription list no later than 16 February  2023 (subscription has been made). Shares subscribed for shall be paid in cash no later than 8 March  2023. The new shares shall entitle to dividend as from the first record date for dividend to occur after the registration of the new share issue with the Swedish Companies Registration Office.The board of directors proposes that the Chairman of the Board  or whomever the Chairman appoints in his place  shall be authorized to make such minor adjustments of the above resolution that may be necessary in connection with the registration with the Swedish Companies Registrations Office and Euroclear.Documents pursuant to Chapter 13  Section 6 of the Swedish Companies Act have been prepared.A resolution by the general meeting according to the proposal requires  according to the Swedish Companies Act  for its validity the support of shareholders representing at least 90 per cent of both the votes cast and the shares represented at the meeting.Issue 8 - Election of new member of the Board and resolution on remunerationA group of shareholders in Hilbert Group representing approx. 62 per cent of the votes propose that Stuart Connolly is elected new member of the Board. They also propose that Stuart Connolly receives a yearly board remuneration of SEK 110 000.D. Other informationNumber of shares and votesAt the time of the issuance of this notice  i.e. before the registration of the directed Issue  the total number of shares in Hilbert Group is 48 800 000 divided into 8 500 000 A-shares (ten votes) and 40 300 000 B-shares (one vote). The total number of votes is 125 300 000.The company holds no own shares.Available documentsThe documents to be held available according to the Swedish Companies Act are available at Advokatfirman Nerpin on the address Birger Jarlsgatan 2 in Stockholm and on Hilbert Group's website  www.hilbert.group and be distributed to shareholders who request it from Hilbert Group and state their postal address or e-mail address.Processing of personal dataFor information on how your personal data is processed  see https://www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdf.Stockholm in February 2023HILBERT GROUP AB (Publ)The Board of DirectorsFor additional information  please contact:Niclas SandstrÃ¶mCEO Hilbert Group ABPhone: +46 8 502 353 00Email: ir@hilbert.groupErik NerpinChairman of the Board of Hilbert Group ABPhone: +46 70 620 73 59Email: erik.nerpin@advokatnerpin.comAbout UsHilbert Group AB is an investment firm with sole focus on digital assets  primarily cryptocurrencies and blockchain technologies. The business model is diversified into four verticals - asset management  proprietary trading  equity investments and data & analytics.Hilbert Group's vision is to be a world class digital asset investment firm with the ambition to provide first class services to its clients and shareholders  to help accelerate the technological revolution that is digital assets  and to expand people's knowledge of this emerging asset class.Hilbert Group is listed on Nasdaq First North Growth Market (ticker HILB B) with Eminova Fondkommission (phone +46 8 684 211 10 | adviser@eminova.se) as Certified Adviser.This information is information that Hilbert Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication  through the agency of the contact persons set out above  at 2023-02-17 09:00 CET.AttachmentsNotice of extraordinary general meeting in Hilbert Group ABPower Of Attorney EGM 20230306SOURCE: Hilbert GroupView source version on accesswire.com:https://www.accesswire.com/739773/Notice-of-Extraordinary-General-Meeting-in-Hilbert-Group-AB",neutral,0.03,0.97,0.0,mixed,0.49,0.05,0.46,True,English,"['Extraordinary General Meeting', 'Hilbert Group AB', 'Notice', 'Swedish Companies Registrations Office', 'CEO Niclas SandstrÃ¶m', 'Swedish Companies Registration Office', 'Swedish Companies Act', 'Voting rights registrations', 'second banking day', 'Chief Risk Officer', 'unrestricted premium reserve', 'personal identity number', 'other group companies', 'separate subscription list', 'first record date', 'Hilbert Group AB', ""B. Shareholders' right"", ""shareholders' preferential right"", 'extraordinary general meeting', 'Euroclear Sweden AB', 'new share issue', 'voting register', 'share premium', 'hilbert.group', 'other document', 'registration number', 'registration certificate', 'new member', 'Advokatfirman Nerpin', 'Birger Jarlsgatan', '3rd floor', 'A. Entitlement', 'share register', 'due time', 'significant harm', 'minutes Determination', 'press release', 'Hans-Peter Bermin', 'share capital', 'minor adjustments', 'new issue', 'subscription price', 'Resolution proposals', ""shareholders' register"", 'new shares', 'telephone number', 'respective nominee', 'C. Agenda', 'dated power', 'agenda Election', 'shares Election', ""directors' resolution"", 'Documents', 'ACCESSWIRE', 'February', 'HILB-B', 'EGM', 'Monday', 'March', '10:00 AM', 'Stockholm', 'participation', 'notification', 'Friday', 'company', 'intention', 'Tuesday', 'notice', 'writing', 'post', 'Mailbox', 'name', 'address', 'advisors', 'order', 'account', 'preparation', 'accordance', 'routines', 'proxy', 'written', 'attorney', 'authorization', 'copy', 'form', 'website', 'board', 'circumstances', 'assessment', 'item', 'relation', 'Opening', 'chairman', 'approval', 'persons', 'remuneration', 'B-shares', 'loan', 'Lex', 'Chapter', 'following', 'terms', 'conditions', 'SEK', 'issuance', 'deviation', 'cash', 'place', 'connection', 'Section']",2023-02-17,2023-02-18,finance.yahoo.com
18762,Euroclear,Twitter API,Twitter,Asian American caucus defends East West CEO against espionage claims #AAA Websites Euroclear Fintech https://t.co/twItRWFsyE #regtech,nan,Asian American caucus defends East West CEO against espionage claims #AAA Websites Euroclear Fintech https://t.co/twItRWFsyE #regtech,neutral,0.01,0.86,0.14,neutral,0.01,0.86,0.14,True,English,"['Asian American caucus', 'East West CEO', 'espionage claims', 'regtech', 'Asian American caucus', 'East West CEO', 'espionage claims', 'regtech']",2023-02-18,2023-02-18,Unknown
18763,Euroclear,Twitter API,Twitter,A credit union teams with HGTV house flippers to revitalize Detroit #AAA Websites Euroclear Fintech https://t.co/wqFXfcUp3R #regtech,nan,A credit union teams with HGTV house flippers to revitalize Detroit #AAA Websites Euroclear Fintech https://t.co/wqFXfcUp3R #regtech,neutral,0.02,0.98,0.0,neutral,0.02,0.98,0.0,True,English,"['credit union teams', 'HGTV house flippers', 'Detroit', 'credit union teams', 'HGTV house flippers', 'Detroit']",2023-02-18,2023-02-18,Unknown
18764,Euroclear,Twitter API,Twitter,Latest banking news #AAA Websites Euroclear Fintech https://t.co/28oaLZe5Wa #regtech,nan,Latest banking news #AAA Websites Euroclear Fintech https://t.co/28oaLZe5Wa #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Latest banking news', 'AAA Websites Euroclear', 'Fintech', 'Latest banking news', 'AAA Websites Euroclear', 'Fintech']",2023-02-17,2023-02-18,Unknown
18765,Deutsche Boerse,NewsApi.org,https://www.reuters.com/markets/europe/comeback-commerzbank-join-germanys-dax-blue-chip-index-2023-02-17/,In comeback  Commerzbank to join Germany's DAX blue-chip index,"Germany's Commerzbank <a href=""https://www.reuters.com/companies/CBKG.DE"" target=""_blank"">(CBKG.DE)</a> will rejoin the DAX index on Feb. 27  Deutsche Boerse <a href=""https://www.reuters.com/companies/DB1Gn.DE"" target=""_blank"">(DB1Gn.DE)</a> announced late onâ€¦","[1/2] A company logo is pictured at the headquarters of Germany's Commerzbank AG in Frankfurt  Germany  February 13  2020. REUTERS/Ralph Orlowski/File PhotoFRANKFURT  Feb 17 (Reuters) - Germany's Commerzbank (CBKG.DE) will rejoin the DAX index on Feb. 27  Deutsche Boerse (DB1Gn.DE) announced late on Friday  marking a comeback for Germany's No. 2 lender after it was removed from the club of blue-chip companies in 2018.The return to the index comes after Commerzbank launched a major overhaul two years ago that saw thousands of job cuts and branch closures that restored profitability.""This shows that we are on the right track with our restructuring - and spurs us on to continue with the same energy "" Commerzbank AG said on Twitter in response to the announcement.Reuters Graphics Reuters GraphicsIn 2018  Commerzbank  still partly owned by the German government after a bailout  was expelled from the DAX index to make room for a rising technology star  underscoring the declining fortunes of the nation's top banks.But that star was Wirecard AG   a payments company that collapsed in 2020 after a years-long fraud was exposed  embarrassing the German government and staining the nation's reputation as a safe haven investment.Following Wirecard's demise  Deutsche Boerse AG  which compiles the DAX index  revamped it to include 40 companies  rather than the previous 30  and made membership criteria tougher.Since its founding in 1988  the DAX has been Germany's answer to the Dow Jones Industrial Average in New York and the FTSE in London  with its members forming the corporate elite in one of the world's largest economies.Other members include Siemens AG  Volkswagen AG  and Allianz SE.Commerzbank will replace Linde Plc (LIN.N)  which is giving up its listing in Germany.Reporting by Tom Sims; editing by Chris Reese and Jonathan OatisOur Standards: The Thomson Reuters Trust Principles.",neutral,0.0,1.0,0.0,negative,0.0,0.06,0.94,True,English,"['DAX blue-chip index', 'comeback', 'Commerzbank', 'Germany', 'The Thomson Reuters Trust Principles', 'Dow Jones Industrial Average', 'Ralph Orlowski/File Photo', 'safe haven investment', 'rising technology star', 'Deutsche Boerse AG', 'Reuters Graphics', 'Siemens AG', 'Volkswagen AG', 'company logo', 'CBKG.DE', 'DB1Gn.DE', 'No. 2 lender', 'major overhaul', 'job cuts', 'branch closures', 'right track', 'same energy', 'German government', 'declining fortunes', 'top banks', 'payments company', 'years-long fraud', 'membership criteria', 'New York', 'corporate elite', 'largest economies', 'Allianz SE', 'Linde Plc', 'Tom Sims', 'Chris Reese', 'Jonathan Oatis', 'Wirecard AG', 'Commerzbank AG', 'DAX index', 'blue-chip companies', 'Other members', '40 companies', 'headquarters', 'Germany', 'Frankfurt', 'Feb.', 'Friday', 'comeback', 'club', 'return', 'thousands', 'profitability', 'restructuring', 'Twitter', 'response', 'announcement', 'bailout', 'room', 'nation', 'reputation', 'demise', 'previous', 'founding', 'answer', 'FTSE', 'London', 'world', 'LIN.', 'listing', 'Reporting', 'editing', 'Standards']",2023-02-17,2023-02-18,reuters.com
18766,Deutsche Boerse,Bing API,https://uk.style.yahoo.com/comeback-commerzbank-join-germanys-dax-212906818.html,In comeback  Commerzbank to join Germany's DAX blue-chip index,FRANKFURT (Reuters) - Germany's Commerzbank will rejoin the DAX index on Feb. 27  Deutsche Boerse announced late on Friday  marking a comeback for Germany's No. 2 lender after it was removed from the club of blue-chip companies in 2018. The return to the ...,"FRANKFURT (Reuters) - Germany's Commerzbank will rejoin the DAX index on Feb. 27  Deutsche Boerse announced late on Friday  marking a comeback for Germany's No. 2 lender after it was removed from the club of blue-chip companies in 2018.The return to the index comes after Commerzbank launched a major overhaul two years ago that saw thousands of job cuts and branch closures that restored profitability.""This shows that we are on the right track with our restructuring - and spurs us on to continue with the same energy "" Commerzbank AG said on Twitter in response to the announcement.GRAPHIC: Commerzbank shares - https://www.reuters.com/graphics/COMMERZBANK-CFO/klpygkxdxpg/chart.pngIn 2018  Commerzbank  still partly owned by the German government after a bailout  was expelled from the DAX index to make room for a rising technology star  underscoring the declining fortunes of the nation's top banks.But that star was Wirecard AG  a payments company that collapsed in 2020 after a years-long fraud was exposed  embarrassing the German government and staining the nation's reputation as a safe haven investment.Following Wirecard's demise  Deutsche Boerse AG  which compiles the DAX index  revamped it to include 40 companies  rather than the previous 30  and made membership criteria tougher.Since its founding in 1988  the DAX has been Germany's answer to the Dow Jones Industrial Average in New York and the FTSE in London  with its members forming the corporate elite in one of the world's largest economies.Other members include Siemens AG  Volkswagen AG  and Allianz SE.Commerzbank will replace Linde Plc  which is giving up its listing in Germany.(Reporting by Tom Sims; editing by Chris Reese and Jonathan Oatis)",neutral,0.0,1.0,0.0,negative,0.0,0.02,0.98,True,English,"['DAX blue-chip index', 'comeback', 'Commerzbank', 'Germany', 'Dow Jones Industrial Average', 'safe haven investment', 'rising technology star', 'Deutsche Boerse AG', 'Siemens AG', 'Volkswagen AG', 'No. 2 lender', 'major overhaul', 'job cuts', 'branch closures', 'right track', 'same energy', 'German government', 'declining fortunes', 'top banks', 'payments company', 'years-long fraud', 'membership criteria', 'New York', 'corporate elite', 'largest economies', 'Allianz SE', 'Linde Plc', 'Tom Sims', 'Chris Reese', 'Jonathan Oatis', 'Wirecard AG', 'Commerzbank AG', 'DAX index', 'blue-chip companies', 'Other members', 'Commerzbank shares', '40 companies', 'FRANKFURT', 'Reuters', 'Germany', 'Feb.', 'Friday', 'comeback', 'club', 'return', 'thousands', 'profitability', 'restructuring', 'Twitter', 'response', 'announcement', 'GRAPHIC', 'COMMERZBANK-CFO', 'bailout', 'room', 'nation', 'reputation', 'demise', 'previous', 'founding', 'answer', 'FTSE', 'London', 'world', 'listing']",2023-02-17,2023-02-18,uk.style.yahoo.com
18767,Deutsche Boerse,Bing API,https://www.teletrader.com/commerzbank-to-replace-linde-on-dax/news/details/59492046,Commerzbank to replace Linde on DAX,Deutsche Boerse announced on Friday that Commerzbank AG will rejoin the DAX index. The lender will replace Linde plc on the index from February 27  the exchange stated. Commerzbank had earlier been on the DAX but was removed from it in 2018. Earlier this ...,TELETRADER NewsCommerzbank to replace Linde on DAXEPA-EFE/FELIPE TRUEBADeutsche Boerse announced on Friday that Commerzbank AG will rejoin the DAX index.The lender will replace Linde plc on the index from February 27  the exchange stated.Commerzbank had earlier been on the DAX but was removed from it in 2018. Earlier this week  the bank reported a surge in its operating profit for the fourth quarter of 2022.Baha Breaking News (BBN) / NP,neutral,0.01,0.99,0.0,neutral,0.04,0.93,0.03,True,English,"['Commerzbank', 'Linde', 'DAX', 'Baha Breaking News', 'TELETRADER News', 'EPA-EFE/FELIPE TRUEBA', 'Deutsche Boerse', 'operating profit', 'fourth quarter', 'Linde plc', 'Commerzbank AG', 'DAX index', 'Friday', 'lender', 'February', 'exchange', 'surge', 'BBN', 'NP']",2023-02-17,2023-02-18,teletrader.com
18768,Deutsche Boerse,Twitter API,Twitter,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets businessâ€¦ https://t.co/2IOAOyWz0b,nan,German exchange Deutsche Boerse has selected Google Cloud to provide the backbone of its digital assets businessâ€¦ https://t.co/2IOAOyWz0b,neutral,0.05,0.94,0.01,neutral,0.05,0.94,0.01,True,English,"['digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone', 'digital assets business', 'German exchange', 'Deutsche Boerse', 'Google Cloud', 'backbone']",2023-02-18,2023-02-18,Unknown
18769,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse announced on Friday that Commerzbank AG will rejoin the DAX index. The lender will replace Linde plâ€¦ https://t.co/EgGyWpkjCk,nan,Deutsche Boerse announced on Friday that Commerzbank AG will rejoin the DAX index. The lender will replace Linde plâ€¦ https://t.co/EgGyWpkjCk,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['Deutsche Boerse', 'Commerzbank AG', 'DAX index', 'Linde pl', 'Friday', 'lender', 'Deutsche Boerse', 'Commerzbank AG', 'DAX index', 'Linde pl', 'Friday', 'lender']",2023-02-18,2023-02-18,Unknown
18770,EuroNext,NewsApi.org,https://finance.yahoo.com/news/oxurion-receives-transparency-notifications-negma-180000502.html,Oxurion Receives Transparency Notifications from Negma Group,Oxurion Receives Transparency Notifications from Negma Group Leuven  BELGIUM  Boston  MA  US â€“ February 17  2022 â€“ 7.00 PM CET Oxurion NV (Euronext Brussels:...,"Oxurion NVOxurion Receives Transparency Notifications from Negma GroupLeuven  BELGIUM  Boston  MA  US â€“ February 17  2022 â€“ 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with clinical stage assets in vascular retinal disorders  today announced that  pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:Oxurion received a transparency notification on February 14  2023 from Negma Group Ltd. indicating that as of February 9  2023  it held no shares of the then outstanding 493 468 012 shares  and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1Oxurion received a transparency notification on February 13  2023 from Negma Group Ltd. indicating that as of February 8  2023  it held 15 503 696 shares of the then outstanding 493 468 012 shares  and therefore crossed above the threshold (3%) by virtue of acquisition of voting securities. See Annex 2About OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered â€œforward-lookingâ€. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companyâ€™s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.Story continuesFor further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10"" tom.graney@oxurion.comMichael DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.comU SConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com________1. Article 14  first paragraph  of the Law of 2 May 2007 on disclosure of major holdings.ANNEX 1ANNEX 2Attachments",neutral,0.01,0.99,0.0,mixed,0.26,0.15,0.58,True,English,"['Transparency Notifications', 'Negma Group', 'Oxurion', 'applicable U.S. state securities laws', 'potent plasma kallikrein inhibitor', 'U.S. Securities Act', 'next generation standard', 'Negma Group Ltd.', 'diabetic macular edema', 'Chief Executive Officer', 'potential new standard', 'Mary T. Conway', 'Belgian Transparency legislation1', 'Negma Group Leuven', 'clinical stage assets', 'Chief Business Officer', 'U S', 'vascular retinal disorders', 'Such forward-looking statements', 'care ophthalmic therapies', 'CET Oxurion NV', 'voting securities', 'Conway Communications', 'new information', 'Transparency Notifications', 'Euronext Brussels', 'leading cause', 'working-age people', 'other conditions', 'important role', 'successful development', 'novel therapeutic', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'Annual Report', 'United States', 'first paragraph', 'major holdings', 'More information', 'Important information', 'Additional information', 'biopharmaceutical company', 'The Company', 'outstanding 493,468,012 shares', 'vision loss', 'various risks', 'Tom Graney', 'Michael Dillen', 'ICR Westwicke', 'Christopher Brinzey', 'ANNEX 2 Attachments', 'DME patients', '15,503,696 shares', 'Annex 1', 'BELGIUM', 'Boston', 'February', 'threshold', 'virtue', 'disposal', 'acquisition', 'treatment', 'THR-149', 'uncertainties', 'assurance', 'obligation', 'offer', 'invitation', 'sale', 'purchase', 'jurisdiction', 'registration', 'compliance', 'exemption', 'accordance', 'Story', 'Tel', 'Article', '2 May', 'disclosure', '7.00', '32']",2023-02-17,2023-02-18,finance.yahoo.com
18771,EuroNext,NewsApi.org,https://finance.yahoo.com/news/information-total-number-voting-rights-180000625.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA Negma Group Investment Ltd. has converted 320...,Oxurion NVInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMANegma Group Investment Ltd. has converted 320 convertible bonds in Oxurion resulting in a EUR 800 000 capital increase. This is part of Negma Group Investment Ltd.â€™s EUR 15 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US â€“ February 17  2023 â€“ 07.00 PM CET â€“ In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the â€œCompanyâ€ or â€œOxurionâ€)  announces the below information  following the issuance of (i) 34 246 575 new ordinary shares on February 13  2023  for a total amount of EUR 400 000  as the result of the conversion of 160 class B convertible bonds  and (ii) 36 496 350 new ordinary shares on February 15  2023  for a total amount of EUR 400 000  as the result of the conversion of 160 class B convertible bonds  pursuant to the Capital Commitment entered into with Negma Group Investment Ltd.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 564 210 937  outstanding ordinary shares carrying voting rights (compared to 493 468 012 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 77 506 161.32 Total number of securities with voting rights (all ordinary shares) 564 210 937 Total number of ordinary shares (= denominator) 564 210 937 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 694 000 subscription rights (â€œSRsâ€) issued on November 20  2017  entitling their holders to subscribe to a total number of 694 000 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);976 874 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 976 874 securities carrying voting rights (all ordinary shares);534 688 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 534 688 securities carrying voting rights (all ordinary shares);582 248 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 582 248 securities carrying voting rights (all ordinary shares);80 convertible bonds issued on January 25  2023  entitling their holder (Negma Group Investment Ltd.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group Investment Ltd. on August 26  2021  and the addenda thereto dated September 2  2022 and January 25  2023; and100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021.ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Story continuesImportant information about forward-looking statementsCertain statements in this press release may be considered â€œforward-lookingâ€. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companyâ€™s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMichaÃ«l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com1 Press release Oxurion  06/04/2021  Press release Oxurion  02/09/2022 and Press release Oxurion  25/01/2023Attachments,neutral,0.0,1.0,0.0,mixed,0.34,0.17,0.48,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'NEGMA', 'potent plasma kallikrein inhibitor', 'Negma Group Investment Ltd.', 'EUR 15 million Capital Commitment1', '160 class B convertible bonds', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'potential new standard', 'EUR 800,000 capital increase', 'Kreos Capital VI', 'potential market opportunities', 'care ophthalmic therapies', 'Such forward-looking statements', '34,246,575 new ordinary shares', '36,496,350 new ordinary shares', '564,210,937, outstanding ordinary shares', '493,468,012 outstanding ordinary shares', 'Oxurion NV Information', '320 convertible bonds', '80 convertible bonds', '100 convertible bonds', 'Share capital', 'regulated market', 'drug candidate', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', 'updated information', 'L.P.', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'More information', 'Important information', 'press release', 'current expectations', 'various risks', 'Voting Rights', '694,000 subscription rights', 'Total Number', 'subscription agreement', 'vision loss', 'novel therapeutic', 'other conditions', 'Conversion Notice', 'biopharmaceutical company', 'DME patients', 'Denominator', 'back', 'eye', 'Leuven', 'BELGIUM', 'Boston', 'February', '07.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'result', 'completion', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'January', 'terms', 'August', 'addenda', 'UK', 'Israel', 'Cayman', 'Limited', 'treatment', 'THR-149', 'Story', 'uncertainties']",2023-02-17,2023-02-18,finance.yahoo.com
18772,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/PHERECYDES-PHARMA-118443693/news/Pherecydes-Pharma-Inside-Information-Other-news-releases-43023198/?utm_medium=RSS&utm_content=20230218,Pherecydes Pharma : Inside Information / Other news releases,(marketscreener.com)   Not for distribution in the United States  Canada  Japan  Australia  South Africa  or Italy.   Following the announcement of its proposed merger with Erytech    Pherecydes Pharma completes a â‚¬1.5 million capital increase   reâ€¦,"Not for distribution in the United States  Canada  Japan  Australia  South Africa  or Italy. Following the announcement of its proposed merger with Erytech  Pherecydes Pharma completes a â‚¬1.5 million capital increase reserved to its historical shareholders This capital increase  fully subscribed by Auriga IV Bioseeds  Ouest Ventures III and the pool of shareholders represented by Guy Rigaud  historical shareholders of Pherecydes Pharma  is part of the proposed merger of Pherecydes Pharma into Erytech Pharma announced on February 15  2023 1The funds raised through this capital increase will provide Pherecydes Pharma with sufficient resources to finance its cash requirements until the end of H1 2023The subscription price is â‚¬2.09 per share  representing a discount of 21.4% on the last closing price Nantes  February 17  2023  10:30 pm CET - Pherecydes Pharma (FR0011651694 - ALPHE)  a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections (the ""Company"")  announced today the completion of the capital increase announced on February 15  2023 on the occasion of the announcement of its proposed merger with Erytech. The capital increase for a total amount of â‚¬1.5 million was fully subscribed by Auriga IV Bioseeds (represented by Elaia Partners)  Ouest Ventures III (represented by Go Capital) and the pool of shareholders represented by Mr. Guy Rigaud  historical shareholders of Pherecydes Pharma of the Company. Purpose of the issue and use of proceeds The gross proceeds of the capital increase  amounting to â‚¬1.5 million  will be mainly used to finance the company's cash requirements until the completion of the merger  scheduled for June 30  2023 at the latest. Main characteristics of the capital increase The Board of Directors of Pherecydes Pharma  using the delegation of authority conferred on it by the fifth (5th) resolution of the Ordinary and Extraordinary General Meeting of December 15  2022 (capital increase with cancellation of preferential subscription rights for the benefit of categories of persons meeting specific characteristics) (the ""General Meeting"") and in accordance with articles L. 225-138 and subsequent of the French Commercial Code  decided on February 17  2023 to carry out a capital increase by issuing 717 702 new shares with a par value of one euro (â‚¬1) each (the ""New Shares"") on the basis of a price of â‚¬2.092 (the ""Capital Increase""). The subscription price represents a discount of 21.4% on the closing price as of February 17  2023. It is specified that the exchange ratio of the merger as announced in the press release of February 15  2023 (15 new Erytech Pharma shares for 4 Pherecydes Pharma shares) will not be subject to any adjustment due to the capital increase. It is specified that the subscription price of â‚¬2.09 represents a discount of 24.4% on the volume-weighted average of the Company's share price on the Euronext Growth Paris market over the last five (5) trading sessions 1/5Not for distribution in the United States  Canada  Japan  Australia  South Africa  or Italy. The Auriga IV Bioseeds fund (represented by Elaia Partners)  the Ouest Ventures III fund (represented by Go Capital) and the pool of shareholders led by Mr. Guy Rigaud  historical shareholders and also members of the Board of Directors of the Company  will participate in the Capital Increase for a subscription amount of respectively â‚¬747 thousand  â‚¬512 thousand and â‚¬241 thousand representing the entire gross amount of the Capital Increase. It is specified that the subscribers who are also directors of the Board of Directors of Pherecydes Pharma did not take part in the vote of the Capital Increase at the Board of Directors' meeting held on February 17  2023. Following the settlement-delivery operations scheduled on February 22  2023  the share capital of Pherecydes Pharma will amount to 7 939 179 euros  divided into 7 939 179 shares. The New Shares will be assimilated to the existing shares of the Company and will be admitted to trading on the Euronext Growth market in Paris under ISIN number FR0011651694. Impact of the issue on the capital structure The New Shares represent 9.04% of the number of outstanding shares after the Capital Increase. Thus  a shareholder holding 1% of the issued capital before the operation will hold 0.91% of the capital after the operation. The table below details  to the best of the Company's knowledge  the changes in the structure of its share capital following  subject to its completion  the Capital Increase: Pre-capital increase Post-capital increase Shareholders (on a non-diluted basis) (on a non-diluted basis) Nb. % share capital Nb. % share capital shares shares ACE Management 1 384 564 19.17% 1 384 564 17.44% Elaia Partners 1 491 037 20.65% 1 848 357 23.28% Go Capital 1 023 103 14.17% 1 268 285 15.98% Pool GR(*) 484 645 6.71% 599 845 7.56% Other historical shareholders and 1 299 864 18.00% 1 299 864 16.37% management Free float 1 516 207 21.00% 1 516 207 19.10% Treasury shares(**) 22 057 0.31% 22 057 0.28% Total 7 221 477 100% 7 939 179 100% The ""Pool GR"" group is composed of individual shareholders  whether legal entities or individuals  who have entered into a concerted action agreement with each other  which has been brought to the Company's attention. Mr. Guy Rigaud  a member of the Company's Board  belongs to this group. Information as of December 31  2022 preceding the setting of the issue price (amounting to â‚¬2.765)  i.e. a discount of less than the maximum discount of 25% as provided for in the fifth (5th) resolution of the General Meeting. 2/5Not for distribution in the United States  Canada  Japan  Australia  South Africa  or Italy. Information available to the public and risk factors The public's attention is drawn to the risk factors relating to the Company and its business  presented in chapter 3 of the Company's information document  available free of charge on the Company's website (www.pherecydes-pharma.com)and on the Euronext website (www.euronext.com)  as updated in section 1.6 of the 2021 Annual Financial Report and in section 4 of the 2022 half-year financial report  available free of charge on the Company's website (www.pherecydes-pharma.com). The occurrence of some or all of these risks could have an adverse effect on the Company's business  financial condition  results  development or prospects. With the exception of the risks specific to the transaction referred to above  the Company considers that there is no need to update the risk factors as referred to in chapter 3 of the information document as updated in section 1.6 of the 2021 annual financial report and in section 4 of the 2022 half-year financial report. Additionally  investors are invited to consider the following risks specific to this issue: (i) the market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued within the framework of the share capital increase  (ii) the volatility and liquidity of the Company's shares may fluctuate significantly  (iii) divestments of the Company's shares may take place on the market and have a negative effect on its share price  (iv) the Company's shareholders could suffer potentially significant dilution resulting from any future capital increases required to provide the Company with additional financing  and (v) as these shares are not intended to be listed on a regulated market  investors will not benefit from the guarantees associated with regulated markets. This press release does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017  as amended  nor an offer to the public. About Pherecydes Pharma Founded in 2006  Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections  responsible for many serious infections. The Company has developed an innovative approach  precision phage therapy  based on the use of phages  natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria  which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus  Escherichia coli and Pseudomonas aeruginosa. Headquartered in Nantes  Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry  biotechnology sector and academic research. For more information  www.pherecydes-pharma.com Forward-looking statements This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release regarding future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include  but are not limited to  statements preceded by  followed by or including words such as ""target""  ""believe""  ""expect""  ""aim""  ""intend""  ""may""  ""forecast""  ""estimate""  ""plan""  ""project""  ""will""  ""may have""  ""likely""  ""should""  ""expect""  and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's 3/5Not for distribution in the United States  Canada  Japan  Australia  South Africa  or Italy. control that could cause the Company's actual results or performance to differ materially from those expressed or implied by such forward-looking statements. Contacts Pherecydes Pharma NewCap NewCap Thibaut du Fayet Dusan Oresansky / Nicolas Fossiez Arthur RouillÃ© CEO Investor Relations Media Relations investors@pherecydes- pherecydes@newcap.eu pherecydes@newcap.eu pharma.com T. : 01 44 71 94 92 T. : 01 44 71 00 15 Disclaimer This press release does not constitute an offer to sell or the solicitation of an offer to buy ordinary shares of the Company  and shall not constitute an offer  solicitation or sale in any jurisdiction in which such offer  solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017  as amended (the ""Prospectus Regulation""). In France  the transaction described above will take place solely as a reserved share capital increase to the benefit of categories of persons as set forth in the fifth (5th) resolution of the General Meeting pursuant to Article L.225-138 of the French Commercial Code and applicable rules and regulations. With respect to Member States of the European Economic Area (including France)  no action has been taken or will be taken to permit a public offering of the securities referred to in this press release which would require the publication of a prospectus (pursuant to article 3 of the Prospectus Regulation) in any Member State. This press release and the information it contains do not constitute an offer to sell  nor the solicitation of an offer to subscribe for or buy  new ordinary shares in the United States or any other jurisdiction where restrictions may apply including notably the United States  Canada  Australia  Japan  South Africa or Italy. Securities may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration thereunder. Pherecydes Pharma does not intend to conduct a public offering of new ordinary shares in the United States  or in any other jurisdiction. This communication is for distribution only to  and is directed only at (a) persons outside the United Kingdom  (b) persons who have professional experience in matters relating to investments (falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended  the ""Financial Promotion Order"")  and (c) high net worth entities  and other persons to whom it may otherwise lawfully be communicated  falling within Article 49(2) of the Financial Promotion Order (all such persons together being referred to as ""Relevant Persons""). Any investment or investment activity to which this communication refers is valid only as to Relevant Persons and will be binding only on Relevant Persons. Persons who are not a Relevant Person should not act or rely on this communication or any of its contents. Solely for the purposes of each manufacturer's product approval process  the target market assessment in respect of the new ordinary shares has led to the following conclusion  in relation to 4/5",neutral,0.0,0.99,0.0,neutral,0.01,0.95,0.04,True,English,"['Other news releases', 'Pherecydes Pharma', 'Information', 'The Auriga IV Bioseeds fund', 'last five (5) trading sessions', 'Euronext Growth Paris market', 'Euronext Growth market', 'Nb. % share capital shares', 'precision phage therapy', 'complicated bacterial infections', 'fifth (5th) resolution', 'French Commercial Code', 'Ventures III fund', 'The New Shares', 'Mr. Guy Rigaud', 'preferential subscription rights', 'last closing price', 'Extraordinary General Meeting', 'entire gross amount', 'â‚¬1.5 million capital increase', 'Other historical shareholders', '4 Pherecydes Pharma shares', '717,702 new shares', 'subscription amount', 'existing shares', 'outstanding shares', 'Treasury shares', 'total amount', 'share price', 'subscription price', 'Go Capital', 'Post-capital increase', 'United States', 'South Africa', 'sufficient resources', 'cash requirements', 'Elaia Partners', 'gross proceeds', 'Main characteristics', 'specific characteristics', 'par value', 'one euro', 'exchange ratio', 'press release', 'volume-weighted average', 'settlement-delivery operations', 'Free float', 'diluted basis', 'capital structure', ""Directors' meeting"", 'ISIN number', 'ACE Management', 'Erytech Pharma', 'Pool GR', 'biotechnology company', '7,939,179 shares', 'distribution', 'Canada', 'Japan', 'Australia', 'Italy', 'announcement', 'merger', 'February', 'funds', 'end', 'H1', 'discount', 'Nantes', 'ALPHE', 'treatment', 'resistant', 'completion', 'occasion', 'Purpose', 'issue', 'use', 'June', 'Board', 'delegation', 'authority', 'December', 'cancellation', 'benefit', 'categories', 'persons', 'accordance', 'articles', 'adjustment', 'members', 'subscribers', 'vote', '7,939,179 euros', 'Impact', 'table', 'details', 'knowledge', 'changes', '10:30']",2023-02-18,2023-02-18,marketscreener.com
18773,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/DON-T-NOD-ENTERTAINMENT-43444427/news/Don-t-Nod-Entertainment-Successful-completion-of-approximately-EUR-46-million-capital-increase-43014228/?utm_medium=RSS&utm_content=20230217,Don't Nod Entertainment :  Successful completion of approximately EUR 46 million capital increase,(marketscreener.com)  Paris  February 17  2023 -- DON'T NOD an independent studio that creates  develops  and publishes video games  announces today the successful completion of its capital increase with cancellation of the preferential subscription right lâ€¦,"Paris  February 17  2023 -- DON'T NOD an independent studio that creates  develops  and publishes video games  announces today the successful completion of its capital increase with cancellation of the preferential subscription right launched on February 16  2023  through an accelerated book-building process to the benefit of a specified category of persons  for an amount  including share issue premium  of approximately â‚¬45.2 million  and the capital increase with cancellation of the preferential subscription right through a public offering via the PrimaryBid platform for individual investors for an amount  including share issue premium  of approximately â‚¬0.7 million (the ""Fundraising"").â€œI am very happy with the continuous support of our existing shareholders  and I would like to extend my thanks to the institutional and individual investors for their trust in our development â€ said Oskar Guilbert  Chairman and Chief Executive Officer of DON'T NOD.â€œ With the releases in 2023 of 2 new video games and the development of 4 additional original creations and 2 external co-productions  DON'T NOD is leveraging the biggest pipeline of games in its history .The funds raised will enable us to step up our next growth cycle beyond 2025  in the action-RPG segment with strong and proven business potential.â€TERMS AND CONDITIONS OF FUNDRAISINGTotal demand amounted to approximately â‚¬46 million  98.5% from institutional investors and 1.5% from individuals via the PrimaryBid plateform.The Fundraising  for a total amount of approximately â‚¬46 million  including a share issue premium  was carried out  with cancellation of preferential subscription rights  for 4 592 048 new ordinary shares (the ""New Sharesâ€)  within the framework of:a capital increase of approximately â‚¬45 2 million (share issue premium included) with an offer of 4 522 491 new ordinary shares with cancellation of shareholders' preferential subscription rights to the benefit of a category of investors (in accordance with the 12 th resolution of the Company's Combined General Meeting of June 7  2022 and the decisions made by the Board of Directors on February 10  2023 and the Chairman of the Board of Directors on February 16 and 17  2023)  (the ""Reserved Offeringâ€);resolution of the Company's Combined General Meeting of June 7  2022 and the decisions made by the Board of Directors on February 10  2023 and the Chairman of the Board of Directors on February 16 and 17  2023)  (the ""Reserved Offeringâ€); a capital increase with cancellation of shareholders' preferential subscription rights through a public offering intended for individual investors via the PrimaryBid platform  for an amount of approximately â‚¬0.7 million (share issue premium included)  through the issue of 69 557 new shares (in accordance with the 10th resolution of the Company's Combined General Meeting of June 7  2022 and the decisions made by the Board of Directors on February 10  2023 and the Chairman of the Board of Directors on February 16 and 17  2023) (the â€œPrimaryBid Offeringâ€).The New Shares  representing approximately 54% of the Company's share capital  on a non-diluted basis  prior to the completion of the Fundraising  and 35% of the Company's share capital  on a non-diluted basis  after completion of the Fundraising  were issued by decision of the Chairman of the Board of Directors  pursuant to the sub-delegation of competence granted on February 10  2023  by the Company's Board of Directors.The subscription price per share within the framework of the Reserved Offering and the PrimaryBid Offering is equal to â‚¬10  (including â‚¬0.02 in nominal value and â‚¬9.98 of issue premium). This price represents a discount of 5.2% versus the closing DON'T NOD share price on February 16  2023 (i.e.  â‚¬10.55).It is specified that prior to the launch of the Fundraising  Tencent Holdings Limited through its subsidiary Proxima Beta Europe BV (""Tencent"")  made an undertaking to subscribe in the context of the Reserved Offering  for shares in a minimum amount ofâ‚¬35 million. Tencent has been allocated 3 600 000 New Shares in the Reserved Offering.The settlement-delivery of the New Shares and their admission to trading on Paris' Euronext GrowthÂ® market under ISIN code FR0013331212 â€“ ALDNE  will take place on February 21  2023. As of issuance  the New Shares will be subject to all the statutory provisions and assimilated to the existing shares in DON'T NOD. Such shares will bear current dividend rights and will be admitted for trading on Euronext GrowthÂ® Paris market on the same listing line as the Company's shares that are already listed under the same FR0013331212 - ALDNE.Pursuant to Article 1(4) of EU Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017  the Reserved Offering and the PrimaryBid Offering has not given rise and will not require the publication of a prospectus subject to the approval of the French Financial Market Authority (the â€˜AMF').IMPACT OF THE FUNDRAISING ON DON'T NOD SHAREHOLDINGUpon completion of the Fundraising  the share capital of DON'T NOD will amount to â‚¬260 694.48 and will be composed of 13 034 724 ordinary shares with a par value of â‚¬0.02 each.By way of example  a shareholder holding 1% of the Company's capital before the completion of the Fundraising will now hold a 0.65% stake.Subsequent to the Fundraising  the breakdown of DON'T NOD's share capital and voting rights is now the following (on a diluted and non-diluted basis):Prior to the Fundraising :Shares & voting rights at 31.12.2022 Capital(diluted from employees)(1) Shareholders Shares % Voting rights(2) % Shares % Loskent(3) 241 708 2.9% 483 416 4 2% 241 708 2.7% Kostadin Yanev 2 448 050 29.0% 4 896 100 42 4% 2 448 050 27.3% Modern Vision Entertainment(4) 395 031 4.7% 790 062 6 8% 395 031 4.4% Employees 137 086 1.6% 137 086 1 2% 662 212 7.4% Tencent(5) 1 875 000 22.2% 1 875 000 16 3% 1 875 000 20.9% Float 3 345 801 39.6% 3 352 153 29 1% 3 345 801 37.3% TOTAL 8 442 676 100% 11 533 817 100% 8 967 802 100%Theorical dilution Double vote rights obtained on January 10th  2020 Company controlled by Oskar Guilbert Company controlled Kostadin Yanev Indirectly controlled by an affiliated companyAfter the Fundraising :Shares & voting rights at 31.12.2022 Capital(diluted from employees) (1) Shareholders Shares % Voting rights(2) % Shares % Loskent(3) 241 708 1.9% 483 416 3.0% 241 708 1.8% Kostadin Yanev 2 448 050 18.8% 4 896 100 30.4% 2 448 050 18.1% Modern Vision Entertainment(4) 395 031 3.0% 790 062 4.9% 395 031 2.9% Employees 137 086 1.1% 137 086 0.9% 662 212 4.9% Tencent(5) 5 475 000 42.0% 5 475 000 34.0% 5 475 000 40.4% Float 4 337 849 33.3% 4 344 201 26.9% 4 337 849 32.0% TOTAL 13 034 724 100% 16 125 865 100% 13 559 850 100%Theorical dilution Double vote rights obtained on January 10th  2020 Company controlled by Oskar Guilbert Company controlled Kostadin Yanev Indirectly controlled by an affiliated companyFINANCIAL INTERMEDIARIES & ADVISORSTP ICAP Midcap acts as Lead Manager and Bookrunner for this Reserved Offering.Within the framework of the PrimaryBid Offering  investors were only able to subscribe via the PrimaryBid platform (https://primarybid.fr/) or through PrimaryBid partners listed on the PrimaryBid website.CBR & AssociÃ©s (FranÃ§ois Le Roquais) acts as legal counsel for this Reserved Offering. ACTUS finance & communication act as financial communication adviser.DISCLAIMERThe Company specifies that  to its knowledge  no potential investor holds insider information.This press release may not be released  published or distributed  directly or indirectly  in the United States (including its territories and possessions  any state of the United States and the District of Columbia)  Canada  Australia  Japan  South Africa or any other country in violation of the laws of the relevant jurisdiction.This press release is not constitute (and there will be no) an offer for sale or subscription  or an announcement of a forthcoming offer for sale or subscription  or a solicitation of an offer to acquire or subscribe  or an announcement of a forthcoming solicitation of an offer to acquire or subscribe for securities of the Company in  or to residents  inhabitants or citizens of the United States  Canada  Australia  Japan  South Africa or any jurisdiction where such offer or solicitation without registration  exemption from registration or qualification is not permitted under the applicable law of the relevant jurisdiction or does not satisfy the requirements of the applicable law of the relevant jurisdiction.The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933  as amended (the ""U.S. Securities Act"")  or any other securities regulatory authority  state or jurisdiction of the United States. The Company's securities may not be directly or indirectly offered  sold  resold  transferred or delivered in the United States except pursuant to a valid exemption from the registration requirements imposed by the US Securities Act and in accordance with the applicable laws of any state or jurisdiction of the United States. In addition  there will be no public offering of securities in the United States.This press release may only be distributed (A) outside the United States in accordance with Regulation S of the US Securities Act (i) to persons in the United Kingdom (a) with professional investment experience who fall within the definition of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005  as amended (the ""Order"")  or (b) who are high net worth entities within the meaning of Article 49(2)(a) to (d) of the Order  or (c) to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities of the Company or any member of its group may lawfully be communicated or caused to be communicated; (ii) persons in any other member state of the European Economic Area who are ""qualified investors"" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129  as amended); (iii) certain qualified and/or institutional investors in other selected jurisdictions  in accordance with applicable restrictions ; and to persons in the United States who are ""qualified institutional buyers"" as defined in and in reliance on Rule 114A of the US Securities Act or another exemption from registration or a transaction not subject to registration under the US Securities Act.The Company shall not be liable if any person should violate the foregoing restrictions.About DON'T NODDON'T NOD is an independent French publisher and developer  based in Paris and Montreal  creating original narrative games in the adventure (LIFE is STRANGETM  TELL ME WHYTM  TWIN MIRRORTM)  RPG (VAMPYRTM)  and action (REMEMBER METM) genres. The studio is internationally renowned for unique narrative experiences with engaging stories and characters  and has worked with industry leading publishers Square Enix  Microsoft  Bandai Namco Entertainment  Focus Entertainment  and Capcom. DON'T NOD creates and publishes its own IPs developed in-house  as well as using its knowledge and experience to collaborate with third-party developers whose editorial visions parallel the company's own.Step into the studio's immersive and innovative universe at dont-nod.comDON'T NOD (ISIN code: FR0013331212 - ALDNE) is listed on Euronext Growth ParisDON'T NODOskar GuilbertChief Executive OfficerBenoÃ®t Gisbert-MoraChief Financial Officerinvest@dont-nod.com ACTUS finance & communicationCorinne PuissantAnalyst/Investor relationsTel.: 33 (0)1 53 67 36 77 - dontnod@actus.frAnne-Catherine BonjourPress relationsTel.: 33 (0)1 53 67 36 93 - acbonjour@actus.frThis publication embed ""ðŸ”’ Actusnews SECURITY MASTER "".- SECURITY MASTER Key: lnBukpZqYW+cmJ2dlMtpbWeXZ5djlWGYmpKelmNwY5ibnW+WmJpoaJfJZnBpm2hv- Check this key: https://www.security-master-key.com.Regulated information:Inside Information:- other releases Full and original press release in PDF: https://www.actusnews.com/news/78639-cp_dne_cloture_suzie_vdef_ukb.pdfReceive by email the next press releases of the company by registering on www.actusnews.com  it's freeÂ© 2023 ActusNews",positive,0.68,0.3,0.02,positive,1.0,0.0,0.0,True,English,"['EUR 46 million capital increase', 'Successful completion', 'Entertainment', ""closing DON'T NOD share price"", 'Proxima Beta Europe BV', 'French Financial Market Authority', ""Paris' Euronext GrowthÂ® market"", 'Euronext GrowthÂ® Paris market', ""shareholders' preferential subscription rights"", 'next growth cycle', ""DON'T NOD."", 'current dividend rights', 'Chief Executive Officer', '4 additional original creations', 'proven business potential', 'Combined General Meeting', 'same listing line', 'share issue premium', 'Tencent Holdings Limited', '4,592,048 new ordinary shares', '4,522,491 new ordinary shares', 'The New Shares', '2 new video games', 'subscription price', 'existing shareholders', 'share capital', '69,557 new shares', '3,600,000 New Shares', 'same FR0013331212', 'existing shares', 'Such shares', 'independent studio', 'capital increase', 'book-building process', 'PrimaryBid platform', 'continuous support', 'Oskar Guilbert', '2 external co-productions', 'biggest pipeline', 'action-RPG segment', 'Total demand', 'PrimaryBid plateform', 'diluted basis', 'nominal value', 'ISIN code', 'statutory provisions', 'EU Regulation', 'European Parliament', 'public offering', 'Reserved Offering', 'PrimaryBid Offering', 'individual investors', '12 th resolution', '10th resolution', 'The Fundraising', 'total amount', 'minimum amount', 'institutional investors', 'successful completion', 'cancellation', 'February', 'accelerated', 'benefit', 'category', 'persons', 'thanks', 'trust', 'development', 'Chairman', 'releases', 'history', 'funds', 'strong', 'TERMS', 'CONDITIONS', 'individuals', 'framework', 'accordance', 'Company', 'June', 'decisions', 'Board', 'Directors', 'sub-delegation', 'competence', 'discount', 'launch', 'subsidiary', 'undertaking', 'context', 'settlement-delivery', 'ALDNE', 'place', 'issuance', 'trading', 'Article', 'Council', 'rise', 'publication', 'prospectus', 'approval', 'AMF', 'IMPACT', 'SHAREHOLDING']",2023-02-17,2023-02-18,marketscreener.com
18774,EuroNext,NewsApi.org,https://seekingalpha.com/article/4579351-galp-energia-promising-outlook-2023-will-support-stock-price,Galp Energia: A Promising Outlook For 2023 Will Support The Share Price (GLPEF),Galp Energia is the second largest oil-producing company on the Iberian peninsula  behind Repsol. Read more here.,mtcurado/iStock Unreleased via Getty ImagesIntroductionGalp Energia (OTCPK:GLPEF) (OTCPK:GLPEY) is a Portuguese integrated oil and gas company. It has a production rate of just over 100 000 barrels of oil-equivalent per day  owns a refinery and has recently been investing in renewable energy sources. The stock is still trading below the 15 EUR level it was trading at when I last discussed the company in 2019  despite just having completed a year with phenomenal oil prices which boosted the free cash flow result to almost 1.7B EUR  which is in excess of 2 EUR per share. 2023 likely won't be as strong as the oil prices have been trending lower  but in this article I'll explain why the official guidance for 2023 still makes Galp relatively appealing.Yahoo FinanceGalp's primary listing is on Euronext Lisbon where the stock is trading with GALP as its ticker symbol. There are currently approximately 815M shares outstanding after completing a 150M EUR share buyback program in 2022  resulting in a market capitalization of just over 9.8B EUR. As Galp has announced a 500M EUR share buyback  one could expect the share count to decrease by almost 5% this year  to less than 780M shares. The average daily volume in Lisbon is approximately 2.2 million shares.A look at the 2023 guidance reveals a high base case oil priceGalp's guidance for 2023 is pretty straightforward. The company anticipates an EBITDA of 3.2B EUR and an operating cash flow of 2.2B EUR this year  mainly thanks to another strong result in the upstream segment. Adjusting for the sale of the Angolan assets  Galp anticipates its upstream segment to generate north of 2B EUR in EBITDA and an operating cash flow of in excess of 1.1B EUR.Galp Energia Investor RelationsThe industrial and midstream assets will contribute about 550M EUR in EBITDA and operating cash flow  while the commercial segment will also contribute a few hundred million Euro. The renewables division should generate about 180M EUR in EBITDA and as such  will represent just over 5% of the anticipated consolidated EBITDA. So unlike its Iberian peer Repsol (OTCQX:REPYY) (OTCQX:REPYF)  Galp still is very fossil fuel heavy.What's interesting is that Galp is using a Brent oil price of US$85/barrel in its base case scenario and that's not really conservative. On the other hand  the company does use an EUR/USD exchange rate of 1.15 which is about 8% more conservative than the current FX rate which gets you 1.07 USD for every Euro. This also means that $85 Brent at a 1.15 conversion rate is just under 74 EUR per barrel while the current Brent oil price expressed in Euro is 79 EUR. So although $85 Brent optically looks pretty high  it's actually a slight discount to the current price when expressed in Euro.Galp also uses a refining margin of just $9/barrel. That's also pretty conservative given the strong fourth quarter on the refining side.Fortunately Galp also provided a sensitivity analysis. For every $5 difference in the Brent oil price  the operating cash flow will move by 85M EUR. So applying a Brent oil price of $70 would remove about 255M EUR from the operating cash flow  which would subsequently come in at approximately 1.95B EUR. And for every dollar difference in the refining margin  the operating cash flow will move by 65M EUR.Galp Energia Investor RelationsSo if we would apply $75 Brent  a $10 refining margin and an EUR/USD exchange rate of 1.10  the operating cash flow would be just 25M EUR lower than the base case scenario of 2.2B EUR. The main takeaway here is that the anticipated cash flows appear to be pretty robust.Investment thesisGalp Energia is often overlooked in the energy space. Repsol is by far the most important oil and gas company on the Iberian peninsula and Galp is for sure its smaller brother  but let's not neglect the Portuguese company. Even if the oil price doesn't come in at $85 Brent throughout the year  odds are Galp will still generate in excess of 2B EUR in operating cash flow. And considering the capex (including growth capex) is budgeted at - on average - 1B EUR for the years to come  I think it's okay to assume Galp will pretty consistently generate about 1B EUR in free cash flow per year. Keep in mind Galp only provides guidance on the 'net' capex  so it remains to be seen if we will see any divestments beyond the Angolan sale in the future.This represents approximately 1.35 EUR per share and although that doesn't make the stock look extremely attractive at first sight (its peers are trading at a higher free cash flow yield)  keep in mind this includes some serious investments in the renewable energy space where the company wants to almost triple its operating capacity by 2025.Galp Energia Investor RelationsGiven the strong balance sheet with a net debt of 1.56B EUR (excluding lease liabilities) and a TTM EBITDA of approximately 3.7B EUR (also excluding lease payments)  the debt ratio is just around 0.4. Even if one would apply the lower EBITDA of around 3B EUR in 2023 (the 3.2B EUR guidance minus the anticipated lease payments)  the net debt level will be just around 0.5 times EBITDA. That excludes the proceeds from the anticipated sale of the Angolan assets. Galp entered into an agreement to sell its Angolan upstream business for total net proceeds of 830M USD (on an after-tax basis) including $175M in contingent payments based on the Brent oil price. The US$655M upfront cash payment represents approximately 600M EUR and will further reduce the net debt to less than 1B EUR (of course subject to the pace of the 500M EUR share buyback this year). As the EBITDA guidance already assumes the sale of the Angolan assets  the debt ratio will thus drop below 0.35. This also makes Galp a pure play on Brazil.I'm encouraged by Galp's guidance so I will keep an eye on this company with renewed interest.Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.,neutral,0.06,0.94,0.0,mixed,0.39,0.2,0.42,True,English,"['Galp Energia', 'Promising Outlook', 'Share Price', 'The', 'GLPEF', 'higher free cash flow yield', '150M EUR share buyback program', 'high base case oil price', '500M EUR share buyback', 'free cash flow result', 'Galp Energia Investor Relations', 'current Brent oil price', 'base case scenario', 'operating cash flow', 'average daily volume', 'renewable energy sources', 'strong fourth quarter', 'strong balance sheet', 'EUR/USD exchange rate', 'current FX rate', 'Portuguese integrated oil', 'renewable energy space', 'Iberian peer Repsol', 'hundred million Euro', 'current price', 'strong result', '3.2B EUR guidance', 'cash flows', 'operating capacity', 'oil prices', 'important oil', 'production rate', 'share count', '1.15 conversion rate', '2.2 million shares', 'Iberian peninsula', '15 EUR level', '180M EUR', '1B EUR', 'Getty Images', 'Yahoo Finance', 'primary listing', 'ticker symbol', '815M shares', 'market capitalization', '780M shares', 'upstream segment', 'Angolan assets', 'midstream assets', 'commercial segment', 'renewables division', 'fossil fuel', 'other hand', 'slight discount', 'refining margin', 'refining side', 'sensitivity analysis', 'main takeaway', 'Investment thesis', 'smaller brother', 'first sight', 'serious investments', 'net debt', 'lease liabilities', 'lease payments', 'debt ratio', 'Portuguese company', 'growth capex', ""net' capex"", 'official guidance', 'Euronext Lisbon', 'dollar difference', 'Angolan sale', 'gas company', 'TTM EBITDA', 'lower EBITDA', '$75 Brent', '2 EUR', '1.35 EUR', '1.1B', '2023 guidance', '2.2B', '$5 difference', 'Introduction', 'GLPEF', '100,000 barrels', 'equivalent', 'day', 'refinery', 'stock', 'year', '1.7B', 'excess', 'article', '9.8B', 'less', 'look', 'industrial', 'REPYY', '85M', '255M', '1.95B', '65M', 'odds', 'mind', 'divestments', 'future', 'peers', '1.56B', '3.7B', '3B']",2023-02-18,2023-02-18,seekingalpha.com
18775,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/MAAT-PHARMA-128358114/news/February-17-2023-MaaT-Pharma-Completes-a-Capital-Increase-of-approximately-12-7-Million-with-the-43013941/?utm_medium=RSS&utm_content=20230217,February 17  2023: MaaT Pharma Completes a Capital Increase of approximately Â€12.7 Million with the Support of Current Shareholders,(marketscreener.com)    This press release is not intended for publication or distribution in the United States  Canada  Japan or Australia.     MaaT Pharma Completes a Capital Increase of approximately â‚¬12.7 Million with the Support of Current Sharehâ€¦,"This press release is not intended for publication or distribution in the United States  Canada  Japan or Australia.Lyon  France  February 17  2023 7:30 am CET -MaaT Pharma(EURONEXT: MAAT - the ""Company"")  a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer  today announced the successful completion of a capital increase of approximately â‚¬12.7 million supported by its existing shareholders including Seventure Partners  PSIM Fund represented by Bpifrance Investissement  Biocodex  Invus  CÃ©leste Management  Skyviews Life Sciences and Tocqueville. The funds will support the Company's biomanufacturing expansion and ongoing and future clinical trials.""We are very pleased with the success of this capital increase  and the endorsement from our current investors. This transaction puts MaaT Pharma in a very good position to ensure the implementation of its ongoing and future clinical programs and to support our efforts in obtaining non-dilutive funding. This is also a major step that enables us to strengthen  even further  our biomanufacturing processes in line with the encouraging recent communication from the FDA moving us closer to our objective of initiating the clinical evaluation of our pipeline in the U.S. in parallel with the ongoing clinical program in Europe"" comments HervÃ© Affagard  MaaT Pharma CEO and co-founder.Impact on cash flow and use of proceedsGross proceeds from the transaction are â‚¬12 680 000. The Company's financial visibility will be extended from Q4 2023 into Q2 2024. The Company plans to use the proceeds  along with existing cash and cash equivalents  to finance biomanufacturing and regulatory capabilities which will support the Company's objective to start clinical evaluation in the U.S. subject to the lifting of the clinical hold  and for ongoing clinical development programs for MaaT013 and MaaT033 as well as general corporate purposes.Key characteristics of the share capital increaseMaaT Pharma's Board of Directors using the delegation of powers granted by the 18th resolution of the shareholders' general meeting held on May 31st  2022 (capital increase with cancellation of preferential subscription rights in favor of categories of persons with specific characteristics) and in accordance with article L. 225-138 et seq. of the French Commercial Code (code de commerce)  has decided on February 16  2023 to complete a capital increase of 12 680 000 euros  by way of issuance of 1 585 000 new shares with a nominal value of â‚¬0.10 each (the ""New Shares"") for a subscription price of â‚¬8 each (including premium) (the ""Capital Increase"").The New Shares were issued at a price of â‚¬8  representing a discount of 11% compared to the volume-weighted average of the share price over the last three trading sessions preceding the setting of the price per Share (i.e. the sessions of February 16  15 and 14  2023  the said average amounting to 8.99 euros).Seventure Partners and Biocodex who are existing shareholders and are also represented on the Board of Directors of the Company  as well PSIM Fund represented by Bpifrance Investissement  also an existing shareholder and observer at the Board of Directors of the Company  will participate in the Capital Increase for subscription amounts of 2 million euros  2 million euros and 5 million euros respectively  representing 70.98% of the aggregate gross amount of the Capital Increase. It is specified that the subscribers who are also members of MaaT Pharma's Board of Directors did not take part in the vote of the Capital Increase at the Board of Directors' meeting held on February 16  2023.The subscriptions of existing shareholders to the Capital Increase (including the participation of Seventure Partners  Biocodex and PSIM Fund) represents 12.680 million euros  i.e. the aggregate gross amount of the Capital Increase.Following the settlement-delivery expected to occur on February 21  2023  MaaT Pharma's share capital will amount to â‚¬1 153 173.90 divided into 11 531 739 shares. The New Shares will be fungible with the existing shares of the Company and will be admitted to trading on the regulated market of Euronext in Paris under the ISIN FR0012634822.Impact of the offering on the share capitalThe issuance of the New Shares represents 13.74% of the share capital of the Company after the Capital Increase. On an illustrative basis  a shareholder holding 1% of the Company's share capital before the transaction will now hold a stake of 0.86% after the transaction.The following table specifies the evolution of the share capital of the Company after the Capital Increase:Shareholders Before share capital increase After share capital increase Total number of shares (non diluted basis) % of capital and voting rights (non diluted basis) Total number of shares (diluted basis) % of capital and voting rights (diluted basis) Total number of shares (non diluted basis) % of capital and voting rights (non diluted basis) Total number of shares (diluted basis) % of capital and voting rights (diluted basis) HervÃ© Affagard 190 722 1 92% 313 473 2 97% 196 972 1 71% 319 723 2 64% Total corporate officers (individuals) 190 722 1 92% 313 473 2 97% 196 972 1 71% 319 723 2 64% Seventure funds 2 345 236 23 58% 2 345 236 22 24% 2 595 236 22 51% 2 595 236 21 39% CrÃ©dit Mutuel Innovation SAS 1 412 364 14 20% 1 412 364 13 39% 1 412 364 12 25% 1 412 364 11 64% Biocodex SAS 977 905 9 83% 977 905 9 27% 1 227 905 10 65% 1 227 905 10 12% Symbiosis LLC 2 027 702 20 39% 2 027 702 19 23% 2 027 702 17 58% 2 027 702 16 71% FPCI Fonds PSIM 1 177 439 11 84% 1 177 439 11 16% 1 802 439 15 63% 1 802 439 14 86% Other investors 342 743 3 45% 342 743 3 25% 796 493 6 91% 796 493 6 57% Total historical shareholders 8 283 389 83 28% 8 283 389 78 54% 9 862 139 85 52% 9 862 139 81 30% Employees and consultants 303 203 3 05% 779 983 7 40% 303 203 2 63% 779 983 6 43% Self-holding 11 650 0 12% 11 650 0 11% 11 650 0 10% 11 650 0 10% Free Float 1 157 775 11 64% 1 157 775 10 98% 1 157 775 10 04% 1 157 775 9 54% Total 9 946 739 100 00% 10 546 270 100 00% 11 531 739 100 00% 12 131 270 100 00%Information available to the public and risk factorsInvestors' attention is drawn to the risk factors set out in the 2021 Universal Registration Document filed with the AutoritÃ© des MarchÃ©s Financiers (AMF) on July 5  2022 under number R.22-032 as well as in the 2022 half-year financial report. This document  as well as other regulated information and all of the Company's press releases  can be consulted on the MaaT Pharma website: www.maatpharma.com.",neutral,0.01,0.99,0.0,positive,0.87,0.13,0.0,True,English,"['MaaT Pharma', 'Capital Increase', 'Current Shareholders', 'Support', 'last three trading sessions', 'ongoing clinical development programs', 'future clinical programs', 'French clinical-stage biotech', 'Microbiome Ecosystem TherapiesTM', 'CÃ©leste Management', 'Skyviews Life Sciences', 'encouraging recent communication', 'general corporate purposes', 'French Commercial Code', 'code de commerce', 'future clinical trials', 'aggregate gross amount', 'ongoing clinical program', ""shareholders' general meeting"", 'preferential subscription rights', 'MaaT Pharma CEO', 'share capital increase', 'The New Shares', 'clinical evaluation', 'clinical hold', 'voting rights', '1,585,000 new shares', 'press release', 'United States', 'survival outcomes', 'successful completion', 'existing shareholders', 'Seventure Partners', 'PSIM Fund', 'Bpifrance Investissement', 'current investors', 'good position', 'non-dilutive funding', 'major step', 'U.S.', 'HervÃ© Affagard', 'cash flow', 'Gross proceeds', 'financial visibility', 'existing cash', 'cash equivalents', 'regulatory capabilities', 'Key characteristics', '18th resolution', 'specific characteristics', 'article L.', 'nominal value', 'regulated market', 'following table', 'Total number', 'existing shares', 'share price', ""Directors' meeting"", 'biomanufacturing expansion', 'biomanufacturing processes', '2 million euros', '5 million euros', '12.680 million euros', 'subscription price', 'volume-weighted average', 'illustrative basis', 'The Company', '11,531,739 shares', '680,000 euros', '8.99 euros', 'publication', 'distribution', 'Canada', 'Japan', 'Australia', 'Lyon', 'EURONEXT', 'pioneer', 'MET', 'patients', 'cancer', 'Biocodex', 'Invus', 'Tocqueville', 'funds', 'endorsement', 'transaction', 'implementation', 'efforts', 'line', 'FDA', 'objective', 'parallel', 'Europe', 'founder', 'Impact', 'use', 'Q4', 'Q2', 'lifting', 'MaaT013', 'MaaT033', 'Board', 'delegation', 'powers', 'May', 'cancellation', 'favor', 'categories', 'persons', 'accordance', 'February', 'way', 'issuance', 'premium', 'discount', 'setting', 'observer', 'amounts', 'subscribers', 'members', 'vote', 'subscriptions', 'participation', 'settlement-delivery', 'Paris', 'ISIN', 'offering', 'stake', 'evolution', '0.']",2023-02-17,2023-02-18,marketscreener.com
18776,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/DANSKE-BANK-A-S-1412871/news/Danske-Bank-A-S-Vote-by-correspondance-and-proxy-form-2023-43015032/?utm_medium=RSS&utm_content=20230217,Danske Bank A/S : Vote by correspondance and proxy form 2023,(marketscreener.com)   Voting by correspondence / Voting by proxy   For use at Danske Bank A/S' annual general meeting on Thursday 16 March 2023 at 3.00pm .   I/we hereby vote by correspondence or grant a proxy in accordance with the voting instructioâ€¦,"Voting by correspondence / Voting by proxyFor use at Danske Bank A/S' annual general meeting on Thursday 16 March 2023 at 3.00pm (CET).I/we hereby vote by correspondence or grant a proxy in accordance with the voting instructions stated in the boxes below:Please tick box A)  B)  C) or D)  or vote by correspondence/grant a proxy directly at investor.vp.dk/en/danskebank. If more than one of box A)  B)  C) and D) are ticked off  box C) will apply.ï¯ Vote by correspondence in accordance with the voting instructions stated in the boxes below. Votes cast by correspondence cannot be withdrawn (Tick the ""For""  ""Against"" or ""Abstain"" box) ï¯ I/we grant a proxy to: __________________________________________________________________________________________________Name and e-mail of proxy holder. Please use CAPITAL LETTERS ï¯ I/we grant a proxy to the Board of Directors (with power of delegation) to vote on my/our behalf. ï¯ I/we grant a proxy to the Board of Directors (with power of delegation) to vote in accordance with the voting instructions stated in the boxes below (Tick the ""For""  ""Against"" or ""Abstain"" box).Agenda For Against Abstain Recommendation (The complete proposals are included in the notice of the general meeting) of the Board of Directors 2) Adoption of Annual Report 2022 ï‚¨ ï‚¨ ï‚¨ For 3) Cover of loss according to the adopted Annual Report 2022 ï‚¨ ï‚¨ ï‚¨ For 4) Presentation of the Remuneration Report 2022 for an advisory vote ï‚¨ ï‚¨ ï‚¨ For 5) Election of the number of candidates  which is proposed by the Board of Directors at ï‚¨ ï‚¨ ï‚¨ For the annual general meeting at the latest 5.a Re-election of Martin Blessing ï‚¨ ï® ï‚¨ For 5.b Re-election of Jan Thorsgaard Nielsen ï‚¨ ï® ï‚¨ For 5.c Re-election of Lars-Erik BrenÃ¸e ï‚¨ ï® ï‚¨ For 5.d Re-election of Jacob Dahl ï‚¨ ï® ï‚¨ For 5.e Re-election of Raija-LeenaHankonen-Nybom ï‚¨ ï® ï‚¨ For 5.f Re-election of Allan Polack ï‚¨ ï® ï‚¨ For 5.g Re-election of Carol Sergeant ï‚¨ ï® ï‚¨ For 5.h Re-election of Helle Valentin ï‚¨ ï® ï‚¨ For 5.i Election of Michael Strabo ï‚¨ ï® ï‚¨ Abstain 5.j Election of Caroline Bessermann ï‚¨ ï® ï‚¨ Abstain 6) Re-appointment of Deloitte Statsautoriseret Revisionspartnerselskab as external ï‚¨ ï® ï‚¨ For auditor 7) Proposals from the Board of Directors to amend the Articles of Association 7.a Extension by one year of the existing authorisation in articles 6.5.b and 6.6 of the ï‚¨ ï‚¨ ï‚¨ For Articles of Association regarding capital increases without pre-emption rights and issuance of convertible debt 7.b Authorisation to hold fully electronic general meetings ï‚¨ ï‚¨ ï‚¨ For 8) Extension of the Board of Directors' authorisation to acquire own shares ï‚¨ ï‚¨ ï‚¨ For 9) Adoption of the remuneration of the Board of Directors in 2023 ï‚¨ ï‚¨ ï‚¨ For 10) Adjustments to the Group's Remuneration Policy 2023 ï‚¨ ï‚¨ ï‚¨ For 11) Renewal of the existing indemnification of Directors and Officers with effect until the ï‚¨ ï‚¨ ï‚¨ For annual general meeting in 2024 12) Proposals from shareholders 12.a.(1) Proposal from shareholder ActionAid Denmark regarding policy for direct ï‚¨ ï‚¨ ï‚¨ Against lending in the Climate Action Plan and the Position Statement on Fossil Fuels 12.a.(2) Proposal from shareholder ActionAid Denmark regarding the asset ï‚¨ ï‚¨ ï‚¨ Against management policy in the Climate Action Plan 12.b Proposal from shareholder Frank Aaen regarding lending to and investments in ï‚¨ ï‚¨ ï‚¨ Against companies involved in research and expansion of new fossil fuels 13) Authorisation to the chairman of the general meeting ï‚¨ ï‚¨ ï‚¨ ForIf I/we have dated and signed this form but not stated if I/we want to grant a proxy or vote by correspondence  it is because I/we have granted a proxy to the Board of Directors to vote on my/our behalf  save for voting instructions submitted for specific agenda items by ticking off boxes in the table above  in that such voting instructions  if any  will be considered submitted in accordance with box D) above.To the extent that I/we have ticked off box A) or box D) above but not submitted voting instructions for one or more agenda items by ticking off boxes in the table above  the proxy/vote by correspondence will be used in accordance with the ""Recommendation of the Board of Directors"" for such non-ticked off agenda items.A proxy applies to all business dealt with at the general meeting. If new proposals are submitted for voting  including amendments to proposals or proposals for election to the Board of Directors or appointment of external auditors  which do not appear on the agenda  the proxy holder will vote on my/our behalf according to the best of the proxy holder's belief  including  to the extent reasonable  in accordance with the recommendation of the Board of Directors. Votes by correspondence will be included if new proposals submitted for voting  including amendments to proposals or proposals for electionPlease date and sign the form and send it to VP Securities A/S  c/o Euronext Securities  Nicolai Eigtveds Gade 8  DK-1402 Copenhagen K or as a scanned copy by e-mail to CPH-investor@euronext.com. VP Securities A/S must receive the proxy form no later than Monday 13 March 2023 at 11.59pm (CET). If the form is used for voting by correspondence  VP Securities A/S must receive the form no later than Wednesday 15 March 2023 at 4.00pm (CET).",neutral,0.0,1.0,0.0,negative,0.16,0.36,0.47,True,English,"['Danske Bank A/S', 'proxy form', 'correspondance', 'Jan Thorsgaard Nielsen', 'Deloitte Statsautoriseret Revisionspartnerselskab', 'shareholder ActionAid Denmark', 'Climate Action Plan', 'shareholder Frank Aaen', 'Nicolai Eigtveds Gade', 'electronic general meetings', 'Lars-Erik BrenÃ¸e', 'VP Securities A/S', 'annual general meeting', 'latest 5.a Re-election', 'new fossil fuels', 'specific agenda items', 'Euronext Securities', '5.e Re-election', 'Annual Report', '5.b Re-election', '5.c Re-election', '5.d Re-election', '5.f Re-election', '5.g Re-election', '5.h Re-election', 'Thursday 16 March', 'CAPITAL LETTERS', 'advisory vote', 'Martin Blessing', 'Jacob Dahl', 'Allan Polack', 'Carol Sergeant', 'Helle Valentin', 'Michael Strabo', 'Caroline Bessermann', 'capital increases', 'pre-emption rights', 'convertible debt', 'existing indemnification', 'Position Statement', 'Copenhagen K', 'Monday 13 March', 'voting instructions', 'box A', 'Remuneration Report', 'management policy', 'new proposals', 'one year', 'existing authorisation', 'external auditors', '5.i Election', '5.j Election', 'box D', 'Remuneration Policy', 'complete proposals', 'proxy holder', 'Abstain Recommendation', ""Directors' authorisation"", 'proxy form', 'external \uf0a8', 'correspondence', 'use', '3.00pm', 'accordance', 'boxes', 'grant', 'investor', 'dk', 'danskebank', 'Votes', 'Name', 'mail', 'Board', 'power', 'delegation', 'behalf', 'notice', 'Adoption', 'Cover', 'loss', 'Presentation', 'number', 'candidates', 'Raija-LeenaHankonen-Nybom', 'appointment', 'Articles', 'Association', 'Extension', 'issuance', 'shares', 'Adjustments', 'Group', 'Renewal', 'Officers', 'effect', 'shareholders', 'direct \uf0a8', 'lending', 'asset', 'investments', 'companies', 'research', 'expansion', 'chairman', 'table', 'extent', 'proxy/vote', 'business', 'amendments', 'belief', 'copy', '11.59pm']",2023-02-17,2023-02-18,marketscreener.com
18777,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SEADRILL-LIMITED-134161509/news/Seadrill-2022-AGM-CEO-Letter-43014527/?utm_medium=RSS&utm_content=20230217,Seadrill : 2022 AGM CEO Letter,(marketscreener.com)   Dear Shareholders    2022 was an extraordinary and transformative year for Seadrill. The management team and I are extremely proud of our employees  both offshore and onshore  for their efforts and contributions in achieving so mucâ€¦,Dear Shareholders 2022 was an extraordinary and transformative year for Seadrill. The management team and I are extremely proud of our employees  both offshore and onshore  for their efforts and contributions in achieving so much through the year. We find ourselves at a fascinating time for our industry in the face of geopolitical tensions and economic headwinds. Last year the need for affordable and reliable sources of energy was felt acutely around the globe and we believe as a company we have a crucial role to play in that regard. We believe the steps the company took laid the foundations for growth and enhanced performance for years to come.The board of directors and the management team have made it clear that we are highly focused on delivering value to you - our shareholders. As we reflect on the past year  we are firmly of the view that we achieved this through the delivery of safe and efficient operations for our customers and the execution of several important strategic initiatives  none more so than the sale of our jack-ups in the Kingdom of Saudi Arabia in October and the all-stock acquisition of Aquadrill LLC that we announced in late December and expect to close mid-2023. Looking ahead through 2023 and beyond  at the beginning of what we believe will be a sustained upcycle for offshore drilling  we are confident that Seadrill is very well-placed to capitalize on market developments and reaffirm our focus on generating value and returns for shareholders.In February 2022  Seadrill successfully emerged from its financial restructuring. Soon thereafter we re-entered public markets in April with a listing on the Euronext Expand in Oslo  followed by an up-listing to the main Oslo BÃ¸rs in November. The Norwegian investor community is closely associated with Seadrill and we intend to build on existing relationships and foster new ones. In October  we re-entered U.S. markets by establishing our primary listing on the New York Stock Exchange. The steps we took in the capital markets last year were crucial for the company and its shareholders  improving liquidity in our equity and broadening our investor base. We look forward to working proactively and collaboratively with existing and prospective shareholders and investors as we continue to assess options with regard to the optimization of Seadrill's capital structure.Along with these milestones in capital markets  over the course of 2022 we repositioned Seadrill strategically to focus on key segments and geographies  where we believe we can differentiate the company and create value.In September  we announced the sale of our jack-up business in the Kingdom of Saudi Arabia to ADES Arabia Holding Ltd. The strategic rationale for this transaction was compelling  crystalizing highly attractive valuations on an implied equity basis and creating an opportunity for the company to utilize the sale proceeds to significantly deleverage. The interest rate environment during 2022 changed markedly  driven by the fallout from the COVID-19 pandemic and geopolitical headwinds  and we regarded the opportunity to deleverage as vitally important. We executed debt paydowns of USD 442 million in the fourth quarter after closing the transaction. In taking this step we anticipate realizing interest savings of approximately USD 75 million per annum  enhancing the company's free cash flow outlook.,neutral,0.0,0.99,0.0,mixed,0.49,0.2,0.3,True,English,"['2022 AGM CEO Letter', 'Seadrill', 'free cash flow outlook', 'several important strategic initiatives', 'ADES Arabia Holding Ltd', 'main Oslo BÃ¸rs', 'New York Stock Exchange', 'Norwegian investor community', 'interest rate environment', 'U.S. markets', 'stock acquisition', 'strategic rationale', 'Saudi Arabia', 'investor base', 'interest savings', 'public markets', 'capital markets', 'management team', 'fascinating time', 'geopolitical tensions', 'economic headwinds', 'reliable sources', 'crucial role', 'efficient operations', 'Aquadrill LLC', 'late December', 'sustained upcycle', 'offshore drilling', 'market developments', 'financial restructuring', 'capital structure', 'key segments', 'attractive valuations', 'COVID-19 pandemic', 'geopolitical headwinds', 'debt paydowns', 'fourth quarter', 'transformative year', 'past year', 'existing relationships', 'equity basis', 'Dear Shareholders', 'prospective shareholders', 'primary listing', 'sale proceeds', 'extraordinary', 'Seadrill', 'employees', 'efforts', 'contributions', 'industry', 'face', 'need', 'affordable', 'energy', 'globe', 'company', 'regard', 'steps', 'foundations', 'growth', 'performance', 'years', 'board', 'directors', 'value', 'view', 'delivery', 'safe', 'customers', 'execution', 'Kingdom', 'October', 'beginning', 'focus', 'returns', 'February', 'April', 'Euronext', 'November', 'The', 'liquidity', 'investors', 'options', 'optimization', 'milestones', 'course', 'geographies', 'September', 'transaction', 'opportunity', 'fallout', 'annum']",2023-02-17,2023-02-18,marketscreener.com
18778,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-3840782/news/BGHL-GBP-NAV-s-43013843/?utm_medium=RSS&utm_content=20230217,BGHL (GBP): NAV(s),(marketscreener.com) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-3840782/news/BGHL-GBP-NAV-â€¦,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 16 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 27.2139 Â£ 23.9792 Estimated MTD return -0.18 % -0.13 % Estimated YTD return -2.00 % -1.83 % Estimated ITD return 172.14 % 139.79 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -18.42 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.76 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 238.7094 Class GBP A Shares (estimated) Â£ 127.9798The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'GBP', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'London Stock Exchange plc', 'A N/A Average Price', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'A N/A Range', 'Sterling Shares Shares', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', '800 N/A Shares', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'treasury', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-17,2023-02-18,marketscreener.com
18779,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610354/0/en/BGHL-EUR-NAV-s.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED      Ordinary Shares      The Directors of Boussard & Gavaudan...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 16 Feb 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 27.2139 Â£ 23.9792 Estimated MTD return -0.18 % -0.13 % Estimated YTD return -2.00 % -1.83 % Estimated ITD return 172.14 % 139.79 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -18.42 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.76 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 297 058 126 294 Held in treasury 800 N/A Shares Issued 12 297 858 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 238.7094 Class GBP A Shares (estimated) Â£ 127.9798The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'EUR', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'London Stock Exchange plc', 'A N/A Average Price', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'A N/A Range', 'Sterling Shares Shares', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', '800 N/A Shares', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'treasury', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-02-17,2023-02-18,globenewswire.com
18780,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GALP-ENERGIA-SGPS-S-A-35373/news/Galp-Energia-SGPS-S-A-informs-about-weekly-report-on-share-repurchase-transactions-43021740/?utm_medium=RSS&utm_content=20230217,Galp Energia SGPS S A : informs about weekly report on share repurchase transactions,(marketscreener.com)   February 17  2023   Weekly report on share repurchases   In the context of the share repurchase programme of Galp Energia SGPS  SA's ordinary shares with the purpose to reduce the issued share capital  the Company informs about â€¦,"February 17  2023Weekly report on share repurchasesIn the context of the share repurchase programme of Galp Energia SGPS  SA's ordinary shares with the purpose to reduce the issued share capital  the Company informs about the transactions occurred during the period from 15 February 2023 to 17 February 2023 (inclusive).According to the information provided by the intermediary appointed to make the purchases  Galp has acquired shares in Euronext Lisbon regulated market  as detailed in the table below (aggregated information):Day Number of Shares Weighted Average Price (â‚¬/sh) Transactions Amount (â‚¬k) 15/02/2023 198 418 â‚¬11.6358 â‚¬2 309 16/02/2023 158 825 â‚¬11.8561 â‚¬1 883 17/02/2023 169 125 â‚¬11.7559 â‚¬1 988Galp has currently 526 368 treasury shares (equivalent to 0.06% of the share capital)  which were bought for an aggregate amount of â‚¬6.2 m.All the detailed information regarding Galp's buyback programmes  including the details on daily trades  are available on our website  here.Galp Energia  SGPS  S.A.Investor Relations: Contacts: Website: www.galp.com/corp/en/ Otelo Ruivo  Director Tel: +351 21 724 08 66 Email: investor.relations@galp.com JoÃ£o G. Pereira Teresa Toscano Address: Reuters: GALP.LS Tommaso Fornaciari Rua TomÃ¡s da Fonseca  Bloomberg: GALP PL CÃ©sar Teixeira Torre A  1600-209 Lisbon  PortugalThis document may include forward-looking statements. All statements other than statements of historical facts are  or may be deemed to be  forward-looking statements. Forward-looking statements express future expectations that are based on management's expectations and assumptions as of the date they are disclosed and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in such those statements. Accordingly  neither Galp nor any other person can assure that its future results  performance or events will meet those expectations  nor assume any responsibility for the accuracy and completeness of the forward-looking statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Galp to market risks and statements expressing management's expectations  beliefs  estimates  forecasts  projections  and assumptions. These forward-looking statements may generally be identified by the use of the future  gerund or conditional tense or the use of terms and phrases such as ""aim""  ""ambition""  ""anticipate""  ""believe""  ""consider""  ""could""  ""develop""  ""envision""  ""estimate""  ""expect""  ""goals""  ""intend""  ""may''  ""objectives""  ""outlook""  ""plan""  ""potential""  ""probably""  ""project""  ""pursue""  ""risks""  ""schedule""  ""seek""  ""should""  ""target""  ""think""  ""will"" or the negative of these terms and similar terminology. This document may include data and information provided by third parties  which are not publicly available. Such data and information should not be interpreted as advice and you should not rely on it for any purpose. You may not copy or use this data and information except as expressly permitted by those third parties in writing. To the fullest extent permitted by law  those third parties accept no responsibility for your use of such data and information except as specified in a written agreement you may have entered into with those third parties for the provision of such data and information. Galp and its respective representatives  agents  employees or advisers do not intend to  and expressly disclaim any duty  undertaking or obligation to  make or disseminate any supplement  amendment  update or revision to any of the information  opinions or forward-looking statements contained in this document to reflect any change in events  conditions or circumstances. This document does not constitute investment advice nor forms part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or otherwise acquire securities of Galp or any of its subsidiaries or affiliates in any jurisdiction or an inducement to engage in any investment activity in any jurisdiction.",neutral,0.0,1.0,0.0,negative,0.0,0.2,0.8,True,English,"['Galp Energia SGPS S A', 'share repurchase transactions', 'weekly report', 'LS Tommaso Fornaciari Rua TomÃ¡s da Fonseca', 'GALP PL CÃ©sar Teixeira Torre A', 'JoÃ£o G. Pereira Teresa Toscano', 'Euronext Lisbon regulated market', 'S.A.', 'share repurchase programme', 'Galp Energia SGPS', 'market risks', 'share repurchases', 'share capital', 'Weekly report', 'Day Number', 'Average Price', 'aggregate amount', 'buyback programmes', 'daily trades', 'Otelo Ruivo', 'historical facts', 'actual results', 'other person', 'future results', 'other things', 'potential exposure', 'future, gerund', 'conditional tense', 'similar terminology', 'third parties', 'fullest extent', 'written agreement', 'respective representatives', 'investment activity', 'unknown risks', 'forward-looking statements', 'ordinary shares', 'Transactions Amount', '526,368 treasury shares', 'investment advice', 'future expectations', 'Such data', 'detailed information', 'Investor Relations', '9 Lisbon', 'GALP.', 'February', 'context', 'purpose', 'Company', 'period', 'intermediary', 'table', 'details', 'website', 'Contacts', 'Director', 'Email', 'Address', 'Reuters', 'Bloomberg', 'Portugal', 'document', 'management', 'assumptions', 'date', 'uncertainties', 'performance', 'events', 'responsibility', 'accuracy', 'completeness', 'beliefs', 'estimates', 'forecasts', 'projections', 'use', 'terms', 'phrases', 'aim', 'ambition', 'objectives', 'outlook', 'plan', 'schedule', 'writing', 'law', 'provision', 'agents', 'employees', 'advisers', 'duty', 'undertaking', 'obligation', 'supplement', 'amendment', 'revision', 'opinions', 'change', 'conditions', 'circumstances', 'forms', 'offer', 'solicitation', 'securities', 'subsidiaries', 'affiliates', 'jurisdiction', 'inducement', '1600']",2023-02-17,2023-02-18,marketscreener.com
18781,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/NOKIA-OYJ-56358470/news/Nokia-Announces-Final-Results-for-its-Tender-Offers-and-the-New-Notes-Issue-43016651/?utm_medium=RSS&utm_content=20230217,Nokia Announces Final Results for its Tender Offers and the New Notes Issue,(marketscreener.com) Nokia CorporationStock Exchange Release17 February 2023 at 14:30 EET NOT FOR RELEASE  PUBLICATION OR DISTRIBUTION IN OR INTO  OR TO ANY PERSON LOCATED OR RESIDENT IN OR AT ANY ADDRESS IN  THE UNITED STATES OF AMERICA  ITS TERRITORIES AND â€¦,"Nokia CorporationStock Exchange Release17 February 2023 at 14:30 EETNOT FOR RELEASE  PUBLICATION OR DISTRIBUTION IN OR INTO  OR TO ANY PERSON LOCATED OR RESIDENT IN OR AT ANY ADDRESS IN  THE UNITED STATES OF AMERICA  ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO  THE U.S. VIRGIN ISLANDS  GUAM  AMERICAN SAMOA  WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS)  ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO.Nokia Announces Final Results for its Tender Offers and the New Notes IssueEspoo  Finland â€“ Nokia Corporation (â€œNokiaâ€)  announced on 9 February 2023 that it has separately invited holders of each Series of the Notes (as defined below) issued under Nokia's EUR 5 000 000 000 Euro Medium Term Note Programme (each such invitation a â€œTender Offerâ€ and  together  the â€œTender Offersâ€) to tender their EUR 750 000 000 2.000 per cent. Notes due 15 March 2024 (the â€œ2024 Notesâ€)  EUR 500 000 000 2.375 per cent. Notes due 15 May 2025 (the â€œ2025 Notesâ€) and EUR 750 000 000 2.000 per cent. Notes due 11 March 2026 (the â€œ2026 Notesâ€ and  together with the 2024 Notes and the 2025 Notes  the ""Notes"" and each a ""Seriesâ€) for purchase for cash up to the Maximum Acceptance Amount (as defined in the Tender Offer Memorandum).The Tender Offers were made on the terms and subject to the conditions set out in the tender offer memorandum dated 9 February 2023 (the â€œTender Offer Memorandumâ€). Capitalised terms not defined herein have the meaning ascribed to them in the Tender Offer Memorandum.The Expiration Deadline for the Tender Offers was 4.00 p.m. (London time) on 16 February 2023.Nokia hereby informs Noteholders that set out in the table below is: (i) each Series Acceptance Amount; (ii) the aggregate nominal amount of Notes tendered for purchase pursuant to each Tender Offer; (iii) each Purchase Yield; (iv) each Interpolated Mid-Swap Rate; (v) each Purchase Price; (vi) the pro-ration factor that will be applied to valid tenders of Notes of each Series; and (vii) the aggregate nominal amount of each Series of the Notes that remain outstanding following settlement of the Tender Offers.Notes ISIN / Common Code Purchase Spread Interpolated Mid-Swap Rate Purchase Yield Purchase Price Aggregate nominal amount tendered for purchase Series Acceptance Amount Pro-ration Factor Aggregate nominal amount that remain outstanding following settlement 2024 Notes XS1577731604 / 157773160 -35 bps 3.588% 3.238%% 98.728% EUR 372 472 000 EUR 372 472 000 100% EUR 377 528 000 2025 Notes XS2171759256 / 217175925 +5 bps 3.530% 3.580% 97.456% EUR 207 843 000 EUR 207 843 000 100% EUR 292 157 000 2026 Notes XS1960685383 / 196068538 +25 bps 3.395% 3.645% 95.331% EUR 256 879 000 EUR 119 685 000 approximately 43.513% EUR 630 315 000The Final Acceptance Amount is EUR 700 000 000.Nokia will also pay Accrued Interest in respect of the Notes purchased pursuant to the Tender Offers.On 10 February 2023  Nokia priced a new issue of â‚¬500 000 000 4.375 per cent. Notes due 21 August 2031 (the â€œNew Notesâ€). Application will be made for the New Notes to be admitted to listing and trading on Euronext Dublin.The New Financing Condition has been satisfied  subject to the issuance of the New Notes. The New Notes have been priced and a subscription agreement between Nokia and the joint bookrunners named therein for the purchase of  and subscription for  the New Notes has been signed and remains in full force and effect as of the date hereof.The Settlement Date for the Tender Offers and the New Notes is expected to be 21 February 2023.Notes purchased by Nokia pursuant to the Tender Offers will be immediately cancelled. Notes which have not been validly submitted and accepted for purchase pursuant to the Tender Offers will remain outstanding after the Settlement Date.The Tender Offers have now expired and no further Notes can be tendered for purchase.Joint Dealer ManagersBofA Securities SA  Citigroup Global Markets Limited  Deutsche Bank Aktiengesellschaft and UniCredit Bank AG (the â€œJoint Dealer Managersâ€) are acting as Joint Dealer Managers for the Tender Offers. Investors with questions may contact the Joint Dealer Managers at the addresses and numbers shown below.BofA Securities SA Citigroup Global Markets Limited 51  rue La BoÃ©tie75008 ParisFrance Citigroup CentreCanada SquareCanary WharfLondon E14 5LBUnited Kingdom Tel.: +33 1 877 01057Attn.: Liability Management GroupEmail: DG.LM-EMEA@bofa.com Tel: +44 20 7986 8969Attn.: Liability Management GroupEmail: liabilitymanagement.europe@citi.com Deutsche Bank Aktiengesellschaft UniCredit Bank AG Mainzer Landstr. 11-1760329 Frankfurt am MainGermany UniCredit Bank AGArabellastraÃŸe 1281925 MunichGermany Tel: +44 207 545 8011Attn.: Liability Management GroupTel: +39 02 8862 0581Attn.: Liability ManagementEmail: corporate.lm@unicredit.deCopies of the Tender Offer Memorandum can be requested from the Tender Agent  Kroll Issuer Services Limited  at: +44 20 7704 0880 or at nokia@is.kroll.com .DISCLAIMERThis announcement must be read in conjunction with the Tender Offer Memorandum. No offer or invitation to acquire any securities is being made pursuant to this announcement. The distribution of this announcement and the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this announcement and/or the Tender Offer Memorandum comes are required by each of Nokia  the Dealer Managers and the Tender Agent to inform themselves about  and to observe  any such restrictions.About NokiaAt Nokia  we create technology that helps the world act together.As a trusted partner for critical networks  we are committed to innovation and technology leadership across mobile  fixed and cloud networks. We create value with intellectual property and long-term research  led by the award-winning Nokia Bell Labs.Adhering to high standards of integrity and security  we help build the capabilities needed for a more productive  sustainable and inclusive world.Inquiries:NokiaCommunicationsPhone: +358 10 448 4900Email: press.services@nokia.comMaria Vaismaa  Global Head of Public RelationsNokiaInvestor RelationsPhone: +358 40 803 4080Email: investor.relations@nokia.comForward-looking statementsCertain statements herein that are not historical facts are forward-looking statements. These forward-looking statements reflect Nokia's current expectations and views of future developments and include statements regarding: A) expectations  plans  benefits or outlook related to our strategies  product launches  growth management  sustainability and other ESG targets  operational key performance indicators and decisions on market exits; B) expectations  plans or benefits related to future performance of our businesses (including the expected impact  timing and duration of COVID-19 and the general macroeconomic conditions on our businesses  our supply chain and our customersâ€™ businesses) and any future dividends and other distributions of profit; C) expectations and targets regarding financial performance and results of operations  including market share  prices  net sales  income  margins  cash flows  the timing of receivables  operating expenses  provisions  impairments  taxes  currency exchange rates  hedging  investment funds  inflation  product cost reductions  competitiveness  revenue generation in any specific region  and licensing income and payments; D) ability to execute  expectations  plans or benefits related to changes in organisational structure and operating model; E) impact on revenue with respect to litigation/renewal discussions; and F) any statements preceded by or including ""continue""  â€œbelieveâ€  â€œcommitâ€  â€œestimateâ€  â€œexpectâ€  â€œaimâ€  â€œinfluenceâ€  ""willâ€ or similar expressions. These forward-looking statements are subject to a number of risks and uncertainties  many of which are beyond our control  which could cause our actual results to differ materially from such statements. These statements are based on managementâ€™s best assumptions and beliefs in light of the information currently available to them. These forward-looking statements are only predictions based upon our current expectations and views of future events and developments and are subject to risks and uncertainties that are difficult to predict because they relate to events and depend on circumstances that will occur in the future.",neutral,0.01,0.99,0.0,mixed,0.33,0.1,0.56,True,English,"['New Notes Issue', 'Final Results', 'Tender Offers', 'Nokia', '5,000,000,000 Euro Medium Term Note Programme', 'Mid-Swap Rate Purchase Yield Purchase Price', 'UniCredit Bank AG Mainzer Landstr', 'purchase Series Acceptance Amount Pro-ration Factor', 'THE U.S. VIRGIN ISLANDS', 'Nokia Corporation Stock Exchange Release', 'rue La BoÃ©tie', 'Citigroup Global Markets Limited', 'Germany UniCredit Bank AG', 'The New Financing Condition', 'The Final Acceptance Amount', 'Interpolated Mid-Swap Rate', 'Maximum Acceptance Amount', 'NORTHERN MARIANA ISLANDS', 'U.S. PERSON', 'France Citigroup Centre', 'Deutsche Bank Aktiengesellschaft', 'Frankfurt am Main', 'The Expiration Deadline', 'Joint Dealer Managers', 'Common Code Purchase', 'aggregate nominal amount', 'Liability Management Group', 'Tender Offer Memorandum', 'BofA Securities SA', 'The Tender Offers', 'The New Notes', 'The Settlement Date', 'New Notes Issue', 'Final Results', 'new issue', 'joint bookrunners', 'SECURITIES ACT', 'Tender Agent', 'UNITED STATES', 'PUERTO RICO', 'AMERICAN SAMOA', 'WAKE ISLAND', '0,000,000 2.000 per cent', 'valid tenders', 'Accrued Interest', 'Euronext Dublin', 'full force', 'Canada Square', 'Canary Wharf', 'United Kingdom', 'ArabellastraÃŸe', 'Capitalised terms', 'London time', 'subscription agreement', 'Notes ISIN', '2024 Notes XS1577731604', 'Notes XS2171759256', '2025 Notes', '2026 Notes', '17 February', '14:30 EET', 'DISTRIBUTION', 'INTO', 'ADDRESS', 'POSSESSIONS', 'GUAM', 'DISTRICT', 'COLUMBIA', 'REGULATION', 'JURISDICTION', 'Espoo', 'Finland', '9 February', 'holders', 'invitation', 'cash', 'conditions', 'meaning', '16 February', 'table', 'respect', '10 February', 'Application', 'trading', 'issuance', 'effect', 'Investors', 'questions', 'numbers', 'Paris', 'Attn.', 'Email', 'DG.', 'LM-EMEA', 'Munich', 'Copies', 'Kroll', '4.00', '44']",2023-02-17,2023-02-18,marketscreener.com
18782,EuroNext,NewsApi.org,https://www.irishtimes.com/business/2023/02/17/healthbeacon-expects-to-hit-annual-revenues-of-25m-next-year/,HealthBeacon expects to hit annual revenues of â‚¬25m next year,Early indications are that the availability and cost pressures experienced in the first half of 2022 continue to subside,Dublin-based medical technology company HealthBeacon has said it expects to generate annual recurring revenue of â‚¬25 million by the end of the first quarter of 2024.The company  which was founded in 2013 and is led by chief executive and co-founder Jim Joyce  issued a trading update on Friday for the year ended December 31st  2022  in advance of full year results to be announced on March 31st.The group  which floated on Euronext Dublin last December  said it continued to make progress across all parts of its business throughout 2022. The company expects to achieve â€œan early to mid-teens euro revenue run rateâ€ by the end of 2023.â€œThe medium term opportunity remains significant and the company is very well positioned to grow meaningfully over the coming quarters and years â€ it said.READ MOREIt said the supply chain disruption experienced in the first half of 2022 was overcome through extensive liaison with key supply chain partners and the onboarding of new strategic suppliers to overcome component availability issues.Early indications in 2023 are that the availability and cost pressures experienced in the first half of 2022 â€œcontinue to subsideâ€.HealthBeacon recorded 14 756 technology deployments  up from 10 187 units the year before. It adjusted the guidance on 100 000 units from end of the first quarter of 2024 to the end of the second quarter of the same year.It said it continued to build out sales infrastructure with additional customers  drugs and geographies added across the specialty pharma and pharma client base. It now has 28 contracted clients  up from 23Its clients include Evernorth  the NHS  Accord Healthcare  and Clonmel Healthcare. Unit deployment with Evernorth will commence in the second quarter and ramp up significantly through the remainder of 2023.It said â€œsignificant technology deploymentsâ€ are on track to commence in the first half of this year including a â€œblockbuster drugâ€.HealthBeacon has approved projects with three of the top five specialty pharmacy organisations in the US market  which distribute medications that are complex in clinical logistics and patient management  typically indicated for chronic illnesses such as arthritis.A second and subsequent speciality pharmacy organisations will launch early in the third quarter and into the fourth quarter with unit deployment ramping up.,neutral,0.01,0.99,0.0,mixed,0.24,0.13,0.63,True,English,"['annual revenues', 'HealthBeacon', 'early to mid-teens euro revenue run rate', 'top five specialty pharmacy organisations', 'subsequent speciality pharmacy organisations', 'key supply chain partners', 'Dublin-based medical technology company', 'annual recurring revenue', 'supply chain disruption', 'medium term opportunity', 'new strategic suppliers', 'significant technology deployments', 'component availability issues', 'full year results', 'Early indications', '14,756 technology deployments', 'first quarter', 'chief executive', 'Jim Joyce', 'trading update', 'Euronext Dublin', 'coming quarters', 'first half', 'extensive liaison', 'cost pressures', 'sales infrastructure', 'additional customers', 'client base', 'Accord Healthcare', 'Clonmel Healthcare', 'Unit deployment', 'blockbuster drug', 'US market', 'clinical logistics', 'patient management', 'chronic illnesses', 'third quarter', 'fourth quarter', 'same year', 'second quarter', 'HealthBeacon', 'end', 'founder', 'Friday', 'December', 'advance', 'March', 'group', 'progress', 'parts', 'business', 'years', 'READ', 'onboarding', '10,187 units', 'guidance', '100,000 units', 'drugs', 'geographies', 'clients', 'Evernorth', 'NHS', 'remainder', 'track', 'projects', 'medications', 'arthritis', '28']",2023-02-17,2023-02-18,irishtimes.com
18783,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/VISIOMED-GROUP-SA-8235236/news/Visiomed-Group-Sa-Visiomed-Group-joins-forces-with-two-powerful-partners-to-enter-the-Saudi-ma-43015851/?utm_medium=RSS&utm_content=20230217,Visiomed Group Sa :  Visiomed Group joins forces with two powerful partners to enter the Saudi market.,(marketscreener.com)  Paris  February 16th  2023Visiomed Group   a group specializing in innovative healthcare technologies and services  has taken a new step regarding its presence in Saudi Arabia after signing of a letter of intent and entering into exclâ€¦,"Paris  February 16th  2023Visiomed Group (FR0013481835â€“ ALVMG)  a group specializing in innovative healthcare technologies and services  has taken a new step regarding its presence in Saudi Arabia after signing of a letter of intent (LOI) and entering into exclusive discussions with Abrar Communications Co. (â€œAbrarâ€) as announced in November 2022[1]. As part of this process  Visiomed Group has decided to create a joint venture with two powerful partners  Abrar and Al-Ghazzawi Group.The formation phase of the joint venture that will bring together Visiomed Group's operations in Saudi Arabia has been launched  in partnership with Abrar and Al-Ghazzawi Group. Following the recent signing of a shareholders' agreement  announced via the release of 2022 results[2]  business licenses were requested. These licenses will allow Visiomed Group to position itself in the preventive care  diagnostics and large-scale medical screening markets  key business lines already successfully developed in Dubai via Smart Salem.Industrial partners with a strong local footprint and recognized track record in supporting foreign companies establishing operations in Saudi ArabiaTo ensure a successful expansion into a new major market  Visiomed Group has made the strategic choice to join forces with two partners with a strong local presence. The initial agreement entered with Abrar has consequently been extended to Al-Ghazzawi Group.Founded in 1993  Abrar (www.abrars.co) is a leading Saudi player in the deployment and integration of technological solutions  particularly for the transportation  telecommunication  defense  and energy sectors. As an industrial partner  Abrar is recognized for its success in assisting foreign companies establishing operations in Saudi Arabia (e.g.  Thales and Motorola). The Group currently employs over 400 people in Saudi Arabia in Riyadh  Jeddah  Dammam  Madinah and Yanbu.Al-Ghazzawi Group (www.ghazzawigroup.com) is one of the largest family-owned conglomerates in Saudi Arabia operating in multiple sectors including real estate development  trading  catering  legal services  manufacturing  and telecommunication. The Group is continuously looking to invest in new projects where it can leverage its skills  experience  and expertise. Al-Ghazzawi Group sealed many partnerships with foreign companies (including Nokia) and currently employs over 1 200 people.Structure of the joint ventureThe company will be 59% owned by Visiomed Group  36% by Abrar and 5% by Al-Ghazzawi Group.Visiomed will bring its expertise in healthcare and preventive care (medical analysis  radiology  data analysis and management)  as well as its experience in the roll-out of innovative medical centers.As industrial groups with strong footprints in Saudi Arabia  Abrar and Al-Ghazzawi Group will play a key role in implementing the joint-venture through their engagement with local stakeholders (including counterparts from the healthcare  real estate  infrastructure  legal and financial sectors).During this initial incorporation phase  the company will be capitalized by its shareholders (â‚¬125k  including â‚¬74k from Visiomed Group)  prior to defining a broader financing plan  that will include funding from local banks.Strategic positioning and a first target locationThe priority segments will be Iqama Medical Tests (Medical Fitness)  health tests for insurance renewals (a market representing nearly 3.5 million tests per year in Saudi Arabia) and medical check-ups.The aim is to open a first medical center in Riyadh in 2023  located in the heart of the King Abdullah Financial District (KAFD). Now covering c. 1.6 million square meters of land and consisting of over 80 buildings  including nearly 60 office towers  KAFD is a densely populated area and represents a strategic location for Visiomed Group's entry into the Saudi market.Dr. Rafat Samman  Founder and CEO of Abrar  and Member of the Executive Board of the French-Saudi Chamber of Commerce  said: â€œAs part of our strategic development plan in the healthcare sector  finding a credible partner in the medical and diagnostics field was essential. We are honored to be part of this new company alongside our partner Visiomed Group. Visiomed Group's recent success  its strong growth in the United Arab Emirates in the Medical Fitness market and its vision around preventive care provide the basis for a promising start in Saudi Arabia. We are proud to welcome Visiomed Group to our network of industrial partners  which includes Thales and Motorola. Saudi Arabia is growing rapidly  and these partnerships enable us to play an active role in the development of our economy.â€Eng. Radwan Samman  Development Director at Abrar  said: â€œThe growing demand for medical screening and preventive care in Saudi Arabia was a key factor in our decision to expand our operations in this industry. Visiomed Group will become our strategic partner. Driven by the Ministry of Health's comprehensive plan to develop and modernize the healthcare sector  we are confident that our strategy to establish a presence in Riyadh  and subsequently in other parts of Saudi Arabia  will be a success.â€Guillaume Bremond  Visiomed Group Chairman  said: â€œEstablishing a new company in Saudi Arabia is the second phase of our expansion plan in the Middle East. We are honored to be able to launch this project alongside Abrar and Al-Ghazzawi Group  two experienced and top tier partners. The Saudi market is booming  with considerable demand for fast  digital and reliable medical services. Firstly  Saudi Arabia's population is projected to grow from 36 million in 2022 to over 50 million by 2030. Secondly  extensive investment programs are planned between now and 2030 that include over $60 billion in healthcare infrastructure investments  of which $1.5 billion invested in digital transformation  with contribution of private companies playing a key role. The expansion of Visiomed Group into Saudi Arabia was therefore a natural step.â€Visiomed Group CEO Thomas Picquette said: â€œWe are delighted to cement our collaboration in Saudi Arabia with two prestigious industrial partners. The combined expertise of our respective groups will be a powerful asset to address this dynamic market  which is driven by a desire to make the best preventive care and healthcare services available for everyone. All our teams are now working actively to ensure a swift implementation of our development plan and vision in Saudi Arabia.â€Visiomed Group will keep the market regularly informed of the progress of this new strategic venture.About VISIOMED GROUPFounded in 2007  VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.The Group now has two subsidiaries and holdings:Smart Salem  the first digital medical analysis center accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates  100% owned by Visiomed Group.The Smart Salem offer is based on know-how in medical analysis  radiology and data analysis and processing to detect nearly 35 diseases in 7 minutes in a patient (in particular HIV  hepatitis and tuberculosis) by offering reliable results  readability and exceptional patient experience enabled by advanced artificial intelligence and virtual reality technologies.Smart Salem's â€œMedical Fitness Assessmentâ€ offer resulting from this know-how thus makes it possible to obtain a residence or work visa in the space of 30 minutes compared to 10 to 15 days in historical health centers.Smart Salem is a technological platform offering many growth opportunities  as shown by the opening of the second center in Dubai in September 2022 and the authorization received for the opening of a third center  planned to open in the first quarter of 2023.Bewellthy  created in 2022  a leading player in connected health and teleconsultation solutions and is 49.88% owned by Visiomed Group.Bewellthy offers an enriched technological universe combining medical devices  software and ""health and well-being concierge"" services to meet all the needs and use cases of telehealth.Bewellthy's flagship product  VisioCheck  is the 1st telemedicine station weighing less than 300g for healthcare professionals  available as a case  station or modular healthcare space.Bewellthy is now deploying its solutions and services in France and abroad  particularly in Italy and the USA.Based in Paris  VISIOMED GROUP is listed on Euronext Growth (ALVMG). More information on www.visiomed-group.com.CONTACTSJÃ©rÃ´me FABREGUETTES-LEIB Fatou-KinÃ© N'DIAYE Investor Relations Financial Press Relations visiomed@actus.fr fndiaye@actus.fr Phone: +33 1 53 67 36 78 Phone: +33 1 53 67 36 75Â© Visiomed Group SA 2023. The brands mentioned are the property of their respective authors. Reproduction prohibited  even partial  without prior authorization.[1] Visiomed Group enters into exclusive discussions with Abrar Communications Co. to tap the Saudi market[2] Record year 2022 marked by exceptional growth (99%)  positive normalized EBITDA and strategic decisions opening up great prospects for 2023This publication embed ""ðŸ”’ Actusnews SECURITY MASTER "".- SECURITY MASTER Key: lpibYJlok5fFmG9vZ8hmaWJlbpdpxpKVaWnJk2NsaZyVaJ9hxZxnbsrHZnBpm2lm- Check this key: https://www.security-master-key.com.Regulated information:Inside Information:- Operations of the issuer (acquisitions  salesÃƒÂ¢Ã‚Â€Ã‚Â¦) Full and original press release in PDF: https://www.actusnews.com/news/78640-alvmg_cp_point_etape_ksa_ven.pdfReceive by email the next press releases of the company by registering on www.actusnews.com  it's freeÂ© 2023 ActusNews",neutral,0.01,0.99,0.0,positive,0.77,0.22,0.0,True,English,"['two powerful partners', 'Visiomed Group Sa', 'Saudi market', 'forces', 'King Abdullah Financial District', 'large-scale medical screening markets', 'largest family-owned conglomerates', 'Dr. Rafat Samman', 'United Arab Emirates', 'Eng. Radwan Samman', 'broader financing plan', 'innovative medical centers', 'first target location', 'first medical center', '1.6 million square meters', 'leading Saudi player', 'strong local footprint', 'initial incorporation phase', 'key business lines', 'Iqama Medical Tests', 'innovative healthcare technologies', 'two powerful partners', 'new major market', 'real estate development', 'Medical Fitness market', 'strategic development plan', 'Abrar Communications Co.', 'strong local presence', 'financial sectors', '3.5 million tests', 'two partners', 'strategic location', 'comprehensive plan', 'formation phase', 'initial agreement', 'abrars.co', 'medical analysis', 'strong footprints', 'local stakeholders', 'local banks', 'medical check-ups', 'strong growth', 'key role', 'key factor', 'Saudi market', 'new step', 'Industrial partners', 'new projects', 'Development Director', 'strategic choice', 'Strategic positioning', 'Saudi Arabia', 'exclusive discussions', 'joint venture', 'recent signing', 'business licenses', 'preventive care', 'Smart Salem', 'track record', 'foreign companies', 'successful expansion', 'technological solutions', 'energy sectors', 'multiple sectors', 'data analysis', 'industrial groups', 'priority segments', 'insurance renewals', '60 office towers', 'Executive Board', 'French-Saudi Chamber', 'promising start', 'active role', 'growing demand', 'Al-Ghazzawi Group', 'The Group', 'Visiomed Group', 'health tests', 'healthcare sector', 'strategic partner', 'new company', ""shareholders' agreement"", 'many partnerships', 'diagnostics field', 'recent success', 'legal services', 'Paris', 'February', 'ALVMG', 'letter', 'intent', 'LOI', 'November', 'process', 'operations', 'release', 'Dubai', 'forces', 'deployment', 'integration', 'transportation', 'telecommunication', 'defense', 'Thales', 'Motorola', '400 people', 'Riyadh', 'Jeddah', 'Dammam', 'Madinah', 'Yanbu', 'ghazzawigroup', 'trading', 'manufacturing', 'skills', 'experience', 'expertise', 'Nokia', '1,200 people', 'Structure', 'radiology', 'management', 'roll-out', 'joint-venture', 'engagement', 'counterparts', 'funding', 'year', 'aim', 'heart', 'KAFD', 'c.', 'land', '80 buildings', 'area', 'entry', 'Founder', 'CEO', 'Member', 'Commerce', 'vision', 'basis', 'network', 'economy', 'decision', 'industry', 'Ministry', 'strategy']",2023-02-17,2023-02-18,marketscreener.com
18784,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/02/17/2610572/0/en/Nokia-Announces-Final-Results-for-its-Tender-Offers-and-the-New-Notes-Issue.html,Nokia Announces Final Results for its Tender Offers and the New Notes Issue,Nokia CorporationStock Exchange Release17 February 2023 at 14:30 EET          NOT FOR RELEASE  PUBLICATION OR DISTRIBUTION IN OR INTO  OR TO ANY PERSON......,"English FinnishNokia CorporationStock Exchange Release17 February 2023 at 14:30 EETNOT FOR RELEASE  PUBLICATION OR DISTRIBUTION IN OR INTO  OR TO ANY PERSON LOCATED OR RESIDENT IN OR AT ANY ADDRESS IN  THE UNITED STATES OF AMERICA  ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO  THE U.S. VIRGIN ISLANDS  GUAM  AMERICAN SAMOA  WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS)  ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO.Nokia Announces Final Results for its Tender Offers and the New Notes IssueEspoo  Finland â€“ Nokia Corporation (â€œNokiaâ€)  announced on 9 February 2023 that it has separately invited holders of each Series of the Notes (as defined below) issued under Nokia's EUR 5 000 000 000 Euro Medium Term Note Programme (each such invitation a â€œTender Offerâ€ and  together  the â€œTender Offersâ€) to tender their EUR 750 000 000 2.000 per cent. Notes due 15 March 2024 (the â€œ2024 Notesâ€)  EUR 500 000 000 2.375 per cent. Notes due 15 May 2025 (the â€œ2025 Notesâ€) and EUR 750 000 000 2.000 per cent. Notes due 11 March 2026 (the â€œ2026 Notesâ€ and  together with the 2024 Notes and the 2025 Notes  the ""Notes"" and each a ""Seriesâ€) for purchase for cash up to the Maximum Acceptance Amount (as defined in the Tender Offer Memorandum).The Tender Offers were made on the terms and subject to the conditions set out in the tender offer memorandum dated 9 February 2023 (the â€œTender Offer Memorandumâ€). Capitalised terms not defined herein have the meaning ascribed to them in the Tender Offer Memorandum.The Expiration Deadline for the Tender Offers was 4.00 p.m. (London time) on 16 February 2023.Nokia hereby informs Noteholders that set out in the table below is: (i) each Series Acceptance Amount; (ii) the aggregate nominal amount of Notes tendered for purchase pursuant to each Tender Offer; (iii) each Purchase Yield; (iv) each Interpolated Mid-Swap Rate; (v) each Purchase Price; (vi) the pro-ration factor that will be applied to valid tenders of Notes of each Series; and (vii) the aggregate nominal amount of each Series of the Notes that remain outstanding following settlement of the Tender Offers.Notes ISIN / Common Code Purchase Spread Interpolated Mid-Swap Rate Purchase Yield Purchase Price Aggregate nominal amount tendered for purchase Series Acceptance Amount Pro-ration Factor Aggregate nominal amount that remain outstanding following settlement 2024 Notes XS1577731604 / 157773160 -35 bps 3.588% 3.238%% 98.728% EUR 372 472 000 EUR 372 472 000 100% EUR 377 528 000 2025 Notes XS2171759256 / 217175925 +5 bps 3.530% 3.580% 97.456% EUR 207 843 000 EUR 207 843 000 100% EUR 292 157 000 2026 Notes XS1960685383 / 196068538 +25 bps 3.395% 3.645% 95.331% EUR 256 879 000 EUR 119 685 000 approximately 43.513% EUR 630 315 000The Final Acceptance Amount is EUR 700 000 000.Nokia will also pay Accrued Interest in respect of the Notes purchased pursuant to the Tender Offers.On 10 February 2023  Nokia priced a new issue of â‚¬500 000 000 4.375 per cent. Notes due 21 August 2031 (the â€œNew Notesâ€). Application will be made for the New Notes to be admitted to listing and trading on Euronext Dublin.The New Financing Condition has been satisfied  subject to the issuance of the New Notes. The New Notes have been priced and a subscription agreement between Nokia and the joint bookrunners named therein for the purchase of  and subscription for  the New Notes has been signed and remains in full force and effect as of the date hereof.The Settlement Date for the Tender Offers and the New Notes is expected to be 21 February 2023.Notes purchased by Nokia pursuant to the Tender Offers will be immediately cancelled. Notes which have not been validly submitted and accepted for purchase pursuant to the Tender Offers will remain outstanding after the Settlement Date.The Tender Offers have now expired and no further Notes can be tendered for purchase.Joint Dealer ManagersBofA Securities SA  Citigroup Global Markets Limited  Deutsche Bank Aktiengesellschaft and UniCredit Bank AG (the â€œJoint Dealer Managersâ€) are acting as Joint Dealer Managers for the Tender Offers. Investors with questions may contact the Joint Dealer Managers at the addresses and numbers shown below.BofA Securities SA Citigroup Global Markets Limited 51  rue La BoÃ©tie75008 ParisFrance Citigroup CentreCanada SquareCanary WharfLondon E14 5LBUnited Kingdom Tel.: +33 1 877 01057Attn.: Liability Management GroupEmail: DG.LM-EMEA@bofa.com Tel: +44 20 7986 8969Attn.: Liability Management GroupEmail: liabilitymanagement.europe@citi.com Deutsche Bank Aktiengesellschaft UniCredit Bank AG Mainzer Landstr. 11-1760329 Frankfurt am MainGermany UniCredit Bank AGArabellastraÃŸe 1281925 MunichGermany Tel: +44 207 545 8011Attn.: Liability Management GroupTel: +39 02 8862 0581Attn.: Liability ManagementEmail: corporate.lm@unicredit.deCopies of the Tender Offer Memorandum can be requested from the Tender Agent  Kroll Issuer Services Limited  at: +44 20 7704 0880 or at nokia@is.kroll.com .DISCLAIMERThis announcement must be read in conjunction with the Tender Offer Memorandum. No offer or invitation to acquire any securities is being made pursuant to this announcement. The distribution of this announcement and the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this announcement and/or the Tender Offer Memorandum comes are required by each of Nokia  the Dealer Managers and the Tender Agent to inform themselves about  and to observe  any such restrictions.About NokiaAt Nokia  we create technology that helps the world act together.As a trusted partner for critical networks  we are committed to innovation and technology leadership across mobile  fixed and cloud networks. We create value with intellectual property and long-term research  led by the award-winning Nokia Bell Labs.Adhering to high standards of integrity and security  we help build the capabilities needed for a more productive  sustainable and inclusive world.Inquiries:NokiaCommunicationsPhone: +358 10 448 4900Email: press.services@nokia.comMaria Vaismaa  Global Head of Public RelationsNokiaInvestor RelationsPhone: +358 40 803 4080Email: investor.relations@nokia.comForward-looking statementsCertain statements herein that are not historical facts are forward-looking statements. These forward-looking statements reflect Nokia's current expectations and views of future developments and include statements regarding: A) expectations  plans  benefits or outlook related to our strategies  product launches  growth management  sustainability and other ESG targets  operational key performance indicators and decisions on market exits; B) expectations  plans or benefits related to future performance of our businesses (including the expected impact  timing and duration of COVID-19 and the general macroeconomic conditions on our businesses  our supply chain and our customersâ€™ businesses) and any future dividends and other distributions of profit; C) expectations and targets regarding financial performance and results of operations  including market share  prices  net sales  income  margins  cash flows  the timing of receivables  operating expenses  provisions  impairments  taxes  currency exchange rates  hedging  investment funds  inflation  product cost reductions  competitiveness  revenue generation in any specific region  and licensing income and payments; D) ability to execute  expectations  plans or benefits related to changes in organisational structure and operating model; E) impact on revenue with respect to litigation/renewal discussions; and F) any statements preceded by or including ""continue""  â€œbelieveâ€  â€œcommitâ€  â€œestimateâ€  â€œexpectâ€  â€œaimâ€  â€œinfluenceâ€  ""willâ€ or similar expressions. These forward-looking statements are subject to a number of risks and uncertainties  many of which are beyond our control  which could cause our actual results to differ materially from such statements. These statements are based on managementâ€™s best assumptions and beliefs in light of the information currently available to them. These forward-looking statements are only predictions based upon our current expectations and views of future events and developments and are subject to risks and uncertainties that are difficult to predict because they relate to events and depend on circumstances that will occur in the future.",neutral,0.01,0.99,0.0,mixed,0.34,0.15,0.51,True,English,"['New Notes Issue', 'Final Results', 'Tender Offers', 'Nokia', '5,000,000,000 Euro Medium Term Note Programme', 'Mid-Swap Rate Purchase Yield Purchase Price', 'UniCredit Bank AG Mainzer Landstr.', 'THE U.S. VIRGIN ISLANDS', 'Nokia Corporation Stock Exchange Release', 'rue La BoÃ©tie', 'Citigroup Global Markets Limited', 'Germany UniCredit Bank AG', 'The New Financing Condition', 'The Final Acceptance Amount', 'Interpolated Mid-Swap Rate', 'purchase Series Acceptance Amount', 'NORTHERN MARIANA ISLANDS', 'U.S. PERSON', 'France Citigroup Centre', 'Maximum Acceptance Amount', 'Deutsche Bank Aktiengesellschaft', 'Frankfurt am Main', 'The Expiration Deadline', 'aggregate nominal amount', 'Joint Dealer Managers', 'Common Code Purchase', 'Liability Management Group', 'Tender Offer Memorandum', 'EUR 750,000,000 2.000 per cent', 'BofA Securities SA', 'The Tender Offers', 'The New Notes', 'The Settlement Date', 'New Notes Issue', 'Final Results', 'new issue', 'joint bookrunners', 'SECURITIES ACT', 'English Finnish', 'UNITED STATES', 'PUERTO RICO', 'AMERICAN SAMOA', 'pro-ration factor', 'valid tenders', 'Accrued Interest', 'Euronext Dublin', 'full force', 'Canada Square', 'Canary Wharf', 'United Kingdom', 'ArabellastraÃŸe', 'Capitalised terms', 'London time', 'subscription agreement', 'Notes ISIN', '2024 Notes XS1577731604', 'Notes XS2171759256', '2025 Notes', '2026 Notes', '17 February', '14:30 EET', 'DISTRIBUTION', 'INTO', 'ADDRESS', 'POSSESSIONS', 'GUAM', 'WAKE', 'DISTRICT', 'COLUMBIA', 'REGULATION', 'JURISDICTION', 'Espoo', 'Finland', '9 February', 'holders', 'invitation', 'cash', 'conditions', 'meaning', '16 February', 'table', 'respect', '10 February', 'Application', 'trading', 'issuance', 'effect', 'Investors', 'questions', 'numbers', 'Paris', 'Attn.', 'Email', 'DG.', 'LM-EMEA', 'Munich', 'Copies', '4.00', '44']",2023-02-17,2023-02-18,globenewswire.com
18785,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/VALNEVA-SE-54466/news/Pfizer-and-Valneva-Issue-Update-on-Phase-3-Clinical-Trial-Evaluating-Lyme-Disease-Vaccine-Candidate-43013654/?utm_medium=RSS&utm_content=20230217,Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15,(marketscreener.com) New York & Saint-Herblain   February 17  2023 â€“ Pfizer Inc. and Valneva SE today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccâ€¦,"New York & Saint-Herblain (France)  February 17  2023 â€“ Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer  as the study sponsor  has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy  safety and immunogenicity of an investigational Lyme disease vaccine candidate  VLA15. These study participants  representing approximately half of the total recruited participants in the trial  are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator. The discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event.GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. These standards are designed to put participantsâ€™ interests first and ensure high scientific integrity. Once Pfizer learned of potential violations of GCP  it conducted a thorough review of the operations and data collection at the clinical trial sites run by the third party and followed standard operating safeguards to determine the correct course of action.The clinical trial remains ongoing with other sites not operated by the third party  and Pfizer continues to enroll new participants at those sites. The companies intend to work with regulatory authorities  and as previously announced 1 2 aim for Pfizer to potentially submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025  pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan.Participants are being notified and Pfizer has also notified the FDA  other regulatory agencies and the independent Institutional Review Board for this study.Integrity of data collected in clinical trials is critical to provide evidence and confidence in a potential vaccine or medicineâ€™s safety and efficacy. Pfizer and Valneva are committed to collecting robust data needed for potential regulatory submission of VLA15. While VLA15 is still under investigation  to date the companies have been encouraged by the data from the Phase 2 clinical studies  which demonstrated strong immunogenicity and acceptable safety and tolerability profiles.2-4About VLA15VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi  the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. Blocking OspA inhibits the bacteriumâ€™s ability to leave the tick and infect humans. The vaccine covers the six most common OspA serotypes expressed by the Borrelia burgdorferi sensu lato species that are prevalent in North America and Europe. VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA15  with updates to the terms within this agreement made in June 2022.5 6 The program was granted Fast Track designation by the U.S. FDA in July 2017.7About Lyme DiseaseLyme disease is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks.8 It is considered the most common vector-borne illness in the Northern Hemisphere.9 While the true incidence of Lyme disease is unknown  it is estimated to annually affect approximately 476 000 people in the United States and 130 000 people in Europe.10 11 Early symptoms of Lyme disease (such as a gradually expanding erythematous rash called Erythema migrans or more nonspecific symptoms like fatigue  fever  headache  mild stiff neck  arthralgia or myalgia) are often overlooked or misinterpreted. Left untreated  the disease can disseminate and cause more serious complications affecting the joints (arthritis)  the heart (carditis) or the nervous system.12 The medical need for vaccination against Lyme disease is steadily increasing as the geographic footprint of the disease widens.10About Pfizer: Breakthroughs That Change Patientsâ€™ LivesAt Pfizer  we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality  safety and value in the discovery  development and manufacture of health care products  including innovative medicines and vaccines. Every day  Pfizer colleagues work across developed and emerging markets to advance wellness  prevention  treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies  we collaborate with health care providers  governments and local communities to support and expand access to reliable  affordable health care around the world. For more than 170 years  we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition  to learn more  please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News  LinkedIn  YouTube and like us on Facebook at Facebook.com/Pfizer.Pfizer Disclosure NoticeThe information contained in this release is as of February 17  2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.This release contains forward-looking information about an investigational Lyme disease vaccine candidate  VLA15  and a collaboration between Pfizer and Valneva for VLA15  including their potential benefits  VALOR  a Phase 3 clinical study investigating the efficacy  safety and immunogenicity of VLA15  and the timing of potential regulatory submissions  that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include  among other things  the uncertainties inherent in research and development  including the ability to meet anticipated clinical endpoints  commencement and/or completion dates for our clinical trials  regulatory submission dates  regulatory approval dates and/or launch dates  including uncertainties relating to the time needed to recruit and enroll participants  and accrue cases in the Phase 3 trial  and uncertainties relating to an agreement with regulatory authorities on any modifications to the clinical trial plan as needed  as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for VLA15; whether and when any such applications may be approved by regulatory authorities  which will depend on myriad factors  including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and  if approved  whether VLA15 will be commercially successful; decisions by regulatory authorities impacting labeling  manufacturing processes  safety and/or other matters that could affect the availability or commercial potential of VLA15; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; whether our collaboration with Valneva will be successful; uncertainties regarding the impact of COVID-19 on Pfizerâ€™s business  operations and financial results; and competitive developments.A further description of risks and uncertainties can be found in Pfizerâ€™s Annual Report on Form 10-K for the fiscal year ended December 31  2021 and in its subsequent reports on Form 10-Q  including in the sections thereof captioned â€œRisk Factorsâ€ and â€œForward-Looking Information and Factors That May Affect Future Resultsâ€  as well as in its subsequent reports on Form 8-K  all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.About Valneva SEValneva is a specialty vaccine company focused on the development  manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic  including candidates against the chikungunya virus and Lyme disease.Valneva Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva  including with respect to the progress and recruitment of clinical trials  discussions with regulatory agencies  modifications to clinical trial plans  results of clinical trials  and timing for filing for potential regulatory approval of product candidates. In addition  even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release  those results or developments of Valneva may not be sustained in the future. In some cases  you can identify forward-looking statements by words such as ""could "" ""should "" ""may "" ""expects "" ""anticipates "" ""believes "" ""intends "" ""estimates "" ""aims "" ""targets "" or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results  performance or achievements to be materially different from any future results  performance or achievement expressed or implied by these forward-looking statements. In particular  the expectations of Valneva could be affected by  among other things  uncertainties involved in the development and manufacture of vaccines  unexpected clinical trial results or delays  unexpected regulatory actions or delays  competition in general  currency fluctuations  the impact of the global and European credit crisis  and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties  there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release and disclaim any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events  or otherwise.Media ContactsPfizerMedia Relations:PfizerMediaRelations@pfizer.com212-733-1226Investor Relations:IR@pfizer.com212-733-4848ValnevaLaÃ«titia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 7099laetitia.bachelot-fontaine@valneva.comJoshua Drumm  Ph.D.VP Global Investor RelationsM +1 917 815 4520joshua.drumm@valneva.comReferencesPfizer. Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15. August 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease. Accessed: February 2023. Valneva. Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate. December 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-six-month-antibody-persistence. Accessed: February 2023 Valneva. Valneva Pfizer Report Positive Phase 2 Pediatric Data for Lyme Vaccine Candidate. April 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-report-positive-phase-2-pediatric-data-for-lyme-disease-vaccine-candidate/ Accessed: July 2022. Valneva. Valneva Pfizer Report Positive Phase 2 Data for Lyme Disease Vaccine Candidate. February 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-report-further-positive-phase-2-data-for-lyme-disease-vaccine-candidate/ Accessed: July 2022. Valneva. Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine  VLA15. April 2020. Available at: https://valneva.com/press-release/valneva-and-pfizer-announce-collaboration-to-co-develop-and-commercialize-lyme-disease-vaccine-vla15/ Accessed: July 2022 . Valneva. Valneva and Pfizer Enter into Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15. June 2022. Available at: https://valneva.com/press-release/valneva-and-pfizer-enter-into-an-equity-subscription-agreement-and-update-terms-of-collaboration-agreement-for-lyme-disease-vaccine-candidate-vla15/ Accessed: July 2022. Valneva. Valneva Receives FDA Fast track Designation for its Lyme Disease Vaccine Candidate VLA15. July 2017. Available at: https://valneva.com/press-release/valneva-receives-fda-fast-track-designation-for-its-lyme-disease-vaccine-candidate-vla15/ Accessed: July 2022. Stanek G  Wormser GP  Gray J  et al. Lyme borreliosis. Lancet. 2012; 4;379(9814):461-73. Gern L  Falco RC. Lyme disease. Rev Sci Tech. 2000 Apr;19(1):121-35. Center for Disease Control and Prevention. Lyme Disease. Data and Surveillance. April 2021. Available at: https://www.cdc.gov/lyme/datasurveillance/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Flyme%2Fstats%2Findex.html Accessed July 2022. Sykes RA  et al. An estimate of Lyme borreliosis incidence in Western Europe. Journal of Public Health 2017; 39(1): 74-81 Center for Disease Control and Prevention. Lyme Disease. Signs and Symptoms of Untreated Lyme disease. January 2021. Available at: https://www.cdc.gov/lyme/signs_symptoms/index.html Accessed July 2022.Attachment",neutral,0.0,0.97,0.03,mixed,0.3,0.11,0.59,True,English,"['Lyme Disease Vaccine Candidate VLA15', 'Valneva Issue Update', 'Phase 3 Clinical Trial', 'Pfizer', 'six most common OspA serotypes', 'Borrelia burgdorferi sensu lato species', 'investigational multivalent protein subunit vaccine', 'third-party clinical trial site operator', 'investigational Lyme disease vaccine candidate', 'independent Institutional Review Board', 'outer surface protein A', 'participant-reported adverse event', 'Biologics License Application', 'Marketing Authorisation Application', 'Fast Track designation', 'expanding erythematous rash', 'mild stiff neck', 'health care products', 'Good Clinical Practice', 'clinical trial plan', 'European Medicines Agency', 'strong immune response', 'standard operating safeguards', 'Borrelia burgdorferi bacteria', 'U.S. Food', 'high scientific integrity', 'potential regulatory submission', 'clinical trial sites', 'Phase 2 clinical studies', 'satisfactory safety profile', 'other regulatory agencies', 'scientific quality standard', 'Phase 3 clinical study', 'U.S. FDA', 'investigational vaccine', 'potential vaccine', 'thorough review', 'Phase 3 studies', 'other sites', 'clinical trials', 'clinical researchers', 'regulatory authorities', 'innovative medicines', 'clinical development', 'New York', 'Euronext Paris', 'significant percentage', 'Outdoor Recreationists', 'international ethical', 'third party', 'correct course', 'Drug Administration', 'successful completion', 'strong immunogenicity', 'tolerability profiles', 'North America', 'systemic infection', 'Ixodes ticks', 'vector-borne illness', 'Northern Hemisphere', 'true incidence', 'United States', 'Early symptoms', 'nonspecific symptoms', 'serious complications', 'nervous system', 'medical need', 'geographic footprint', 'global resources', 'emerging markets', 'potential violations', 'study sponsor', 'safety concerns', 'acceptable safety', 'data collection', 'robust data', 'participantsâ€™ interests', 'new participants', 'Valneva SE', 'collaboration agreement', 'study participants', 'Pfizer Inc.', 'Pfizer colleagues', 'Saint-Herblain', 'France', 'February', 'PFE', 'Nasdaq', 'VLA', 'VALOR', 'efficacy', 'half', 'GCP', 'discontinuation', 'standards', 'operations', 'action', 'companies', 'MAA', 'modifications', 'evidence', 'confidence', 'mechanism', 'humans', 'pre-clinical', 'April', 'updates', 'terms', 'June', 'program', 'July', '476,000 people', '130,000 people', 'fatigue', 'fever', 'headache', 'arthralgia', 'myalgia', 'joints', 'arthritis', 'heart', 'carditis', 'vaccination', 'Breakthroughs', 'Lives', 'science', 'value', 'discovery', 'manufacture', 'vaccines']",2023-02-17,2023-02-18,marketscreener.com
18786,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/CABKA-N-V-115395161/news/Cabka-N-Half-Year-Report-2022-43020371/?utm_medium=RSS&utm_content=20230217,Cabka N : Half Year Report 2022,(marketscreener.com)   Cabka N.V.   Amsterdam   Interim Report   &   Unaudited interim condensed   consolidated financial statements   first six months   of 2022   Cabka N.V. | 2022HY Interim...https://www.marketscreener.com/quote/stâ€¦,Cabka N : Half Year Report 2022 02/17/2023 | 10:06am EST Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields Cabka N.V. Amsterdam Interim Report & Unaudited interim condensed consolidated financial statements first six months of 2022 Cabka N.V. | 2022HY Interim Report | Page 1 of 32 Company Statement Introduction to the first six months of Cabka N.V. in 2022 This half-year report is the first of its kind published by Cabka N.V. (Cabka) marking the transformation of Cabka from a privately owned company to a listed company following the support of 100% of Dutch Star Companies TWO B.V. (DSC2) shareholders for a business combination of Cabka Group GmbH and DSC2 into Cabka N.V. and subsequent listing on Euronext Amsterdam  on 1 March 2022. This report covers all operations of Cabka N.V. as of 1 January 2022 so retroactive from listing on 1 March 2022. Governance As a result of the listing governance of Cabka changed significantly to meet the requirements as a listed company. A two-tier Board was installed with a Management Board consisting of Mr. Tim Litjens CEO and Mr. Necip KÃ¼pcÃ¼ CFO as well as a Supervisory Board of six members: Mr. Manuel Beja (Chair) Mr. Gat Ramon (Vice-Chair)  Mr. Niek Hoek (Vice-Chair)  Mrs. Tova Posner Henkin  Mrs. Jeanine Holscher  and Mr. Stephan Nanninga. Of the supervisory board members Messrs. Ramon  Hoek and Nanninga are not considered independent in accordance with the Dutch Corporate Governance Code. Mr. Ã–zgÃ¼r Yildirim is the corporate secretary for both the Management Board and Supervisory Board. The Board of Management is further supported by a Management Team including Mr. Geert de Wilde as Chief Operations Officer  Mr. Jean-Marc van Maren as Chief Product Development Officer  and as of 1 July 2022 Mr. Wouter van der Woerd as Chief People officer responsible for HR and organizational development. Financial and operational performance first six months of 2022 The first half of 2022 was dominated by the Russian invasion of Ukraine on 24 February and its subsequent impact on social and economic developments as well as financial markets. Although Cabka had no direct exposure to the Ukraine  Russia or Belarus  indirect impact was significant. First and foremost  as energy and material prices increased unprecedentedly leading to significantly higher costs for energy and materials. Cabka is leading the industry in pricing and has achieved several price increases to compensate for the higher input costs. Nevertheless  despite compensation in pricing the higher production costs led to at least a temporarily margin pressure due to delays in passing on increased costs to customers as well as lower margins as (energy and material) costs now represent a higher fraction of total revenues. On the other hand  as lumber prices and supplies are far more impacted than plastics  the relative competitive position of plastic pallets and large containers improved. Overall  we have seen exceptionally strong commercial results showing high demand for our products that continued throughout the half year leading to strong sales over the period of EUR 102.2 million (up 27% YoY). Various rounds of price increases and indexation covered rapidly rising costs for energy and materials (albeit with a delay)  accounting for a total favorable price effect of 15% Year-on-Year. The remaining 40% of the increase was based on organic growth especially from customized solutions underlining Cabka's focus on key strategic objectives. The US-business with large containers was highly successful with a multi-year contract with Target bringing in significant revenues as of the third quarter 2022. Also  the European large container market looks promising as reflected in the new contracts with  among others  BMW and a leading material handling company starting up production in Q3 of 2022 but only resulting in new sales in the first half of next year. Although Cabka has been able to compensate most of its higher costs through its product prices  the steep rise over a short period had bottom line impact (albeit partly temporarily due to a delay in translating higher costs into price increases). With an additional price increase of 5% announced early July for 1 August  pricing should be at par with costs at that moment and providing no extreme increases going further. In order to be able to react more dynamically to Cabka N.V. | 2022HY Interim Report | Page 2 of 32 the currently highly volatile conditions in the energy and material market  an indexed pricing adjustment mechanism has been introduced as a prerequisite for all new contracts. The increase in sales and ability to translate cost increases into product prices clearly reflects the resilient and strong market position of Cabka. In addition  Cabka was able to partly mitigate impact of the shortage and price increase of materials as Cabka sources a high amount of feed stock (up to 70%) from internal production recycling activities. However  due to lagging in time as well as an overall higher cost base  margins are affected at least in the short-term. The restructuring of the Eco business with the closure of Genthin and shift to Weira is set to additionally improve long-term profitability albeit having a temporarily negative operational impact of EUR 0.8 million in the second quarter of 2022. This was mainly triggered by the temporary shutdown of production to facilitate the move  which conclusively reduced the intake of mixed plastics. However  this effect is expected to be offset in the second half of the year as economies of scale and increase of additional processing capacities should result in a higher output. Overall  the 27% increase in total revenues over the first half year compared to the same period of 2021 could not fully compensate the 67% increase in the costs for materials  energy and purchased services resulting in just a EUR 5 million higher gross profit at EUR 47.3 million (2021HY: EUR 42.3 million) and a lower relative gross margin (gross profit/sales) down to 46.3% from 52.4% in 2021HY. Overall management is positive on top line development and absolute margins  however  long- term impact on the relative margins is highly depending on the development of costs for energy and materials and the probability of returning to the levels of previous years. To improve margins management closely followed market developments and the opportunity to translate cost inflation in prices. In addition  several actions were initiated primarily focused to reduce costs with a target of 10% for this year and local management requested to also allow for bottom-up initiatives to drive local costs down. Given the current markets Cabka is shifting its own production facilities to higher added value (customized) products and using tollers as much as possible for more standardized products. EBITDA Group EBITDA excluding extraordinary items came in at EUR 13.1 million (2021HY: EUR 14.7 million). This result primarily reflects the trends underlying the development in revenue and gross profit. The latter is affected especially as due to lag in price increases some EUR 1.2 million in higher energy costs over the first quarter 2022 could not be recovered. Further a lower intake of mixed plastics due to the physical consolidation led to missing revenues in the Eco Products business of EUR 0.8 million in the second quarter of the year. Additionally  higher production and revenues in the first half year 2022 (+27%) resulted in higher personnel and operating expenses versus the comparable period in prior year. Salary and wage adjustments in the entire Group were made beginning of the second quarter to compensate inflationary developments. The table below compares the buildup of EBITDA excluding extraordinary items as reported earlier based on German GAAP to the current IFRS based figures. Buildup EBITDA from German GAAP to IFRS 2022 HY 2021 HY in EURk EBITDA German GAAP 12 217 13 555 IFRS 16 (leasing) 1 555 1 487 IFRS 15 (revenue recognition) 3 113 Share based payment expense (PS/PSU) -220 0 Reclassification other taxes in expenses -495 -418 EBITDA IFRS 13 060 14 737 Cabka N.V. | 2022HY Interim Report | Page 3 of 32 Cash flows and cash position The first half-year saw a lower cash conversion as absolute Net Working Capital was higher than usual at EUR 38.8 million or 20.3%1 (HY 2021: 18.7%) although still within the mid-term guidance of approximately 20%. Higher requirements for working capital were mainly driven by inflation as higher product pricing leads to higher inventory value and higher receivables. Nevertheless  actions were taken to improve the NWC position which is expected to normalize in line with the supply side. Cash flows from operating activities came in at EUR -11.0 million  predominantly by the increase of Net Working Capital by EUR 11.4 million. Based on higher demand for products in the first half year 2022 the trade account receivables increased by EUR 2.6 million and the inventories by EUR 8.6 million. The latter is caused by producing certain customer demands on stock  but also by inflation. Additionally  some of the raw materials were secured at still decent cost prices versus market developments. Trade account payables were reduced by EUR 0.2 million. The other non-cash transactions are including primarily the value change of warrants EUR 3.5 million and change in share-based programs EUR 1.5 million besides other non-cash items. Cash flows from investing activities totaling EUR 32.8 million are including sale of assets EUR 0.7 million  investments for growth  maintenance  and replacement EUR 10.9 million  intangible asset of EUR 0.2 million  US minority shares EUR 1.8 million and the cash injection from the Business combination of EUR 45.2 million. Cash flows from financing activities combined from repayments and receipt are totaling EUR 4.7 million. The changes in cash and cash equivalents result in a cash position of EUR 36.5 million. CAPEX Group CAPEX for first six months of 2022 came in at EUR 13 million including the acquisition of minority shares of the US subsidiary totaling EUR 1.8 million. The remaining investments mainly account for ECO Restructuring and new molds (EUR 8.7 million). Maintenance and replacement CAPEX is at EUR 2.4 million or with 2.3% of revenues in line with then mid-term guidance (app. 4%) also due to the significant increase in revenues. Commercial performance The first half of 2022 showed record sales of EUR 102.2 million a 27% increase over the same period last year. Growth was especially strong in reusable transport packaging (RTP)  whereas RTP US up 49% to EUR 15.0million as well in customized solutions and contract manufacturing in Europe  up respectively 40% to EUR 18.7 million and 46% to EUR 20.3 million. The increase of European RTP portfolio to EUR 32.6 million was approximately in line with the regular price increases  while ECO products temporarily shrunk by 6% as a result of the relocation of activities to Weira. The geographical spread of sales did not significantly change in the first half-year except for sales in the US that showed a very strong increase by 50% to EUR 15 million (2021HY: EUR 10 million). Average daily order intake in first half-year 2022 was up 36% compared to same period last year  with especially high order intake for June as a result of the new multi-year Target contract. Strategic progress Cabka has made substantial progress with regard to its strategic objectives. With major long- term commercial contracts  the company is underlining its focus on providing highly customized solutions and is growing its footprint in the large container segment. Actual NWC includes liabilities for invoices to be received in trade payables under IFRS  corresponding NWC under German GAAP would be app. 24% of revenue Cabka N.V. | 2022HY Interim Report | Page 4 of 32 Operationally  the closure of the Genthin site on 31 May 2022  enables the company to concentrate all Eco production activities in the Weira plant. This consolidation helps Cabka in its efforts to continuously improve production efficiencies within its Eco-product lineup. Principal risks As every company in these challenging times  Cabka underlies some business-related risks that must be mentioned. Though central risks have been previously detailed in the Shareholder Circular issued in the course of Cabka's IPO on 1 March 2022  there are some factors that need to be revisited or addressed separately. The war between Russia and Ukraine has not had direct implications for the organization. Nonetheless  it caused high uncertainty in the energy markets which led to highly volatile prices for gas and energy in general. As a production company specialized in injection molding  energy scarcity and ambiguous energy pricing are highly relevant factors for Cabka and are  thus  being closely monitored on a regular basis. The war in the region has not only impacted value chains and commodity prices but has also created pressure on finance markets and exchange rates. As a result  the Euro has suffered from substantial depreciation versus the US-Dollar in Q3-2022. This is an important factor for Cabka due to its operations and broad customer base in the United States. With this leading to US revenues increasing there are also positive implications to this development. In the context of the USA  another geopolitical risk to be wary of is the tension with China around Taiwan. Although Cabka does not conduct business in the area and there is therefore no direct impact expected in case of an escalation  the situation might have implications in a broader  possibly global  scope. Finally  while the signing of another major long-term supply agreement in the FLC--business with US-retailer Target entails promising revenue outlooks for Cabka and helps the company to further establish its strong competitive position  it can also be associated with risks. As mentioned in the Shareholder Circular  a material share of Cabka's revenue is dependent on a limited group of large customers. The new agreement must also be accounted for in this context. The associated large volumes are also expected to intermittently occupy large shares of Cabka's overall production capacity  limiting the possibility to produce other products. However  this risk is being mitigated by an additional machine  that was acquired especially for the realization of said volumes. ESG Cabka is striving to be the circularity leader in its industry. As to circularity  with our products in the first half of 2022 for 87% made from recycled materials  100% reusable with take-back clauses for recycling and supporting the collection of additional plastics for recycling we clearly established a leading position. The average for Europe was in 2021 still at 14% recycled plastics targeting to get to 33% by 2030.2 This year we turned focus not only to the recycling of plastics  but also on how we recycle plastics. Until recently Cabka -as a privately owned company- did not specifically measure ESG performance and efforts. To counteract this  Cabka has initiated efforts to outline an ESG Strategy. Currently  the first stage of the ESG Strategy Project is ongoing with the goal to establish a running reporting structure by the end of 2022. The project comprises of a thorough analysis of Cabka's current ESG position and stakeholder expectations to meet the requirements according to the non-financial reporting directive (NFRD). A double materiality assessment supported by PwC Netherlands was conducted leading to the establishment of base ambition levels that were agreed upon with the full management team in June. Systemiq April 2022 report Reshaping plastics. Pathway to a circular climate neutral plastics system in Europe Cabka N.V. | 2022HY Interim Report | Page 5 of 32 This is an excerpt of the original content. To continue reading it  access the original document here. Attachments Original LinkOriginal DocumentPermalink Disclaimer Cabka NV published this content on 17 February 2023 and is solely responsible for the information contained therein. Distributed by Public  unedited and unaltered  on 17 February 2023 15:05:06 UTC.Â© Publicnow 2023 All news about CABKA N.V. 02/17 Cabka N : Half Year Report 2022 PU 01/26 Cabka CFO To Step Down In February; Interim Successor Appointed MT 01/26 Frank Roerink appointed as interim Chief Financial Officer of Cabka GL 01/26 Frank Roerink appointed as interim Chief Financial Officer of Cabka GL 01/26 Cabka N.V. Announces Chief Financial Officer Changes CI 2022 Cabka N : Draft AGM Minutes May 31 2022 PU 2022 Cabka N : AGM Minutes May 31 2022 PU 2022 Cabka N : Cabka continues to post strong sales figures in third quarter 2022 PU 2022 Cabka N : continues to post strong sales figures in third quarter 2022 PU 2022 Cabka N : Halfjaarlijkse financiÃ«le verslaggeving PUFinancials EUR USD Sales 2022 208 M 221 M 221 M Net income 2022 -2 45 M -2 61 M -2 61 M Net Debt 2022 31 0 M 33 0 M 33 0 M P/E ratio 2022 -60 0x Yield 2022 1 09% Capitalization 165 M 176 M 176 M EV / Sales 2022 0 95x EV / Sales 2023 0 87x Nbr of Employees 700 Free-Float 28 7% Chart CABKA N.V. Duration : Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max. Period : Day Week Technical analysis trends CABKA N.V. Short Term Mid-Term Long Term Trends Bullish Neutral Bearish Income Statement Evolution Please enable JavaScript in your browser's settings to use dynamic charts. Consensus Sell Buy Mean consensus BUY Number of Analysts 1 Last Close Price 6 90 â‚¬ Average target price 11 23 â‚¬ Spread / Average Target 62 7% EPS Revisions Please enable JavaScript in your browser's settings to use dynamic charts. Managers and Directors Stephan Ronald Nanninga Member-Supervisory Board Sector and Competitors 1st jan. Capi. (M$) CABKA N.V. 12.75% 176 BERRY GLOBAL GROUP  INC. 4.07% 7 592 APTARGROUP  INC. 0.65% 7 226 FP CORPORATION -6.46% 2 165 SHANGHAI ZIJIANG ENTERPRISE GROUP CO.  LTD. 18.40% 1 316 SCIENTEX 11.80% 1 266,neutral,0.0,1.0,0.0,mixed,0.24,0.1,0.66,True,English,"['Half Year Report', 'Cabka N', 'Mr. Necip KÃ¼pcÃ¼ CFO', 'Mr. Wouter van der Woerd', 'Cabka N.V. Amsterdam Interim Report', 'Mr. Jean-Marc van Maren', 'Mr. Tim Litjens CEO', 'Mr. Ã–zgÃ¼r Yildirim', 'Mr. Geert de Wilde', 'Mrs. Tova Posner Henkin', 'internal production recycling activities', 'indexed pricing adjustment mechanism', 'total favorable price effect', 'European large container market', 'overall higher cost base', 'Dutch Corporate Governance Code', 'leading material handling company', 'Chief Product Development Officer', 'Mr. Manuel Beja', 'Chief People officer', '2022HY Interim Report', 'Dutch Star Companies', 'Mrs. Jeanine Holscher', 'TWO B.V.', 'multiple email addresses', 'relative competitive position', 'key strategic objectives', 'Mr. Gat Ramon', 'Mr. Niek Hoek', 'Mr. Stephan Nanninga', '2022 Cabka N.V.', 'Chief Operations Officer', 'strong commercial results', 'strong market position', 'first six months', '32 Company Statement Introduction', 'Cabka Group GmbH', 'bottom line impact', 'several price increases', 'higher input costs', 'additional price increase', 'Half Year Report', 'higher production costs', 'supervisory board members', 'Euronext Amsterdam', 'Unaudited interim', 'material market', 'six members', 'cost increases', 'half-year report', 'corporate secretary', 'organizational development', 'total revenues', 'first half', 'large containers', 'product prices', 'higher costs', 'higher fraction', 'material prices', 'material) costs', 'strong sales', 'listed company', 'extreme increases', 'First name', 'business combination', 'listing governance', 'two-tier Board', 'operational performance', 'Russian invasion', 'subsequent impact', 'economic developments', 'direct exposure', 'indirect impact', 'margin pressure', 'lower margins', 'other hand', 'lumber prices', 'plastic pallets', 'high demand', 'Various rounds', 'rising costs', 'organic growth', 'multi-year contract', 'significant revenues', 'third quarter', 'new contracts', 'next year', 'steep rise', 'volatile conditions', 'high amount', 'feed stock', 'Management Board', 'Management Team', 'financial statements', 'subsequent listing', 'financial markets', 'new sales', 'DSC2) shareholders', 'short period', 'commas', 'Message', 'fields', 'Page', 'kind', 'transformation', 'support', '1 March', '1 January', 'requirements', 'Chair', 'Messrs', 'accordance', '1 July', 'HR', 'Ukraine', '24 February', 'social', 'Belarus', 'energy', 'materials', 'industry', 'compensation', 'delays', 'customers', 'supplies', 'plastics', 'products', 'indexation', 'solutions', 'focus', 'US-business', 'Target', 'others', 'BMW', 'Q3', '1 August', 'par', 'moment', 'order', 'prerequisite', 'ability', 'resilient', 'shortage', 'time']",2023-02-17,2023-02-18,marketscreener.com
18787,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/autoliv-board-of-directors-approves-renewal-of-emtn-programme-301750184.html,Autoliv: Board of Directors approves renewal of EMTN Programme,"STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- The Funding Committee of the Board of Directors of Autoliv  Inc. (NYSE: ALV) (SSE: ALIVsdb) (the ""Company"") approved on February 14  2023 the renewal for one year of its â‚¬3 000 000 000 guaranteed euro medium term note â€¦","STOCKHOLM  Feb. 17  2023 /PRNewswire/ -- The Funding Committee of the Board of Directors of Autoliv  Inc. (NYSE: ALV) (SSE: ALIVsdb) (the ""Company"") approved on February 14  2023 the renewal for one year of its â‚¬3 000 000 000 guaranteed euro medium term note programme (the ""EMTN Programme"")  which was originally established on 11 April 2019.The renewal of the EMTN Programme will allow the Company to take advantage of the funding opportunities provided by the capital markets and institutional investors through the future issuance of notes (the ""Notes""). The Notes issued by the Company under the EMTN Programme will be unconditionally and irrevocably guaranteed by the Company's subsidiary  Autoliv ASP  Inc. (the ""Guarantor"").The base listing particulars dated February 17  2023 (the ""Base Listing Particulars"")  which has been prepared by the Company and the Guarantor in connection with the EMTN Programme  has been approved by Euronext Dublin and is available for viewing on the website of Euronext Dublin (http://www.ise.ie).InquiriesTreasury: Par-Ola Wirenlind  Tel +46 (0) 7 030 332 78Investors & Analysts: Anders Trapp  Tel +46 (0) 8 587 206 71Investors & Analysts: Henrik Kaar  Tel +46 (0)8 587 206 14Media: Gabriella Ekelund  Tel +46 (70) 612 64 24About AutolivAutoliv  Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies  we develop  manufacture and market protective systems  such as airbags  seatbelts  and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions  such as pedestrian protection  connected safety services and safety solutions for riders of powered two wheelers. At Autoliv  we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2022  our products saved close to 35 000 lives and reduced more than 450 000 injuries.Our close to 70 000 associates in 27 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation  research  and development at our 14 technical centers  with their 20 test tracks. Sales in 2022 amounted to US $ 8.8 billion. For more information go to www.autoliv.com.Important InformationNOTHING IN THIS COMMUNICATION CONSTITUTES AN OFFER TO SELL  OR THE SOLICITATION OF AN OFFER TO BUY  ANY SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES REFERRED TO IN THE BASE LISTING PARTICULARS (THE ""SECURITIES"") HAVE NOT BEEN  AND WILL NOT BE  REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933  AS AMENDED (THE ""SECURITIES ACT"")  OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES  AND THE SECURITIES MAY NOT BE OFFERED OR SOLD  DIRECTLY OR INDIRECTLY  WITHIN THE UNITED STATES OR TO  OR FOR THE ACCOUNT OR BENEFIT OF  U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) EXCEPT PURSUANT TO AN EXEMPTION FROM  OR IN A TRANSACTION NOT SUBJECT TO  THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE OR LOCAL SECURITIES LAWS.Safe Harbor StatementThis communication contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities  events or developments that Autoliv  Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations  various assumptions and data available from third parties.Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However  there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks  uncertainties and other factors which may cause actual future results  performance or achievements to differ materially from the future results  performance or achievements expressed in or implied by such forward-looking statements.Numerous risks  uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this communication or any other document  we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995  and we assume no obligation to update publicly or revise any such statements in light of new information or future events  except as required by law.The following files are available for download:https://mb.cision.com/Main/751/3718209/1858691.pdf Autoliv: Board of Directors approves renewal of EMTN Programme (PDF)SOURCE Autoliv",neutral,0.01,0.99,0.0,mixed,0.57,0.03,0.4,True,English,"['EMTN Programme', 'Autoliv', 'Board', 'Directors', 'renewal', 'â‚¬3,000,000,000 guaranteed euro medium term note programme', 'Private Securities Litigation Reform Act', 'UNITED STATES SECURITIES ACT', 'market protective systems', 'major automotive manufacturers', 'close to 70,000 associates', 'U.S. PERSONS', 'automotive safety systems', 'connected safety services', 'base listing particulars', 'Safe Harbor Statement', 'LOCAL SECURITIES LAWS', 'The Funding Committee', 'mobility safety solutions', 'Such forward-looking statements', 'actual future results', 'actual results', 'EMTN Programme', 'funding opportunities', 'leading solutions', 'one year', 'capital markets', 'future issuance', 'Euronext Dublin', 'ise.ie', 'Inquiries Treasury', 'Par-Ola Wirenlind', 'Anders Trapp', 'Henrik Kaar', 'Gabriella Ekelund', 'Nasdaq Stockholm', 'ALIV.sdb', 'worldwide leader', 'group companies', 'steering wheels', 'two wheelers', '14 technical centers', '20 test tracks', 'OTHER JURISDICTION', 'REGISTRATION REQUIREMENTS', 'historical facts', 'third parties', 'good faith', 'reasonable basis', 'unknown risks', 'other factors', 'Numerous risks', 'other document', 'following files', 'Important Information', 'new information', 'pedestrian protection', 'More Lives', 'APPLICABLE STATE', 'current expectations', 'various assumptions', 'future events', 'institutional investors', 'Autoliv ASP', 'SOURCE Autoliv', '35,000 lives', 'Feb.', 'Board', 'Directors', 'Inc.', 'NYSE', 'ALV', 'SSE', 'ALIVsdb', 'Company', 'February', 'renewal', '11 April', 'advantage', 'notes', 'subsidiary', 'Guarantor', 'connection', 'website', 'Tel', 'Analysts', 'Media', 'airbags', 'seatbelts', 'riders', 'standards', 'products', '450,000 injuries', '27 countries', 'vision', 'quality', 'heart', 'everything', 'innovation', 'research', 'development', 'Sales', 'COMMUNICATION', 'OFFER', 'SELL', 'SOLICITATION', 'BUY', 'ACCOUNT', 'BENEFIT', 'REGULATION', 'EXEMPTION', 'TRANSACTION', 'meaning', 'activities', 'management', 'data', 'assurance', 'uncertainties', 'performance', 'achievements', 'obligation', 'light', 'download', 'cision', 'Main', '46']",2023-02-17,2023-02-18,prnewswire.com
18788,EuroNext,Twitter API,Twitter,Euronext wheat prices pause after volatile weekhttps://t.co/Bw7r5gfenc,nan,Euronext wheat prices pause after volatile weekhttps://t.co/Bw7r5gfenc,neutral,0.01,0.93,0.07,neutral,0.01,0.93,0.07,True,English,"['Euronext wheat prices', 'volatile week', 'Euronext wheat prices', 'volatile week']",2023-02-18,2023-02-18,Unknown
18789,EuroNext,Twitter API,Twitter,Shurgard Self Storage Selected for Euronext BEL ESG Index Tracking Corporate Sustainability Effortsâ€¦ https://t.co/n5uGlMA2RA,nan,Shurgard Self Storage Selected for Euronext BEL ESG Index Tracking Corporate Sustainability Effortsâ€¦ https://t.co/n5uGlMA2RA,neutral,0.07,0.91,0.01,neutral,0.07,0.91,0.01,True,English,"['Euronext BEL ESG Index Tracking', 'Shurgard Self Storage', 'Corporate Sustainability Efforts', 'Euronext BEL ESG Index Tracking', 'Shurgard Self Storage', 'Corporate Sustainability Efforts']",2023-02-18,2023-02-18,Unknown
18790,EuroNext,Twitter API,Twitter,The CAC 40  the benchmark stock market index for the 40 largest market caps on the Euronext Paris  Europe's second-â€¦ https://t.co/Ikt0cN8q0L,nan,The CAC 40  the benchmark stock market index for the 40 largest market caps on the Euronext Paris  Europe's second-â€¦ https://t.co/Ikt0cN8q0L,neutral,0.05,0.94,0.02,neutral,0.05,0.94,0.02,True,English,"['benchmark stock market index', '40 largest market caps', 'The CAC', 'Euronext Paris', 'Europe', 'benchmark stock market index', '40 largest market caps', 'The CAC', 'Euronext Paris', 'Europe']",2023-02-18,2023-02-18,Unknown
18791,EuroNext,Twitter API,Twitter,@PointBlank_Algo 'Strage' how Euronext has decided to push the same narative and not do reports.This is becoming pathetic.,nan,@PointBlank_Algo 'Strage' how Euronext has decided to push the same narative and not do reports.This is becoming pathetic.,negative,0.0,0.0,0.99,negative,0.0,0.0,0.99,True,English,"['same narative', 'PointBlank', 'Euronext', 'reports', 'same narative', 'PointBlank', 'Euronext', 'reports']",2023-02-18,2023-02-18,Unknown
18792,EuroNext,Twitter API,Twitter,@Coredao_Org Euronext marks our total of 20 billion yuan? That's not the right number we need them to apologize,nan,@Coredao_Org Euronext marks our total of 20 billion yuan? That's not the right number we need them to apologize,negative,0.0,0.0,1.0,negative,0.0,0.0,1.0,True,English,"['20 billion yuan', 'right number', 'total', '20 billion yuan', 'right number', 'total']",2023-02-18,2023-02-18,Unknown
